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16 Summary 
A  series  of  studies  is  described  in  which  specific  and  conventional  insulin 
immunoassays,  the  hyperinsulinaemic  clamp  technique  and  forearm  venous 
occlusion  plethysmography  with  local  intra-arterial  infusions  have  been  used  to 
investigate: 
"  the  effect  of  insulin  assay  specificity  on  the  relationships  among  serum  insulin 
concentrations,  insulin  sensitivity,  and  blood  pressure  in  diabetic  and  non- 
diabetic  subjects  with  and  without  essential  hypertension  (Chapter  5) 
"  the  effect  of  sustained  physiological  activation  of  the  renin-angiotensin  system 
induced  by  moderate  dietary  sodium  restriction  on  insulin  sensitivity  in 
patients  with  non-insulin-dependent  diabetes  mellitus  (Chapter  6) 
"  the  relationship  between  endothelial  function  and  insulin  sensitivity  in  healthy 
subjects  (Chapter  7) 
Prior  to  these  investigations,  preliminary  studies  (Chapters  3  and  4)  were 
performed  in  order  to  validate  aspects  of  the  clinical  physiological  techniques 
required  for  the  measurement  of  blood  flow  and  insulin  sensitivity. 
17 (i)  The  reproducibility  of  bilateral  forearm  venous  occlusion  plethysmography 
Studies  using  this  technique  to  measure  changes  in  forearm  blood  flow  (FBF) 
during  intra-arterial  infusions  of  vasoactive  substances  often  report  changes  in 
blood  flow  ratio  (expressing  responses  in  the  intervention  arm  as  a  ratio  of 
responses  in  the  control  arm)  rather  than  absolute  values  for  flow.  However, 
unilateral  measurements  are  reported  by  other  investigators,  and  the  possibility 
was  considered  that  the  method  used  for  expressing  responses  might  influence  the 
conclusions  reached.  A  reproducibility  study  was  performed  (Chapter  3)  which 
demonstrated  that  the  between-day  intra-subject  variability  of  bilateral  forearm 
venous  occlusion  plethysmography  (FBF  ratios)  was  less  than  that  of  unilateral 
FBF  measurements.  The  bilateral  technique  was  used  thereafter  where  possible. 
(ii)  The  effect  of  hand-warming  on  insulin  sensitivity  and  forearm  blood  flow 
Given  that  investigation  of  haemodynamic  influences  on  insulin-mediated  glucose 
uptake  were  a  major  theme  of  these  studies,  validation  studies  were  performed 
(Chapter  4)  to  investigate  whether  arterialisation  of  venous  blood  by  the 
18 commonly-used  technique  of  hand-warming  during  the  hyperinsulinaemic 
euglycaemic  clamp  had  systemic  haemodynamic  effects  or  effects  on  the 
measurement  of  insulin  sensitivity.  The  results  of  these  studies  in  healthy  subjects 
showed  that  hand-warming  (by  the  heated-air  hand  box  technique)  has  the 
potential  to  confound  the  results  of  studies  using  the  euglycaemic  clamp 
technique,  particularly  those  with  a  case-control  design  and  those  assessing  the 
haemodynamic  effects  of  insulin. 
(i)  The  effect  of  insulin  assay  specificity  on  the  relationships  among  serum 
insulin  concentrations,  insulin  sensitivity,  and  blood  pressure 
Serum  insulin  concentrations  have  been  used  as  markers  of  insulin  resistance  in 
population  studies  examining  the  relationship  between  insulin  resistance  and 
blood  pressure.  It  was  hypothesised  that  differences  in  cross-reactivity  of  the 
antibodies  used  in  conventional  insulin  immunoassays  with  proinsulin  and 
proinsulin-like  molecules  might  account  for  variations  in  the  reported 
relationship  between  insulin  and  blood  pressure.  The  relationships  were  therefore 
examined  among  fasting  and  post-glucose  load  serum  insulin  concentrations 
19 (determined  by  both  specific  and  conventional  assays),  insulin  sensitivity 
(measured  by  the  euglycaemic  clamp  technique),  and  blood  pressure,  in  a  group  of 
56  diabetic  (NIDDM)  and  non-diabetic  subjects  (Chapter  5).  The  results 
demonstrated  that  the  relationships  among  serum  insulin  concentrations,  insulin 
sensitivity  and  blood  pressure  were  independent  of  insulin  assay  specificity. 
(ii)  The  effect  of  dietary  sodium  restriction  on  insulin  sensitivity  in  non- 
insulin-dependent  diabetes  mellitus 
Previous  studies  conducted  in  the  CIRU  had  demonstrated  an  insulin-sensitising 
effect  of  acute  infusion  of  the  potent  vasoconstrictor  hormone  angiotensin  H 
(ANG  II)  in  patients  with  NIDDM.  The  effect  on  insulin  sensitivity  of  sustained 
physiological  activation  of  the  renin-angiotensin  system  was  therefore  examined 
in  patients  with  NIDDM  using  sodium  restriction  (40  mmoVday)  in  a  randomised, 
double-blind,  placebo-controlled  crossover  protocol  (Chapter  6).  The  results 
demonstrated  a  12%  reduction  in  insulin  sensitivity  associated  with  moderate 
dietary  sodium  restriction  in  these  patients,  providing  further  insights  into  the 
20 effects  of  the  renin-angiotensin  system  on  glucose  metabolism  in  patients  with 
NIDDM. 
(iii)  The  relationship  between  insulin  sensitivity  and  endothelial  function 
There  is  evidence  that  insulin-mediated  vasodilatation  is  reduced  in  states  of 
insulin  resistance.  Observation  of  the  co-existence  of  endothelial  dysfunction  and 
insulin  resistance  in  a  number  of  cardiovascular  disease  states  generated  the 
hypothesis  of  the  existence  of  a  physiological  link  between  endothelial  nitric 
oxide  production  and  insulin-mediated  glucose  uptake.  Forearm  vascular 
endothelial  function  was  therefore  measured  in  healthy  subjects  across  a  range  of 
insulin  sensitivity  (Chapter  7).  The  results  demonstrated,  for  the  first  time,  a 
positive  relationship  between  basal  endothelial  nitric  oxide  production  and 
insulin  sensitivity  in  healthy  young  males.  The  hypothesis  is  discussed  that 
physiological  insulin  sensitivity  may  in  part  be  determined  by  an  endothelium- 
dependent  effect  of  insulin  to  promote  glucose  uptake  by  increasing  blood  flow 
(and  hence  delivery  of  insulin  and  glucose)  to  insulin-sensitive  tissues. 
21 Chapter  1. 
Introduction  and  background 
1.0  Introduction 
Hormone  resistance  can  be  defined  as  a  subnormal  biologic  response  to  a  given 
concentration  of  that  hormone.  Insulin  resistance  is  thought  to  be  the  most 
prevalent  form  of  hormone  resistance,  and  diabetes  mellitus  was  differentiated 
into  insulin-sensitive  and  insulin-insensitive  types  nearly  60  years  ago  (Himsworth 
1936).  As  insulin  has  important  and  diverse  effects  on  carbohydrate,  lipid,  and 
protein  metabolism  (Table  1.1),  mediated  by  a  complex  receptor  and  second 
messenger  system  (Section  1.6),  it  is  not  surprising  that  insulin  resistance  has  been 
implicated  in  the  pathogenesis  of  a  broad  spectrum  of  disorders  with  metabolic 
features  including  obesity,  diabetes  mellitus,  ovarian  hyperandrogenism,  and, 
possibly,  essential  hypertension  (Moller  and  Flier  1991).  By  convention,  the  term 
"insulin  resistance"  usually  refers  to  decreased  sensitivity  of  tissues  to  the  actions 
of  insulin  on  glucose  homeostasis,  i.  e.  resistance  to  insulin-mediated  glucose 
uptake.  Conversely,  "insulin  sensitivity"  refers  to  sensitivity  of  tissues  to  insulin- 
dependent,  as  opposed  to  insulin-independent,  glucose  disposal. 
1.1  Insulin  resistance  and  disease 
The  most  important  recognised  physiologic  determinants  of  insulin  sensitivity, 
which  varies  up  to  three-fold  in  non-obese  individuals  with  normal  glucose 
22 Table  1.1  Physiological  actions  of  insulin 
Action  Tissue  Mechanism 
Carbohydrate  metabolism 
Glucose  transport  (uptake) 
enhanced 
Glucose  phosphorylation  (initial 
step  for  entry  of  glucose  into 
glycolysis) 
Glucose  oxidation  enhanced 
All  tissues  except  brain, 
enterocytes,  hepatocytes, 
renal  tubular  cells, 
pancreas 
Liver,  muscle 
Recruitment  of  glucose 
transport  proteins  from 
intracellular  pool  to 
plasma  membrane 
Induction  of  glucokinase 
Glycogen  synthesis  enhanced 
Pentose  phosphate  shunt  stimulated 
Glycogenolysis  inhibited 
Gluconeogenesis  inhibited 
Protein  metabolism 
Amino  acid  transport  enhanced 
Protein  synthesis  enhanced 
Protein  degradation  inhibited 
Lipid  metabolism 
Fatty  acid  synthesis 
Triglyceride  synthesis 
Lipolysis  inhibited 
Uptake  of  very-low-density 
lipoproteins  (VLDL)  and  free 
fatty  acids  enhanced 
Reverse  cholesterol  transport  by 
high-density  lipoproteins  (HDL) 
promoted 
Ketone  body  synthesis  inhibited 
Liver,  muscle  Pyruvate  dehydrogenase 
activated 
Liver,  muscle  Induction  of  glycogen 
synthase 
Adipose  tissue  - 
Liver  Inhibition  of  phosphorylase 
Liver  Indirect  via  decreased 
availability  of  acetyl  coA 
(decreased  allosteric 
stimulation  of  pyruvate 
carboxylase) 
Liver,  muscle  Direct 
Liver,  muscle  Direct 
Liver,  muscle  - 
Liver  Induction  of  acetyl  CoA 
carboxylase,  fatty  acid 
synthetase 
Liver,  adipose  tisse  Increased  availability  of  a- 
glycero-phosphate  from 
glycolysis  promotes 
esterification  of  fatty  acids 
Adipose  tissue  Hormone-sensitive  lipase 
Adipose  tissue  Lipoprotein  lipase 
Adipose  tissue  Hepatic  triglyceride  lipase 
Liver  Increased  malonyl  CoA 
inhibits  carnitine  acyl 
transferase  I 
Electrolytes 
Cellular  potassium  uptake  enhanced  Na+-K+ATPase 
23 tolerance,  are  age,  body  mass  index,  gender,  regional  fat  distribution,  and  physical 
fitness  (Hollenbeck  and  Reaven  1987;  Yki-Jarvinen  1995).  In  addition,  there  are  a 
number  of  pathophysiological  states  which  are  associated  with  an  impaired 
sensitivity  to  insulin-mediated  glucose  uptake. 
1.1.1  Insulin  resistance  in  non-insulin  dependent  diabetes  mellitus 
A  small  subset  of  patients  with  non-insulin  dependent  diabetes  mellitus  (NIDDM) 
have  clearly  defined  molecular  defects  resulting  in  insulin  resistance.  These  are 
inherited,  often  in  an  autosomal  dominant  manner  (Kadowaki  et  al  1988,  Maasen 
and  Kadowaki  1996,  Bell  1996).  However,  it  is  fairly  clear  that  resistance  to 
insulin-mediated  glucose  uptake  (both  peripheral  and  hepatic)  also  plays  a  major 
role  in  the  pathogenesis  of  common  forms  of  NIDDM  (DeFronzo  et  al  1992),  and 
that  the  relationship  is  independent  of  obesity  (Ludvik  et  al  1995).  Considerable 
controversy  remains  regarding  the  mechanism  of  hormone  resistance  in  NIDDM 
(Section  1.6),  and  its  relative  importance  with  respect  to  abnormalities  of  insulin 
secretion  (Hales  1994). 
The  controversy  reflects  in  part  a  philosophical  difficulty  in  disentangling  the 
complex  and  mutually-perpetuating  relationship  between  the  two  metabolic 
processes:  peripheral  insulin  resistance  may  lead  initially  to  a  compensatory 
insulin  secretory  response  and  eventually  to  ß  -cell  "exhaustion"  (Del  Prato  et  al 
1994);  conversely,  hypoinsulinaemia  and  consequent  hyperglycaemia  lead  to 
secondary  insulin  resistance  (Hales  1994).  In  addition,  perturbations  of  either 
process  may  affect  hepatic  glucose  production.  The  debate  also  reflects  a  lack  of 
24 longitudinal  studies,  and  methodological  problems  with  measurement  of  both 
circulating  serum  insulin  concentrations  (Section  1.3.1;  Robbins  et  al  1996)  and  of 
insulin  sensitivity  (Section  1.5). 
1.1.2  Insulin  resistance  in  essential  hypertension 
In  an  early  study  conducted  in  a  small  group  of  patients  with  essential 
hypertension,  the  presence  of  hormone  resistance  was  inferred  from  normal  or 
elevated  blood  glucose  profiles  in  the  presence  of  high  serum  insulin 
concentrations  (Welborn  et  al  1966).  Nineteen  years  later  an  association  between 
serum  insulin  concentrations  and  blood  pressure  was  reported  in  a  large  Israeli 
population  (Modan  et  al  1985),  supporting  the  notion  that  essential  hypertension 
was  an  insulin  resistant  state.  Since  then,  using  more  direct  metabolic 
measurements  of  hormone  resistance  (see  Section  1.4),  American  and  Italian 
groups  have  reported  decreased  insulin-mediated  glucose  uptake  insulin  in  non- 
obese  essential  hypertensive  patients  (Fenrannini  et  al  1987;  Shen  et  al  1988). 
Such  data  have  led  to  speculation  that  hyperinsulinaemia  and/or  insulin  resistance 
might  play  a  role  in  mediating  the  atherosclerotic  complications  of  hypertension 
(Modan  et  al  1985,  Reaven  1988).  Furthermore,  as  the  abnormality  did  not  appear 
to  be  present  in  secondary  hypertension  (Shamiss  et  al  1992),  it  was  proposed  that 
it  might  be  important  in  the  pathogenesis  of  essential  hypertension.  This  is 
discussed  in  detail  in  Section  1.2. 
Much  recent  scientific  attention  has  focused  on  the  clustering  of 
hyperinsulinaemia,  insulin  resistance,  hypertension,  glucose  intolerance  and 
25 abnormal  lipid  metabolism  within  individuals  of  a  population.  Data  from  the 
Framingham  Heart  Study  indicate  that  up  to  50%  of  patients  with  diabetes  have 
elevated  blood  pressure,  and  the  incidences  of  both  diabetes  and  hypertension 
increase  progressively  with  the  degree  of  obesity  (Kannei  and  McGhee  1979). 
The  constellation  of  subclinical  cardiovascular  risk  factors  in  an  individual  patient 
has  been  termed  "syndrome  X"  (Reaven  1988),  "the  insulin  resistance  syndrome" 
(Haffner  et  al  1992),  and  "the  deadly  quartet"  (Kaplan  1989).  However,  the 
existence,  mechanism  and  pathophysiological  significance  of 
hyperinsulinaemia/insulin  resistance  in  essential  hypertension  remain 
controversial. 
1.1.3  Insulin  resistance,  hyperlipidaemia  and  atherosclerosis 
There  is  considerable  evidence  that  insulin  resistance  plays  a  role  in  the  promotion 
of  atherosclerosis,  the  principal  macrovascular  complication  of  both  hypertension 
and  NIDDM.  Lipoproteins  are  central  to  atherogenesis  (Ross  1993),  and  insulin 
has  a  complex  interaction  with  their  metabolism  (Reaven  and  Chen  1988, 
Ginsberg  1991).  Under  physiological  circumstances,  insulin  suppresses  free  fatty 
acid  (FFA)  release  from  adipose  tissue  and  promotes  peripheral  uptake  of  very- 
low-density  lipoproteins  (VLDL)  and  FFAs  by  activating  lipoprotein  lipase  (LPL). 
Reduced  availability  of  FFAs  favours  a  decline  in  hepatic  VLDL  synthesis,  and 
insulin-mediated  activation  of  hepatic  triglyceride  lipase  promotes  reverse 
cholesterol  transport  by  high-density  lipoproteins  (HDL).  In  obesity  and  NIDDM, 
there  is  a  shift  in  the  net  balance  of  lipolysis  and  re-esterification  of  FFAs, 
producing  a  rise  in  their  circulating  concentration  (Groop  et  al  1991);  this  results 
26 from  subnormal  adipose  tissue  LPL  activity  (Taskinen  et  al  1982).  FFAs  in  turn 
aggravate  resistance  to  insulin-mediated  glucose  disposal  in  skeletal  muscle,  by 
competing  for  oxidation  with  glucose  in  mitochondria  (Randle  et  al  1963),  shifting 
hepatic  glucose  metabolism  in  favour  of  gluconeogenesis  (via  allosteric  activation 
by  acetyl  CoA  of  pyruvate  carboxylase),  promoting  hepatic  VLDL  production, 
raising  serum  triglyceride  concentrations  (Frayn  et  al  1996),  and  enhancing 
oxidative  stress  (Paolisso  et  al  1996). 
There  is  evidence  that  both  serum  insulin  concentrations  (Stalder  et  al  1981, 
Orchard  et  al  1983,  Laakso  et  al  1987),  and  directly-measured  resistance  to 
insulin-mediated  glucose  uptake  (Laakso  et  al  1990b)  are  correlated  with  serum 
triglyceride  concentrations  in  population  studies.  Reaven  included  dyslipidaemia, 
(low  concentrations  of  plasma  HDL  cholesterol  and  high  concentrations  of  LDL 
cholesterol)  in  his  definition  of  "Syndrome  X"  (Reaven  1988).  Interestingly, 
however,  it  has  been  reported  that  isolated  hypercholesterolaemia  (familial  or 
otherwise)  is  not  associated  with  insulin  resistance  (Karhapaa  et  al  1993,  Sheu  et 
al  1993). 
Several  prospective  epidemiological  studies  have  examined  the  relationship 
between  serum  insulin  concentrations,  as  a  marker  of  insulin  resistance,  and 
coronary  events.  The  5  year  analysis  of  data  from  1059  policemen  in  Helsinki 
revealed  that  the  combined  incidence  of  fatal  and  non-fatal  myocardial  infarction 
was  greater  in  those  who  had  the  highest  fasting  insulin  and  post-glucose  load 
insulin  concentrations  (Pyorala  1979).  Similarly,  in  the  Paris  Prospective  study  of 
7500  male  civil  servants,  fasting  serum  insulin  concentrations  were  related  to  the 
27 incidence  of  coronary  artery  disease  at  11  years  follow-up  independent  of  glucose 
tolerance  and  blood  pressure,  and  was  greater  in  obese  rather  than  non-obese 
subjects  (Ducimetiere  et  al  1980).  A  recent  Canadian  case-control  study  based  on 
a  population  of  2103  men  in  whom  114  ischaemic  events  occurred  over  15  years 
also  reported  an  independent  association  between  baseline  fasting  serum  insulin 
concentrations  and  subsequent  coronary  events  (Despres  et  al  1996).  Similar 
results  were  reported  in  males,  but  not  in  females,  in  a  large  Western  Australian 
population  (Welborn  and  Wearne  1979). 
However,  in  a  large  Welsh  population  (2512  men),  the  initial  cross-sectional 
association  between  fasting  serum  insulin  concentrations  and  ischaemic  heart 
disease  (Lichtenstein  et  al  1987)  was  not  sustained  in  the  longitudinal  phase  of  the 
study:  a  univariate  association  was  wholly  accounted  for  by  serum  triglyceride 
concentrations  and  body  mass  (Yarnell  et  al  1994).  Similar  results  have  been 
reported  in  follow-up  studies  of  smaller  populations  in  Gothenburg  (Welin  et  al 
1992;  n=644),  California  (Ferrara  et  al  1994;  n=  1244),  and  in  a  subgroup 
analysis  of  cases  and  controls  in  the  Multiple  Risk  Factor  Intervention  Trial 
(Orchard  et  al  1994).  However,  the  epidemiological  evidence  in  favour  of  a  role 
for  insulin  in  the  pathogenesis  of  coronary  artery  disease  is  supported  by  numerous 
experimental  studies  showing  that  insulin  accelerates  atherosclerosis  in  vitro 
(Stout  1980;  Stout  1989),  and  clinical  data  from  the  Bypass  Angioplasty 
Revascularisation  Investigation  implicating  direct  deleterious  effects  of  insulin  on 
balloon-injured  vessels  after  percutaneous  transluminal  angioplasty  (Sobel  1996). 
28 1.1.4  Genetic  determinants  of  insulin  resistance 
A  number  of  studies  have  demonstrated  insulin  resistance  in  offspring  (Gulli  et  al 
1992;  Haffner  et  al  1988)  or  first  degree  relatives  (Vaag  et  al  1992)  of  patients 
with  NIDDM,  as  well  as  in  identical  twins  discordant  for  NIDDM  (Vaag  et  al 
1995).  Insulin  resistance  has  also  been  reported  in  the  normotensive  offspring  of 
hypertensive  parents  (Ferrari  et  al  1991).  However,  such  studies  have  included 
only  small  numbers  of  subjects,  and  may  be  confounded  by  inadequate  assessment 
of  variables  such  as  physical  fitness  (Yki-Jarvinen  1995);  in  addition,  twin  studies 
are  potentially  confounded  by  effects  of  the  shared  intra-uterine  environment 
(Barker  et  al  1993a,  Barker  et  al  1993b). 
Insulin  resistance  is  clearly  modifiable  by  environmental  factors,  and  the  extent  to 
which  it  is  genetically  determined  remains  controversial.  In  the  case  of  NIDDM, 
genetic  investigations  are  hampered  by:  a)  the  heterogeneity  of  the  phenotype  (a 
problem  shared  with  essential  hypertension);  b)  confusion  over  the  relative 
primacy  of  insulin  resistance  and  ß-cell  dysfunction  (Section  1.1.1);  c)  the 
arbitrary  diagnostic  thresholds  of  NIDDM  and  IGT,  which  are  based  on  risk  of 
diabetic  complications  in  populations  amongst  whom  glucose  levels  are 
continuously  rather  than  categorically  distributed. 
In  the  case  of  Maturity  Onset  Diabetes  of  the  Young  (MODY),  a  specific 
phenotype  of  NIDDM  characterised  by  early  age  of  onset,  autosomal  dominant 
inheritance,  and  ß-cell  dysfunction,  it  has  been  possible  to  establish  linkage  with 
genes  on  chromosomes  12q,  20q,  and  7p  -  the  latter  gene  codes  for  glucokinase,  a 
29 key  regulatory  enzyme  in  determining  insulin  secretion  by  the  pancreatic  ß-cell 
(Froguel  et  al  1992,  Vionnet  et  al  1992,  Froguel  1996).  In  addition,  despite  the 
difficulties  of  phenotypic  heterogeneity  in  the  common  variant  of  NIDDM,  a 
genome-wide  search  in  affected  sib-pairs  from  an  isolated  Finnish  population  has 
identified  a  major  susceptibility  locus  (D2S125)  on  chromosome  2,  although  the 
mechanism  by  which  it  predisposes  to  the  phenotype  is  unknown  at  present 
(Mahtani  et  al  1996). 
1.1.5  Insulin  resistance  and  non-pharmacological  interventions 
Obesity  is  clearly  associated  with  insulin  resistance  in  both  diabetic  and  non- 
diabetic  subjects  (Bonadonna  et  al  1990,  Cambien  et  al  1987,  Ludvik  et  al  1995), 
particularly  when  associated  with  an  upper-body  fat  distribution  (Kissebah  1982; 
Peiris  et  al  1988);  weight  reduction  results  in  an  improvement  in  insulin  sensitivity 
(Olefsky  et  al  1974)  which  is  correlated  with  blood  pressure  reduction  (Ikeda  et  al 
1996).  Physical  exercise  is  associated  with  an  increase  in  insulin  sensitivity 
(Rodnick  et  al  1987),  even  when  training  bouts  are  too  brief  to  be  associated  with 
weight  reduction  (Rogers  et  al  1988).  The  mechanisms  of  these  effects  remain 
poorly  defined,  but  may  relate  to  skeletal  muscle  capillarisation  (Section  1.6.3). 
In  addition,  insulin  sensitivity  can  be  impaired  by  both  acute  (Attvall  et  al  1993) 
and  chronic  (Facchini  et  al  1992)  cigarette  smoking. 
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As  insulin  resistance  may  be  important  in  mediating  the  atherosclerotic 
complications  of  essential  hypertension,  it  has  been  claimed  that  the  effects  of 
antihypertensive  treatment  on  insulin  sensitivity  may  be  clinically  important, 
independently  of  their  effects  on  blood  pressure  (Rett  et  al  1986,  Pollare  et  al 
1989a).  In  particular,  it  has  been  suggested  that  the  "shortfall"  in  expected 
cardiovascular  mortality  reduction  resulting  from  antihypertensive  treatment 
(Collins  et  al  1990)  may  be  attributed  to  deleterious  effects  of  commonly-used 
antihypertensive  agents  such  as  thiazide  diuretics  on  cardiovascular  risk  factors, 
including  effects  on  insulin  sensitivity.  In  this  context  it  is  noteworthy  that  in 
NIDDM  insulin  sensitivity  improves  during  treatment  with  any  agent  that 
chronically  decreases  blood  glucose  (sulphonlyureas,  biguanides,  chronic  insulin 
therapy),  but  to  date  it  has  not  been  possible  to  demonstrate  reductions  in 
cardiovascular  mortality  attributable  to  such  treatments  (University  Group 
Diabetes  Program  1970). 
The  effects  of  antihypertensive  drugs  on  insulin  sensitivity  have  been  widely 
studied  but  many  of  the  studies  in  the  literature  are  compromised  by  poor  design: 
use  of  indirect  measures  of  insulin  sensitivity,  before-and-after  design,  and  lack  of 
placebo  data  (Donnelly  1992).  The  insulin-sensitising  effect  of  the  ACE-inhibitor 
captopril  reported  by  Pollare  et  al  (1989a)  remains  widely-cited,  but  the  study  was 
compromised  by  carry-over  effects  in  its  intended  crossover  comparison  of 
captopril  and  hydrochlorothiazide.  In  the  consequent  parallel-group  analysis,  the 
treatment  groups  were  poorly  matched  at  baseline,  and  insulin  sensitivity  data  may 
31 simply  have  regressed  towards  the  mean.  Several  recent  double-blind,  placebo- 
controlled  studies  have  demonstrated  that  neither  calcium  antagonists  nor  ACE 
inhibitors  have  significant  effects  on  insulin  sensitivity  (Morris  et  al  1994b, 
Heinemann  et  al  1995,  Giordano  et  a1  1995;  Wiggam  et  al  1996),  although  studies 
demonstrating  an  effect  continue  to  be  reported  (Vuorinen-Markkola  and  Yki- 
Jarvinen  1995).  In  contrast,  a-blockers  may  lead  to  small  improvements  in 
insulin  sensitivity  in  patients  with  NIDDM  (Giorda  et  al  1995).  ß-blockers 
primarily  affect  insulin  secretion  (Kendall  et  al  1988),  but  decreases  in  insulin 
sensitivity  have  been  reported  in  studies  in  which  weight  gain  was  not  taken  into 
consideration  (Pollaxe  et  al  1989b).  Thiazide  diuretics,  although  known  to  cause 
deteriorations  in  glucose  tolerance  in  high  dose  (Murphy  et  al  1982),  have  no 
short-term  effect  on  insulin  sensitivity  when  administered  in  low  dose  (1.25  mg 
daily)  to  non-diabetic  subjects  (Harper  et  al  1994)  or  patients  with  NIDDM 
(Harper  et  al  1995).  However,  data  from  these  short-term  studies  (three  months) 
must  be  taken  in  the  context  of  data  from  longer  term  studies.  In  the  MRC  trial  in 
mild  hypertension  (bendrofluazide  10  mg  daily),  the  risk  of  developing  glucose 
intolerance  over  3  years  was  four  times  higher  in  the  diuretic  group  than  in  the 
placebo  group  (Medical  Research  Council  1985);  a  similar  trend  was  observed  in  a 
nine  year  follow-up  study  of  73  treated  hypertensive  patients  and  65  normotensive 
control  subjects  (Skarfors  et  al  1989). 
Standard  therapies  for  NIDDM,  sulphonylureas  and  biguanides,  have  their  primary 
effects  on  insulin  secretion  and  hepatic  insulin  resistance  respectively,  rather  than 
on  peripheral  insulin  sensitivity  (DeFronzo  et  al  1991,  Groop  1992).  However, 
interesting  observations  have  emerged  from  early  clinical  use  of  "insulin- 
32 sensitising  agents,  "  such  as  the  thiazolidinedione  derivatives,  in  the  treatment  of 
NIDDM  (Petrie  and  Donnelly  1994).  These  novel  agents  exert  transcriptional 
effects  on  fatty  acid  metabolism  (see  Section  1.6.3)  by  activating  a  specific 
subclass  of  a  recently-described  nuclear  receptor  family  of  the  steroid/thyroid 
hormone  superfamily,  peroxisome  proliferator-activated  receptors  (PPARs) 
(Schoonjans  et  al  1996).  Troglitazone,  which  increases  peripheral  insulin 
sensitivity  by  28%  in  obese  subjects,  has  been  reported  to  cause  reductions  in 
blood  pressure  in  man  (Nolan  et  al  1994,  Ogihara  et  al  1995).  However,  these 
studies  were  parallel  group  in  design;  only  the  study  by  Nolan  et  al  was  placebo- 
controlled,  and  baseline  systolic  blood  pressure  was  poorly  matched.  In  a  larger 
study  examining  combination  treatment  with  troglitazone  and  sulphonylureas,  no 
difference  in  blood  pressure  was  observed  between  placebo  and  control  groups 
(Iwamoto  et  a1  1996). 
Interestingly,  the  structure  of  the  troglitazone  molecule  is  similar  to  that  of  vitamin 
E.  A  randomised,  double-blind  placebo-controlled  trial  conducted  in  healthy 
elderly  subjects  examining  the  effect  of  a  pharmacological  dose  of  vitamin  E  on 
insulin  sensitivity  demonstrated  a  44%  increase  in  insulin  sensitivity  as  measured 
by  the  euglycaemic  clamp  technique  (Paolisso  et  al  1994).  It  is  not  clear  whether 
this  action  of  vitamin  E  is  related  to  its  antioxidant  properties  (Section  1.6),  or  to 
PPAR-mediated  effects  on  fatty  acid  metabolism. 
Although  hypercholesterolaemia  in  itself  is  not  thought  on  the  basis  of  the 
available  information  to  be  associated  with  insulin  sensitivity  (Section  1.1.3), 
standard  therapies  for  hypercholesterolaemia  (Shepherd  et  al  1995)  such  as 
33 pravastatin  appear  to  lower insulin  levels  in  patients  with  hypercholesterolaemia 
and  hypertension  (Chan  et  al  1996).  Fish  oil,  which  is  reported  to  have  beneficial 
effects  on  lipid  profiles  (Goh  et  al  1997),  appears  to  have  a  neutral  or  adverse 
effect  on  insulin  sensitivity  (Rivellese  et  al  1996). 
In  summary,  the  effects  of  standard  antihypertensive  drugs  on  insulin  sensitivity, 
appear  to  be  small  and  of  little  clinical  significance.  The  effects  of  traditional  oral 
hypoglycaemic  agents  on  peripheral  insulin  sensitivity  in  NIDDM  are  largely 
indirect.  Newer  agents  and  antioxidant  vitamins  appear  to  have  more  profound 
effects  on  peripheral  insulin  sensitivity,  and  there  are  interesting  parallels  with 
their  effects  on  endothelial  function  (Section  1.7.3). 
1.2  Mechanisms  by  which  hyperinsulinaemia/  insulin  resistance  might  raise 
blood  pressure 
Central  to  the  biological  plausibility  of  any  theory  implicating  insulin  resistance  in 
hypertension  is  knowledge  of  the  mechanism  by  which  a  rise  in  blood  pressure 
might  be  produced.  The  candidate  mechanisms  most  frequently  postulated  are 
effects  of  pancreatic  13-cell  compensatory  hyperinsulinaemia  on  tissues  that 
remain  sensitive  to  insulin.  Chronic  hyperinsulinaemia  in  rats  (Brands  et  al  1991b) 
results  in  hypertension;  however,  this  is  not  the  case  in  dogs  (two  weeks)  (Hall  et 
al  1990;  Brands  et  al  1991a)  or  in  patients  with  insulinoma  (Fujita  et  al  1992).  If 
such  a  mechanism  does  exists,  it  is  clearly  not  a  simple  one. 
34 1)  Insulin  induced  antinatriuresis:  Urinary  sodium  excretion  falls  by  as  much  as 
50%  during  euglycaemic  hyperinsulinaemia  (DeFronzo  1975;  DeFronzo  1981a; 
Baum  1987);  there  appears  to  be  a  direct  effect  of  insulin  on  renal  tubular  sodium 
reabsorption  (Gupta  et  al  1992).  However,  although  patients  with  NIDDM  have 
an  increased  total  body  sodium  (O'Hare  et  al  1985,  Weidmann  et  al  1993),  this 
abnormality  is  not  present  in  young  patients  with  essential  hypertension  (Beretta- 
Piccoli  et  al  1982). 
2)  Activation  of  the  sympathetic  nervous  system:  Acute  hyperinsulinaemia 
activates  the  sympathetic  nervous  system  in  man,  as  evidenced  by  data  from 
microneurography  (Anderson  et  al  1991;  Vollenweider  et  al  1994)  and 
measurements  of  plasma  catecholamines  (Rowe  et  al  1981;  Lembo  et  al  1992)  and 
noradrenaline  spillover  (Landsberg  and  Krieger  1989).  However,  the  pressor 
response  is  balanced  by  vasodilatation  in  healthy  subjects,  and  there  is  no  overall 
increase  in  blood  pressure  (Anderson  and  Mark  1993).  One  might  speculate, 
however,  that  in  subjects  with  essential  hypertension  there  is  attenuation  of 
insulin-mediated  vasodilatation  with  preserved  sympathetic  activation  during 
hyperinsulinaemia  (Sections  1.7.1  and  1.7.3). 
3)  Altered  vascular  smooth  muscle  structure  and  function:  In  pharmacological 
concentrations,  insulin  acts  in  vitro  as  a  growth  factor  via  insulin-like  growth 
factor  receptors  (Banskota  et  al  1989)  and  may  potentiate  the  effects  of 
angiotensin  II  on  DNA  synthesis  (Ko  et  al  1993).  Consequent  vascular 
hypertrophy,  if  produced  in  vivo,  could  act  to  promote  and  maintain  high  blood 
pressure  (Folkow  1979),  but  effects  on  growth  have  not  been  demonstrated  at 
physiological  or  pathophysiological  concentrations  of  insulin. 
35 4)  Ion  transport:  Na-H+/Na+-Li+countertransport  is  one  of  several 
transmembrane  exchange  systems  (Section  1.6.3)  modulated  by  insulin  (Moore 
1983).  Increased  activity  of  maximal  Na-H+/Na-Li+  countertransport  is  a  feature 
of  essential  hypertension  (Canessa  et  al  1980)  and  is  associated  with  insulin 
resistance  (Doria  et  at  1991).  Such  abnormalities  of  transmembrane  ion  exchange 
may  have  effects  on  intracellular  Ca"  and  thus  resting  vascular  tone  (Section 
1.6.3).  It  has  been  proposed  that  both  insulin  resistance  and  increased  maximal 
Na+-H+/Na+-Li+  countertransport  may  be  caused  by  increased  membrane  fluidity, 
via  effects  on  enzyme  activity  and  receptor  binding  (Tong  et  al  1995). 
The  arguments  in  favour  of  an  important  role  for  insulin  in  the  pathogenesis  of 
essential  hypertension  are  weakened  by  variations  in  the  relationship  between 
serum  insulin  concentrations  and  blood  pressure  among  studies  (Section  1.3). 
Furthermore,  insulin  sensitivity  varies  up  to  three-fold  in  healthy  non-obese 
individuals  with  normal  glucose  tolerance  (Hollenbeck  and  Reaven  1987),  while 
insulin  resistance  is  present  in  conditions  such  as  polycystic  ovarian  disease  which 
are  not  associated  with  hypertension  (Zimmerman  et  al  1992).  Neither  acute 
insulin  infusion  in  man  (Anderson  and  Mark  1993),  nor  chronic  insulin  infusion  in 
animals  (Hall  et  al  1990),  leads  to  an  elevation  in  blood  pressure.  Although  the 
three  most  common  conditions  in  which  insulin  resistance  has  been  described 
(obesity,  NIDDM,  essential  hypertension)  frequently  co-exist  within  the  same 
patient,  all  three  exist  separately  in  the  absence  of  the  other  two  in  some 
individuals. 
36 1.3  Relationship  between  serum  insulin  concentrations  and  blood  pressure 
Although  the  "insulin  hypothesis"  of  hypertension  was  generated  initially  from  a 
small  clinical  study  (Welborn  et  al  1966),  it  has  received  considerable  support 
from  cross-sectional  epidemiological  studies  reporting  correlations  between 
radioimmunoassay  measurements  of  serum  insulin  concentrations  (fasting  and 
post-load)  and  blood  pressure  in  a  variety  of  populations;  there  have  been  few 
longitudinal  studies.  In  the  presence  of  normal  glucose  concentrations,  a  high 
serum  insulin  level  may  reflect  insulin  resistance  (acting  as  a  surrogate  measure), 
but  this  relationship  breaks  down  when  ß-cell  "exhaustion"  supervenes.  For  this 
reason,  epidemiological  studies  examining  the  relationship  between  serum  insulin 
concentrations  and  blood  pressure  usually  exclude  subjects  with  frank  diabetes,  or 
stratify  for  levels  of  glucose  tolerance.  The  interpretation  of  correlations  between 
serum  insulin  concentrations  and  blood  pressure  is  generally  that 
hyperinsulinaemia  is  a  compensatory  response  to  insulin  resistance  and  that  this 
may  (or  may  not)  mediate  a  rise  in  blood  pressure. 
Modan  studied  over  2000  non-diabetic  individuals  (male  and  female)  in  an  Israeli 
population  study,  and  reported  higher  "sum"  insulin  after  a  100g  glucose  load  (60 
minute  plus  120  minute  serum  insulin  concentration)  in  hypertensive  subjects  than 
in  normotensive  subjects,  independent  of  body  mass  index  (Modan  et  al  1985).  In 
a  study  of  247  healthy,  non-obese,  normotensive  Italian  factory  workers,  higher 
blood  pressure  was  reported  in  a  hyperinsulinaemic  subgroup,  matched  with 
controls  for  age,  sex,  and  body-mass  index  (Zavaroni  et  al  1989).  In  the  Bogalusa 
Heart  Study,  conducted  in  Louisiana  in  over  3000  young  adults,  fasting  serum 
37 insulin  concentrations  were  related  to  blood  pressure  within  tertiles  of  body  mass 
index  in  all  four  age  groups  (Jiang  et  al  1993a;  Jiang  et  al  1993b).  Cross-sectional 
data  from  the  San  Antonio  Heart  Study,  a  biethnic  population  study  (Mexican 
Americans  and  non-Hispanic  whites)  of  over  2000  individuals  (male  and  female) 
in  Texas,  demonstrated  that  baseline  insulin  concentrations  were  higher  in 
hypertensive  (treated  and  untreated)  than  in  normotensive  subjects,  even  after 
adjustment  for  age,  sex,  ethnicity,  body-mass  index,  and  central  adiposity 
(Morales  et  al  1993).  Similar  results  have  been  reported  in  708  Finnish  and 
Dutch  males  in  a  recent  cross-sectional  analysis  (Feskens  et  al  1995). 
In  longitudinal  data  from  the  San  Antonio  Heart  study,  non-diabetic  subjects  who 
were  hypertensive  (and  hyperinsulinaemic)  at  baseline  had  a  higher  incidence  of 
impaired  glucose  tolerance  and  NIDDM  at  eight  year  follow-up  (Morales  et  al 
1993).  In  a  further  longitudinal  study,  subjects  with  impaired  glucose  tolerance  at 
baseline  had  an  increased  risk  of  hypertension  at  20  years  follow-up  (Salomaa  et  al 
1991). 
However,  a  relationship  between  insulin  and  blood  pressure  has  not  been 
replicated  in  all  studies.  In  a  small  clinic-based  study  (n=36),  Mbanya  reported  no 
difference  in  serum  insulin  concentrations  between  hypertensive  and  normotensive 
subjects;  although  patients  with  NIDDM  were  hyperinsulinaemic,  there  was  no 
correlation  between  blood  pressure  and  serum  insulin  concentrations  (Mbanya  et 
al  1988).  In  a  study  of  similar  design  to  that  of  Modan  et  al.  (1985)  conducted  in  a 
Californian  population,  the  significance  of  the  association  of  post-load  insulin 
with  blood  pressure  was  lost  after  stratification  for  body  mass  index  and  glucose 
38 tolerance  (Asch  et  al.  1991).  Indeed,  body  fat  distribution  is  the  major  determinant 
of  blood  pressure  in  many  population  studies  (Chiang  et  al  1969,  Weinsier  et  al 
1985).  In  a  population  study  conducted  in  Mauritius  (n=5080),  where  the 
population  comprises  three  main  ethnic  groups,  only  very  weak  associations 
between  insulin  and  blood  pressure  were  reported  after  stratification  for 
confounding  variables  including  ethnicity  (Dowse  et  al  1993).  Similar  results 
were  reported  in  a  population  of  649  individuals  (male  and  female)  in  Baltimore 
(Muller  et  al  1993).  In  a  Swedish  population,  elevated  post-load  insulin 
concentrations  in  106  untreated  hypertensives  as  compared  to  41  controls  were 
reported,  but  no  correlation  was  detected  between  blood  pressure  and  fasting 
insulin  concentrations  (Berglund  et  al  1976).  Furthermore,  in  an  additional 
longitudinal  study,  subjects  with  impaired  glucose  tolerance  and 
hyperinsulinaemia  at  baseline  did  not  have  higher  blood  pressure  than  control 
subjects  at  12  years  follow-up  (Vaccaro  et  al  1996). 
1.3.1  Insulin  assay  methodology  as  a  possible  explanation  for  discrepancies  in 
the  relationship  between  serum  insulin  concentrations  and  blood  pressure 
As  already  stated,  obesity,  or regional  adiposity,  may  be  a  significant  confounding 
variable  in  epidemiological  studies  of  the  relationship  between  insulin  and  blood 
pressure  (Caro  1991).  In  addition,  ethnicity  may  explain  some  of  the  differences 
between  studies;  for  example,  there  is  no  evidence  of  a  relationship  between 
hyperinsulinaemia  and  blood  pressure  in  the  Pima  Indians  in  the  United  States,  in 
whom  insulin  resistance  and  hyperinsulinaemia  are  common  (Saad  et  al  1991). 
39 An  alternative  hypothesis  for  discrepancies  between  studies  in  the  relationship 
between  serum  insulin  concentrations  and  blood  pressure  is  cross-reactivity  of 
conventional  insulin  assays  with  proinsulin  and  its  partially-processed  split  and 
des  amino  forms  (Figure  1.1).  The  insulin  portion  of  the  proinsulin  molecule  is 
very  similar  in  structure  to  that  of  the  free  insulin  molecule  (Frank  et  al  1972, 
Crowther  et  al  1994).  Thus,  any  antibody  which  is  able  to  differentiate  insulin 
from  proinsulin  or  split  forms  must  have  epitope  specificity  for  residues  near  the 
split  sites  (for  example  a  free  NH2-terminus  on  the  A-chain),  or  must  induce 
conformational  change. 
Circulating  insulin  derives  from  processing  of  proinsulin  in  the  pancreatic  islet  ß- 
cell  by  three  endopeptidase  enzymes:  the  prohormone  convertases  (PC  1(3)  and 
PC2),  and  carboxypeptidase  H.  Thus,  proinsulin  is  cleaved  initially  at  either  the 
32-33  site  (PC  1(3))  or  the  65-66  site  (PC2)  to  form  either  32-33  split  proinsulin  or 
65-66  split  proinsulin  respectively.  A  two-amino  acid  fragment  (31,32  or  64,65)  is 
then  cleaved  (carboxypeptidase  H)  from  the  split  forms  to  form  either  des  31,32 
split  proinsulin  (which  is  the  major  metabolite)  or  des  64,65  split  proinsulin 
respectively.  These  products  are  then  further  cleaved  by  the  other  prohormone 
convertase  to  form  insulin  and  inactive  C-peptide.  Glucose  strongly  stimulates  the 
production  of  both  proinsulin  and  PC  1(3),  but  not  PC2:  this  is  thought  to  result  in 
the  processing  of  des  31,32  to  insulin  becoming  rate-limiting  as  ambient  glucose 
concentrations  rise  (Hales  1994). 
40 Figure  1.1  The  proinsulin  processing  pathway 
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41 Radioimmunoassays  (RIAs)  currently  in  use  for  human  insulin  are  descended  from 
those  available  since  1959,  before  the  discovery  of  proinsulin  (Steiner  and  Oyer 
1967),  and  its  detection  in  the  human  circulation  (Mako  et  al  1977).  Since  use  of 
these  assays  has  mainly  been  limited  to  pathophysiological  studies  in  small 
numbers  of  subjects,  there  have  been  few  attempts  at  inter-laboratory 
standardisation.  As  conventional  radioimmunoassays  have  different  cross- 
reactivity  with  intact  proinsulin  (30-100%  on  a  molar  basis),  they  may  variably 
overestimate  true  serum  insulin  concentrations  (Heding  1977;  Robbins  et  al  1996). 
The  first  more  specific  immunoradiometric  assay  (IRMAs)  for  human  insulin  was 
developed  in  1968,  but  did  not  become  widely  available,  mainly  due  to  the 
requirement  for  relatively  large  amounts  of  immunoaffinity-purified  antibody  for 
iodination  (Miles  and  Hales  1968).  More  recently,  monoclonal  antibody  based 
sensitive  and  specific  immunoradiometric  assays  for  insulin,  intact  proinsulin,  65- 
66  split,  and  32-33  split  proinsulin  products  have  been  developed  (Sobey  et  al 
1989;  Alpha  et  al  1992). 
Use  of  these  specific  insulin  assays  has  yielded  some  unexpected  results.  Temple 
et  al  reported  that  patients  with  NIDDM  were  in  fact  insulin  deficient,  rather  than 
hyperinsulinaemic,  and  had  relative  hyperproinsulinaemia  (Temple  et  al  1988). 
Another  group  of  investigators  could  not  replicate  these  results  using  an  indirect 
RIA  method  in  which  sum  proinsulin  and  proinsulin  split-product  levels  were 
measured  (using  a  non-specific  RIA)  and  subtracted  from  total  immunoreactive 
serum  insulin  concentrations  (also  measured  using  a  non-specific  RIA);  they  found 
"true"  serum  insulin  concentrations  to  be  elevated  in  NIDDM  patients  (Reaven  et 
al  1993)  This  was  the  case  even  when  results  were  checked  in  a  sub-group  by 
42 immunoaffinity  chromatographic  extraction  and  reverse-phase  HPLC.  In  a 
subsequent  study  published  jointly  by  the  two  groups  of  investigators,  insulin, 
proinsulin,  and  32-33  split  proinsulin  were  measured  by  both  HPLC  and 
immunoradiometric  assays  in  the  same  samples  from  diet-treated  patients  with 
NIDDM  and  control  subjects  (Ostrega  et  al  1995).  The  results  demonstrated  that 
in  the  fasting  state  serum  concentrations  of  all  three  analytes  were  elevated  in  the 
patients,  independent  of  ethnicity;  at  30  minutes  after  an  oral  glucose  load  serum 
insulin  concentrations  were  lower  in  the  patients,  but  proinsulin  and  32-33  split 
proinsulin  concentrations  were  higher;  unfortunately,  samples  were  not  taken  at 
120  minutes  post-load.  Such  data  underline  the  potential  significance  of 
hyperproinsulinaemia  in  conditions  previously  assumed  to  be  associated  with 
hyperinsulinaemia. 
1.3.2  Relationship  between  specific  serum  insulin  concentrations  and  blood 
pressure 
There  are  few  published  data  using  specific  assays  to  measure  serum  insulin  and 
proinsulin  concentrations  in  essential  hypertension.  In  500  self-selected  patients 
attending  for  health  screening  in  Newcastle,  serum  insulin  concentrations  were 
measured  using  a  relatively  specific  in-house  assay  with  5.3%  molar  cross- 
reactivity  with  intact  proinsulin  and  5.0%  molar  cross-reactivity  with  32,33  split 
proinsulin  (Winocour  et  al  1991).  In  this  study,  both  fasting  and  two  hour  post- 
load  serum  insulin  concentrations  were  only  weakly  and  inconsistently  associated 
with  blood  pressure.  In  a  further  study,  365  randomly-selected  subjects  from  a 
Caucasian  population  underwent  an  oral  glucose  tolerance  test,  and  serum  insulin 
43 concentrations  were  measured  by  both  a  conventional  radioimmunoassay  (cross- 
reactivity  of  80%  with  both  proinsulin  and  split  proinsulin)  and  by  an  "insulin- 
specific"  radioimmunoassay  (Grootenhuis  et  al  1994).  In  a  multiple  regression 
analysis,  after  adjustment  for  age,  gender,  body  mass  index,  waist  hip  ratio,  and  2- 
hour  blood  glucose,  only  insulin  concentrations  as  measured  by  the  specific  assay 
were  significantly  related  to  diastolic  blood  pressure.  In  the  Phase  II  cohort  of  the 
San  Antonio  Heart  study  (Morales  et  al  1993),  serum  insulin  concentrations  were 
measured  by  both  a  specific  (cross-reactivity  with  proinsulin  0.2%)  and  a  non- 
specific  assay  (cross-reactivity  with  proinsulin  70-100%).  Serum  insulin 
concentrations  were  weakly  correlated  with  blood  pressure  in  non-diabetic 
subjects  after  adjusting  for  age,  body  mass  index,  waist-to-hip  ratio,  gender,  and 
ethnicity,  but  there  was  essentially  no  difference  in  the  relationship  attributable  to 
assay  specificity;  confidence  in  this  finding  was  diminished  somewhat  by  the 
reporting  of  higher  insulin  concentrations  with  the  specific  than  with  the 
conventional  assay  (Haffner  et  al  1994). 
In  summary,  while  it  has  been  suggested  that  insulin  assay  specificity  may 
influence  the  relationship  between  serum  insulin  concentrations  and  blood 
pressure,  the  few  published  studies  that  have  examined  this  relationship 
measuring  serum  insulin  concentrations  using  specific  insulin  assays  have 
produced  conflicting  results.  Insulin  sensitivity  was  not  measured  in  any  of  these 
studies. 
44 1.3.3  Proinsulin-like  molecules  and  cardiovascular  risk 
The  A  and  B  chains  of  intact  proinsulin  have  50%  structural  homology  with 
insulin-like  growth  factor-1  (Peavy  et  al  1985).  Proinsulin-like  molecules  form 
between  5  and  20%  of  fasting  immunoreactive  insulin  in  normal  subjects,  and 
circulate  in  disproportionate  quantities  with  respect  to  insulin  in  patients  with 
impaired  glucose  tolerance  (Davies  et  al  1992;  Krentz  et  al  1993),  but  not  obesity 
(Shiraishi  et  al  1991),  NIDDM  (Schmidli  et  al  1993),  or  polycystic  ovarian 
syndrome  (Conway  et  al  1993).  The  proportion  of  proinsulin-like  molecules 
secreted  with  respect  to  insulin  by  the  the  pancreatic  islets  can  be  reduced  by 
dietary  therapy  in  NIDDM  (Davies  et  al  1994).  Intact  proinsulin  has  only  7%  of 
the  activity  of  insulin  in  stimulating  glucose  disposal  in  humans,  but  partially- 
processed  split  and  des  amino  products  have  higher  biological  activities  and  are 
thought  to  bind  to  the  insulin  receptor  (Peavy  et  al.  1985).  Proinsulin  has  a  longer 
elimination  half-life  than  insulin  and  the  endopeptidase  converting  enzymes 
required  for  processing  to  insulin  are  not  present  outwith  the  pancreatic  islets 
(Section  1.3.1). 
Many  of  the  large-scale  studies  reviewed  above  (Section  1.3)  examining  the 
relationship  between  insulin  concentrations  and  blood  pressure  in  non-diabetic 
subjects  used  insulin  concentrations  derived  from  conventional 
radioimmunoassays  with  a  high  degree  of  cross-reactivity  with  proinsulin  and  its 
partially-processed  intermediates  (Berglund  et  al  1976,  Modan  et  al  1985,  Morales 
et  al  1993,  Jiang  et  al  1993,  Feskens  et  al  1995).  Several  lines  of  evidence 
support  the  hypothesis  that  cross-reacting  proinsulin-like  molecules  (rather  than 
45 insulin  molecules)  might  play  a  role  in  the  pathogenesis  of  insulin  resistance  and/ 
or  hypertension/  atherosclerosis.  These  include  observations  of  adverse  events 
during  the  clinical  use  of  proinsulin  (Galloway  et  al  1992),  the  association 
between  serum  concentrations  of  proinsulin-like  molecules  and  birth  weight 
(Hales  et  al  1991,  Barker  et  al  1993a,  Fall  et  al  1995)  and  the  association  between 
serum  proinsulin  and  angiographic  severity  of  coronary  atherosclerosis 
(Bavenholm  et  al  1995).  In  both  diabetic  (Nagi  et  al  1990),  and  non-diabetic 
subjects  (Haffner  et  al  1994)  there  is  epidemiological  evidence  that  proinsulin 
concentrations  are  related  to  blood  pressure.  A  potential  mechanism  for  a  causal 
relationship  between  proinsulin  and  atherosclerosis  is  provided  by  the  observation 
that  proinsulin-like  molecules  promote  in  vitro  synthesis  of  plasminogen  activator 
type-1  (PAI-1)  -a  potent  risk  factor  for  coronary  artery  disease  (Aznar  et  al  1988; 
Negri  et  al  1993)  -  in  cultured  cells  (Nordt  et  al  1994).  Clinical  studies  suggest 
that  PAI-1  activity  is  related  to  insulin  resistance  in  patients  with  NIDDM 
(Panahloo  et  al  1995),  but  not  in  larger  population-based  groups  (Mykannen  et  al 
1994). 
Such  data  raise  the  possibility  that  circulating  proinsulin-like  molecules  may  have 
biologically  significant  effects  on  either  blood  pressure  or  atherogenesis. 
However,  the  case  has  been  reported  of  an  individual  patient  with  extremely  high 
levels  of  proinsulin  and  split  proinsulin  products  (secondary  to  a  prohormone 
convertase  mutation)  with  no  evidence  of  cardiovascular  disease  (Chan  et  al  1987; 
Steiner  et  al  1990).  Further  investigation  into  the  extent  to  which  cross-reactivity 
with  proinsulin-like  molecules  affects  the  relationship  between  serum  insulin 
concentrations  and  blood  pressure  is  clearly  required. 
46 1.4  Hyperinsulinaemia  or  insulin  resistance? 
It  has  been  suggested  that  insulin  resistance  and  hypertension  may  be  directly 
linked  independent  of  hyperinsulinaemia  (Sowers  1990).  If  this  was  the  case, 
examining  the  relationship  between  serum  insulin  concentrations  and  blood 
pressure  might  be  misleading  as  serum  insulin  concentrations  (being  determined 
by  a  compensatory  response),  would  have  to  be  regarded  as  surrogate  measures  of 
insulin  resistance  (Morris  et  al  1994b;  Nilsson  et  al.  1994).  Evidence  in  favour  of 
this  hypothesis  is  provided  by  studies  showing  a  higher  degree  of  correlation 
between  insulin  sensitivity  and  blood  pressure  than  between  hyperinsulinaemia 
and  blood  pressure  in  both  non-diabetic  (Nilsson  et  al  1994;  Yokota  et  al  1995) 
and  diabetic  subjects  (Pinkney  et  al  1994). 
Systematic  investigation  of  this  hypothesis,  and  in  particular  the  impact  of 
potentially  confounding  variables  (obesity,  ethnicity)  when  insulin  resistance 
rather  than  hyperinsulinaemia  is  measured,  has  been  hampered  by  the  cumbersome 
nature  of  more  direct  means  of  measuring  insulin  sensitivity,  making  large  studies 
extremely  labour-intensive  (Section  1.5).  In  the  largest  study  to  examine  the 
association  between  insulin  resistance  (rather  than  hyperinsulinaemia)  and 
atherosclerosis,  insulin  sensitivity  was  measured  using  minimal  model  analysis  in 
a  total  of  1397  subjects  from  a  multi-ethnic  population,  along  with  intima-media 
thickness  of  the  carotid  artery  as  an  index  of  atherosclerosis  (Howard  et  al  1996). 
Insulin  resistance  and  intima-media  thickness  were  positively  associated  in  both 
Hispanic  and  non-Hispanic  whites,  and  the  association  was  independent  of  serum 
47 insulin  concentrations;  full  blood  pressure  data  from  this  population  have  not  yet 
been  reported.  In  the  largest  study  (n  =  88)  to  examine  the  relationship  between 
directly-measured  insulin  resistance  and  hypertension,  and  the  effect  of  obesity  on 
this  relationship,  the  association  between  hypertension  and  insulin  resistance 
appeared  to  be  independent  of  body  mass  index  (Maheux  et  al.  1994,  Figure  1.2). 
Thus,  evidence  to  date  suggests  that  insulin  resistance  per  se  may  be  more 
important  than  hyperinsulinaemia  in  the  pathogenesis  of  hypertension.  However, 
the  paucity  of  data  regarding  the  relationship  between  insulin  resistance  and  blood 
pressure,  taken  together  with  the  abundance  of  data  already  available  on  the 
relationship  between  serum  immunoreactive  insulin  and  blood  pressure,  indicate 
the  need  for  closer  examination  of  the  effect  of  assay  specificity  on  the 
relationships  among  serum  insulin  concentrations,  insulin  sensitivity,  and  blood 
pressure. 
1.5  Measurement  of  insulin  sensitivity 
As  discussed  above,  fasting  serum  insulin  concentrations  can  be  regarded  as 
surrogate  measurements  of  insulin  sensitivity,  and  are  dependent  on  an  intact  ß- 
cell  insulin  secretory  response.  It  may,  however,  be  desirable  to  measure  insulin 
sensitivity  more  directly: 
1)  in  order  better  to  understand  the  pathophysiology  of  disease  processes 
2)  in  order  to  distinguish  potential  insulin-sensitising  effects  of  interventions 
from  effects  on  insulin  secretion 
48 Figure  1.2  Steady  state  plasma  glucose  (an  index  of  insulin  sensitivity) 
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49 3)  in  the  evaluation  of  the  efficacy  of  novel  treatments 
There  is  no  overall  consensus  regarding  methodology,  and  a  number  of  different 
methods  are  in  current  use. 
1.5.1  The  oral  glucose  tolerance  test 
This  is  one  of  the  simplest  approaches  to  assessing  insulin  sensitivity,  and  was 
used  by  Himsworth  in  his  original  report  of  the  existence  of  insulin-sensitive  and 
insulin-insensitive  types  of  diabetes  (Himsworth  1936).  Two  oral  glucose 
tolerance  tests  (OGTT)  were  performed  on  the  same  individual,  but  an  intravenous 
insulin  injection  was  administered  at  the  beginning  of  one  of  these.  In  the  absence 
of  knowledge  of  serum  insulin  concentrations,  insulin  sensitivity  was  inferred 
from  the  ratio  of  the  areas  under  the  curve  of  glucose  concentrations.  With  the 
development  of  insulin  immunoassays  (Yalow  and  Berson  1960),  endogenous 
insulin  levels  could  be  measured  during  the  OGTT  and  insulin  resistance  could  be 
inferred  from  the  presence  of  high  serum  insulin  concentrations  in  the  presence  of 
a  normal  or  high  serum  glucose  concentrations,  without  the  requirement  for  a 
second  study  day  or  an  intravenous  injection;  this  approach  (Welborn  et  al  1966) 
has  been  used  by  many  investigators  since. 
However,  carbohydrate  metabolism  involves  a  series  of  complex  and  inter-related 
metabolic  processes  (Figure  1.3)  none  of  which  are  interrupted  in  this  procedure. 
50 Figure  1.3  Insulin-regulated  glucose  and  lipid  metabolism 
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51 When  a  patient  undergoes  an  experimental  intervention,  and  an  OGTT  is 
performed  both  before  and  after,  it  is  impossible  to  draw  conclusions  regarding 
insulin  sensitivity  from  the  changes  in  glucose  and  insulin  profiles  unless  the 
intervention  is  known  to  have  no  effects  on  insulin  secretion  and  hepatic  glucose 
production.  In  addition,  there  is  substantial  test-retest  biological  variation  (Mooy 
et  al  1996). 
1.5.2  Hyperinsulinaemic  euglycaemic  clamp 
For  the  reasons  cited  above,  more  sophisticated  methods  of  measurement  of 
insulin  sensitivity  have  been  developed.  From  first  principles,  measurement  of 
hormone  responsiveness  requires  a  stable  relationship  between  serum  hormone 
concentrations  and  a  measurable  hormone-dependent  metabolic  response;  ideally, 
the  relationship  should  be  examined  at  different  hormone  concentrations  and  a 
dose-response  curve  constructed. 
The  most  direct  method  of  measuring  insulin  sensitivity,  and  arguably  the  "gold 
standard"  (Keen  1994)  is  the  hyperinsulinaemic  euglycaemic  clamp  technique 
(Andres  et  al  1966,  DeFronzo  et  al  1979).  In  brief  (Section  2.4.1),  plasma  insulin 
is  raised  acutely  to  a  steady-state  level,  usually  lOOpU/ml  above  fasting,  and  the 
investigator  infuses  sufficient  glucose  to  maintain  euglycaemia  (usually  5.2 
mmol/1)  (see  Figure  1.4).  Steady  state  insulin  concentrations  are  usually  achieved 
within  30  minutes,  but  the  maximal  hypoglycaemic  stimulus  usually  occurs  at  60- 
120  minutes:  the  glucose  infusion  rate  requires  constant  incremental  adjustments, 
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53 on  the  basis  of  frequent  bedside  arterial  serum  glucose  measurements,  until  steady 
state  euglycaemia  is  achieved. 
Thus,  the  glucose-insulin  feedback  loop,  central  to  the  regulation  of  ambient 
glucose  concentrations,  is  disrupted  and  placed  under  the  control  of  the 
investigator.  In  most  healthy  subjects,  endogenous  secretion  of  insulin  is 
suppressed  by  about  40%  (Service  et  al  1978)  and  endogenous  (hepatic) 
production  of  glucose  (EGP)  is  suppressed  by  85-90%  (DeFronzo  et  al  1978).  At 
steady  state,  the  rate  of  glucose  uptake  by  tissues  (rate  of  disappearance)  is  equal 
to  the  rate  of  glucose  infusion.  The  calculation  of  insulin  sensitivity  (insulin- 
mediated  glucose  uptake)  reflects  the  amount  of  glucose  metabolised,  (M  value  = 
mg  of  infused  glucose  per  kg  of  body  weight  per  minute)  and  is  based  upon  the 
glucose  infusion  rate  over  the  last  60  minutes  of  the  180  minute  procedure.  If 
steady  state  serum  insulin  concentrations  vary  significantly  between  individuals,  it 
may  be  necessary  to  adjust  M  by  calculating  the  insulin  sensitivity  index  (S1p) 
(Bergman  1989)  (Section  2.4.2): 
There  are  a  number  of  additional  considerations  regarding  the  euglycaemic  clamp 
technique: 
1)  Adjustment  of  glucose  infusion  rate:  The  glucose  infusion  rate  can  be  adjusted 
either  manually  or  using  a  computerised  (Biostator)  glucose-controlled  infusion 
system  (Ponchner  et  al  1984).  It  has  been  claimed  that  with  manual  adjustment 
the  investigator  can  influence  the  glucose  infusion  rate  (Greenfield  et  al  1981),  and 
it  may  therefore  be  preferable  if  the  investigator  is  blinded  to  the  treatment  codes 
if  manual  adjustment  is  used  in  clinical  pharmacological  studies. 
54 2)  Level  of  glycaemia:  Total  glucose  uptake  can  be  sub-divided  into  insulin- 
dependent  glucose  disposal  (hormone-mediated  increase  in  fractional  extraction  of 
glucose),  and  insulin-independent  glucose  disposal  (glucose  mass  action,  or 
glucose  effectiveness).  The  effect  of  glucose  per  se  to  enhance  glucose  disposal 
can  be  demonstrated  in  studies  in  which  insulin  secretion  is  blocked  by  infusion  of 
somatostatin  during  infusion  of  exogenous  glucose  (Capaldo  et  al  1986);  insulin- 
independent  glucose  disposal  is  thought  to  account  for  about  80%  of  basal  glucose 
uptake  in  the  fasting  state  (Kahn  et  al  1994).  In  individuals  with  higher  fasting 
glucose  levels,  the  distinction  between  insulin-dependent  and  -independent 
glucose  disposal  becomes  more  important,  as  the  proportion  of  glucose  disposal 
that  is  insulin-independent  may  be  higher  (Cherrington  et  al  1978).  When 
assessing  insulin  sensitivity  there  are  two  potential  solutions:  subjects  can  either 
be  brought  to  euglycaemia  prior  to  the  start  of  the  procedure,  or  the  procedure  can 
be  performed  at  the  fasting  glucose  concentration  and  an  adjustment  made  for 
glucose  pool  size  (DeFronzo  et  al  1979,  Greenfield  et  al  1981).  The  disadvantage 
of  the  former  approach  is  that  the  process  of  normalising  blood  glucose 
concentrations  may  in  itself  affect  insulin  sensitivity  by  activating 
counterregulatory  systems,  and  this  effect  may  be  larger  for  higher  blood  glucose 
concentrations;  however,  the  latter  procedure  ("isoglycaemic  clamp")  requires  a 
mathematical  correction  if  comparisons  are  to  be  made  with  data  from 
euglycaemic  clamp  studies.  In  practice,  where  insulin  sensitivity  is  to  be 
compared  between  individuals,  and  none  have  a  fasting  glucose  concentration  of 
>  10  mmol/1,  it  seems  reasonable  to  clamp  serum  glucose  at  euglycaemia  (Section 
2.4.1).  Where  the  effect  of  an  intervention  is  to  be  assessed  in  individuals  with 
varying  fasting  glucose  levels,  an  isoglycaemic  clamp  may  be  preferable. 
55 3)  Cellular  potassium  uptake:  Infusion  of  insulin  and  glucose  in  vivo  causes  a 
dose-dependent  fall  in  plasma  potassium  by  promoting  cellular  uptake;  however, 
at  a  threshold  level,  splanchnic  potassium  exchange  switches  from  net  uptake  to 
net  release  and  clinically  significant  hypokalaemia  has  not  been  described 
(DeFronzo  et  al  1980).  It  has  been  argued  that  serum  potassium  should  also  be 
"clamped",  as  differential  effects  of  interventions  on  potassium  metabolism  may 
have  secondary  effects  on  glucose  metabolism  (Heinemann  et  al  1995). 
4)  Arterial  and  venous  sampling:  Arterial  blood  glucose  concentrations,  which 
represent  an  average  of  the  processes  occurring  in  the  various  tissues  of  the  body, 
were  used  in  the  original  description  of  the  hyperinsulinaemic  clamp  technique 
(DeFronzo  et  al  1979).  Venous  blood  glucose  data  are  more  easily  obtained  in 
man  but  depend  upon  metabolism  in  the  organ  drained;  since  there  is  a  high  tissue 
glucose  extraction  rate  during  hyperinsulinaemia  (resulting  in  a  large 
arteriovenous  glucose  gradient),  the  use  of  venous  glucose  concentrations  to  adjust 
the  glucose  infusion  rate  would  be  expected  to  lead  to  an  overestimation  of  insulin 
sensitivity.  Most  investigators  now  adjust  the  glucose  infusion  rate  on  the  basis  of 
"arterialised"  venous  blood  from  the  superficial  dorsal  veins  of  the  hand  (Liu  et  al 
1992).  The  assumption  is  that  hand-warming  (by  a  warm  blanket  or  a  heated-air 
hand  box)  increases  blood  flow  through  digital  arteries,  creating  a  functional 
arteriovenous  shunt  (Ferrannini  et  al  1987,  Yki-Jarvinen  1987).  There  is  some 
concern,  however,  that  the  heated-air  hand  box  may  itself  confound  the 
measurement  of  insulin  sensitivity.  This  is  examined  in  Chapter  4. 
5)  Endogenous  glucose  production:  Endogenous  (hepatic)  glucose  production 
(EGP)  may  not  be  completely  suppressed,  particularly  in  insulin  resistant  subjects, 
in  which  case  M  provides  an  underestimation  of  whole-body  glucose  uptake. 
56 Some  interventions  may  affect  hepatic  and  peripheral  insulin  sensitivity 
differentially;  EGP,  an  index  of  hepatic  insulin  sensitivity,  can  be  estimated  using 
radiolabelled  tracer  techniques  (Section  2.5.2). 
6)  Hypoglycaemia:  This  is  potentially  a  problem  if  the  procedure  is  not  carefully 
supervised,  and  the  investigator  must  remain  at  the  bedside  throughout  the 
procedure.  Rebound  hypoglycaemia  can  effectively  be  prevented  by  continuing 
the  glucose  infusion  for  20  minutes  after  the  insulin  infusion  is  completed. 
7)  Reproducibility:  In  the  original  report  by  DeFronzo  et  al  (1979),  euglycaemic 
clamps  were  repeated  in  only  four  individuals.  Reproducibility  data  from  the 
clamp  technique  as  performed  in  the  current  thesis  are  quoted  in  Section  2.4.2 
(Morris  et  al  1994a). 
In  summary,  the  clamp  provides  a  direct  reproducible  measurement  of  insulin 
sensitivity.  It  is  not  critically  dependent  on  insulin  assay  data  and  can  be 
combined  with  other  metabolic  techniques.  However,  it  is  labour  intensive, 
expensive,  and  requires  special  equipment. 
1.5.3  Insulin  suppression  test  (IST) 
This  method  of  assessing  insulin  sensitivity  was  developed  in  parallel  with  the 
clamp  (Shen  et  al  1970).  Endocrine  suppression  is  produced  pharmacologically 
during  a  similar  level  of  exogenous  hyperinsulinaemia  to  that  of  the  clamp,  but  the 
glucose  infusion  rate  is  not  varied  by  the  investigator  (Figure  1.5).  Thus  the 
steady  state  glucose  concentration  (SSPG)  is  used  as  an  index  of  insulin 
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58 sensitivity:  high  SSPG  indicates  low  insulin  sensitivity.  In  earlier  studies, 
adrenaline  and  propanolol  were  infused  to  inhibit  endogenous  insulin  secretion, 
but  this  method  has  now  been  superseded  by  infusion  of  somatostatin  (Harano  et 
al  1978)  or  its  commercially  available  analogue,  octreotide  (Mimura  et  al  1994). 
Use  of  octreotide  allows  the  study  of  subjects  in  whom  the  technique  was 
previously  contra-indicated.  There  are  a  number  of  theoretical  disadvantages  of 
the  insulin  suppression  test.  Like  the  euglycaemic  clamp  technique,  no  account  is 
taken  of  insulin-independent  glucose  disposal.  In  addition,  because  individuals 
reach  steady  state  at  different  glucose  levels,  SSPG  is  an  unpredictably  non-linear 
function  of  insulin-dependent  glucose  disposal,  and  there  may  be  inaccuracies  at 
extremes  of  insulin  resistance.  In  insulin  resistant  subjects,  who  have  higher 
levels  of  SSPG,  the  renal  threshold  for  glucose  will  be  exceeded,  leading  to  an 
overestimation  of  insulin  sensitivity;  conversely,  in  more  insulin  sensitive 
subjects,  glucose  levels  may  fall  into  the  hypoglycaemic  range  and  induce 
(partially-inhibited)  counter-regulatory  responses,  a  decrease  in  measured  insulin 
sensitivity,  and  even  unpleasant  symptoms.  In  addition,  the  endocrine  suppression 
agents  themselves  may,  in  theory,  induce  differential  changes  in  insulin  sensitivity 
between  subjects,  and  no  account  is  taken  of  hepatic  glucose  production. 
Despite  these  considerations,  a  high  degree  of  correlation  between  SSPG  (derived 
from  the  insulin  suppression  test)  and  M  (as  measured  by  the  euglycaemic  clamp 
technique)  has  been  reported  by  both  the  original  authors  (Greenfield  et  al  1981) 
and  an  independent  group  of  investigators  using  the  octreotide-modified  version 
(Mimura  et  al  1994).  In  addition,  the  insulin  suppression  test  appears  to  be 
59 reproducible  (Greenfield  et  at  1981),  and  has  been  used  to  examine  insulin 
resistance  in  a  wide  variety  of  physiological  and  pathophysiological  states.  It  has 
the  advantages  of  being  cheap  and  simple  to  perform  and  interpret,  and  requires 
little  special  equipment. 
1.5.4  Intravenous  glucose  tolerance  test  (IVGTT)  with  minimal  model 
analysis 
Using  complex  mathematical  modelling,  this  approach  was  developed  in  order  to 
estimate  the  relationship  between  serum  insulin  concentrations  and  insulin- 
dependent  glucose  disposal  without  the  need  to  break  the  glucose-insulin  feedback 
loop  (Bergman  et  al  1987).  The  clinical  procedure  is  simple  to  perform  (Figure 
1.6):  an  intravenous  glucose  load  (usually  0.3  mg/kg)  is  administered  and  frequent 
blood  samples  (22  over  three  hours)  are  withdrawn  for  determination  of  glucose 
and  insulin.  Data  can  be  analysed  using  commercially  available  computer 
software  (MINMOD,  Pacini  et  al  1986). 
In  the  analysis,  insulin  sensitivity  is  derived  from  a  model  which  was  found  to 
provide  the  simplest  and  most  accurate  mathematical  simulation  of  glucose 
metabolism  in  dogs.  Measured  insulin  concentrations  are  entered  into  the  model, 
which  compares  the  actual  rate  of  decline  of  glucose  concentrations  after  the 
initial  peak  with  the  predicted  concentrations  in  order  to  derive  an  estimate  for 
insulin-dependent  glucose  disposal  (Si).  A  measure  of  insulin-independent 
glucose  disposal  is  also  derived  (SG),  along  with  estimates  of  first  and  second- 
60 Figure  1.6  The  intravenous  glucose  tolerance  test 
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61 phase  insulin  secretion.  Si  was  originally  reported  to  be  highly  correlated  with  the 
insulin  sensitivity  index  as  measured  by  the  hyperinsulinaemic  euglycaemic  clamp 
(Bergman  et  al  1987).  Nevertheless,  a  number  of  improvements  to  the  model  and 
modifications  of  the  clinical  procedure  have  been  introduced  by  the  authors  since 
its  original  description.  For  example,  it  may  be  necessary  to  administer  an 
intravenous  bolus  of  tolbutamide  (300  mg)  (Yang  and  Bergman  1987),  or 
subcutaneous  insulin  0.03  U/kg  (Finegood  et  al  1990),  at  t=20  mins  in  order  to 
produce  adequate  insulinaemia  for  estimation  of  Si  in  patients  with  a  poor  second- 
phase  insulin  response.  However,  in  the  hands  of  an  independent  group  of 
investigators,  assessing  the  validity  of  the  technique  prior  to  the  large  Insulin 
Resistance  Atherosclerosis  Study  (Howard  et  al  1996),  Si  from  minimal  model 
analysis  had  only  a  reasonable  correlation  with  clamp-derived  insulin  sensitivity 
when  investigated  across  the  spectrum  of  glucose  tolerance  (r  =  0.5-0.6).  In 
addition,  there  was  a  considerable  discrepancy  in  the  absolute  values  derived  from 
the  two  techniques  (Saad  et  al  1994).  The  reproducibility  of  minimal  model 
analysis  appears  to  be  dependent  upon  the  frequency  of  blood  sampling:  in  one 
study,  use  of  only  12  as  opposed  to  22  samples  in  the  NGTT  resulted  in  an 
unacceptable  increase  in  the  intra-subject  coefficient  of  variation  of  Si  from  20% 
to  28%  (Steil  et  al  1994). 
In  effect,  the  IVGTT  with  minimal  model  analysis  replaces  more  complex 
experiments  yielding  direct  measurements  with  simple  experiments  requiring 
complicated  analysis.  It  can  be  used  more  easily  than  the  clamp  for  larger  studies 
and  has  gained  widespread  acceptance.  The  disadvantage  of  using  a  model  is  that, 
by  definition,  only  an  approximate  description  of  the  real  system  is  provided. 
62 1.5.5  Other  methods 
As  even  the  most  complex  techniques  for  the  measurement  of  insulin  sensitivity 
have  significant  disadvantages,  some  investigators  have  chosen  to  compromise  by 
deriving  alternative  indices  of  insulin  sensitivity.  There  is  a  clear  need  for  a 
generally-accepted  and  readily  calculated  index  of  insulin  sensitivity  which  can  be 
applied  to  large  populations  of  non-diabetic  subjects  and  patients  with  NIDDM 
from  easily  collected  data.  A  number  of  indices  have  been  proposed  including 
HOMA  (homeostasis  model  assessment;  Matthews  et  al  1985),  FIRI  (fasting 
insulin  resistance  index;  Duncan  et  al  1996),  fasting  insulin,  2-hour  insulin,  "sum" 
insulin,  and  AUC  insulin  (Modan  et  at  1985;  Scheen  et  at  1995).  These  variables 
have  been  validated  against  clamp-derived  measurements  of  insulin  sensitivity 
only  in  small  groups  of  subjects  and,  although  all  incorporate  serum  insulin 
concentrations,  the  effect  of  cross-reactivity  with  proinsulin-like  molecules  in  the 
insulin  assays  used  to  determine  these  concentrations  has  not  previously  been 
evaluated. 
1.6  Mechanisms  of  insulin  resistance 
Under  physiological  circumstances,  skeletal  muscle  is  the  main  site  of  insulin- 
mediated  glucose  disposal  in  man  (DeFronzo  et  al  1981b,  Yki-Jarvinen  et  al 
1983).  Physiological  insulin  resistance,  occurring  in  response  to  stress,  pregnancy 
or  puberty,  may  be  explained  by  increased  circulating  concentrations  of  counter- 
regulatory  hormones  with  insulin  antagonist  properties  (catecholamines,  cortisol, 
growth  hormone,  sex  steroids).  Mechanisms  for  resistance  to  insulin  action  in 
common  pathophysiological  states  remain  unknown.  In  essential  hypertension 
(Natali  et  al  1991;  Capaldo  et  al  1991),  NIDDM  (DeFronzo  1992),  and  obesity 
63 (Olefsky  1981)  the  main  site  of  insulin  resistance  is  skeletal  muscle  tissue,  but  in 
NIDDM  adipose  tissue  is  also  resistant  to  insulin  action  (Kasigawi  et  al  1983, 
Groop  et  al  1991).  Despite  these  similarities,  however,  it  is  worth  noting  that  the 
insulin  resistance  associated  with  each  of  these  common  disease  states  may  not 
share  a  common  mechanism. 
In  obesity,  in  the  absence  of  hypertension  or  glucose  intolerance,  insulin  resistance 
is  global  with  decreased  oxidative  and  non-oxidative  glucose  disposal  (measured 
by  indirect  calorimetry),  increased  lipid  oxidation,  impaired  suppression  of 
lipolysis  and  decreased  potassium  uptake  (Olefsky  and  Kolterman  1981; 
Bonadonna  et  al  1990).  In  NIDDM,  lipid  oxidation  and  potassium  uptake  are 
relatively  unaffected,  but  the  other  abnormalities  are  present  (Olefsky  and 
Kolterman  1981;  Groop  et  al  1991).  In  essential  hypertension,  limited  data 
suggest  that  the  defect  is  pathway-specific  i.  e.  there  is  selective  impairment  of 
non-oxidative  glucose  metabolism  (glycogen  synthesis)  (Ferranini  et  al  1987). 
Once  established,  powerful  mechanisms  exist  by  which  insulin  resistance  is 
perpetuated.  For  example,  in  obese  subjects,  an  enlarged  fat  mass  results  in 
increased  serum  concentrations  of  free  fatty  acids  (FFAs),  which  aggravate 
resistance  to  insulin  action  on  hepatic  glucose  and  lipid  metabolism  and  skeletal 
muscle  glucose  metabolism  (Section  1.1.3)  (Groop  et  al  1991).  Indeed,  it  has  been 
argued  that  the  relationship  between  insulin  resistance,  serum  insulin 
concentrations,  and  glucose  tolerance  in  apparently  healthy  subjects  is  mediated  to 
a  significant  degree  by  changes  in  ambient  serum  FFA  concentrations  (Reaven 
1988). 
64 In  the  search  for  specific  defects  in  insulin  action,  much  attention  has  been  given 
over  the  last  decade  to  the  investigation  of  events  involving  the  interaction  of 
insulin  with  its  receptor,  and  to  post-receptor  events  in  insulin  action.  However, 
in  conditions  associated  with  more  global  resistance  to  the  actions  of  insulin  such 
as  obesity  and  NIDDM,  pre-receptor  factors  may  be  important.  Selective 
impairment  of  particular  pathways  is  easier  to  reconcile  with  a  post-receptor 
mechanism. 
1.6.1  Receptor  defects  in  insulin  action 
The  insulin  receptor  is  a  tetrameric  transmembrane  protein  which  has  been  cloned 
(Ebina  et  al  1985),  and  whose  three-dimensional  structure  is  known  (Hubbard  et  al. 
1994)  (Figure  1.7).  After  binding  of  insulin  to  the  a-subunit,  autophosphorylation 
of  tyrosine  kinase  in  the  ß-subunit  initiates  further  intracellular  events.  Various 
structural  mutations  in  the  insulin  receptor  locus  leading  to  receptor  binding 
abnormalities  have  been  described  in  individual  patients  with  extreme  insulin 
resistance  (leprechaunism,  type  A  insulin  resistance,  Rabson-Mendenhall 
syndrome),  but  most  of  these  have  been  found  in  one  family  only  (Accili  et  al 
1992,  Bell  1996,  Taylor  1996).  In  addition,  receptor  down-regulation  can  develop 
as  a  consequence  of  hyperinsulinaemia:  in  obesity  there  are  fewer  insulin  receptors 
in  both  adipose  tissue  and  skeletal  muscle  (Caro  1991);  by  the  time  of 
development  of  NIDDM,  there  is  also  evidence  of  altered  receptor  expression  in 
skeletal  muscle  (Haring  and  Mehnert  1993)  and  monocytes  (Rizza  et  al  1981). 
Insulin  receptor  number  and  binding  are  normal  in  spontaneously  hypertensive  rats 
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66 (Reaven  et  al.  1989),  and  although  there  are  few  human  data  in  essential 
hypertension,  changes  in  receptor  number  and  function  are  usually  assumed  to  be 
secondary. 
1.6.2  Post-receptor  defects  in  insulin  action 
Defects  in  tyrosine  kinase  activation  by  the  activated  insulin  receptor  (Freidenberg 
et  al  1987)  have  been  reported  in  NIDDM.  Following  tyrosine  kinase  activation, 
intracellular  molecules  such  as  insulin  receptor  substrate  (IRS-  1)  and  serine- 
threonine  kinases  are  phosphorylated.  IRS-1  is  thought  to  act  as  an  adaptor 
molecule,  linking  the  receptor  kinase  to  the  various  cellular  activities  regulated  by 
insulin,  including  P13-kinase  (White  and  Kahn  1994):  no  direct  phosphorylation  of 
the  proteins  involved  in  glycogen  synthesis  or  glucose  transport  has  been 
described.  Two  genetic  polymorphisms  of  IRS-1  have  been  described  with  a 
combined  prevalence  of  12%  in  a  Danish  population;  one  of  these  may  interact 
with  obesity  in  determining  insulin  sensitivity,  as  assessed  by  the  IVGTT  (Clausen 
et  al  1995).  To  date,  none  of  the  obvious  candidate  genes  from  the  insulin 
signalling  pathway  have  pointed  to  a  major  locus  of  mutation  (Kahn  1995),  and 
this  has  led  to  a  search  for  molecules  which  may  actively  inhibit  insulin  action 
(Maddux  et  al  1995).  Membrane  glycoprotein  PC-1  may  play  a  part  in  insulin 
resistance  in  some  individuals  with  NIDDM,  but  there  are  no  data  in  essential 
hypertension. 
Further  candidates  for  defects  in  insulin  action  are  glucose  transporters,  a  family 
of  structurally  related  proteins  (classified  as  GLUT  1-5  and  7),  which  accelerate 
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mechanisms  (Klip  et  al  1994;  Gould  1994).  In  skeletal  muscle,  it  appears  that 
only  the  insulin-sensitive  facilatative  transporter  protein  GLUT-4  is  translocated  to 
the  plasma  membrane  in  response  to  the  phosphorylation  cascade  initiated  by 
insulin  (Hirshman  et  al  1990;  Livingstone  et  al  1995).  Functionally  important 
mutations  of  glucose  transporter  proteins  have  not  yet  been  described  in  man,  and 
there  is  no  consistent  decrease  in  GLUT-4  protein  levels  in  skeletal  muscle  of 
diabetic  humans  or  animals  (Pedersen  et  al  1990;  Handberg  et  al  1990),  although 
reduced  levels  of  GLUT-4  (Garvey  et  al  1988,  Bastard  et  al  1995)  and  GLUT-5 
(Bastard  et  al  1995)  have  been  reported  in  adipose  tissue  from  obese  patients  with 
NIDDM.  There  is  one  report  of  reduced  levels  of  GLUT-4  in  skeletal  muscle 
tissue  from  morbidly  obese  patients  with  NIDDM  (Dohm  et  al  1991) 
A  number  of  intrinsic  defects  in  intracellular  pathways  of  glucose  metabolism 
have  been  identified  in  NIDDM.  For  example,  glycogen  synthase  activity  in 
skeletal  muscle  has  been  shown  to  correlate  with  insulin  sensitivity  in  a  population 
of  obese  patients  with  variable  degrees  of  glucose  tolerance  (Bogardus  et  al  1984). 
However,  if  such  defects  were  primary,  it  should  be  possible  to  demonstrate  an 
accumulation  of  free  intracellular  glucose,  and  this  does  not  appear  to  be  the  case 
(Garvey  and  Birnbaum  1993). 
The  description  of  multiple  abnormalities  of  insulin  signalling,  glucose  transport, 
and  intracellular  glucose  metabolism  in  NIDDM  suggests  either  that  some  of  these 
may  be  secondary  to  hyperglycaemia,  or  that  there  is  heterogeneity  in  the 
condition. 
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In  order  to  access  its  specific  cell-surface  receptor  in  target  tissues,  insulin 
secreted  into  the  portal  vein  must  travel  through  the  vascular  space,  undergo 
transcapillary  transport,  and  diffuse  through  the  interstitial  space.  Therefore  it  has 
been  suggested  that  factors  governing  delivery  of  insulin  and  substrate  glucose  to 
insulin-sensitive  tissues  may  be  important  in  determining  overall  sensitivity  to 
insulin-mediated  glucose  uptake  (Laakso  et  al  1990a).  Studies  in  dogs  (Yang  et  al 
1989)  measuring  thoracic  duct  lymphatic  insulin  concentrations,  and  in  lean  and 
obese  volunteers  (Jansson  et  al  1993,  Castillo  et  al  1994)  measuring  interstitial 
insulin  concentrations  in  microdialysis  fluid  and  lymph  during  hyperinsulinaemia, 
suggest  that  transport  of  insulin  across  the  endothelial  barrier  is  saturable,  and  may 
be  rate-limiting  for  insulin  action.  In  addition,  there  is  evidence  that  insulin 
sensitivity  may  be  determined  in  part  by  the  ability  of  insulin  to  promote  its  own 
passage  through  the  vascular  space.  This  may  be  limited  by  structural  or  functional 
defects. 
Microvascular  changes:  Lillioja  et  al.  (1987)  demonstrated  a  correlation  between 
capillary  density  of  skeletal  muscle  and  insulin  sensitivity  as  measured  by  the 
euglycaemic  clamp  technique,  suggesting  a  role  for  microvascular  haemodynamic 
factors  in  determining  insulin-mediated  glucose  uptake  (Julius  et  al  1991).  In 
support  of  this  hypothesis,  there  is  evidence  that  individuals  with  predominantly 
type  I  (red,  aerobic,  slow  twitch,  insulin  sensitive)  skeletal  muscle  fibres  have  a 
higher  capillary  density  than  individuals  with  a  higher  proportion  of  type  IIB 
(white,  anaerobic,  fast  twitch,  insulin  resistant)  skeletal  muscle  fibres  (Juhlin- 
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fibres  by  5-10%  in  either  direction,  mainly  via  the  plasticity  of  type  IIA  fibres 
(Tonino  1989). 
Haemodynamic  effects  of  insulin:  Insulin  given  systemically  has  been  shown  to 
cause  vasodilatation  by  most  investigators  (Laakso  et  al  1990a,  Anderson  et  al 
1991,  Vollenweider  et  al  1993).  In  addition,  locally-administered  insulin  in 
pharmacological  doses  has  a  similar  effect  (Creager  et  al  1985).  However,  studies 
which  have  examined  the  direct  effects  on  vascular  tone  of  more  physiological 
local  hyperinsulinaemia  in  man  have  reported  either  weak  vasodilatation 
(Neahring  et  al  1993),  no  effect  (Yki-Jarvinen  et  al  1987,  Capaldo  et  al  1990, 
Natali  et  al  1990,  Natali  et  al  1991;  Utriainen  et  al  1995),  or  no  effect  combined 
with  an  ability  to  attenuate  the  vasoconstrictor  effects  of  sympathetic  nervous 
system  activation  (Lembo  et  al  1994)  or vasoactive  peptides  (Sakai  et  al  1993).  It 
should  be  noted,  however,  that  local  intra-arterial  administration  of  insulin  alone 
causes  relative  hypoglycaemia  in  the  relevant  vascular  bed;  co-infusion  of  D- 
glucose,  to  achieve  local  euglycaemic  hyperinsulinaemia  amplifies  the 
vasodilating  effect  of  insulin  from  20%  to  60%  (Ueda  et  al  1995).  Further  insights 
into  the  physiological  haemodynamic  effects  of  insulin  can  be  gleaned  from 
studies  conducted  in  the  post-prandial  state:  while  a  high  fat  meal  is  a  relatively 
poor  stimulant  of  both  insulin  secretion  and  calf  vasodilatation,  co-infusion  of 
insulin  produces  a  threefold  amplification  of  the  response  (Kearney  et  al  1996). 
In  support  of  these  findings,  insulin-mediated  vasodilatation  in  vitro  appears  to  be 
dependent  on  local  glucose  uptake  (Kahn  et  al  1995).  It  appears  from  these 
studies  that  insulin  may  have  not  only  systemically-mediated  but  also  locally- 
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could  result  in  a  functional  defect  in  the  ability  of  insulin  to  promote  its  own 
passage  through  the  vascular  space,  leading  to  decreased  access  of  insulin  to  its 
receptors  in  target  tissues  such  as  skeletal  muscle  and  adipose  cells. 
There  are  a  number  of  mechanisms  by  which  insulin  might  cause  physiological 
vasodilatation  or  attenuation  of  vasoconstriction: 
1)  Direct  effect  on  vascular  smooth  muscle  relaxation:  Vascular  smooth  muscle 
cells  contract  in  response  to  an  increase  in  intracellular  Ca++,  which  is  increased 
basally  in  NIDDM  and  essential  hypertension  in  a  variety  of  human  tissues  (Levy 
and  Gavin  1994).  Physiological  vasodilatation  may  occur  via  decreased 
intracellular  Ca++,  either  as  a  result  of  increased  calcium  efflux  or  decreased 
calcium  influx.  Conversely,  increased  vascular  reactivity  may occur  because  of 
decreased  basal  calcium  efflux  or  increased  basal  calcium  influx.  Activity  of 
Ca++ATPase,  the  major  cation  pump  system  responsible  for  calcium  efflux,  is 
reduced  in  erythrocytes  of  insulin  resistant  obese  Zucker  rats  (Zemel  et  al  1990), 
but  there  are  few  data  concerning  Ca++ATPase  activity  in  relevant  human  tissues 
(Levy  et  al  1994).  In  addition,  insulin  has  the  ability  to  decrease  calcium  influx  by 
stimulating  ouabain-sensitive  vascular  smooth  muscle  Na+-K+ATPase,  causing 
cellular  hyperpolarisation  and  closure  of  voltage-gated  calcium  channels  (Kahn  et 
al  1993;  Levy  and  Gavin  1994;  Tack  et  al  1996b);  this  action  of  insulin  may  also 
be  affected  by  insulin  resistance,  resulting  in  increased  vascular  reactivity. 
2)  Indirect  effect  on  vascular  smooth  muscle  relaxation  via  release  of  or  inhibition 
of  a  local  vasoactive  substance:  Insulin  might  vasodilate  by  stimulating  release  of 
endothelially-released  vasodilator  substances  (nitric  oxide,  prostacyclin),  or 
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endothelin)  (Section  1.7.3). 
3)  Indirect  effect  coupled  to  tissue  metabolic  activity:  Vasodilatation  may  occur 
via  a  mechanism  linked  to  metabolic  demand  i.  e.  increased  insulin-mediated 
cellular  glucose  uptake  may  result  in  production  of  a  signal  which  couples 
substrate  delivery  with  fuel  requirement  by  increasing  blood  flow.  If  this  is  the 
case,  decreased  insulin-mediated  vasodilatation  is  a  consequence  of  decreased 
insulin-mediated  glucose  uptake.  In  accordance  with  this  hypothesis,  it  has  been 
reported  that  insulin-mediated  vasodilatation  in  hamster  cremaster  muscle  is 
inhibited  by  adenosine  receptor  antagonism  (McKay  and  Hester  1996). 
4)  Antagonism  of  vasoconstrictors:  Insulin  may  antagonise  the  vasoconstrictor 
effects  of  the  sympathetic  nervous  system  and  circulating  vasoconstrictor 
substances  (Section  1.7.1).  It  is  possible  that  more  than  one  of  these  mechanisms 
are  important  in  producing  insulin-mediated  vasodilatation,  or  that  there  are 
interactions  between  different  mechanisms. 
Assuming  that  insulin  has  a  physiological  vasodilator  action,  it  is  conceivable  that 
impairment  of  this  response  might  result  in  increased  vascular  resistance  i.  e.  a 
potential  direct  link  between  insulin  resistance  and  hypertension,  independent  of 
hyperinsulinaemia  (Sowers  et  al  1990).  Studies  based  on  the  Fick  principle  (tissue 
glucose  uptake  as  the  product  of  blood  flow  and  arteriovenous  glucose  difference) 
conducted  using  the  leg  perfusion  technique  during  systemic  hyperinsulinaemia 
have  examined  the  relative  contributions  of  decreased  substrate  (glucose)  delivery 
and  decreased  tissue  glucose  extraction  to  insulin-sensitive  tissues  in  insulin 
resistant  states.  The  findings  of  these  studies  have  been  consistent  in  NIDDM 
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showing  that  insulin  resistance  in  these  subjects  is  closely  paralleled  by  a 
decreased  ability  of  insulin  to  stimulate  skeletal  muscle  blood  flow  (decreased 
substrate  delivery).  Furthermore,  blood  pressure  is  poitively  correlated  with  the 
ability  of  insulin  to  cause  vasodilatation  in  healthy  subjects  (Baron  et  al  1993). 
The  notion  that  attenuation  of  insulin-mediated  vasodilatation  and  decreased 
capillary  recruitment,  limiting  the  ability  of  insulin  to  promote  delivery  of  itself 
and  its  substrate  glucose  to  target  tissues,  are  important  in  the  pathophysiology  of 
insulin  resistance  has  been  termed  the  "haemodynamic  hypothesis.  "  In  support  of 
this,  sensitivity  to  insulin-mediated  venodilatation  is  highly  correlated  with 
insulin-mediated  glucose  uptake  in  healthy  individuals  (Feldman  et  al  1995). 
Extending  the  hypothesis  to  a  pathophysiological  setting,  a  paradoxical  forearm 
vasoconstrictor  effect  of  systemic  insulin  infusion  has  been  demonstrated  at 
physiological  concentrations  in  a  small  group  of  obese  hypertensive  subjects;  this 
effect  was  associated  with  a  small  rise  in  blood  pressure  (Gudbjornsdottir  et  al 
1995).  However,  these  observations  were  made  in  the  context  of  inhibition  of 
endogenous  insulin  secretion  by  somatostatin,  which  may  have  had  other  effects. 
The  haemodynamic  hypothesis  of  insulin  resistance  implies  that  in  the  presence  of 
insulin  resistance  the  proportion  of  insulin-mediated  glucose  uptake  which  is 
facilitated  under  physiological  conditions  by  insulin-mediated  vasodilatation  is 
diminished.  However,  the  relative  importance  of  the  vascular  effects  of  insulin 
(increased  delivery  of  substrate)  over  its  endocrine  effects  (increased  fractional 
extraction  of  glucose)  remains  the  subject  of  controversy.  Baron  et  al  have 
73 reported  that  intra-arterial  infusion  of  the  endothelium-dependent  vasodilator 
methacholine  into  the  leg  vascular  bed  during  hyperinsulinaemia  increases  glucose 
uptake  (Baron  et  al  1994b),  and  have  presented  calculations  demonstrating  that 
insulin-stimulated  glucose  uptake  would  be  improved  by  up  to  40%  if  the  blood 
flow  response  to  insulin  was  normal  in  obesity  (Laakso  et  al  1990a).  It  has  also 
been  reported  that  increases  in  forearm  blood  flow  per  se  mediated  by  exogenous 
bradykinin  result  in  increased  glucose  uptake  (Dietze  et  al  1996).  However,  some 
studies  in  hypertensive  patients  have  demonstrated  reduced  skeletal  muscle 
glucose  uptake  in  the  absence  of  any  difference  in  insulin-stimulated  blood  flow 
(Capaldo  et  al  1991;  Natali  et  al  1991).  In  addition,  not  all  groups  have 
demonstrated  an  increase  in  insulin-mediated  glucose  uptake  as  a  consequence  of 
increasing  muscle  blood  flow.  In  one  study,  a  100%  augmentation  of  forearm 
blood  flow  (achieved  by  infusing  adenosine)  in  insulin-resistant  patients  with 
essential  hypertension  resulted  in  no  change  in  muscle  glucose  uptake  during 
hyperinsulinaemia  (Natali  et  al  1994),  while  in  another  study  a  bradykinin-induced 
58%  increase  in  leg  blood  flow  during  hyperinsulinaemia  resulted  in  no  change  in 
femoral  muscle  glucose  uptake  (Nuutila  et  al  1996).  Furthermore,  a  study  in 
healthy  volunteers  using  positron  emission  tomography  to  measure  both  leg  blood 
flow  and  tissue  glucose  uptake  during  insulin-mediated  vasodilatation 
demonstrated  no  change  in  glucose  uptake  (Raitakari  et  al  1996).  It  has  been 
argued  that  whereas  blood  flow  appears  to  contribute  to  glucose  disposal  after  an 
oral  glucose  tolerance  test  (Baron  et  al  1990),  it  makes  little  contribution  after  a 
more  physiological  mixed  meal  (Mijares  and  Jensen  1995),  and  that  the  ability  of 
insulin  to  stimulate  leg  blood  flow  is  not  impaired  after  such  a  meal  in  NIDDM 
(Dela  et  al  1995).  It  should  be  noted  that  volunteers  are  essentially  immobilised 
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isolated  perfused  rat  hind-limb  demonstrate  that,  in  the  context  of  muscle 
contraction,  blood  flow  is  a  more  potent  determinant  of  glucose  uptake  (Hespel  et 
al  1995). 
Haemodynamic  determinants  of  blood  flow  are  an  attractive  hypothesis  for  the 
more  global  forms  of  insulin  resistance  found  in  obesity  and  NIDDM,  but  it  is 
difficult  to  reconcile  a  haemodynamic  mechanism  with  the  reported  pathway- 
specific  nature  of  insulin  resistance  in  essential  hypertension  (Ferrannini  et  al 
1987;  Natali  et  al  1991).  While  this  is  an  important  consideration,  it  should  be 
noted  that  data  on  pathway  specificity  are  based  entirely  on  the  technique  of 
indirect  calorimetry  and  have  been  extensively  studied  by  only  one  group  of 
investigators. 
1.7  Haemodynamic  influences  on  insulin  sensitivity 
From  the  above  considerations,  it  appears  that  in  some  conditions,  insulin 
sensitivity  may  be  determined,  at  least  in  part,  by  blood  flow  to  insulin-sensitive 
tissues.  While  structural  phenomena  such  as  capillary  rarefaction  and  vascular 
smooth  muscle  hypertrophy  (Folkow  1979)  might  account  for  haemodynamic 
differences  in  insulin  sensitivity  between  essential  hypertensives  and  control 
subjects,  blood  flow  to  skeletal  muscle  is  also  regulated  by  neural,  hormonal,  and 
paracrine  mechanisms.  For  example,  a  change  in  the  basal  functional  activity  of 
the  sympathetic  nervous  system  or  the  circulating  renin-angiotensin  system,  or  a 
change  in  the  basal  endothelial  release  of  locally-acting  vasoactive  substances  (for 
example  angiotensin  II,  endothelin,  or  nitric  oxide)  might  result  in  an  acute  change 
in  insulin  sensitivity.  In  addition,  functional  impairments  in  insulin-mediated 
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chronic  up-  or  down-regulation  of  any  of  these  systems  might  result  in  capillary 
rarefaction  and  microvascular  structural  changes,  potentially  leading  to  more 
stable  insulin  resistance  (Julius  et  al  1991). 
1.7.1  Sympathetic  nervous  system 
It  has  already  been  mentioned  that  acute  euglycaemic  hyperinsulinaemia 
concomitantly  stimulates  peripheral  sympathetic  efferent  outflow  and 
vasodilatation  (Anderson  et  al  1991  -  Section  1.2):  the  net  effect  in  healthy 
volunteers  is  no  change  in  blood  pressure.  However,  there  does  appears  to  be 
"cross-talk"  between  insulin  and  the  sympathetic  nervous  system:  insulin 
resistance  and  consequent  hyperinsulinaemia  may  activate  the  sympathetic 
nervous  system  (Rowe  et  al  1981);  alternatively,  activation  of  the  sympathetic 
nervous  system  (by  lower  body  negative  pressure)  may  cause  acute  insulin 
resistance  (Jamerson  et  al  1992).  Adrenaline,  and  to  a  lesser  extent  noradrenaline, 
can  reduce  insulin  sensitivity  acutely  partly  by  stimulating  hepatic 
gluconeogenesis  but  predominantly  by  blocking  peripheral  glucose  uptake  (Sacca 
et  al  1980;  Rizza  et  al  1979).  In  addition,  it  has  been  reported  that  physiological 
vasoconstrictor  effects  of  both  specific  a2-agonists  and  reflex  sympathetic 
activation  (probably  mediated  by  both  al-  and  a2-adrenoceptor  mechanisms)  in 
the  forearm  can  be  attenuated  by  intra-arterial  infusion  of  insulin  (Lembo  et  al 
1993;  Lembo  et  al  1994). 
Loss  of  insulin-mediated  attenuation  of  a-adrenergic  vasoconstriction  could 
potentially  occur  in  insulin  resistant  states,  and  result  in  both  decreased  skeletal 
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perspective  comes  from  work  by  another  group  (Scherrer  et  al  1993;  Vollenweider 
et  al  1994),  who  have  suggested  that  insulin-mediated  vasodilatation  may 
predominantly  be  a  central  effect  of  insulin  to  increase  sympathetic  outflow 
occurring  via  non-cholinergic  non-adrenergic  vasodilator  fibres  of  the  sympathetic 
nervous  system,  and  that  attenuation  of  this  mechanism,  rather  than  loss  of 
peripheral  insulin-mediated  attenuation  of  a-adrenergic  vasoconstriction,  may  lead 
to  decreased  insulin-mediated  vasodilatation  in  obese  subjects. 
Such  data  are  consistent  with  a  haemodynamic  hypothesis  of  the  physiological 
regulation  and  pathophysiological  impairment  of  insulin  sensitivity.  However, 
neither  increased  sympathetic  nervous  system  activation  (Jones  et  al  1979; 
Lindqvist  et  al  1993;  Floras  and  Hara  1993)  nor  decreased  forearm  blood  flow  are 
universal  features  of  essential  hypertension,  and  the  area  is  replete  with 
contradictory  findings.  For  example,  it  has  been  reported  that  systemic 
hyperinsulinaemia  augments  rather  than  attenuates,  noradrenaline  pressor 
responsiveness  in  healthy  volunteers  (Gans  et  al  1991)  and  obese  subjects  (Baron 
et  al  1994a).  Furthermore,  another  group  of  investigators  have  reported  a- 
adrenergic  sympathetic  effects  of  systemic  hyperinsulinaemia  in  patients  with 
NIDDM  which  become  attenuated  as  the  disease  progresses  (Tack  et  al  1996a). 
If  a  physiological  balance  exists  in  normal  subjects  between  insulin-mediated 
vasodilatation  and  sympathetic  nervous  system  mediated  vasoconstriction,  it 
would  be  predicted  that  euglycaemic  hyperinsulinaemia  in  subjects  with  spinal 
cord  injuries  would  result  in  a  depressor  response.  However,  in  such  a  study, 
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adrenaline  was  reported  in  a  small  group  of  such  subjects  compared  with  their 
healthy  siblings;  no  blood  pressure  data  were  presented,  but  the  authors  did  not 
comment  on  any  hypotensive  responses  (Karlsson  et  al  1995). 
In  summary,  data  regarding  the  interaction  between  the  sympathetic  nervous 
system  and  insulin  sensitivity  both  in  physiological  and  pathophysiological  states 
are  conflicting,  and  it  is  difficult  to  dissect  out  the  hormonal  and  haemodynamic 
effects  of  particular  interventions  on  individual  aspects  of  the  complex 
homeostatic  mechanisms  in  play.  While  most  work  has  concentrated  on  the 
vasoconstricting  effects  of  a-adrenergic  stimulation,  as  induced  experimentally  by 
lower  body  negative  pressure,  physiological  sympathetic  system  activation  is  more 
likely  to  include  concurrent  vasodilating  ß2-adrenergic  stimulation.  A 
complicating  factor  is  that  many  euglycaemic  clamp  investigations  carried  out  in 
humans  utilise  the  hand-warming  technique  for  arterialisation  of  venous  blood 
(Ferrannini  et  al  1987;  Yki-Jarvinen  et  al  1987).  This  in  itself  may  have 
independent  haemodynamic  effects  and  may  influence  sympathetic  nervous 
system  activity  (Moan  et  al  1995;  Section  1.5.2(4)  and  Chapter  4). 
1.7.2  Renin-angiotensin  system 
The  renin-angiotensin  (RAS)  system  is  a  complex  neuroendocrine  system  with 
circulating,  tissue,  and  tissue-bound  components  (Ganten  et  al  1989).  It  is 
important  in  the  physiological  regulation  of  blood  pressure  in  response  to  changes 
in  dietary  sodium.  The  main  effector  hormone  angiotensin  II  (ANGII),  formed 
from  angiotensin  I  by  angiotensin  converting  enzyme  (ACE)  has  diverse  effects  in 
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promotes  sodium  re-absorption  in  the  proximal  renal  tubule  in  patients  with 
insulin  resistant  states  (Rowe  et  al  1981),  so  that  insulin  resistant  patients  have  a 
high  total  body  sodium  (O'Hare  et  al  1985).  Failure  of  suppression  of  the  RAS  in 
response  to  this  insulin-mediated  sodium  retention  is  a  potential  mechanism  by 
which  sodium  accumulates  in  diabetes  (Weidmann  et  al  1993). 
Interest  in  the  interactions  between  the  RAS  and  insulin-mediated  glucose  uptake 
originated  from  reports  of  effects  of  ACE  inhibitors  on  glucose  metabolism  (see 
Section  1.1.6)  and  evidence  of  enhancement  by  insulin  of  ANGII-mediated 
aldosterone  release  (Rocchini  et  al  1990).  There  are  few  data  on  the  effects  of 
individual  components  of  the  RAS  on  glucose  transport,  but  it  is  often  assumed 
that  ANGH,  like  other  counter-regulatory  hormones,  down-regulates  pathways  of 
insulin-mediated  glucose  metabolism:  it  has  been  shown  to  have  gluconeogenic 
and  glycogenolytic  properties  (DeWitt  and  Putney  1983;  Kneer  and  Lardy  1983), 
and  may  enhance  release  of  norepinephrine,  an  insulin  antagonist,  from 
sympathetic  nerves  (Taddei  et  al  1995). 
Although  most  available  data  suggest  that  ACE  inhibitors  have  very  little  effect  on 
insulin  sensitivity  (Section  1.1.6),  some  investigators  have  reported  decreases  in 
fasting  glucose  or  increases  in  insulin  action.  This  has  led  to  speculation 
regarding  whether  such  effects  are  either  hormonal  or  haemodynamic,  and  whether 
they  are  mediated  by  angiotensin  II  withdrawal  or  bradykinin  potentiation  (Jauch 
et  al  1987,  Dietze  et  al  1996).  Previous  studies  have  examined  whether  any 
insulin-sensitising  effect  of  ACE  inhibitors  is  likely  to  be  due  to  angiotensin  II 
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volunteers  during  euglycaemic  clamp  studies  (Morris  et  al  1993;  Widgren  et  al 
1993;  Riser  et  al  1993;  Buchanan  et  al  1993).  Data  from  these  studies  indicate 
that  angiotensin  II  increases  insulin  sensitivity  when  given  in  pressor  doses,  and 
has  a  small  insulin-sensitising  effect  (detected  only  in  larger  studies)  when  given 
in  weakly  pressor  doses. 
The  mechanism  for  such  unexpected  insulin-sensitising  effects  of  ANGII  has  been 
elucidated  in  studies  in  which  leg  blood  flow  was  measured  during  systemic 
ANGII  infusions:  at  high  doses  of  this  potent  vasoconstrictor  hormone,  blood  flow 
to  the  leg  vascular  bed  actually  increased  as  a  result  of  redistribution  from  the 
renal  vascular  bed  (Buchanan  et  al  1993).  Thus  the  effect  of  angiotensin  II  on 
insulin  sensitivity  was  accounted  for  by  a  haemodynamic  rather  than  hormonal 
mechanism.  In  a  similar  study  in  patients  with  NIDDM,  using  subpressor  and 
weakly  pressor  doses  of  angiotensin  II  (calculated  to  have  no  effect  on  renal  blood 
flow),  a  similar  increase  in  insulin  sensitivity  was  observed  (Morris  et  al  1994c). 
Since  this  effect  was  larger  at  the  lower  dose,  was  not  associated  with  an  increase 
in  blood  pressure,  and  was  not  associated  with  a  change  in  insulin-mediated 
disposal  of  other  substrates  (potassium,  triglycerides),  it  was  postulated  that  there 
may  be  an  additional  non-haemodynamic  effect  of  angiotensin  II  on  insulin- 
mediated  glucose  disposal.  One  potential  candidate  mechanism  for  such  an  effect 
is ANGII-mediated  activation  of  protein  kinase  C  via  receptor-linked  formation  of 
diacylglycerol  (Smrcka  et  al  1991,  Considine  and  Caro  1993).  Alternatively, 
there  is  recent  evidence  that  ANGII  inhibits  insulin-stimulated  PI  3-kinase  activity, 
and  it  is  reasonable  to  speculate  that  this  may  in  turn  inhibit  insulin-stimulated 
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al  1996). 
These  observations  were  derived  from  acute  experiments  and  are  difficult  to 
reconcile  with  the  reported  effect  of  ACE  inhibition  on  insulin  sensitivity,  unless 
such  effects  are  mediated  by  potentiation  of  bradykinin  (Dietze  et  al  1996). 
Studies  examining  the  effect  of  longer-term  activation  of  the  renin-angiotensin 
system  (by  dietary  salt  depletion)  on  glucose  metabolism  have  been  limited  to 
healthy  volunteers,  and  the  findings  have  been  conflicting  (Section  6.4).  All  three 
of  these  studies  were  open  in  design,  and  all  compared  a  diet  higher  in  sodium 
than  would  be  achieved  in  most  populations  with  a  diet  lower  in  sodium  than  is 
easily  achievable  outwith  a  clinical  research  environment. 
As  far  as  can  be  ascertained,  the  effect  of  dietary  salt  depletion  on  insulin 
sensitivity  has  not  previously  been  investigated  in  patients  with  NIDDM. 
1.7.3  Endothelial  release  of  nitric  oxide  and  other  paracrine  substances 
Endothelial  cells  form  a  monolayer  lining  the  luminal  surface  of  all  blood  vessels. 
Over  the  last  fifteen  years,  the  importance  of  the  vascular  endothelium  in  the 
regulation  of  peripheral  vascular  tone  has  been  recognised  (Furchgott  and 
Zawadzki  1980),  in  addition  to  its  important  effects  on  the  regulation  of 
haemostasis,  the  control  of  cell  growth,  and  the  transport  of  plasma  molecules 
(Henderson  1996).  Endothelial  cells  synthesise  and  secrete  vasodilator 
(endothelium-derived  relaxing  factor,  endothelium-derived  hyperpolarising  factor, 
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substances  (Boulanger  and  Vanhoutte  1994).  It  is  now  clear  that  endothelium- 
derived  relaxing  factor  (EDRF)  is  the  inorganic  gas  nitric  oxide  (NO)  (Palmer  et  al 
1987)  which  has  multiple  effects  in  co-ordinating  and  regulating  the 
cardiovascular  system.  In  particular,  NO  causes  relaxation  of  vascular  smooth 
muscle  by  activating  guanylate  cyclase.  It  is  synthesised  from  the  amino  acid  L- 
arginine  by  three  isoforms  of  NO  synthase:  endothelial  (eNOS),  neuronal  (nNOS), 
and  inducible  (iNOS):  eNOS  is  constitutive  in  nature,  but  can  be  activated  by  5- 
hydroxytryptamine,  substance  P,  or  bradykinin. 
Endothelial  damage  may  be  an  early  step  in  the  pathogenesis  of  atherosclerosis 
(Ross  1993)  and  it  is  has  been  proposed  that  asymptomatic  endothelial  dysfunction 
may  be  an  early  marker  for  this  condition  (Henderson  1996).  One  mechanism  by 
which  endothelial  damage  may  occur  is  local  generation  of  superoxide  anions, 
either  by  endothelial  cells  or  by  monocytes  attached  to  the  endothelium  (Chin  et  al 
1992,  Keaney  1993).  Although  the  precise  mechanism  by  which  superoxide 
anions  are  generated  is  unknown,  it  may  relate  to  dyslipidaemia,  particularly  high 
concentrations  of  VLDL,  low  concentrations  of  HDL  (see  Section  1.1.3),  and  high 
concentrations  of  small,  dense  LDL  or  oxidised  LDL  (Witzum  1993).  The 
presence  of  superoxides  causes  enhanced  destruction  of  nitric  oxide,  limiting  the 
availability  of  NO  to  promote  vasodilation. 
Although  it  may  be  an  oversimplification  to  envisage  a  global  syndrome  of 
endothelial  dysfunction,  there  have  been  two  main  approaches  towards  quantifying 
endothelial  function  in  vivo  for  prospective  studies.  The  first  of  these  is 
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von  Willebrand  factor  (Stehouwer  et  al  1991),  thrombomodulin  (van  den  Berg 
1995,  Blann  et  al  1996),  and  tPA  (Jensen  et  al  1989).  This  is  a  simple  approach 
and  can  be  easily  applied  to  large  groups  of  subjects;  however,  many  of  the 
markers  are  not  specific  to  endothelial  cells.  The  second  approach  is  to  use 
dynamic  tests,  which  are  more  sophisticated  and  labour-intensive.  Venous 
occlusion  plethysmography  (Section  2.7)  is  used  to  measure  forearm  blood  flow 
(which  is  mainly  determined  by  small  skeletal  muscle  resistance  vessels)  in 
response  to  endothelium-dependent  and  -independent  vasodilators  and 
vasoconstrictors.  Endothelial  muscarinic  receptors  (Panza  et  al  1990),  or 
bradykinin  receptors  (Kelm  et  al  1996),  can  be  stimulated  to  cause  NO  release  by 
infusing  acetylcholine  or  bradykinin  locally  into  the  brachial  artery;  while  the 
blood  flow  response  is  measured  distally.  Sodium  nitroprusside,  which  is  an 
endothelium-independent  donor  of  NO,  can  be  used  as  an  experimental  control  for 
sensitivity  of  adjacent  vascular  smooth  muscle  to  NO,  emulating  in  vivo  the 
above-mentioned  experiments  of  Furchgott  in  the  organ  bath  (Furchgott  and 
Zawadzki  1980).  An  alternative,  less  invasive,  test  of  endothelial  function, 
involving  measurement  of  flow-mediated  vasodilatation,  has  been  described  using 
high  resolution  doppler  ultrasound  with  wall-tracking  following  release  of  a  wrist 
cuff  inflated  to  suprasystolic  pressures  (Celermajer  et  al  1992,  Celermajer  et  al 
1993). 
Inhibition  of  endothelial  nitric  oxide  synthase  (eNOS)  in  the  forearm  using  local 
infusion  of  its  stereospecific  substrate  inhibitor  No-monomethyl-L-Arginine  (L- 
NMMA)  results  in  a  30-40%  decrease  in  blood  flow  (Valiance  et  al  1989).  This 
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forearm  blood  flow,  and  provides  the  basis  for  an  alternative  dynamic  test  of 
endothelial  function.  The  vasoconstrictor  response  to  L-NMMA  is  an  index  of 
basal  endothelial  nitric  oxide  production,  i.  e.  the  proportion  of  resting  vasodilator 
tone  which  can  be  attributed  to  NO  production  (Calver  et  al  1992).  In  this 
situation,  vasoconstrictor  responses  to  noradrenaline,  or  another  endothelium- 
independent  vasoconstrictor,  may  be  used  as  an  experimental  control. 
Decreased  basal  endothelial  nitric  oxide  synthesis  has  been  reported  using  this 
technique  in  essential  hypertension  (Calver  et  al  1992),  although  responses  to 
endothelium-dependent  agonists  vary  between  studies  (Panza  et  al  1990; 
Cockcroft  et  al  1994).  In  addition,  impaired  endothelium-dependent 
vasodilatation  has  been  demonstrated  in  normotensive  subjects  with  a  family 
history  of  essential  hypertension  (Taddei  et  al  1992).  Other  conditions 
characterised  by  impairment  of  agonist-stimulated  or  basal  endothelial  function 
include  hypercholesterolaemia  (Creager  et  al  1990;  Chowienczyk  et  al  1992), 
atherosclerosis  (Chester  et  al  1990,  Egashira  et  al  1993,  Anderson  et  al  1995), 
NIDDM  (McVeigh  et  al  1992),  obesity  (Steinberg  et  al  1996)  and  cigarette 
smoking  (Jacobs  et  al  1993;  Kiowski  et  al  1994).  It  is  striking  that  many  of  these 
conditions  are  also  characterised  by  impairment  of  insulin-mediated  glucose 
uptake  (Section  1). 
Like  insulin  sensitivity,  endothelial  function  is  modifiable  by  non-pharmacological 
and  pharmacological  interventions.  Exercise  (Hornig  et  al  1996)  and  lipid- 
lowering  treatment  (Leung  et  al  1993;  Treasure  et  at  1995)  can  improve 
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with  endothelium-dependent  vasodilators  intra-arterially  (Creager  et  al  1992; 
Imaizumi  et  al  1992)  or  orally  (Clarkson  et  al  1996)  is  reported  to  normalise 
endothelial  function  in  hypercholesterolaemic  subjects.  Both  ACE-inhibitors  and 
calcium  antagonists  may  improve  endothelial  function  in  hypertensive  subjects 
(Lyons  et  al  1994),  but  there  are  also  negative  studies  (Kiowski  et  al  1993). 
The  antioxidant  vitamin  E  has  been  shown  to  prevent  the  onset  of  defective 
endothelium-dependent  relaxation  in  streptozotocin  diabetic  rat  aorta  (Keegan  et 
al  1995),  and  vitamin  C  improves  endothelial  function  in  patients  with  NIDDM 
(Ting  et  al  1996).  The  beneficial  effect  of  the  antioxidant  lipid-lowering  agent 
probucol  on  coronary  endothelium-dependent  relaxation  in  man  was  greater  than 
that  produced  by  a  similar  degree  of  lipid  lowering  therapy  using  another  agent 
(Anderson  et  al  1995).  There  is  some  evidence  that  positive  effects  on  endothelial 
function  may  translate  into  actual  outcome  benefits:  in  the  Cambridge  Heart 
Antioxidant  Study  study,  pharmacological  doses  of  vitamin  E  were  associated 
with  decreased  coronary  events  compared  with  placebo  when  administered  to 
patients  following  myocardial  infarction  (Stephens  et  al  1996). 
Most  of  the  agents  above  which  alter  endothelial  function  are  reported  to  produce 
similar  effects  on  insulin  sensitivity.  One  of  the  few  agents  which  appears  to 
produce  a  dissociated  effect  is  fish  oil,  which  has  a  neutral  or  adverse  effect  on 
insulin  sensitivity  (Section  1.1.6),  and  a  beneficial  effect  on  endothelial  function 
(Chin  and  Dart  1994). 
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insulin  resistance  are  observed,  and  the  improvements  produced  in  both 
abnormalities  by  similar  interventions,  raise  the  hypothesis  that  they  are 
physiologically  linked.  It  has  recently  been  demonstrated  in  experiments  co- 
infusing  insulin  and  L-NMMA  in  human  skeletal  muscle  vascular  beds,  that 
insulin-mediated  vasodilatation  is  dependent  on  endothelial  nitric  oxide 
synthesis/release  (Scherrer  et  al  1994;  Steinberg  et  al  1994).  This  is  corroborated 
by  in  vitro  data  demonstrating  inhibition  of  insulin-mediated  vasodilatation  in  rat 
cremaster  muscle  by  L  -NMMA  (Chen  and  Messina  1996).  Thus,  endothelial 
dysfunction  may  cause  insulin  resistance  either  indirectly,  or  by  attenuating 
insulin-mediated  endothelium-dependent  vasodilatation.  Alternatively,  decreased 
insulin  sensitivity  may  cause  decreased  basal  production  of  eNOS, 
perhaps  by  limiting  availability  of  L-arginine  substrate  or  one  of  the  other 
cofactors  required  for  NO  synthesis.  A  third  possibility  is  that  decreased  basal 
endothelial  nitric  oxide  production  and  impaired  insulin  sensitivity  are 
manifestations  of  a  common  genetic  or  environmental  antecedent,  such  as 
impaired  vascular  development.  As  far  as  can  be  ascertained,  endothelial  function 
has  not  previously  been  measured  in  a  group  of  subjects  characterised  for  insulin 
sensitivity  using  the  euglycaemic  clamp  technique. 
86 1.8  Aims  of  thesis 
To  assess: 
1)  the  effect  of  insulin  assay  specificity  on  the  relationships  among  serum  insulin 
concentrations,  insulin  sensitivity,  and  blood  pressure  in  diabetic  and  non-diabetic 
subjects  with  and  without  essential  hypertension. 
2)  the  effect  of  sustained  physiological  activation  of  the  renin-angiotensin  system 
induced  by  moderate  dietary  sodium  restriction  on  insulin  sensitivity  in  patients 
with  NIDDM. 
3)  To  assess  the  relationship  between  endothelial  function  and  insulin  sensitivity 
in  healthy  subjects. 
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Methods 
2.0  Summary 
In  this  chapter,  the  general  protocols  for  the  clinical  techniques  used  in  the  studies 
presented  in  the  thesis  are  described. 
2.1  Patients  and  healthy  volunteers 
All  the  clinical  assessments  were  performed  in  the  Clinical  Investigation  and 
Research  Unit  (CIRU),  Department  of  Medicine  and  Therapeutics,  Western 
Infirmary. 
Non-diabetic  hypertensive  patients  were  recruited  from  patients  attending  either 
the  Glasgow  Blood  Pressure  Clinic  or  the  Cardiovascular  Risk  Factor  Clinic  at 
the  Western  Infirmary,  while  subjects  with  NIDDM  were  identified  from  patients 
attending  the  Diabetes  Clinics  at  Gartnavel  General  Hospital.  Non-diabetic 
normotensive  control  subjects  and  healthy  volunteers  were  recruited  by 
advertisement  (medical  and  nursing  students  were  excluded).  A  total  of  113 
healthy  volunteers  and  patients  with  essential  hypertension  and/or  NIDDM 
completed  the  protocols,  all  of  which  were  individually  approved  by  the  Ethics 
Committee  of  the  West  Glasgow  Hospitals  University  NHS  Trust. 
Hypertensive  subjects  were  either  newly  diagnosed  and  previously  untreated,  or 
patients  in  whom  current  antihypertensive  therapy  was  ineffective  or  poorly 
88 tolerated.  Previously-treated  patients  discontinued  their  medication  and  were 
assessed  for  recruitment  against  the  predefined  entry  criteria  after  a  treatment-free 
period  of  at  least  four  weeks. 
NIDDM  was  defined  according  to  WHO  criteria  (World  Health  Organisation 
1980).  Newly-diagnosed  patients  were  stabilised  on  diet  for  two  months  prior  to 
study  entry,  and  patients  with  retinopathy  (by  direct  fundoscopy), 
microalbuminuria,  and  those  whom  had  been  previously  treated  with  insulin  or 
oral  hypoglycaemic  agents  were  excluded. 
Healthy  volunteers  who  were  taking  any  form  of  medication  were  excluded. 
Patients  whom  had  been  treated  with  thiazide  diuretics  in  the  previous  six  months 
were  excluded,  as  were  patients  with:  secondary  forms  of  hypertension,  co- 
existing  disease  requiring  regular  medication,  a  raised  serum  creatinine,  a  history 
of  myocardial  infarction,  angina  pectoris,  intermittent  claudication  or  stroke,  or 
alcohol  intake  >  20  units  weekly. 
All  subjects  participating  in  these  studies  underwent  an  oral  glucose  tolerance  test 
in  order  to  screen  for  impaired  glucose  tolerance  or  confirm  the  previous 
diagnosis  of  diabetes. 
2.2  General  clinical  protocol 
Before  study  entry,  all  patients  and  volunteers  underwent  a  health  questionnaire 
and  full  clinical  screening  including  physical  examination,  routine  biochemistry, 
89 haematology,  dip-stick  urinalysis,  and  an  electrocardiogram  as  a  screening  test  for 
significant  cardiovascular  disease  or  end-organ  damage. 
After  informed  consent  was  obtained,  each  individual  was  asked  to  refrain  from 
any  strenuous  exercise  for  the  duration  of  the  study  and  to  maintain  his  or  her 
usual  diet.  Patients  with  NIDDM  were  instructed  to  adhere  to  an  isocaloric  diet 
throughout  the  study  consisting  of  approximately  55%  carbohydrate,  25%  fat,  and 
20%  protein. 
On  each  day  on  which  a  clinical  assessment  was  to  be  performed,  subject  were 
transported  by  taxi  to  the  CIRU  at  0800hrs  after  an  overnight  fast  from  2200hrs. 
All  subjects  were  asked  to  avoid  alcohol  and  caffeine  in  the  24  hours  prior  to  an 
assessment;  in  those  studies  in  which  smokers  were  not  excluded,  subjects  were 
asked  to  refrain  from  smoking  for  24  hours  prior  to  attendance.  A  light  meal  was 
provided  at  the  end  of  each  assessment  prior  to  taxi  transport  home. 
2.3  Clinical  and  morphometric  measurements 
2.3.1  Body  mass  index 
Body  weight  and  height  were  measured  with  subjects  in  light  clothes  and  without 
shoes  to  the  nearest  0.5  kg  of  weight  and  to  the  nearest  0.5  cm  of  height.  The 
same  equipment  was  used  throughout  the  study,  and  the  calibration  of  the 
weighing  scales  (Seca,  Germany)  was  checked  regularly.  Body  mass  index  (BMI, 
kg/m2)  was  calculated  as: 
90 BMI  = 
2.3.2  Waist-to-hip-ratio 
Body  weight  (kg) 
(height  (m))2 
Waist  circumference  (midway  between  the  lowest  rib  margin  and  the  iliac  crest  at 
the  end  of  gentle  expiration),  and  hip  circumference  (at  the  widest  level  of  the 
greater  trochanters),  were  measured  to  the  nearest  0.5  cm  while  the  subject  was 
standing. 
2.3.3  Blood  pressure  and  heart  rate 
During  all  the  clinical  studies  the  technique  of  blood  pressure  and  heart  rate 
measurement  was  uniform.  Systolic  and  diastolic  blood  pressure,  and  heart  rate 
were  measured  after  10  minutes  supine  rest  by  an  oscillometric  technique  using  a 
Dinamap  Critikon  (Johnson  and  Johnson  Professional  Products  Ltd.,  U.  K.  )  semi- 
automatic  sphygmomanometer,  maintained  and  calibrated  at  regular  intervals  by 
the  Department  of  Clinical  Physics,  Western  Infirmary.  Small  (22cm  x  10  cm), 
medium  (31cm  x  12  cm),  and  large  (39cm  x  16  cm)  blood  pressure  cuffs  were 
available  at  all  times  in  order  to  comply  with  the  recommendations  of  the  British 
Hypertension  Society  (Petrie  et  al  1986).  Hypertension  was  defined  as  a  mean 
supine  diastolic  BP  of  >_  95  mmHg,  or  systolic  BP  >_  160  mmHg,  on  three 
readings  after  10  minutes  supine  rest  (Sever  et  al  1993). 
91 2.3.4  Oral  glucose  tolerance  test 
Subjects  attended  the  CIRU  according  to  the  usual  protocol  (Section  2.2).  An 
intravenous  cannula  (Venflon,  Helsinborg,  Sweden)  with  a  three-way  tap  was 
placed  in  an  antecubital  vein.  After  20  minutes  of  semi-recumbent  rest,  a  blood 
sample  was  withdrawn  from  the  cannula.  Subjects  ingested  75  grams  of 
powdered  glucose  dissolved  in  100mis  of  water  orally  at  0  minutes,  and  further 
blood  samples  were  withdrawn  at  30,60,90,  and  120  minutes  for  later  analysis  of 
plasma  glucose  and  serum  insulin  concentrations. 
2.4  Hyperinsulinaemic  clamp  technique 
Insulin  sensitivity  was  assessed  using  a  modification  (180  rather  than  120 
minutes)  of  the  hyperinsulinaemic  clamp  described  by  DeFronzo  et  al  (1979). 
2.4.1  General  clinical  procedure 
Subjects  attended  the  CIRU  according  to  the  usual  protocol  (Section  2.2).  Two 
18  gauge  intravenous  cannulae  were  inserted:  the  first  retrogradely  into  the  right 
dorsal  hand  vein  for  blood  sampling,  and  the  second  antegradely  into  the  left 
antecubital  fossa  for  administration  of  infusions.  Three-way  taps  enabled  easy 
sampling  and  simultaneous  infusion  of  insulin  and  dextrose. 
The  infusion  of  soluble  human  insulin  (Actrapid,  NovoNordisk  A/S,  DK2880 
Bagsvaerd,  Denmark)  was  prepared  in  45m1s  (10%  vol/vol)  of  each  patient's  own 
92 blood  in  order  to  minimise  adsorption  of  insulin  to  the  plastic  surfaces  of  syringes 
and  infusion  lines.  It  was  administered  using  a  Braun  Perfusor  pump  as  a  primed, 
constant  rate  infusion  for  180  minutes,  with  the  aim  of  achieving  a  steady-state 
serum  insulin  concentration  approximately  120µU/ml  above  the  basal  fasting 
level.  The  priming  regime  was  as  follows: 
0-4  minutes  4.5  mU/kg/min 
4-7  minutes  3.0  mU/kg/min 
7-180  minutes  1.5  mU/kg/min 
20  minutes  of  supine  rest  were  allowed  after  placement  of  cannulae.  Blood 
pressure  and  heart  rate  were  measured  (Section  2.3.3)  and  baseline  blood  samples 
withdrawn  before  insulin  infusion  commenced  at  time(t)  =0  mins.  A  variable 
rate  infusion  of  20%  dextrose  (Baxter  Healthcare,  Norfolk,  U.  K.  )  was 
administered  via  an  IMED  infusion  system  (IMED,  Abingdon,  UK)  from  t=  2- 
180  mins  (Figure  1.4).  Serum  glucose  concentrations  were  maintained  at 
euglycaemia  (target  serum  glucose  5.2  mmol/1)  in  studies  comparing  insulin 
sensitivity  between  groups  of  subjects  with  heterogeneous  fasting  glucose  levels 
(i.  e.  patients  with  NIDDM  and  non-diabetics)  (Chapter  5)  and  in  studies  within 
groups  of  subjects  of  normal  glucose  tolerance  (Chapters  4  and  7).  For  the 
euglycaemic  clamps  in  patients  with  NIDDM,  serum  glucose  concentrations  were 
gradually  normalised  with  an  infusion  of  soluble  insulin  (2  U/hr)  prior  to 
commencing  the  procedure.  In  studies  assessing  the  effect  of  an  intervention  on 
insulin  sensitivity  in  patients  with  NIDDM  (Chapter  6),  serum  glucose 
concentrations  were  maintained  at  isoglycaemia  [target  serum  glucose  =  fasting 
93 glucose  (Greenfield  et  al  1981;  Saad  et  al  1994)]  in  order  to  avoid  the  potentially 
confounding  effect  of  inter-individual  variations  in  fasting  serum  glucose 
concentrations  (Section  1.5.4).  The  infusion  rate  was  adjusted  for  body  weight 
for  each  individual  and  expressed  as  mg  glucose/kg  body  weight/minute 
(mg/kg/min).  For  example,  the  infusion  rate  of  20%  dextrose  equal  to 
1mg/kg/min  for  a  70  kg  individual  would  be  calculated  as: 
60  minutes  x  70  kg  =  21  ml/hour 
200g  glucose 
At  5  minute  intervals,  2  ml  blood  samples  were  withdrawn  from  the  cannulated 
dorsal  hand  vein.  Cannula  patency  was  maintained  using  a  slow  infusion  of  0.9% 
saline;  a  total  of  approximately  100  ml  was  administered  during  each 
procedure.  After  centrifugation  at  the  bedside,  the  serum  glucose  concentration 
was  determined  (Section  2.8.2),  and  the  dextrose  infusion  rate  was  manually 
adjusted  to  maintain  target  serum  glucose  concentration.  The  dorsal  hand  vein 
was  surrounded  by  a  heated  box  (55'C)  with  the  aim  of  arterialising  venous  blood 
(Section  2.6  and  Chapter  4). 
2.4.2  Calculation  of  insulin  sensitivity  from  the  euglycaemic 
hyperinsulinaemic  clamp 
During  hyperinsulinaemia  with  steady-state  plasma  glucose  concentrations 
(usually  during  the  last  40-60  minutes  of  the  procedure),  the  rate  of  glucose 
infusion  is  equal  to  that  of  glucose  removal  from  the  glucose  space  (i.  e.  glucose 
metabolised,  M).  Assuming  suppression  of  endogenous  glucose  production,  the 
94 M-value  is  an  estimate  of  total  body  glucose  metabolism,  and  reflects  the  ability 
of  insulin  to  enhance  tissue  glucose  disposal  (Section  2.5). 
In  practice,  the  glucose  infusion  rate  must  be  modified  by  two  factors  before  it  can 
be  equated  with  M: 
M=I-  UC+SC 
where:  I=  glucose  infusion  rate  (mg/kg/min) 
UC  =  correction  for  urinary  glucose  loss 
(usually  negligible  during  a  euglycaemic 
clamp) 
SC  =  "space  correction"  (mg/kg/min) 
(for  inevitable  deviations  from  euglycaemia) 
The  space  correction  is  calculated  as  follows  (DeFronzo  et  al  1979): 
SC  =  (5.2  -G)  x  17.86  x  0.095 
where:  G=  ambient  glucose  concentration  over  last  40 
minutes  of  clamp  (mmoIl) 
17.86  =  unit  conversion  factor  (mmol/l  to  mg/dl) 
0.095  =  glucose  space  constant 
When  the  achieved  ambient  glucose  concentration  at  steady  state  is  less  than  the 
desired  value  of  5.2  mmol/1  (too  little  glucose  has  been  infused)  the  space 
correction  will  be  positive:  M  will  therefore  be  greater  than  I;  the  converse  also 
applies. 
95 In  some  groups  of  subjects,  particularly  those  who  are  obese,  use  of  a  weight- 
adjusted  insulin  infusion  protocol  may  result  in  higher  steady-state  serum  insulin 
concentrations,  and  in  this  situation,  the  M-value  underestimates  the  degree  of 
insulin  resistance.  The  insulin  sensitivity  index  (Sip  x  104  dl/(min.  kg)  per  mU/1)  is 
therefore  calculated  from  the  glucose  infusion  rate  and  ambient  insulin  and 
glucose  concentrations  at  steady  state  (Bergman  et  al  1987): 
SIP  =  iRd  /  (Al  x  G) 
where:  ORd  =  increment  in  glucose  uptake  (basal  to 
steady  state) 
AI  =  increment  in  insulin  concentration 
(basal  to  steady  state) 
G=  steady  state  glucose  concentration 
The  reproducibility  of  M  has  previously  been  evaluated  in  the  Clinical 
Investigation  and  Research  Unit:  between-day  intra-subject  coefficient  of 
variation  is  6%  in  healthy  subjects  (Morris  et  al  1994a). 
2.5  Measurement  of  endogenous  (hepatic)  glucose  production  using  tracer 
infusates 
Hepatic  glucose  production  (both  basally  and  during  hyperinsulinaemia)  was 
measured  using  tracer  infusates. 
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The  protocol  was  identical  to  that  given  above  (Section  2.4.1)  except  for  the 
following  modifications.  A  primed  continuous  infusion  of  HPLC  purified  [3- 
3H]glucose  was  given  during  a2  hour  equilibration  period  (t  =  -120  to  0  mins,  and 
continued  throughout  the  procedure).  In  order  to  avoid  the  underestimation  of 
endogenous  glucose  production  associated  with  inter-compartmental  tracer  fluxes, 
a  variable  rate  infusion  of  exogenous  20%  dextrose  pre-labelled  with  [3_3  H] 
glucose  aiming  to  match  basal  plasma  glucose  specific  activity  was  administered 
from  2-150  minutes  (Finegood  et  al  1987,  Levy  et  al  1989,  Finegood  et  al  1990, 
Hother-Nielsen  and  Beck-Nielsen  1990,  Hother-Nielsen  et  al  1992,  Neely  et  al 
1992). 
2.5.2  Calculation  of  endogenous  glucose  production 
The  specific  activity  of  glucose  in  plasma  is  measured  in  disintegrations  per 
minute  (dpm)  per  pmol  of  plasma  glucose  (Section  2.8.3).  At  steady  state,  the 
total  rate  of  glucose  appearance  (Tra,  pmol/min)  can  be  calculated  by  dividing  the 
rate  of  tracer  administration  (dpm/min)  by  the  glucose  specific  activity  (SA  = 
dpm/pmol)  of  plasma.  Endogenous  (hepatic)  glucose  production  (EGP)  is 
determined  by  subtracting  the  known  rate  of  exogenous  glucose  infusion  (I)  [per 
kg  of  body  weight]  from  the  rate  of  glucose  appearance  (Ra)  [per  kg  of  body 
weight]. 
EGP=Ra  -I 
97 In  practice,  steady  state  assumptions  may not  be  fully  met,  and  the  non-steady 
state  equations  of  Steele  et  al  (1956),  as  modified  by  DeBodo  (1963)  may  be  used 
as  follows  to  determine  rates  of  glucose  appearance  (Ra)  and  disappearance  (Rd) 
during  t=  -30  to  0  mins  and  t=  120  to  150  mins,  assuming  a  pool  fraction  of  0.65 
and  an  extracellular  volume  of  190  ml/kg. 
The  calculation  of  endogenous  glucose  production  (EGP)  can  be  summarised  as 
follows: 
i)  Assuming  steady  state  (ss): 
Tra(,,  )  =  Ftotal/SA  (pmoVmin) 
where: 
SA  =  glucose  specific  activity  (dpm/min) 
Ftotal  =  (Rconst  X  r"const  )+(Rdex  X  Fdex)  (dpm/min) 
F,  onst  =  specific  activity  of  constant  [3-3H]glucose 
infusion  (dpm/min) 
rate  of  constant  [3-3H]glucose  infusion 
(mimin) 
Fd,  x  =  specific  activity  of  variable  [3-3H]glucose 
infusion  (dpm/min) 
Rd,  x  =  rate  of  variable  [3-3H]glucose  infusion 
(ml/min) 
98 ii)  Adjusting  for  deviations  from  steady  state: 
Tra(USS)  =  Trass)  -  error  term 
where: 
Error  term  =  (p.  V.  G.  dSA/dt.  weight)/SA  (pmol/min) 
and:  p=  pool  fraction  (0.65) 
V=  volume  of  distribution  (190  ml/kg) 
G=  plasma  glucose  concentration 
(mmol/1) 
SA  =  glucose  specific  activity  of  plasma 
(dpm/min) 
weight  =  weight  (kg) 
iii)  Final  steps: 
Ra(,,  )  =  Tra(ss)/weight  (pmol/kg/min) 
Ra(  )=  Tra(nss)/weight  (pmol/kg/min) 
Rd  =  Ra  -  d(am) 
where: 
d  l)  =  p.  V.  dG/dt 
(see  above) 
GIR  =  (Rdex  X  Cox)/weight  (pmollkg/min) 
(see  above) 
where: 
GIR  =  rate  of  exogenous  glucose  infusion 
(umol/kg/min) 
C&x  =  20%  dextrose  concentration  in  pmol/ml 
EGP  =  Ra(.,,  )  -  GIR  (pmol/kg/min) 
(divide  by  conversion  factor  5.55  for  mg/kg/min) 
99 2.6  Arterialisation  of  venous  blood 
In  the  original  description  of  the  euglycaemic  clamp,  the  glucose  infusion  rate 
was  adjusted  according  to  glucose  values  in  arterial  blood  (DeFronzo  et  al  1979). 
However,  in  order  to  avoid  cannulation  of  systemic  arteries,  many  investigators 
now  adjust  the  glucose  infusion  rate  on  the  basis  of  "arterialised"  venous  blood 
withdrawn  from  the  retrogradely  cannulated  dorsal  hand  vein;  this  technique  was 
examined  in  the  study  described  in  Chapter  4,  and  was  used  in  the  clinical  studies 
described  in  Chapter  5,6  and  7.  Thus,  the  ipsilateral  hand  was  placed  in  a 
cylindrical  perspex  heated-air  hand  box  at  the  beginning  of  the  period  of  supine 
rest  prior  to  the  start  of  the  procedure  (Liu  et  al  1992).  Under  thermostatic 
conditions,  the  heated  box  maintains  the  ambient  temperature  surrounding  the 
hand  at  55°C  (University  of  Nottingham,  Department  of  Physiology  and 
Pharmacology,  UK). 
2.7  Forearm  venous  occlusion  plethysmography 
Forearm  blood  flow  (FBF)  was  measured  in  the  studies  described  in  this  thesis 
using  forearm  venous  occlusion  plethysmography  (Chapters  3,4,  and  7).  In  this 
technique,  the  measurement  of  flow  is  derived  from  the  rate  of  change  in  forearm 
volume  during  intermittent  occlusion  of  venous  return  (with  continued  arterial 
inflow).  The  original  technique,  dating  from  the  late  nineteenth  century,  required 
the  use  of  cumbersome  water  jackets  to  measure  changes  in  forearm  volume 
(reviewed  in  Greenfield  et  al  1963),  but  has  been  more  readily  applicable  since  the 
advent  of  mercury  strain  gauges  together  with  a  mathematical  method  for  deriving 
100 changes  in  forearm  volume  (expressed  in  ml  of  blood  flow/  100ml  forearm/ 
minute)  from  changes  in  circumference  (Whitney  1953).  The  development  of  an 
electrical  calibration  technique  for  strain  gauges  (Hokanson  1975),  and  the 
availability  of  computerised  chart  recorders,  has  led  to  increasing  use  of  the 
technique  to  assess  the  effects  on  resistance  vessel  tone  of  agents  infused  directly 
into  the  brachial  artery  at  subsystemic  doses  (Barcroft  et  al  1954,  Collier  and 
Robinson  1974,  Benjamin  et  al  1989,  Benjamin  et  al  1995,  Calver  et  at  1992).  An 
additional  refinement  is  the  simultaneous  measurement  of  forearm  blood  flow  in 
both  arms:  measurements  in  the  experimental  arm  are  adjusted  for  systemic 
changes  unrelated  to  the  local  stimulus  by  expressing  the  two  measurements  as  a 
ratio: 
101 Figure  2.1  Plethysmographic  traces:  a  schematic  representation 
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where: 
F=  now 
i=  infused  arm 
ni  =  non-infused  arm 
v=  vehicle 
d=  drug 
The  reproducibility  of  FBF  measurement  by  this  technique  is  evaluated  in  Chapter 
3. 
2.7.1  General  clinical  procedure 
Temperature  was  maintained  at  25-26°C  and  lighting  was  dimmed;  the  room  was 
quiet  and  sealed.  Subjects  lay  supine  with  arms  supported  on  foam  blocks  in  the 
same  position  on  each  occasion.  Paediatric  arterial  occlusion  cuffs  (Hokanson 
SC5,  PMS  instruments,  Maidenhead,  Berkshire)  were  placed  around  the  wrists 
and  inflated  to  200  mmHg  for  three  minutes  during  each  set  of  recordings. 
Collecting  cuffs  were  placed  around  the  upper  arms,  and  inflated  and  deflated  (40 
103 mmHg)  in  a  15  second  cycle  (Hokanson  SC  10).  Rapid  cuff  inflation  was 
achieved  using  a  commercially  available  air  source  (Hokanson  AG  101),  coupled 
to  rapid  cuff  inflators  (Hokanson  E20).  On  the  first  study  day,  the  left  forearm 
was  measured  at  the  largest  circumference,  and  a  strain  gauge  (Hokanson  forearm 
set)  2  cm  shorter  was  selected.  The  distance  from  the  olecranon  was  measured 
and  recorded  in  order  to  standardise  strain  gauge  position  from  day  to  day.  The 
strain  gauge  was  calibrated  electrically  on  the  arm  to  the  chart  recorder 
programme  (MacLab,  AD  instruments,  UK)  and  test  readings  were  recorded. 
In  studies  examining  the  effect  of  local  intra-arterial  infusions  on  FBF,  a  27G 
unmounted  steel  needle  (Cooper's  Needleworks,  Birmingham,  U.  K.  )  was  inserted 
under  local  anaesthesia  into  the  brachial  artery  of  the  non-dominant  arm  for 
drug  infusion.  Cannula  patency  was  maintained  using  an  infusion  of  0.9%  saline 
(1  ml/min).  All  solutions  were  prepared  in  0.9%  sodium  chloride  in  the  Pharmacy 
Sterile  Productions  Unit,  Western  Infirmary. 
Blood  flow  recordings  began  45  seconds  after  wrist  cuff  inflation,  and  continued 
for  135  seconds.  Subjects  were  allowed  to  acclimatise  to  inflation  and  deflation 
of  the  wrist  and  upper  arm  cuffs  for  30  minutes  before  two  baseline  measurements 
10  minutes  apart:  the  mean  of  these  was  used  as  the  baseline  FBF.  Local 
incremental  doses  of  drugs  (see  Chapter  7)  were  dissolved  in  0.9%  saline  and 
infused  intra-arteri  ally  at  a  constant  rate  of  imi/min. 
104 2.7.2  Calculation  of  forearm  blood  flow 
Data  were  acquired  via  a  MacLab  II  chart  recorder  (AD  instruments,  Hampstead, 
London).  Forearm  blood  flow  (FBF)  was  derived  from  the  slope  of  the 
plethysmographic  traces  (Figure  2.1)  on  the  chart  recorder  according  to  the 
equation  of  Whitney  (1953).  Each  blood  flow  measurement  was  the  mean  of  five 
sequential  recordings.  Slopes  were  calculated  from  data  points  by  acquiring  co- 
ordinates  using  MacChart  software  (AD  instruments),  and  pasting  them  into  a 
customised  spreadsheet 
2.8  Laboratory  methods 
Venous  blood  samples  for  laboratory  assay  were  withdrawn  from  the  right  dorsal 
hand  vein  cannula  and  collected  into  plain  (insulin,  electrolytes,  triglycerides), 
lithium  heparin  (aldosterone),  potassium  EDTA  (renin),  or  heparinised  tubes 
(blood  gas  analysis).  Samples  for  All  measurement  were  collected  into  tubes 
containing  a  mixture  of  enzyme  inhibitors  (25  mM  a-phenanthroline,  125  mM 
EDTA,  2%  ethanol,  0.2%  neomycin  sulphate,  and  20  pM  human  renin  inhibitor 
H142).  All  samples  were  immediately  placed  in  crushed  ice  prior  to 
centrifugation  (3000  rpm,  4°  C),  decanting,  and  storage  at  -20  °  C,  except  those  for 
insulin  (which  were  kept  at  room  temperature  for  20  minutes  prior  to  processing). 
Samples  for  All  measurement  were  stored  at  -70'C.  Blood  gas,  lipid,  electrolyte, 
and  glucose  analyses  were  performed  in  the  hospital  routine  laboratory  on  the  day 
of  sampling.  Other  assays  were  performed  in  batches  in  the  laboratories  of  the 
Department  of  Medicine  and  Therapeutics. 
105 2.8.1  Serum  insulin  concentrations 
Serum  insulin  concentrations  were  determined  using  three  commercially 
available  insulin  assay  kits,  with  different  degrees  of  cross-reactivity  with 
proinsulin  and  its  partially  processed  split  and  des-  amino  products.  The 
Lifescreen  Insulin  EASIA,  (Watford,  U.  K)  is  an  immunoenzymometric  assay 
specific  for  insulin  (inter-assay  coefficient  of  variation  (CV)  =  6.7%  at  4.2  mU/1, 
3.5%  at  9.8  mU/l,  and  3.3%  at  81  mU/1).  The  Incstar  insulin  assay  (Stillwater, 
Minnesota,  USA)  is  a  radioimmunoassay  with  a  molar  cross-reactivity  with  intact 
proinsulin  of  30%  (inter-assay  CV  8-11%).  The  Pharmacia  insulin  RIA  100 
(Uppsala,  Sweden)  is  a  radioimmunoassay  with  a  molar  cross-reactivity  with 
intact  proinsulin  of  62%  (inter-assay  CV  =  5.8%  at  11.6  mU/1,6.4%  at  32.7  mU/l, 
and  6.5%  at  65.2  mU/1).  Serum  insulin  concentrations  were  expressed  in  uU/ml. 
The  assay  used  in  each  study  was  dictated  by  the  experimental  design:  the  Incstar 
assay  was  used  to  measure  the  level  of  hyperinsulinaemia  achieved  at  steady  state 
during  clamp  procedures,  while  serum  insulin  concentrations  measured  with  both 
the  Lifescreen  and  Pharmacia  assays  were  used  as  "specific"  and  "conventional" 
assays  in  the  assessment  of  the  importance  of  assay  specificity  (Chapter  5). 
2.8.2  Serum  and  plasma  glucose  concentrations 
During  the  hyperinsulinaemic  clamp  procedures,  serum  glucose  was  measured  at 
the  bedside  by  the  glucose  oxidase  method  using  a  Beckman  2  glucose  analyser 
(Beckman  Instruments,  Fullerton,  CA,  USA;  inter-assay  coefficient  of  variation  = 
2%).  Results  were  expressed  in  mmol/l.  For  assessment  of  glucose  levels  during 
106 oral  glucose  tolerance  tests,  samples  were  collected  in  as  plasma  in  fluoride- 
oxalate  tubes  and  analysed  in  the  hospital  routine  biochemistry  laboratory. 
2.8.3  Glucose  specific  activity 
Plasma  for  glucose  specific  activity  was  deproteinized  using  Ba(OH)2  and  ZnSO4 
by  the  method  of  Somogyi  (Somogyi  1945);  after  centrifugation,  the  supernatant 
was  passed  sequentially  through  anion  and  cation  exchange  columns  to  remove 
charged  molecules.  3H  activity  was  detected  in  an  automatic  liquid  scintillation 
counter.  Results  were  expressed  in  dpm/pmol  (Section  2.5.2).  Aliquots  of  tracer 
infusate  and  labelled  exogenous  dextrose  infusion  were  spiked  into  fasting  venous 
plasma  and  were  processed  in  parallel  with  plasma  samples  to  allow  calculation  of 
[3-3H]glucose  infusion  rates. 
2.8.4  Plasma  aldosterone  concentrations 
Plasma  aldosterone  concentrations  were  measured  in  batches  by  a  commercially 
available  radioimmunoassay  kit  (Biodata,  Milan)  according  to  the  technique 
described  by  MacKenzie  and  Clements  (1974).  Results  were  expressed  in  pmoUl. 
The  intra-  and  inter-assay  coefficents  of  variation  were  5.0  and  5.4%  respectively. 
107 2.8.5  Plasma  renin  activity 
Plasma  renin  activity  was  determined  by  radioimmunoassay  of  angiotensin  I 
formation  from  angiotensinogen  using  a  commercially  available  kit  (Biodata, 
Milan);  results  were  expressed  as  ng  AI/ml/hour.  Intra-  and  inter-assay 
coefficients  of  variation  were  4.9%  and  7.8%  respectively. 
2.8.6  Plasma  angiotensin  II  concentrations 
Plasma  ANG  II  was  assayed  after  HPLC  separation  by  direct  radioimmunoassay 
according  to  the  technique  described  by  Ducsterdieck  and  McElwee  (1971). 
Results  were  expressed  in  pmol/l.  The  intra-  and  inter-assay  coefficients  of 
variation  were  6.4%  and  8.8%  respectively  (Morton  and  Webb  1985). 
2.8.7  Serum  potassium  concentrations 
Potassium  (mmo/1)  was  measured  in  the  hospital  routine  biochemistry  laboratory 
by  diluting  ion-selective  electrode  on  an  Olympus  AU5200  auto-analyser. 
2.8.8  Blood  gas  analysis 
Blood  gas  analysis,  including  partial  pressure  of  oxygen  (PO2,  kPa),  was 
performed  in  the  hospital  routine  biochemistry  laboratory  using  a  Coming  288 
blood  gas  analyser  (Ciba  Corning  Diagnostics,  Halsted,  UK). 
108 2.8.9  Serum  lipid  concentrations 
Cholesterol  and  triglycerides  (mmol/1)  were  measured  in  the  hospital  routine 
biochemistry  laboratory  using  an  enzymatic  technique  in  a  Multistat  ULS 
centrifugal  analyser. 
2.9  Statistical  analysis 
All  data  were  checked  for  normality  using  the  Shapiro-Wilks  test  (Minitab 
statistical  package,  Minitab  Inc,  Pennsylvania,  USA),  and  skewed  data  were 
logarithmically  transformed  (logio)"  Where  appropriate,  summary  measures 
including  area-under  the  curve  (AUC)  were  calculated  (Matthews  et  al  1990). 
The  following  procedures  were  performed  using  Minitab  and  are  described  in  the 
individual  chapters:  Bland-Altman  plots  (Altman  1991),  paired  and  unpaired  t- 
tests;  simple  correlation  (Pearson);  multiple  linear  regression;  one-,  two-,  and 
three-way  analysis  of  variance  (subject,  treatment,  time  and  their  interactions 
fitted  as  terms).  95%  confidence  intervals  are  given  in  most  cases.  Unless 
otherwise  stated,  the  level  of  statistical  significance  (a)  was  taken  to  be  p<0.05; 
where  comparison  of  repeated  measures  made  over  time  between  groups  was 
required,  three-way  analysis  of  variance  was  performed  with  Bonferroni-corrected 
t-tests  at  individual  time-points.  Coefficients  of  variation  were  calculated  from 
the  square  root  of  the  total  error  term  of  the  adjusted  mean  squares  from  two-way 
ANOVA  (Bland  and  Altman  1996).  Where  normally  distributed  data  are  grouped, 
the  error  bars  show  mean  ±  standard  deviation. 
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The  reproducibility  of  bilateral  forearm  venous  occlusion  plethysmography 
3.0  Summary 
Forearm  venous  occlusion  plethysmography  is  frequently  used  to  assess  the 
effects  on  vascular  tone  of  agents  infused  directly  into  the  brachial  artery  at 
subsystemic  doses.  In  the  studies  described  in  this  thesis,  the  technique  was  used 
both  in  the  assessment  of  forearm  blood  flow  (FBF)  responses  to  hand-warming 
(Chapter  4),  and  in  the  assessment  of  endothelial  function  (Chapter  7).  Prior  to 
commencing  these  studies,  a  clinical  study  examining  the  reproducibility  of 
forearm  plethysmography  was  conducted. 
3.1  Introduction 
Forearm  plethysmography  is  frequently  used  to  assess  the  effects  on  vascular  tone 
of  agents  infused  directly  into  the  brachial  artery  at  subsystemic  doses.  Most 
investigators  now  use  electrically-calibrated  strain  gauges  to  derive  forearm  blood 
flow  (FBF)  from  changes  in  forearm  circumference  induced  by  intermittent 
venous  occlusion  (Whitney  1953,  Greenfield  et  al  1963,  Hokanson  1975, 
Benjamin  et  al  1995).  Despite  adequate  assessment  of  the  accuracy  of  strain  gauge 
plethysmography  when  compared  with  other  techniques  (Clarke  and  Hellon  1957, 
Dahn  and  Hallbrook  1970),  the  reproducibility  of  the  technique  is  less  well  estab- 
lished  (Roberts  et  al  1986,  Altenkirch  et  al  1990). 
Roberts  et  al.  (1986)  studied  between-day  intra-subject  variability  of  baseline 
unilateral  FBF  in  six  subjects  on  six  occasions  using  unilateral  measurements. 
110 They  reported  reasonable  reproducibility  of  baseline  FBF  with  intra-subject 
coefficients  of  variation  (CV)  ranging  between  7.8  and  15.6%  (mean  10.5%),  but 
poor  reproducibility  after  systemic  exercise  (CV  13.0-29.0%).  In  contrast, 
Altenkirch  et  al.  (1990),  studied  intra-subject  variability  of  baseline  unilateral  FBF 
in  twelve  subjects  on  three  occasions.  They  reported  a  pooled  CV  of  25%  and 
concluded  that  the  technique  was  "poorly  suitable"  for  pharmacological  trials.  In 
a  further  study,  between-day  intra-subject  FBF  reproducibility  data  were  quoted 
for  only  a  subgroup  of  subjects,  of  whom  several  were  excluded  from  analysis 
because  of  poor  within-day  baseline  blood  flow  reproducibility  (Egan  et  al  1988). 
Simultaneous  bilateral  measurement  of  FBF  as  a  method  of  reducing  variability 
was  first  proposed  over  40  years  ago  in  reports  of  experiments  using  water-filled 
plethysmographs  (Greenfield  and  Patterson  1954).  The  same  method  has  been 
adopted  by  many  investigators  when  performing  strain-gauge  plethysmography:  in 
theory,  measurements  are  adjusted  for  systemic  changes  unrelated  to  the  local 
stimulus  by  expressing  flow  in  the  experimental  arm  as  a  ratio  of  concurrent  flow 
in  the  non-infused  (control)  arm  (FBF  ratio)  (Calver  et  al  1992,  Cockcroft  et  al 
1993).  However,  some  investigators  simply  report  data  from  the  experimental 
arm  along  with  a  general  statement  that  blood  flow  did  not  change  significantly  in 
the  control  arm  (McVeigh  et  al  1992);  some  continue  to  use  the  unilateral 
technique  (Panza  et  al  1990,  Sakai  et  al  1993,  Clarke  et  al  1989);  and  others  at 
times  report  measurements  of  forearm  vascular  resistance  (FVR  =  mean  arterial 
pressure/  FBF)(Benjamin  et  al  1989,  Panza  et  al  1990).  It  is  possible  therefore 
that  use  of  suboptimal  methods  for  expressing  responses  may  influence  the 
conclusions  reached;  alternatively  relatively  invasive  measurements  may  be  made 
on  an  unnecessarily  large  number  of  subjects  to  detect  a  difference  between 
groups. 
III In  view  of  the  lack  of  adequate  published  information  on  the  reproducibility  of 
this  widely  used  technique,  the  aims  of  the  present  study  were  to  determine:  1)  the 
infra-subject  variability  of  bilateral  forearm  venous  occlusion  plethysmography 
(FBF  ratios)  in  untrained  healthy  male  subjects  at  rest,  after  standardised  unilateral 
forearm  exercise,  and  during  infra-arterial  infusions  of  vasoconstrictor  substances; 
2)  whether  bilateral  plethysmography  is  more  reproducible  than  unilateral 
plethysmography;  and  3)  the  reproducibility  of  forearm  vascular  resistance 
(unilateral  and  bilateral). 
3.2  Methods: 
All  studies  were  performed  after  several  months  of  initial  training  in 
plethysmography. 
3.2.1  Subjects 
All  subjects  were  male  non-smokers,  normotensive  (BP  <  140/90  mmHg),  with  no 
family  history  of  hypertension  or  diabetes  mellitus. 
a)  Study  1.  Nine  healthy  male  subjects  were  studied  on  three  separate  days  one 
week  apart  at  the  same  time  of  day,  at  least  three  hours  after  their  last  meal. 
b)  Study  2.  Five  healthy  subjects  were  studied  fasting  at  0900  on  two  occasions, 
one  month  apart. 
3.2.2  Clinical  procedures 
The  general  procedures  for  intra-arterial  infusions  and  for  measurement  and 
calculation  of  forearm  blood  flow  are  detailed  in  Section  2.7.1. 
a)  Study  1.  The  protocol  is  illustrated  in  Figure  3.1.  Experimental  conditions  were 
designed  to  resemble  as  closely  as  possible  those  reported  by  other  groups  (and 
which  were  to  be  used  in  the  studies  in  this  thesis). 
112 b)  Study  2.  The  protocol  is  illustrated  in  Figure  3.1.  Infusions  were:  1) 
noradrenaline  (Levophed,  Sanofi-Winthrop)  15,30,150,300  pmolmin;  and  2) 
angiotensin  II  (Hypertensin,  Ciba-Geigy)  1,5,10,50  pmol/min  (six  minutes  at 
each  dose);  the  order  of  infusions  was  randomised  between  subjects,  but  each 
subject  received  the  infusions  in  the  same  order  on  the  two  study  days. 
3.2.3  Statistical  analysis  and  assessment  of  intra-subject  variability 
In  Study  1,  intra-subject  variability  was  expressed  as  coefficients  of  variation 
(CV),  which  were  calculated  using  two-way  ANOVA  (subject  and  day  as  terms) 
using  MINITAB  (Pennsylvania,  USA):  the  square  root  of  the  total  error  term  of 
the  adjusted  mean  squares  from  ANOVA  was  divided  by  the  mean  and  expressed 
as  a  percentage  (Bland  and  Altman  1996).  The  Shapiro-Wilks  test  was  used  in 
order  to  check  that  residuals  were  normally  distributed.  A  standard  statistical  test 
for  comparing  co-efficients  of  variation  derived  in  this  way  has  not  been 
described.  In  Study  2,  following  Bland  and  Altman  (Altman  1991),  intra-subject 
variability  was  expressed  as  the  difference  between  responses  on  days  1  and  2 
plotted  against  the  mean  response  on  days  1  and  2  for  each  individual  subject  at 
each  dose:  as  the  differences  were  not  normally  distributed,  the  interquartile  range 
of  the  differences  was  calculated  as  a  summary  statistic. 
113 Figure  3.1  Experimental  protocols  for  Study  1  (upper  panel)  and  Study  2 
(lower  panel).  Bold  bars  represent  3  minute  periods  of  FBF 
measurements  (see  Methods).  B1=  baseline  1,  B2  =  baseline  2. 
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114 3.3  Results 
3.3.1  Baseline  and  post-exercise  measurements 
Baseline  and  post-exercise  unilateral  FBF  and  FBF  ratios  for  each  subject  on  the 
three  study  days  (Study  1)  are  shown  in  Figure  3.2.  Coefficents  of  variation  (CV) 
are  summarised  in  Table  3.1. 
a)  Forearm  blood  flow:  At  rest,  intra-subject  variability  of  baseline  FBF  ratios 
was  19%  compared  with  39%  and  31%  for  left  and  right  unilateral  FBF 
measurements  respectively.  After  ipsilateral  exercise,  unilateral  readings  became 
more  reproducible  (32  vs  17%);  by  20  minutes  after  exercise,  the  previous 
pattern  had  been  re-established  (19  vs  27%). 
b)  Forearm  vascular  resistance:  At  rest,  intra-subject  variability  of  baseline  FVR 
ratios  was  14%  compared  with  29%  and  27%  for  left  and  right  unilateral  FVR 
measurements  respectively.  After  ipsilateral  exercise,  unilateral  readings  became 
more  reproducible  (40  vs  14%);  by  20  minutes  after  exercise,  the  previous 
pattern  had  been  re-established  (17  vs  32%). 
3.3.2  Responses  to  intra-arterial  infusions 
Blood  flow  responses  to  both  sets  of  intra-arterial  infusions  (angiotensin  H  and 
noradrenaline)  on  days  1  and  2  are  shown  conventionally  as  grouped  data 
(mean±SEM)  in  Figure  3.3;  the  individual  data  are  shown  in  Figure  3.4 
(angiotensin  II)  and  Figure  3.5  (noradrenaline).  Plots  of  the  differences  between 
responses  on  days  1  and  2  (Figure  3.6),  indicated  that  variability  of  unilateral  FBF 
between  study  days  was  higher  than  that  of  FBF  ratios  for  both  infusions.  This 
was  confirmed  by  the  inter-quartile  ranges  of  the  differences  (FBF  ratios  vs  FBF): 
angiotensin  II  14  vs  18%;  noradrenaline  16  vs  27%. 
115 Table  3.1 
Intra-subject  variability  of  baseline  and  post-exercise  responses  expressed 
independently  in  each  arm  and  as  a  ratio  of  left/right  arms  (Study  1) 
Left  Right  ratio 
CV  (%)  CV(%)  CV(%) 
Baseline  Blood  pressure  7  -  - 
Heart  rate  9  -  - 
FBF  39  31  19 
FVR  29  27  14 
Post-exercise  FBF  17  29  32 
FVR  14  32  40 
10  minutes  FBF  25  26  28 
post-exercise 
FVR  33  30  24 
20  minutes  FBF  25  27  19 
post-exercise 
FVR  32  27  17 
CV,  coefficient  of  variation  (%)  -  calculated  using  two-way  ANOVA  (see 
Methods);  those  less  than  20%  are  highlighted  in  bold. 
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121 3.4  Discussion 
In  the  subjects  studied:  1)  intra-subject  variability  (CV)  of  bilateral  FBF 
measurements  (FBF  ratios)  was  19%  at  rest;  2)  FBF  ratios  were  more 
reproducible  than  unilateral  FBF  measurements  (CV  31-39%)  at  rest  and  during 
intra-arterial  infusions,  but  not  after  unilateral  forearm  exercise;  3)  forearm 
vascular  resistance  (FVR)  as  an  alternative  method  of  expressing  responses 
resulted  in  a  small  improvement  in  reproducibility  over  FBF  at  rest  and  after 
exercise.  These  findings  have  implications  for  the  interpretation  and  design  of 
studies  in  which  venous  occlusion  plethysmography  is  used  to  measure  responses 
to  local  intra-arterial  infusions. 
Bilateral  plethysmography  using  FBF  ratios  to  express  results  was  first  proposed 
in  the  context  of  water  plethysmography  over  40  years  ago  as  a  means  of 
controlling  for  systemic  changes  unrelated  to  the  local  stimulus  (Greenfield  and 
Paterson  1954).  However,  infra-subject  variability  data  have  not  previously  been 
reported  for  FBF  ratios,  which  are  frequently  and  currently  used  to  express  results 
of  studies  using  strain  gauge  plethysmography.  In  the  present  study,  FBF  ratios  at 
rest  were  reasonably  reproducible  for  physiological  measurements,  albeit  with  a 
higher  coefficient  of  variation  (19%)  than  concurrent  blood  pressure  (7%)  and 
heart  rate  (9%)  measured  by  semi-automatic  sphygmomanometer.  Previous 
studies  have  addressed  intra-subject  variability  only  of  unilateral  measurements  of 
FBF  and  have  reported  coefficients  of  variation  of  7.8-15.6%  (Roberts  et  al  1986) 
and  25%  at  rest  (Altenkirch  et  al  1990).  It  is  noteworthy  that  studies  reporting 
unilateral  FBF  measurements  have  produced  conflicting  findings  (Panza  et  al 
1990,  Cockcroft  et  al  1994);  In  the  present  study,  intra-subject  variability  of 
unilateral  measurements  at  rest  was  31-39%. 
122 When  data  from  the  intra-arterial  infusion  studies  are  plotted  in  the  conventional 
manner  as  grouped  data  (mean±SEM)(Figure  3.3),  they  appear  similar  to  those 
reported  by  other  investigators,  suggesting  that  similar  reproducibility  was 
achieved.  However,  inspection  of  Figures  3.4  and  3.5  reveals  the  considerable 
intra-subject  variability  that  is  concealed  by  such  plots.  This  variability  was 
considerably  reduced  when  results  were  expressed  as  FBF  ratios  (Figure  3.6). 
Given  that  similar  reproducibility  was  achieved  to  that  of  other  investigators  in  the 
infra-arterial  infusion  studies,  how  can  the  higher  coefficients  of  variation  in  the 
resting  measurements  in  Study  1  be  explained?  Between-day  variations  in  FBF 
measurements  must  derive  either  from  intrinsic  variability  in  blood  flow  or  from 
experimental  error.  Even  at  rest,  FBF  constantly  changes  in  response  to  changes 
in  sympathetic  nervous  system  activity,  mental  arousal,  and  ambient  temperature. 
It  is  possible  that  the  relatively  high  variability  in  the  present  study  in  comparison 
with  that  of  Roberts  et  al.  (1986)  might  be  explained  on  the  basis  of  inadequate 
control  of  the  experimental  environment  and  the  general  level  of  arousal  of  the 
subjects.  However,  it  is  unlikely  that  the  subjects  in  the  present  study  experienced 
a  more  variable  environment  than  that  experienced  by  subjects  in  other  studies, 
since  they  were  studied  in  a  quiet  room  and  were  allowed  to  become  acclimatised 
for  a  full  30  minutes  not  just  to  room  temperature,  which  was  stable,  but  also  to 
cuff  inflation  and  deflation.  In  many  published  studies,  acclimatisation  periods 
are  of  10  minutes  or  less  (Cockcroft  et  al  1993).  Concurrently-measured  blood 
pressure  and  heart  rate  in  the  present  study  were  reproducible  between  days, 
suggesting  reasonably  consistent  experimental  conditions. 
A  further  possible  source  of  day-to-day  variability  may  have  been  in  positioning 
of  strain  gauges  on  the  forearm.  However,  strain  gauges  of  exactly  the  same 
length  were  used  on  each  occasion  with  each  subject  and  care  was  taken  with 
positioning.  In  further  studies  carried  out  since  the  completion  of  this  study 
123 similar  between-day  coefficients  of  variation  for  baseline  FBF  and  FBF  ratio  to 
those  reported  have  been  observed,  suggesting  that  the  data  presented  in  this  study 
do  not  simply  reflect  the  early  portion  of  a  "learning  curve"  on  the  part  of  the 
investigators.  Some  variability  in  Study  1  could  be  attributed  to  the  non-fasting 
state  of  the  subjects,  but  the  aim  was  to  evaluate  the  technique  in  the  conditions 
reportedly  used  by  most  investigators  (Benjamin  et  al  1989,  Calver  et  al  1992). 
An  alternative  possibility  is  that  intra-subject  variability  was  in  part  subject- 
dependent:  the  subjects  in  the  present  study  were  "naive"  to  plethysmography,  but 
many  studies  are  carried  out  using  subjects  who  have  undergone  such 
measurements  before.  The  importance  of  subject-dependent  factors  was 
acknowledged  by  Greenfield  and  Patterson  (who  mostly  used  each  other  as 
experimental  subjects):  "the  results  of  these  experiments  (in  other  subjects)..  . 
were  similar  ... 
but  they  were  rather  more  scattered"  (Greenfield  and  Patterson 
1954).  The  study  by  Roberts  et  al.  (Roberts  et  al  1986)  may  have  been  conducted 
in  "trained"  subjects.  While  such  subjects  may  be  suitable  for  pharmacological 
studies,  investigation  of  pathophysiological  mechanisms  in  man  depends  upon 
studies  in  patients,  and  reproducibility  data  in  naive  healthy  volunteers  may  be 
more  relevant. 
The  final  aim  of  the  present  study  was  to  assess  whether  expressing  responses  as 
forearm  vascular  resistance  (FVR)(i.  e.  corrected  for  changes  in  mean  arterial 
pressure  as  measured  by  a  semi-automatic  sphygmomanometer)  would  decrease 
intra-subject  variability.  There  was  a  tendency  for  FVR  and  FVR  ratios  to  be 
more  reproducible  than  FBF  and  FBF  ratios  for  baseline  and  post-exercise 
readings,  but  it  is  doubtful  whether  the  magnitude  of  the  improvement  in 
reproducility  would  be  relevant  in  practice.  It  should  be  noted  that  invasive 
measurements  of  arterial  pressure  were  not  performed,  and  it  remains  possible  that 
this  would  result  in  a  larger  improvement. 
124 After  unilateral  forearm  exercise,  simple  unilateral  FBF  measurements  were  more 
reproducible  than  FBF  ratios.  It  is  likely  that  this  was  due  to  a  combination  of 
two  factors.  Firstly,  the  unilateral  exercise  task  may  have  been  sufficiently 
vigorous  to  produce  a  near  maximal  response;  there  are  previous  data  to 
demonstrate  the  reproducibility  of  maximal  FBF  (minimal  FVR)  (Takeshita  et  al 
1980).  Secondly,  blood  flow  in  the  contralateral  arm  during  this  task  appears  to 
have  varied  in  an  inconsistent  manner  between  days. 
In  conclusion,  the  present  study  provides  evidence  that  bilateral  plethysmography, 
expressing  responses  in  the  intervention  arm  as  a  ratio  of  responses  in  the  control 
arm,  is  more  reproducible  than  unilateral  plethysmography.  In  addition,  the  data 
demonstrate  that  correcting  measurements  of  blood  flow  for  small  variations  in 
mean  arterial  pressure  (forearm  vascular  resistance)  results  in  only  a  small 
improvement  in  reproducibility.  These  findings  have  clear  implications  for  the 
design  of  clinical  studies,  in  particular  the  calculation  of  sample  size,  and  sound  a 
note  of  caution  for  investigators  setting  up  the  technique  in  a  new  centre.  It  is 
important  that  the  method  of  expressing  responses  is  considered  before  the 
uncritical  acceptance  of  findings  of  studies  using  plethysmography  to  examine 
arterial  responses  in  cardiovascular  disorders. 
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Potential  confounding  haemodynamic  effect  of  hand-warming  on  the 
measurement  of  insulin  sensitivity 
4.0  Summary 
Hand-warming  is  frequently-employed  during  the  hyperinsulinaemic  euglycaemic 
clamp  procedure  in  order  to  arterialise  venous  blood.  The  effect  of  hand-warming 
on  the  value  for  insulin  sensitivity  derived  from  the  clamp  was  assessed  in  two 
clinical  studies,  which  are  described  in  this  chapter. 
4.1  Introduction 
In  the  clinical  studies  described  in  Chapters  5,6,  and  7,  insulin-mediated  glucose 
uptake  (insulin  sensitivity  or  M)  was  assessed  using  the  hyperinsulinaemic 
euglycaemic  clamp  technique  (Section  1.5.2).  Adjustment  of  the  glucose  infusion 
rate  on  the  basis  of  venous  glucose  concentrations  would  be  expected  to  lead  to  an 
overestimation  of  insulin  sensitivity,  and  most  investigators  now  use  glucose 
concentrations  measured  in  "arterialised"  venous  blood  (Liu  et  al  1992).  Hand- 
warming  (by  a  warm  blanket  or  a  heated-air  hand  box)  is  used  to  increase  blood 
flow  through  digital  arteries,  creating  a  functional  arteriovenous  shunt;  blood  is 
sampled  from  the  superficial  dorsal  veins  of  the  hand  (Ferrannini  et  al  1987,  Yki- 
Jarvinen  1987) 
However,  in  contrast  to  predictions  made  from  the  above  theoretical 
considerations,  there  is  evidence  from  several  groups  of  investigators  that  M- 
values  as  measured  by  the  euglycaemic  clamp  are  similar  when  the  glucose 
126 infusion  rate  is  adjusted  according  to  arterialised  blood  or  mixed  venous  blood 
(Andrews  et  al  1984,  Wahab  et  al  1992,  Nauck  et  al  1996).  In  addition,  it  has 
been  observed  that  hand-warming,  at  least  by  the  warm  blanket  technique,  affects 
body  temperature  and  contralateral  forearm  subcutaneous  blood  flow  during  oral 
glucose  tolerance  testing  (Astrup  et  al  1988),  and  may  cause  sympathetic  nervous 
system  activation  during  the  euglycaemic  clamp  (Moan  et  al  1995).  Although  the 
heated-air  hand  box  is  reported  to  have  lesser  systemic  effects  than  the  warm 
blanket  (Gallen  and  MacDonald  1990),  concern  remains  regarding  the 
appropriateness  of  hand-warming  during  metabolic  studies,  particularly  those  in 
which  concurrent  measurements  of  blood  flow  have  been  used  to  draw 
conclusions  about  insulin-mediated  vasodilatation  and  forearm  glucose  uptake 
(Yki-Jarvinen  et  al  1987,  Hunter  et  al  1994,  Walker  et  al  1995). 
The  aim  of  Study  1  was  to  determine  if  hand-warming  by  the  heated-air  hand  box 
affected  the  calculated  value  for  insulin  sensitivity  (M)  derived  from  the 
euglycaemic  clamp  technique.  It  was  therefore  assessed  whether  there  was  any 
difference  in  M  when  the  procedure  was  performed  with  the  box  in  situ  but 
switched  off  and  the  glucose  infusion  rate  adjusted  in  the  usual  manner  according 
to  ipsilateral  dorsal  hand  vein  samples  (effect  of  arterialisation).  In  order  to 
control  for  effects  of  hand-warming  other  than  those  resulting  simply  from  a 
change  in  local  ipsilateral  glucose  concentrations,  M  was  also  compared  when  the 
procedure  was  performed  with  the  box  switched  either  on  or  off  with  the  glucose 
infusion  rate  adjusted  according  to  samples  from  the  contralateral  antecubital 
vein.  It  was  reasoned  that,  as  blood  glucose  concentrations  in  this  deep  vein  were 
unlikely  to  be  affected  by  warming  the  other  hand  (Roddie  et  al  1956),  any 
127 difference  in  M-values  obtained  with  the  box  switched  on  as  opposed  to  off  would 
be  attributable  to  systemic  haemodynamic  effects  of  hand-warming.  It  was 
anticipated  that  M-values  obtained  from  antecubital  vein  clamps  (box-on  and  box- 
off)  would  be  higher  than  those  obtained  from  dorsal  hand  vein  clamps  because  of 
the  relatively  minor  extraction  of  glucose  in  the  capillary  beds  of  the  hand 
compared  with  those  of  the  forearm  during  euglycaemic  hyperinsulinaemia. 
Direct  arterial  puncture  to  obtain  true  arterial  glucose  measurents  was  not  per- 
formed,  as  the  primary  aim  was  to  examine  whether  hand-warming  affected 
derived  insulin  sensitivity:  this  was  addressed  with  minimum  invasiveness  using 
the  above  design. 
In  the  light  of  the  findings  of  the  first  study,  the  aim  of  Study  2  was  to  assess  the 
effect  of  hand-warming  (by  the  same  method)  on  contralateral  forearm  blood  flow 
(FBF),  using  venous  occlusion  plethysmography. 
4.2  Methods 
4.2.1  Subjects 
a)  Study  1.  Eight  healthy  normotensive  fasting  male  subjects  aged  21-35  years 
with  normal  glucose  tolerance  attended  four  study  days,  one  week  apart. 
b)  Study  2.  Five  healthy  normotensive  fasting  subjects  (one  female)  with  normal 
glucose  tolerance  attended  two  study  days  (random  order). 
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a)  Study  1.  On  each  study  day,  one  of  four  modified  euglycaemic  clamps  (Section 
2.4)  was  performed,  according  to  a  random  order  Latin  Square  design.  After  20 
minutes  of  supine  rest  with  the  right  hand  placed  in  a  heated-air  hand  box  at  55°C 
(University  of  Nottingham,  Department  of  Physiology  and  Pharmacology),  a 
primed  infusion  of  soluble  human  insulin  (1.5  mU/kg/min;  Actrapid, 
NovoNordisk  A/S,  DK2880  Bagsvaerd,  Denmark)  along  with  a  variable  rate 
infusion  of  20%  dextrose  (Baxter  Healthcare,  Norfolk,  U.  K.  )  was  administered  via 
a  right  antecubital  vein  for  three  hours  to  maintain  euglycaemia  at  5.2  mmol/1. 
The  infusion  rate  was  adjusted  on  the  basis  of  samples  (every  5  minutes)  from  an 
ipsilateral  right  dorsal  hand  vein  or  a  contralateral  left  arm  antecubital  vein 
according  to  study  day  (random  order)  as  follows:  1)  heated  box,  ipsilateral 
samples;  2)  box  in  situ  but  switched  off,  ipsilateral  samples;  3)  heated  box, 
contralateral  samples;  4)  box  in  situ  but  switched  off  and  contralateral  samples. 
Care  was  taken  to  place  cannulae  in  the  same  veins  on  each  study  day  for  each 
subject.  Patency  of  the  main  sampling  cannula  was  maintained  using  a  slow 
infusion  (0.5  ml/minute)  of  0.9%  sodium  chloride.  Blood  samples  were 
withdrawn  at  0,60,120,  and  180  minutes  for  measurement  of  serum  insulin 
(Section  2.8.1),  potassium  (Section  2.8.7),  and  triglycerides  (Section  2.8.9). 
Blood  samples  were  withdrawn  simultaneously  from  both  the  right  dorsal  hand 
vein  and  the  left  antecubital  vein  for  measurement  of  p02  (Section  2.8.8)  and 
serum  glucose  (Section  2.8.2)  at  0,60,120,  and  180  minutes.  Blood  pressure  (left 
arm)  and  heart  rate  were  measured  every  10  minutes  (Dinamap  Critikon). 
129 b)  Study  2.  Temperature  was  maintained  at  25-26°C  and  lighting  was  dimmed; 
the  room  was  quiet  and  sealed.  Subjects  lay  supine  with  arms  supported  on  foam 
blocks  in  the  same  position  on  each  occasion.  A  paediatric  cuff  (Hokanson  SC5, 
PMS  instruments,  Maidenhead,  Berkshire)  was  placed  around  the  left  wrist  and 
inflated  to  200  mmHg  for  three  minutes  during  each  set  of  measurements.  A 
collecting  cuff  was  placed  around  the  upper  arm,  and  inflated  (40  mmHg)  and 
deflated  in  a  15  second  cycle  (Hokanson  SC  10).  Rapid  cuff  inflation  was 
achieved  using  a  commercially  available  air  source  (Hokanson  AG101),  coupled 
to  a  rapid  cuff  inflator  (Hokanson  E20).  On  the  first  day,  the  left  forearm  was 
measured  at  the  largest  circumference,  and  a  strain  gauge  (Hokanson  forearm  set) 
2  cm  shorter  was  selected.  The  distance  from  the  olecranon  was  measured  and 
recorded  in  order  to  standardise  strain  gauge  position  from  day  to  day.  The  strain 
gauge  was  calibrated  electrically  on  the  arm  to  the  chart  recorder  programme. 
Blood  flow  measurements  began  45  seconds  after  wrist  cuff  inflation,  and 
continued  for  135  seconds.  Subjects  were  allowed  to  acclimatise  to  inflation  and 
deflation  of  the  wrist  and  upper  arm  cuffs  for  30  minutes  before  the  recording  of 
two  sets  of  baseline  measurements,  ten  minutes  apart:  the  mean  FBF  during  these 
two  sets  of  measurements  was  used  as  the  baseline  forearm  blood  flow.  After  the 
baseline  measurements  were  completed,  the  right  arm  was  placed  in  a  heated-air 
hand  box  at  either  55°C  or  room  temperature.  Unilateral  left  arm  FBF 
measurements  were  continued  at  5  minutes,  and  subsequently  at  10  minute 
intervals,  up  to  125  minutes. 
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a)  Study  1.  The  primary  end-points  (M-values)  in  conditions  1  vs  2  (right  dorsal 
hand  vein),  and  3  vs  4  (left  antecubital  vein),  were  compared  using  paired  t-tests 
(Minitab  statistical  package,  Minitab  Inc,  Pennsylvania,  USA).  Differences 
within  and  between  treatments  (box-on  vs.  box-off)  in  blood  glucose,  p02,  and 
other  metabolic  variables  were  assessed  by  three-way  analysis  of  variance 
(Section  2.9). 
b)  Study  2.  All  data  were  acquired  via  a  MacLab  H  Chart  recorder  (AD 
instruments,  Hampstead,  London).  Percentage  change  in  blood  flow  from  mean 
baseline  in  the  left  arm  was  analysed  using  three-way  analysis  of  variance. 
4.3  Results 
4.3.1  Insulin  sensitivity 
When  clamps  were  performed  according  to  samples  taken  from  the  contralateral 
antecubital  vein,  derived  insulin  sensitivity  (M)  was  significantly  lower  on  box-on 
vs.  box-off  days  (mean±SD  10.2±3.0  vs.  13.0±3.8  mg/kg/min,  p<0.05,95%  C.  I.  - 
0.2,  -5.3;  Figure  4.1,  right  panel).  However,  when  clamps  were  performed  on 
the  basis  of  samples  from  the  ipsilateral  dorsal  hand  vein,  there  was  no  difference 
in  calculated  insulin  sensitivity  between  box-on  and  box-off  days  (9.2±2.1  vs. 
9.0±1.7mg/kg/min,  pß.  57,95%  C.  I.  -0.5,  +0.9;  Figure  4.1,  left  panel). 
4.3.2  Arterialisation  of  venous  blood 
a)  Oxygenation:  In  samples  of  blood  taken  from  the  right  dorsal  hand  vein,  there 
was  a  mean  difference  of  2.0  kPa  in  arterialised-venous  P02  between  box-on  and 
131 box-off  days:  this  was  statistically  significant  [p  <  0.01,  interaction  between 
treatment  (box-on  vs  box-off)  and  time,  Figure  4.2  upper  panel].  However,  there 
were  no  statistically  significant  differences  in  p02  values  in  the  left  antecubital 
vein  between  box-on  and  box-off  days  (not  shown). 
b)  Glucose  levels:  There  were  no  significant  differences  in  glucose  levels 
between  box-on  and  box-off  days  in  samples  from  either  the  ipsilateral  dorsal 
hand  vein  (Figure  4.2,  lower  panel)  or  the  contralateral  antecubital  vein.  Blood 
glucose  during  the  final  40  minutes  of  the  clamps  was  less  variable  in  box-on 
conditions:  coefficients  of  variation  for  right  dorsal  hand  vein  studies  were  4.8% 
(box  on)  and  7.9%  (box-off);  for  left  antecubital  vein  conditions  they  were  7.9% 
(box-on)  and  10.0%  (box-off). 
3)  Haemodynamic  effects 
a)  Study  1.  Mean  heart  rate  throughout  the  procedure  was  6  beats  per  minute 
higher  in  conditions  in  which  the  heated  box  was  used  [p  <  0.05,  interaction 
between  treatment  (box-on  vs.  box-off)  and  time,  Figure  4.3  upper  panel].  There 
were  no  significant  differences  in  blood  pressure  between  study  days  (Figure  4.3, 
lower  panel). 
b)  Study  2.  Baseline  left  forearm  blood  flow  (mean±SD)  was  similar  in  both 
conditions:  2.63  ±  1.05  vs.  2.72  ±  1.25  ml/100ml  forearm/min  for  box-on  vs. 
box-off  day.  Left  FBF  expressed  as  percentage  change  from  baseline  was  higher 
during  right  hand-warming  than  during  the  control  condition  [p  <  0.05  for  the 
interaction  between  treatment  (box-on  vs.  box-off)  and  time,  Figure  4.4].  There 
132 0 
C) 
o 
Up 
"-  r.  lij 
r-  "M 
Ob  Jj 
Öu 
=i 
cr 
ý  "ý 
ÖÖ 
äUU 
'O 
~0e, 
U  pq  C  Oý 
:Z  r-  ;8U 
Ü  C) 
U 
%d^' 
cd  C)  U 
CC 
cz  ti  Z.  V 
as ý, ýo 
W 
I- 
A 
A 
I- 
a.  + 
C 
0 
U 
is 
.r 
A 
y 
CL 
ý[ 
N  to  N  Co  st 
0 
x 
0 
133 
C 
0 
x 
0 
cr) 
ui 
LID 
ON 
OO 
V 
CL 
U, 
rn 
Lin 
CL 
C 
o,  I  ý 
0N  Co  qe 
cm 
(uiw/BI/Bw)  enlQA-y4 
133 Figure  4.2  Arterialisation  of  venous  blood  during  euglycaemic  clamps. 
Oxygen  tension  (upper  panel,  pO2,  kPa),  glucose  levels 
(lower  panel,  mmoL4)  measured  in  the  ipsilateral  dorsal  hand 
vein  in  box-on  and  box-off  conditions. 
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134 Figure  4.3  Heart  rate  and  blood  pressure  during  euglycaemic  clamps. 
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135 Figure  4.4  Contralateral  forearm  blood  flow  during  hand-warming 
Change  in  left  forearm  blood  flow  expressed  as  a  percentage  of 
baseline  (mean±SD)  during  right  hand-warming  and  control. 
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0  30  60  90  120 Figure  4.5  Insulin,  triglycerides,  and  potassium  levels  during  euglycaemic  clamps. 
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0  60  120  180 was  no  difference  in  heart  rate  between  the  two  conditions  (e.  g.  at  65  minutes 
63.6±8.65  vs  63.2±11.4  beats  per  minute,  pß.  85  for  the  interaction  between 
treatment  and  time). 
4)  Insulin,  triglycerides  and  potassium 
Mean±SD  steady-state  insulin  concentrations  for  the  four  study  days  were 
127±21.4µU/ml,  121±28.8µU/ml,  122±29.4µU/ml,  and  126±27.8µU/ml 
respectively;  there  were  no  significant  differences  in  insulin  levels  between  days 
(Figure  4.5).  There  were  no  significant  differences  between  study  days  in 
potassium  or  triglycerides  levels,  which  had  decreased  significantly  from  baseline 
by  60  minutes  (p  <  0.05,  Figure  4.5). 
4.4  Discussion 
Hand-warming  is  widely  used  in  metabolic  investigation,  and  euglycaemic  clamps 
are  almost  invariably  performed  using  glucose  levels  in  arterialised  blood  to 
determine  the  required  rate  of  glucose  infusion.  In  addition,  hand-warming  has 
been  used  in  studies  measuring  blood  flow  and  forearm  glucose  uptake  during 
hyperinsulinaemia  (Yki-Jarvinen  1987,  Hunter  et  al  1994,  Walker  et  al  1995). 
The  principal  aim  of  the  present  controlled  studies  was  to  determine  if  hand- 
warming  by  the  heated-air  hand  box  method  affected  the  value  for  insulin 
sensitivity  (M)  derived  from  the  euglycaemic  clamp  technique.  It  was  hypothe- 
sised  that  hand-warming  might  have  two  independent  effects  on  the  derived  M- 
value:  (1)  the  usually  accepted  mechanism,  i.  e.  improving  the  approximation  of 
heated  superficial  dorsal  hand  vein  glucose  concentrations  to  arterial  glucose 
138 concentrations  (thereby  decreasing  the  required  infusion  rate  and  reducing  over- 
estimation  of  M)  -  i.  e.  arterialisation;  and  (2)  causing  thermoregulatory  alter- 
ations  in  cardiovascular  regulation  outwith  the  warmed  arm  -  i.  e.  systemic 
haemodynamic  effects.  It  was  felt  important  to  define  the  effect  of  hand-warming 
on  blood  flow,  as  such  an  effect  might  potentially  confound  investigations  of  the 
cardiovascular  effects  of  systemic  hyperinsulinaemia. 
In  order  to  dissect  out  which  of  the  two  putative  effects  was  predominant 
(arterialisation  or  systemic  haemodynamic  effects)  three  control  conditions  were 
used:  one  in  which  the  heated  box  was  switched  off  and  the  clamp  was  performed 
according  to  ipsilateral  samples  in  the  usual  manner,  and  a  further  two  in  which 
the  box  was  switched  either  on  or off  and  the  clamp  was  performed  according  to 
deep  venous  glucose  levels  in  a  site  (the  contralateral  arm)  unlikely  to  be  affected 
by  arterialisation  (Roddie  et  al  1956).  It  was  reasoned  that  if  arterialisation  was 
the  predominant  mechanism  by  which  hand-warming  affected  the  measurement  of 
insulin  sensitivity,  then  the  derived  M-value  should  have  been  lower  when  the 
box  was  switched  on  and  the  clamp  was  performed  according  to  ipsilateral 
samples;  conversely,  there  should  have  been  no  difference  in  derived  M-values 
with  hand-warming  when  clamps  were  performed  according  to  samples  from  the 
contralateral  antecubital  vein. 
In  contrast  with  these  expectations,  hand-warming  resulted  in  no  detectable 
difference  in  derived  M-value  when  clamps  were  performed  according  to 
ipsilateral  samples.  However,  when  clamps  were  performed  according  to  samples 
from  a  site  that  was  not  affected  directly  by  hand-warming  (the  contralateral 
139 antecubital  vein),  a  lower  M-value  resulted.  As  anticipated  a  priori,  M-values 
(box-on  and  box-off)  tended  to  be  higher  when  clamps  were  performed  using 
blood  sampled  from  the  antecubital  site,  because  of  the  higher  extraction  of 
glucose  in  the  capillary  beds  of  the  forearm  compared  with  the  hand  during 
euglycaemic  hyperinsulinaemia.  Although  clamps  were  not  performed  according 
to  directly-sampled  arterial  blood  as  a  "gold  standard,  "  the  study  design  (using 
contralateral  antecubital  vein  clamps)  provided  a  measure  of  the  potential  impact 
of  hand-warming  on  derived  insulin  sensitivity,  while  avoiding  excessive 
invasiveness. 
The  absence  of  any  detectable  effect  of  warming  the  sampling  hand  on  calculated 
M  is  consistent  with  the  reported  findings  of  a  number  of  other  groups,  using 
different  methods  of  hand-warming  (Andrews  et  al  1984,  Wahab  et  al  1992, 
Nauck  et  al  1996).  However,  two  of  these  groups  did  not  confirm  the  degree  of 
arterialisation  by  measuring  oxygenation  of  sampled  blood  (Andrews  et  al  1984, 
Nauck  et  al  1996)  and  the  other  used  a  design  in  which  arterialised  and  mixed 
venous  blood  were  both  withdrawn  from  the  same  (heated)  arm,  thereby  reducing 
any  arterialised-venous  glucose  gradient  (Wahab  et  al  1992).  Data  from  the 
present  study  indicate  that  there  was  effective  arterialisation  (in  terms  of  oxygen 
tension)  when  the  box  was  switched  on  but  that  this,  surprisingly,  did  not  affect 
the  simultaneously-measured  glucose  levels  or  the  derived  values  for  M. 
What  might  be  the  mechanism  by  which  hand-warming  decreased  derived  insulin 
sensitivity  in  clamps  performed  according  to  samples  from  the  contralateral 
antecubital  vein?  Heart  rate  was  significantly  higher  during  prolonged  hand- 
140 warming  and  hyperinsulinaemia  (three  hours)  than  during  the  control  conditions; 
as  far  as  can  be  ascertained,  this  response  has  not  previously  been  described.  An 
increase  in  heart  rate  with  hand-warming  was  not  observed  under 
normoinsulinaemic  conditions  (Study  2),  but  there  was  an  increase  in  contralateral 
forearm  blood  flow.  This  response  has  been  previously  described  (Abramson  et  al 
1965),  although  a  previous  validation  study  of  the  heated  air  hand  box  -  with 
measurements  over  a  period  of  one  hour  only  -  reported  no  statistically  significant 
effect  of  heating  on  contralateral  forearm  blood  flow  compared  with  control 
(Gallen  and  MacDonald  1990).  From  the  results  of  Study  2,  it  would  clearly  be 
possible  for  the  unwary  investigator  to  confuse  the  vasodilator  effects  of  hand- 
warming  with  those  directly  attributable  to  hyperinsulinaemia  in  studies  assessing 
the  importance  of  blunting  of  insulin-mediated  vasodilatation  in  insulin-resistant 
states. 
The  forearm  vasodilator  response  to  leg  heating  is  thought  to  be  mediated  by  the 
sympathetic  nervous  system,  probably  by  a  reciprocal  decrease  in  vasoconstrictor 
tone  and  an  increase  in  vasodilator  tone  (Lewis  et  al  1931,  Barcroft  et  al  1947, 
Moan  et  al  1995).  The  increase  in  heart  rate  and  contralateral  forearm  blood  flow 
observed  in  the  present  study  might  therefore  be  attributed  to  activation  of 
vasodilator  fibres  of  the  sympathetic  nervous  system.  Although  the  two  studies 
were  not  directly  comparable,  and  forearm  blood  flow  was  not  measured  during 
hyperinsulinaemia,  the  present  data  suggest  that  the  haemodynamic  effects  of 
hand-warming  are  more  pronounced  during  hyperinsulinaemia.  Increased  skin 
blood  flow  accounts  for  most  of  the  forearm  vasodilator  response  to  leg-warming 
(Roddie  et  at  1956,  Edholm  et  al  1956),  and  Astrup  and  colleagues  (using  133Xe 
141 clearance)  have  reported  that  hand-warming  during  a  glucose  tolerance  test 
increases  subcutaneous  blood  flow  leaving  total  forearm  blood  flow  unaffected 
(Astrup  et  al  1988).  One  might  speculate  that,  in  the  present  study, 
haemodynamic  effects  observed  during  hand-warming  mediated  the  associated 
changes  in  insulin  sensitivity:  during  hyperinsulinaemia,  hand-warming  may  have 
resulted  in  increased  skin  blood  flow  in  the  contralateral  arm  (and  possibly  other 
sites)  diverting  glucose  delivery  away  from  the  insulin-sensitive  skeletal  muscle 
vascular  bed. 
Despite  the  concerns  raised  by  the  present  study,  it  is  reassuring  that  the  heated-air 
hand  box  had  negligible  effects  on  derived  M-values  when  clamps  were 
performed  in  the  usual  manner.  Haemodynamically-mediated  effects  of  hand- 
warming  on  M-values  may  occur  in  the  same  direction  as  effects  of  true 
"arterialisation"  i.  e.  reducing  overestimation  of  M  with  respect  to  arterial  clamps. 
The  observations  reported  are  limited  to  healthy  male  volunteers,  and 
measurements  of  sympathetic  nervous  system  activation  have  not  been  performed; 
if  all  subjects  were  equally  sensitive  to  such  haemodynamic  effects,  and  clamps 
were  conducted  in  the  usual  manner,  such  effects  would  be  of  little  practical 
importance.  However,  it  may  not  be  safe  to  extrapolate  this  assumption  to 
metabolic  studies  of  patients  with  cardiovascular  disease.  The  findings  would  be 
of  potential  importance  in  a  case-control  comparison  of  insulin  sensitivity  if  one 
group  of  subjects  were  more  sensitive  to  sympathetic  nervous  system  activation 
than  the  other  (Goldstein  1983).  It  is  a  testable  hypothesis  that  a  false  positive 
finding  of  reduced  insulin  sensitivity  in  patients  with  essential  hypertension  might 
142 arise  as  a  result  of  hand-warming,  even  if  clamps  were  conducted  in  the 
conventional  manner. 
Small  baseline  differences  in  glucose  levels  between  superficial  and  deep  veins 
(Baltzan  et  al  1962)  are  known  to  exist,  but  these  do  not  account  for  the  reported 
findings  as  sampling  sites  were  not  compared;  rather,  the  effect  of  hand-warming 
on  derived  M-value  within  each  sampling  site  was  assessed.  Contralateral 
antecubital  vein  clamps  were  used  purely  as  an  experimental  control,  and  it  should 
be  emphasised  that  adjusting  the  glucose  infusion  rate  on  the  basis  of  contralateral 
arm  glucose  values  is  not  recommended  in  clinical  studies.  The  coefficient  of 
variation  of  glucose  levels  was  higher  for  box-on  than  for  box-off  conditions,  but 
this  applied  for  both  sampling  sites  and  is  therefore  unlikely  to  account  for  the 
findings. 
In  summary,  in  these  controlled  studies,  hand-warming  by  the  heated-air  hand 
box  decreased  derived  insulin  sensitivity  (M)  as  measured  by  the  euglycaemic 
clamp  technique  in  healthy  subjects  when  clamps  were  performed  according  to 
samples  from  a  site  unlikely  to  be  affected  by  arterialisation  (the  contralateral 
antecubital  vein).  However,  there  was  no  difference  in  M-value  with  hand- 
warming  when  clamps  were  based  on  samples  from  a  site  in  which  arterialisation 
could  be  demonstrated  (the  ipsilateral  dorsal  hand  vein).  In  addition,  hand- 
warming  appeared  to  cause  an  increase  in  heart  rate  during  hyperinsulinaemia  and 
an  increase  in  contralateral  forearm  blood  flow  under  basal  conditions  (systemic 
haemodynamic  effects).  These  findings  sound  a  note  of  caution  for  the 
interpretation  of  studies  which  have  used  the  euglycaemic  clamp  technique  to 
143 investigate  metabolic  aspects  of  cardiovascular  disease:  hand-warming  has  the 
potential  to  confound  euglycaemic  clamp  studies  with  a  case-control  design, 
particularly  those  assessing  the  haemodynamic  effects  of  insulin. 
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Serum  insulin  concentrations,  insulin  sensitivity,  and  blood  pressure:  is  assay 
specificity  important? 
5.0  Summary 
In  the  clinical  study  described  in  this  chapter,  the  effect  of  insulin  assay  specificity 
on  relationships  among  serum  insulin  concentrations,  insulin  sensitivity  and  blood 
pressure  were  examined  in  a  group  of  56  diabetic  (NIDDM)  and  non-diabetic 
subjects  characterised  for  insulin  sensitivity  using  the  euglycaemic  clamp 
technique. 
5.1  Introduction 
In  non-diabetic  obese  and  hypertensive  individuals,  normal  glucose  tolerance  is 
maintained,  at  least  in  the  short  term,  by  increased  pancreatic  ß-cell  secretion  of 
insulin.  Serum  insulin  concentrations  in  such  individuals  are  raised  in  proportion 
to  the  degree  of  insulin  resistance  and  the  resulting  hyperinsulinaemia  has  been 
implicated  in  the  pathogenesis  of  cardiovascular  disease  (Reaven  1988,  Pyorala 
1979,  Ducimitiere  et  al  1980,  Stout  1989,  Despres  et  al  1996)  (Section  1.1).  Blood 
pressure  appears  to  be  more  closely  related  to  insulin  sensitivity  than  to  serum 
insulin  concentrations  (Pinkney  et  al  1994),  but  measurement  of  insulin 
sensitivity  is  relatively  labour-intensive  and  circulating  insulin  concentrations 
(fasting  and  post-glucose  load)  have  been  used  as  surrogate  measurements  in 
many  of  the  large-scale  studies  which  have  implicated  insulin  resistance  in  the 
145 pathogenesis  of  essential  hypertension  (Berglund  et  al  1976,  Modan  et  al  1985, 
Morales  et  al  1993,  Jiang  et  al  1993a,  Jiang  et  al  1993b,  Feskens  et  al  1995) 
(Section  1.3).  However,  the  relationship  between  insulin  concentrations  and 
blood  pressure  is  variable  among  studies  and  ethnic  groups,  particularly  after 
adjustment  for  confounding  variables  such  as  body  mass  index,  and  its 
existence  and  significance  remain  controversial  (Mbanya  et  al  1988,  Asch  et  al 
1991,  Saad  et  al  1991,  Dowse  et  al  1993,  Muller  et  at  1993). 
Commercially-available  radioimmunoassays  for  insulin  cross-react  with  intact 
proinsulin  and  its  partially-processed  split  and  des-amino  products.  Sensitive  and 
specific  assays  have  now  been  developed  for  these  insulin  precursor  hormones 
(Sobey  et  al  1989,  Alpha  et  al  1992,  Hales  1994)  (Section  1.3.1).  While  pa  tially- 
processed  proinsulin  products  have  decreased  biological  activity  in  terms  of 
glucose  disposal  when  compared  with  insulin,  they  have  longer  half-lives  and  are 
not  converted  to  insulin  in  the  circulation  (Galloway  et  al  1992)  (Section  1.3.3). 
It  has  been  reported  that  total  proinsulin  rather  than  insulin  concentrations  are 
more  strongly  related  to  cardiovascular  risk  factors  in  both  non-diabetic  (Haffner 
et  al  1993,  Mohamed-Ali  et  al  1995)  and  NIDDM  (Nagi  et  al  1990)  populations, 
and  adults  who  were  of  low  birth  weight  appear  to  have  abnormal  proinsulin 
processing  (Hales  et  al  1991).  It  is  possible  that  the  cardiovascular  risk  attributed 
to  hyperinsulinaemia  might  in  part  reflect  cross-reactivity  of  proinsulin-like 
molecules  in  conventional  insulin  assays. 
The  study  was  designed  to  clarify  for  the  first  time  whether  the  relationships 
among  insulin  concentrations,  insulin  sensitivity  (measured  using  the  "gold 
146 standard"  euglycaemic  clamp  technique),  and  blood  pressure  are  affected  by  the 
specificity  of  the  assay  used  to  determine  serum  insulin  concentrations  and  hence 
whether  some  of  the  variability  between  studies  in  the  relationship  between 
insulin  concentrations  and  blood  pressure  might  be  accounted  for  by  use  of 
insulin  assays  with  different  degrees  of  cross-reactivity  with  proinsulin  and  its 
split/  des-amino  products. 
5.2  Methods 
5.2.1  Patients 
56  Caucasian  subjects  (26  patients  with  NIDDM,  30  non-diabetic  subjects) 
(Table  5.1)  were  recruited  (Section  2.1)  and  gave  informed  consent  to  participate 
in  the  study.  Subjects  with  a  body  mass  index  of  <  30  kg/m2  were  classified  as 
"lean";  otherwise  they  were  deemed  "obese.  "  Hypertension  and  NIDDM  were 
diagnosed  according  to  the  criteria  stated  in  Section  2.1. 
5.2.2  Clinical  Procedure 
The  study  design  was  such  that  patients  and  controls  were  studied  concurrently: 
for  each  lean  hypertensive  subject  recruited  (NIDDM  or  non-diabetic),  two 
age-  and  sex-matched  controls  were  recruited:  one  lean  normotensive  and  the 
other  obese  hypertensive.  All  subjects  recruited  attended  an  initial  screening 
visit,  when  baseline  characteristics  were  recorded,  followed  by  two  further 
study  days.  On  the  first  of  these,  a  standard  75g  oral  glucose  tolerance  test  was 
performed  (Section  2.3.4);  fasting  cholesterol  and  triglycerides  were  measured  on 
the  baseline  sample  only  (Section  2.8.9).  On  the  second  day,  a  euglycaemic  clamp 
was  performed  (Section  2.3.5). 
147 5.2.3  Insulin  assays 
Serum  insulin  concentrations  were  determined  by  a  commercially  available 
assay  specific  for  insulin  (Lifescreen,  Insulin  EASIA,  Watford,  U.  K.  )  and  also  by 
a  conventional  assay  with  a  quoted  62%  molar  cross-reaction  with  intact 
proinsulin  (Section  2.8.1). 
5.2.4  Statistical  analysis 
All  data  were  checked  for  normality  using  the  Shapiro-Wilks  test  (Minitab 
statistical  package,  Minitab  Inc,  Pennsylvania,  USA),  and  skewed  data  were 
logarithmically  transformed  (logo)  (Section  2.9).  A  Bland-Altman  plot  of  insulin 
concentrations  as  measured  by  the  two  assays  was  performed  (Altman  1991). 
Area-under-the-curve  (AUC)  insulin  was  calculated  as  a  summary  measure  for 
each  individual  (Matthews  et  al  1990).  Logo  serum  insulin  and  glucose 
concentrations  were  back-transformed  to  give  the  geometric  mean  for  presentation 
of  oral  glucose  tolerance  test  data.  One-way  ANOVA  was  used  in  the  analysis  of 
steady  state  serum  insulin  concentrations  and  insulin  sensitivity  index  by 
subgroup.  Unpaired  t-tests  were  used  for  comparisons  between  subgroups;  in 
order  to  adjust  for  the  use  of  data  from  the  lean  hypertensives  in  both 
comparisons,  97.5%  confidence  intervals  were  used,  and  2p  <  0.05  was  taken  to 
indicate  statistical  significance. 
In  univariate  analysis,  simple  correlations  were  plotted  of  the  relationships  among 
serum  insulin  concentrations,  insulin  sensitivity,  and  blood  pressure  for  the 
specific  and  conventional  assays.  The  relative  contributions  of  other  variables 
(age,  sex,  fasting  and  post-load  glucose  concentrations,  BMI,  waist-to-hip  ratio, 
148 smoking  status,  and  fasting  cholesterol  and  triglyceride  concentrations)  to  the 
relationships  observed  were  examined  by  multiple  regression  analyses  (all  subsets 
and  forward  stepwise).  These  analyses  were  performed  separately  for  both  specific 
and  conventional  assays. 
5.3  Results 
56  subjects  were  recruited  and  completed  the  protocol  without  complication. 
Two  of  the  non-diabetic  subjects  screened  (one  lean  normotensive,  one  lean 
hypertensive)  were  excluded  as  they  were  found  on  the  basis  of  their  post-load 
glucose  concentrations  to  have  impaired  glucose  tolerance  (IGT).  In  addition, 
four  of  the  nine  obese  hypertensive  non-diabetic  subjects  screened  were  found  to 
have  post-load  IGT;  these  subjects  were  not  excluded.  Satisfactory  matching  was 
achieved  between  comparable  subgroups  for  age,  sex,  and  body  mass  index 
although  within  the  NIDDM  group  the  lean  normotensive  and  obese 
hypertensive  subgroups  were  significantly  younger  than  the  lean  hypertensive 
subgroup  (Table  5.1). 
5.3.1  Simple  assay  comparison 
Insulin  concentrations  as  measured  by  the  two  methods  were  highly  correlated 
(r-0.97,  p<0.0001,  Figure  5.1a).  A  Bland-Altman  plot  revealed  that  AUC 
insulin  concentrations  by  the  conventional  method  were  greater  than  or  equal  to 
those  by  the  specific  method  in  52  of  the  56  subjects  (Figure  5.1b).  The  largest 
differences  detected  were  in  the  obese  NIDDM  subjects  and  in  those  obese  non- 
diabetic  subjects  who  were  glucose  intolerant  (Figure  5.1b).  In  the  four  subjects 
149 Table  5.1  Characteristics  of  56  non-diabetic  and  NIDDM  subjects  (mean±SD) 
Lean  Lean  Obese 
normotensive  hypertensive  hypertensive 
Non-diabetic  subjects  n=11  n=10  n=9 
age  (years)  38±8.0  44±8.8  49±10.0 
BMI  (kg/m2)  24.8±2.93  26.5±2.35  32.9±2.79*" 
M/F  10/1  8/2  9/0 
MAP  (mmHg)  92±10.2  119±7.0**  121±11.6x" 
Glucose  intolerant  -  -  4 
Fasting  glucose  (mmol/1)  5.4±0.44  5.3±0.55  5.9±0.56 
Cholesterol  (mmol/1)  4.91±0.80  5.64±1.41  5.03±0.61 
Duration  hypertension  -  3  (2-300)  3  (2-36) 
(months:  median  (range)) 
NIDDM  subjects  n=11  n=7  n=8 
age  (years)  54±7.5  67±6.2**  57±11.9 
BMI  (kg/r2)  25.4±2.91  25.8±2.74  34.4±4.11 
M/F  9/2  6/1  7/1 
MAP  (mmHg)  96±6.3  118±8.0`**  123±5.6=" 
Fasting  glucose  (mmol/I)  9.1±2.49  8.0±1.42  8.2±2.09 
Cholesterol  (mmol/1)  5.87±1.04  4.92±0.50  6.21±0.95 
Duration  hypertension  -  3(3-36)  3(3-41) 
(months:  median  (range)) 
Duration  diabetes  19  (4-98)  10  (2-60)  16  (2-84) 
(months:  median  (range)) 
*=  2p  <  0.05,  **  =  2p  <  0.01,  ***  2p  =<0.001  lean  hypertensive  vs  lean  normotensive 
#=  2p  <  0.05,  ##  =  2p  <  0.01,  ###  2p  =<0.001  obese  hypertensive  vs  lean  hypertensive 
150 in  whom  specific  insulin  concentrations  were  apparently  greater  than  conventional 
insulin  concentrations,  the  magnitude  of  the  difference  was  small  and  reflected  a 
difference  at  a  single  time-point  in  the  later  part  of  the  OGTT. 
5.3.2  Insulin  and  glucose  concentrations 
a)  Insulin:  Fasting  and  AUC  insulin  results  were  similar  for  both  specific  and 
conventional  assays.  In  the  non-diabetic  subjects,  AUC  insulin  was  greater  in 
obese  hypertensive  compared  with  lean  hypertensive  subjects  (2p  <  0.05,  Figure 
5.2);  there  was  a  tendency  for  AUC  insulin  to  be  greater  in  lean  hypertensive 
compared  with  lean  normotensive  subjects,  but  this  did  not  reach  statistical 
significance  (2p  =  0.14,  Figure  5.2).  In  NIDDM  subjects  there  was  a  trend  for 
AUC  insulin  to  be  greater  in  obese  hypertensive  compared  with  lean  hypertensive 
subjects,  whom  in  turn  tended  to  have  higher  AUC  insulin  than  lean 
normotensive  subjects;  however,  these  trends  did  not  reach  statistical  significance 
(Figure  5.2). 
b)  Glucose:  There  were  no  statistically  significant  differences  in  fasting  glucose 
concentrations  within  the  non-diabetic  and  NIDDM  groups  (Table  5.1). 
However,  within  the  non-diabetic  group,  AUC  glucose  was  higher  in  obese 
hypertensive  compared  with  lean  hypertensive  subjects  (2p  <  0.05),  and  in  lean 
hypertensive  compared  with  lean  normotensive  subjects  (2p  <  0.05,  Figure  5.2). 
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158 5.3.3  Insulin  sensitivity 
Mean±SD  steady-state  insulin  concentrations  (µU/ml)  achieved  during  the 
euglycaemic  clamp  procedures  were  higher  in  obese  subjects  [non-diabetic 
subjects  113±20.6  (lean  normotensive),  115±27.2  (lean  hypertensive),  163±38.0 
(obese  hypertensive);  NIDDM  subjects  109±19.0  (lean  normotensive),  121±27.9 
(lean  hypertensive),  and  159±60.6  (obese  hypertensive)],  p<0.01,  ANOVA.  The 
insulin  sensitivity  index  (S.,  ),  correcting  for  steady  state  insulin  concentrations, 
was  therefore  calculated  for  each  subject  (Figure  5.3).  Coefficients  of  variation  of 
blood  glucose  during  the  final  40  minutes  of  the  clamps  were  3.3%  (non-diabetic 
subjects)  and  4.7%  (NIDDM  subjects). 
In  both  the  non-diabetic  subjects  and  subjects  with  NIDDM,  insulin  sensitivity 
index  (Figure  5.3)  was  lower  in  the  sub-groups  with  higher  blood  pressure  and 
increased  weight  (non-diabetic  subjects,  p<0.001;  NIDDM  subjects  p<0.01, 
ANOVA).  When  subgroups  were  compared,  with  adjustment  for  multiple 
comparisons,  insulin  sensitivity  index  was  lower  in  obese  than  lean  hypertensive 
subjects  (non-diabetic  subjects,  2p  <  0.05;  NIDDM  subjects,  2p  <  0.01). 
5.3.4  Insulin  concentrations  and  insulin  sensitivity 
The  univariate  relationships  between  insulin  sensitivity  and  serum  insulin 
concentrations  were  independent  of  assay  specificity  in  both  non-diabetic  subjects 
and  subjects  with  NTDDM  (Table  5.2). 
159 a)  Fasting  insulin 
i)  Non-diabetic  subjects:  There  was  a  negative  correlation  (Figure  5.4)  between 
loglo  fasting  serum  insulin  and  insulin  sensitivity  index  (r--0.59,  p<  0.001,95% 
CI  -0.29,  -0.78  (specific  assay),  r--0.64,  p<0.001,95%  Cl  -0.36,  -0.81 
(conventional  assay). 
ii)  Subjects  with  NIDDM:  There  was  a  negative  correlation  (Figure  5.4)  between 
loglo  fasting  serum  insulin  and  insulin  sensitivity  index  [r=-0.47,  p<0.05,95%  CI 
-0.12,  -0.71  (specific  assay),  r--0.55,  p<0.01,95%  CI  -0.23,  -0.76  (conventional 
assay)]. 
b)  AUC  insulin: 
i)  Non-diabetic  subjects:  There  was  a  negative  correlation  (Figure  5.5)  between 
login  AUC  insulin  and  insulin  sensitivity  (r=-0.81,  p<0.0001,95%  CI  -0.62,  -0.91 
(specific  assay),  r=-0.82,  p<0.0001,95%  CI  -0.64,  -0.91  (conventional  assay)). 
In  multiple  regression  analysis,  AUC  insulin  (measured  by  either  specific  or 
conventional  assay)  was  a  significant  predictor  of  insulin  sensitivity  even  when 
waist-to-hip  ratio  was  included  in  the  model  (Table  5.3). 
ii)  NIDDM  subjects:  There  was  no  significant  relationship  between  logio  AUC 
insulin  and  insulin  sensitivity  index  (r=-0.24,95%  Cl  +0.17,  -0.58  (specific 
assay),  r--0.33,95%  Cl  +0.07,  -0.64  (conventional  assay).  In  multiple  regression 
analysis,  BMI  was  the  only  significant  predictor  of  insulin  sensitivity  (adjusted  R2 
0.46,  t=-4.71,  p<0.00  1). 
160 Table  5.2:  Univariate  correlations  (Pearson's  r)  between  demographic, 
metabolic  and  haemodynamic  measurements  and  insulin  sensitivity 
index  (Sip). 
Non-diabetic  NIDDM 
subjects  (n=30)  subjects  (u=26) 
r-value  r-value 
age  -0.40*  -0.22 
BMI  -0.77***  -0.69 
" 
Systolic  BP  -0.29  -0.16 
Diastolic  BP  -0.40'  -0.51== 
Waist-to-hip  -0.75 
*` 
-0.66`=s 
ratio 
Fasting  glucose  -0.23  -0.21 
(log10) 
Fasting  -0.42"  -0.47' 
triglycerides 
(1ogio) 
Specific  insulin  Conventional  Specific  insulin  Conventional 
assay  insulin  assay  assay  insulin 
assay 
r-value  r-value  r-value  r-value 
Fasting  insulin  -0.59***  -0.64  -0.47s  -0.55`* 
(login) 
30-minute  -0.67"`  -0.68#x`  -0.23  -0.35 
insulin  (log10) 
120  minute  -0.49`-  -0.44-  -0.19  -0.28 
insulin  (10910) 
AUC  insulin  -0.81-0.82"`  -0.24  -0.33 
(login) 
*p<0.05,  **  p<0.01,  ***  p<0.001 
161 5.3.5  Blood  pressure  and  insulin  sensitivity 
a)  Non-diabetic  subjects:  Diastolic  blood  pressure  was  negatively  correlated  with 
insulin  sensitivity  index  (Figure  5.6)  (r=-0.40,  p<0.05,95%  CI  -0.05,  -0.66). 
However,  in  multiple  regression  analysis,  age  was  the  only  significant  predictor  of 
blood  pressure  (adjusted  R2  0.23,  t=3.10,  p<0.01). 
b)  NIDDM  subjects:  Diastolic  blood  pressure  was  negatively  correlated  with 
insulin  sensitivity  index  (Figure  5.6)  (r=-0.51,  p<0.01,95%  CI  -0.15,  -0.75). 
However,  in  multiple  regression  analysis,  the  relationship  was  not  statistically 
significant  after  body  mass  index  was  included  in  the  model  (Table  5.4). 
5.3.6  Insulin  concentrations  and  blood  pressure 
a)  Non-diabetic  subjects:  The  univariate  relationship  between  loglo  AUC 
insulin  and  diastolic  blood  pressure  was  similar  with  both  assays  (Figure  5.7): 
non-diabetic  subjects  r--0.40,  p<0.05,95%  Cl  0.03,0.68  (specific  assay); 
rß.  38,  p<0.05,95%  Cl  0,0.66  (conventional  assay).  However,  in  multiple 
regression  analysis,  AUC  insulin  was  not  a  significant  predictor  of  blood  pressure. 
b)  NIDDM  subjects:  No  significant  relationship  was  detected  with  either  assay: 
r=0.24,  p=0.18,95%  Cl  -0.17,0.58  (specific  assay),  r=0.28,  p=0.17,95%  Cl  - 
0.13,0.60  (conventional  assay). 
162 Table  5.3  Multiple  regression  models  with  insulin  sensitivity  index  (SIP)  as 
dependent  variable  in  non-diabetic  subjects 
Model  AUC  insulin'  Waist-to-hip  Adjusted  t  for  p 
(specific  assay)  ratio  R2  AUC 
insulin 
1  -9.90  0.65  -7.15  <0.001 
(-12.42  to  -7.08) 
2  -6.9  -20.9  0.80  -5.26  <0.001 
(-9.56  to  -4.24)  (-30.35  to  -9.95) 
Model  AUC  insulin'  Waist-to-hip  Adjusted  R2  t  for  p 
(conventional  ratio  AUC 
assay)  insulin 
1  -9.66  0.67  -6.33  <0.001 
(-12.27  to  -7.05) 
2  -6.86  -21.0  0.83  -5.16  <0.001 
(-9.41  to  -4.31)  (-30.66  to  -11.34) 
'AUC  insulin  indicates  area-under-the-curve  insulin,  measured  during  a  standard  oral  glucose 
tolerance  test  (see  text). 
The  table  shows  prediction  of  insulin  sensitivity  index  from  AUC  insulin  and 
waist-to-hip  ratio  by  multiple  regression  analysis  in  30  non-diabetic  subjects. 
Changes  are  shown  as  adjusted  R2  and  t  for  AUC  insulin,  with  forward  stepwise 
addition  of  waist-to-hip  ratio.  AUC  insulin  remains  a  significant  predictor  of  Sip 
after  waist-to-hip  ratio  is  included  in  the  model.  Partial  regression  coefficient  (ß) 
and  95%  confidence  intervals  are  shown.  Predictor  variables:  model  1,  AUC 
insulin;  model  2,  AUC  insulin  plus  waist-to-hip  ratio. 
163 Table  5.4  Multiple  regression  models  with  diastolic  blood  pressure  as  dependent 
variable  in  subjects  with  NIDDM 
Model  Sip  Body  mass  Adjusted  t  for  p 
index  (BMI)  R2  SIP 
1  -2.02  0.23  -2.90  <0.01 
(-3.34  to  -0.65) 
2  -1.00  0.72  0.27  -1.06  0.3 
(-2.84  to  0.84)  (-0.18,1.62) 
'Slp  indicates  insulin  sensitivity  index,  as  measured  by  the  isoglycaemic  clamp  technique  (see  text). 
The  table  shows  prediction  of  diastolic  blood  pressure  from  Sip  and  BMI  in  26 
subjects  with  NIDDM.  Changes  are  shown  as  adjusted  R2  and  t  for  Sup,  with 
forward  stepwise  addition  of  BML  Sip  is  not  a  significant  predictor  of  diastolic  BP 
after  BMI  is  included  in  the  model.  Partial  regression  coefficient  (0)  and  95% 
confidence  intervals  are  shown.  Predictor  variables:  model  1,  Sip;  model  2,  Sip 
plus  BMI. 
164 5.4  Discussion 
The  major  finding  of  this  study  was  that,  in  the  subjects  studied,  the  specificity 
of  the  insulin  assay  used  to  measure  serum  insulin  concentrations  had  no 
detectable  effect  on  the  relationships  observed  amongst  serum  insulin 
concentrations,  insulin  sensitivity,  and  blood  pressure.  Serum  insulin 
concentrations  measured  by  specific  and  conventional  assays  were  highly 
correlated,  and  the  relationships  among  lean,  obese,  and  hypertensive  NIDDM 
and  non-diabetic  subgroups  in  terms  of  serum  insulin  concentrations  were 
almost  identical  irrespective  of  the  assay  method  used.  The  present  study  is  the 
first,  as  far  as  can  be  ascertained,  to  examine  the  relationships  among  serum 
insulin  concentrations  as  measured  by  both  conventional  and  specific  insulin 
assay  methods,  euglycaemic-clamp  derived  insulin  sensitivity,  and  blood 
pressure. 
Many  of  the  large-scale  studies  which  have  examined  the  relationship  between 
insulin  concentrations  and  blood  pressure  in  non-diabetic  subjects  measured 
insulin  using  conventional  radioimmunoassays  with  a  high  degree  of  cross- 
reactivity  with  proinsulin  and  its  partially-processed  intermediates  (Berglund  et  al 
1976,  Modan  et  al  1985,  Morales  et  al  1993,  Jiang  et  al  1993a,  Jiang  et  al  1993b, 
Feskens  et  al  1995).  Three  of  these  studies  (Modan  et  al  1985,  Jiang  et  al  1993a, 
Jiang  et  al  1993b,  Feskens  et  al  1995)  used  the  same  commercially  available 
conventional  assay  kit  (Pharmacia  RIA  100)  that  was  used  in  this  study.  In 
165 contrast,  there  are  few  published  data  on  the  relationship  between  specific 
insulin  concentrations  and  blood  pressure,  and  previous  data  are  conflicting 
(Section  1.3.2). 
The  detailed  nature  of  the  present  study  was  such  that  only  a  relatively  small 
number  of  subjects  could  be  studied  (n=56).  Insulin  sensitivity  was  measured  by 
a  three  hour  euglycaemic  clamp  technique  which  is  the  acknowledged  current 
"gold  standard"  (Keen  1994),  and  the  patients  studied  were  not  taking  potentially- 
confounding  drug  treatment.  In  non-diabetic  subjects,  the  relationship  between 
serum  insulin  concentrations  (as  determined  by  either  assay  method)  and  blood 
pressure  was  almost  identical  to  that  between  euglycaemic  clamp-derived  insulin 
sensitivity  and  blood  pressure.  Taken  with  the  findings  from  the  San  Antonio 
group  (Haffner  et  al  1994),  the  present  data  suggest  that  assay  specificity  is 
unlikely  to  account  for  discrepancies  between  epidemiological  studies  in  the 
strength  of  the  relationship  observed  between  serum  insulin  concentrations  and 
blood  pressure.  It  is  likely  that  such  discrepancies  are  accounted  for  either  by 
differences  in  the  populations  studied  (Dowse  et  al  1993),  or  by  lack  of 
standardisation  of  insulin  assays  between  centres  (Robbins  et  al  1996).  Proinsulin 
and  partially-processed  proinsulin  products  were  not  measured  in  the  present 
study,  but  the  relationships  examined  were  almost  identical  when  insulin 
concentrations  were  measured  with  insulin  assays  of  both  relatively  high  and  no 
cross-reactivity  with  these  molecules.  Disproportionately  elevated  insulin 
concentrations  measured  with  the  conventional  as  opposed  to  specific  insulin 
166 assay,  suggesting  high  levels  of  proinsulin-like  molecules,  were  observed  mainly 
in  obese  (NIDDM  or  non-diabetic  glucose  intolerant)  subjects.  However,  this 
does  not  explain  the  lack  of  a  univariate  relationship  between  serum  insulin 
concentrations  and  blood  pressure  in  these  subjects  as  similar  correlation 
coefficients  and  confidence  intervals  were  observed  when  insulin  concentrations 
were  measured  using  the  specific  assay. 
In  the  subjects  studied,  the  relationships  among  insulin/insulin  sensitivity  and 
blood  pressure  were  confounded  by  age  in  non-diabetic  subjects,  and  by  body 
mass  index  in  subjects  with  NIDDM.  The  importance  of  confounding  variables  in 
this  relationship  has  been  discussed  elsewhere  (Asch  et  al  1991,  Jarrett  1992, 
Haffner  1993);  however,  with  respect  to  the  main  aim  of  the  present  study,  it  can 
be  concluded  that  addition  of  potentially  confounding  variables  to  multiple 
regression  models  had  similar  effects  on  partial  regression  coefficients 
irrespective  of  the  method  used  to  determine  serum  insulin  concentrations. 
In  summary,  this  study  showed  no  differences  attributable  to  insulin  assay 
specificity  in  the  relationships  among  serum  insulin  concentrations,  clamp-derived 
insulin  sensitivity,  and  blood  pressure  in  a  group  of  56  diabetic  and  non-diabetic 
subjects  with  widely-varying  degrees  of  blood  pressure  and  body  mass  index. 
Use  of  specific  assays  which  have  recently  become  commercially  available  in 
future  epidemiological  studies  is  unlikely  to  alter  the  relationships  detected 
between  serum  insulin  concentrations,  insulin  sensitivity  and  blood  pressure. 
167 Chapter  6 
Dietary  salt  restriction  impairs  insulin  sensitivity  in  non-insulin  dependent 
diabetes  mellitus 
6.0  Summary 
In  the  clinical  study  described  in  this  chapter,  the  effect  on  insulin  sensitivity  and 
endogenous  glucose  production  of  activation  of  the  renin-angiotensin  system 
(RAS)  by  dietary  sodium  restriction  was  evaluated  in  patients  with  NIDDM  using 
a  double-blind,  placebo-controlled  design. 
6.1  Introduction 
The  insulin-sensitising  effect  of  acute  angiotensin  II  infusion  on  insulin  sensitivity 
(Section  1.7.2)  in  patients  with  N  DDM  (Morris  et  al  1994c)  is  difficult  to 
reconcile  with  the  reported  insulin-sensitising  effect  of  chronic  ACE  inhibitor 
therapy  in  the  same  patients  (Vuorinen-Markkola  and  Yki-Jarvinen  1995)(Section 
1.1.6).  There  are  no  data  on  the  effect  of  more  sustained  activation  of  the  RAS  on 
insulin-mediated  glucose  uptake  in  patients  with  NIDDM,  and  data  from  open 
studies  of  dietary  sodium  restriction  in  healthy  volunteers  are  conflicting  (Sharma 
et  al  1993,  Donovan  et  al  1993,  Fliser  et  al  1995). 
The  aim  of  this  study  was  to  examine  the  effect  of  physiological  activation  of  the 
RAS  by  dietary  sodium  restriction  on  insulin-mediated  glucose  uptake  in  patients 
with  NIDDM.  This  question  is  not  only  of  metabolic  importance  but  also  of 
168 clinical  relevance.  Total  body  sodium  is  elevated  in  patients  with  diabetes,  and 
thus  `normal'  levels  of  renin  and  angiotensin  II  may  be  inappropriately  high 
(O'Hare  et  al  1985,  Weidmann  et  al  1993).  Pharmacological  and  non- 
pharmacological  interventions  which  influence  insulin  sensitivity  may  have  an 
impact  on  glycaemic  control  and  ultimately  the  incidence  of  diabetic 
complications.  Current  dietary  recommendations  suggest  dietary  sodium 
restriction  for  both  hypertensive  and  normotensive  patients  with  diabetes 
(Nutrition  Study  Group,  European  Association  for  the  Study  of  Diabetes  1988, 
American  Diabetes  Association  1996),  but  the  impact  of  this  intervention  on 
insulin  sensitivity  in  NIDDM  has  not  been  formally  evaluated. 
6.2  Methods 
6.2.1  Patients 
Nine  diet-controlled  Caucasian  patients  with  NIDDM  (one  female),  mean±SD 
5719.7  years,  body  mass  index  (BMI)  29±3.9  kg/m2,  fasting  plasma  glucose 
9.0±2.2  mmol/1  (range  5.7  to  12.4  mmol/1),  HbA1  5.7±0.8  %  (normal  range  3.4- 
4.9%),  total  cholesterol  5.76±1.25  mmol/l  with  median  duration  of  diabetes  12 
months  (range  4-92)  gave  written  informed  consent  to  participate  in  this  study. 
NIDDM  was  confirmed  according  to  WHO  criteria  (World  Health  Organisation 
1980),  and  none  had  evidence  of  retinopathy  (as  determined  by  direct  fundoscopy) 
or  microalbuminuria.  Mean  blood  pressure  on  screening  was  148±25/82±7 
mmHg;  two  were  cigarette  smokers.  Subjects  were  maintained  on  an  isocaloric 
diet  throughout  the  study  consisting  of  55%  carbohydrate,  25%  fat,  and  20% 
169 protein.  They  were  asked  to  refrain  from  tobacco  or  strenuous  exercise,  and  none 
were  receiving  any  proprietary  or  prescription  medication. 
6.2.2  Diets 
The  sodium  replete  (160  mmoUday)  and  sodium  deplete  (40  mmol/day)  diets  were 
allocated  in  a  randomised  double-blind  placebo-controlled  design  for  four  days 
each  (Figure  6.1)  (McFadyen  et  al  1993).  On  day  1,  each  patient  commenced  a  40 
mmol/day  diet  for  4-days  prior  to  the  first  study  day  (day  5);  on  day  8  they  began 
an  identical  4-day  period  prior  to  the  second  study  day  (day  12).  During  these  two 
periods  of  40  mmol/day  sodium  diet,  patients  were  randomised  in  a  crossover 
design  to  receive  a)  slow  sodium  tablets  (Ciba-Geigy,  Horsham,  UK)  120 
mmol/day,  and  b)  matching  placebo  slow  sodium  tablets  (double-blind)  in 
random-order.  On  the  first  day  of  the  sodium  deplete  regime,  patients  received  a 
single  oral  dose  of  frusemide  (40  mg);  this  was  matched  by  an  identical  placebo 
on  the  first  day  of  the  sodium  replete  regime. 
6.2.3  Clinical  Procedure 
Each  patient  attended  two  5-h  study  days  in  the  Clinical  Investigation  and 
Research  Unit  to  evaluate  the  effects  of  the  sodium  deplete  and  sodium  replete 
diets  on  insulin-mediated  glucose  uptake  and  endogenous  glucose  production.  On 
each  occasion,  after  an  overnight  fast  (water  was  permitted),  patients  attended  at 
0800  hrs  and  completed  a  24  hour  urine  collection  on  arrival.  Insulin  sensitivity 
(]N4-value)  and  endogenous  glucose  production  were  assessed  using  the 
170 hyperinsulinaemic  clamp  technique  (DeFronzo  et  al  1979)  with  [3_3  H]glucose 
(Levy  et  al  1989,  Hother-Nielsen  and  Beck-Nielsen  1990,  Hother-Nielsen  et  al 
1992)  (Sections  2.4  and  2.5).  In  order  to  avoid  potentially  confounding  higher 
rates  of  insulin-independent  glucose  disposal  in  patients  with  higher  fasting  serum 
glucose  concentrations,  clamps  were  performed  at  each  patient's  own  fasting 
glucose  level  as  determined  at  the  screening  visit  (i.  e.  clamps  were  isoglycaemic 
rather  than  euglycaemic)  (Saad  et  al  1994).  The  total  activity  of  3H  administered 
to  each  subject  was  5.2  MBq.  Blood  pressure  and  heart  rate  were  measured  every 
10  minutes  throughout  the  procedure.  At  -120,  -60,  -30,  -20,  -10,0,60,120, 
130,140  and  150  minutes,  additional  blood  samples  were  withdrawn  for 
measurement  of  glucose  specific  activity,  serum  insulin,  C-peptide,  triglycerides, 
and  electrolytes  and  plasma  renin  activity  (PRA)  and  aldosterone  (Section  2.8). 
Plasma  ANG  II  was  measured  at  -120,0  and  150  minutes. 
6.2.4  Statistical  analysis. 
Insulin  sensitivity  (M  and  Sjp),  and  endogenous  glucose  production,  were 
compared  on  salt  replete  vs  salt  replete  days  using  paired  t-tests.  Measurements  of 
serum  insulin,  C-peptide,  sodium,  potassium,  PRA,  angiotensin  II  and  aldosterone 
at  individual  time  points  were  compared  between  study  days  by  repeated  measures 
analysis  of  variance  (ANOVA)  using  the  Bonferroni  method  to  correct  for 
multiple  comparisons  (Section  2.9). 
171 Figure  6.1  Study  design 
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172 6.3  Results 
The  hyperinsulinaemic  clamps  and  diets  were  well  tolerated  and  there  were  no 
adverse  events.  Nine  patients  gave  informed  consent  to  enter  the  study,  but  one 
patient  was  withdrawn  owing  to  failure  to  comply  with  diet. 
6.3.1  BP  and  weight. 
There  were  no  significant  differences  in  systolic  BP,  diastolic  BP,  or  weight  on 
the  sodium  replete  and  deplete  diets  (Table  6.1). 
6.3.2  PRA,  plasma  ANG  II,  plasma  aldosterone,  serum  electrolyte  and 
triglyceride  concentrations. 
24  hour  urinary  sodium  excretion  was  significantly  lower  (Table  6.1),  and  the 
corresponding  PRA,  angiotensin  H,  plasma  aldosterone  levels  and  serum  sodium 
concentrations  were  significantly  higher  on  the  sodium  deplete  diet,  both  at 
baseline  and  throughout  the  clamp  studies  (Figures  6.2,6.3).  There  were  no 
significant  differences  in  baseline  or  insulin-mediated  reductions  in  serum 
potassium  or  triglycerides  between  the  two  study  days  (Figure  6.3). 
6.3.3  Serum  insulin,  glucose,  and  C-peptide  concentrations. 
There  were  no  significant  differences  in  fasting  serum  insulin  or  glucose  levels 
with  dietary  sodium  manipulation  (Table  6.1).  Similarly,  there  were  no 
significant  difference  in  steady  state  serum  insulin  concentrations  during  the  two 
study  days  (Figure  6.4). 
173 6.3.4  Insulin  sensitivity  and  endogenous  glucose  production. 
The  coefficients  of  variation  of  serum  glucose  at  steady  state  were  3.1  %  (sodium 
replete)  and  2.4%  (sodium  deplete).  Insulin  sensitivity  (M-value)  was  7.8±2.0 
mg/kg/min  and  6.5±2.2  mg/kg/min  on  the  sodium  replete  and  sodium  deplete 
diets  respectively,  p=0.04,95%  CI  (-1.82,  -0.04)  (Figure  6.5).  Insulin  sensitivity 
index  (S1p)  was  5.8±2.69  and  4.6±2.04  x  104  dl/min.  kg  per  mU/1  on  the  sodium 
replete  and  sodium  deplete  diets  respectively,  p=0.02,95%  Cl  (-2.14,  -0.29). 
Fasting  endogenous  glucose  production  (EGP)  was  similar  on  the  two  diets 
(1.64±0.85  vs  1.48±0.90  mg/kg/min  p=0.74,95%  CI  -0.91,1.22),  but  there  was  a 
trend  towards  blunting  of  insulin-mediated  EGP  suppression  on  the  sodium 
deplete  diet  which  failed  to  reach  statistical  significance  (-0.63±0.94  vs  - 
0.17±1.14  mg/kg/min,  p=0.09,95%  Cl  -1.04,0.10)  (Figure  6.6). 
174 Table  6.1:  Haemodynamic,  metabolic  and  hormonal  measurements  at  baseline 
Mean±SD 
Sodium 
deplete 
Sodium 
replete  p  value 
Systolic  blood  pressure  (mmHg)  130±21  128±12  0.66 
Diastolic  blood  pressure  (mmHg)  78±11  73±10  0.15 
Weight  (kg)  79.4±12.2  80.0±12.1  0.15 
Urinary  sodium  (mmol/day)  67±19.5  197±76.0  0.03* 
Fasting  glucose  (mmol/l)  8.7±2.44  8.5±1.99  0.55 
Fasting  serum  insulin  93±53.8  82±53.9  0.13 
(pmol/1) 
175 Figure  6.2.  MeanSD  profiles  of  PRA,  ANGH,  and  aldosterone  for  2  hours 
before  and  during  clamp. 
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176 Figure  6.3  MeanSD  profiles  of  sodium,  potassium,  and  triglycerides 
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177 Figure  6.4  Mean  SD  profiles  of  insulin  and  C-peptide  for  2  hours  before 
and  during  clamp. 
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180 6.4  Discussion 
The  novel  finding  of  this  double-blind  randomised  placebo-controlled  study  was 
that  moderate  4-day  dietary  sodium  restriction,  accompanied  by  biochemical 
evidence  of  activation  of  the  renin-angiotensin  system  (RAS),  was  associated  with 
a  12%  reduction  in  insulin-mediated  glucose  uptake  in  patients  with  NIDDM. 
This  effect  was  predominantly  on  peripheral  glucose  metabolism,  but  an 
additional  trend  was  observed  towards  an  attenuation  of  hepatic  insulin 
sensitivity. 
As  far  as  can  be  ascertained,  the  effect  of  dietary  sodium  restriction  on  insulin- 
mediated  glucose  uptake  in  patients  with  diabetes  has  not  previously  been 
reported.  However,  the  present  data  are  consistent  with  limited  previously- 
available  information  on  the  insulin  antagonist  effects  of  components  of  the  RAS 
(Section  1.7.2),  and  the  potentiation  by  ANGII  of  sympathetic  neurotransmission 
in  sodium-restricted  subjects  (Taddei  et  al  1995).  The  overall  effect  of  ANGII  on 
insulin  sensitivity  is  complex,  and  the  present  findings  are  difficult  to  reconcile 
with  previous  reports  of  increased  insulin  sensitivity  during  intravenous  infusions 
of  ANGII  in  both  patients  with  NIDDM  (Morris  et  al  1994c)  and  healthy 
volunteers  (Buchanan  et  al  1993,  Widgren  et  al  1993).  While  it  has  been 
suggested  that  insulin-sensitising  effects  of  acute  ANGH  infusion  may  be 
predominantly  due  to  macrovascular  haemodynamic  mechanisms  (redistribution 
of  blood  flow  from  visceral  to  skeletal  muscle  beds  (Buchanan  et  al  1993),  the 
observation  of  insulin-sensitising  effects  at  subpressor  doses  requires  an 
181 alternative  explanation.  For  example,  acute  ANGII  infusion  may  enhance  glucose 
disposal  by  a  microvascular  haemodynamic  mechanism  (redistribution  of  blood 
flow  from  type  2  to  more  insulin-sensitive  type  1  skeletal  muscle  fibres)  or  by  a 
direct  metabolic  effect. 
In  contrast  to  these  acute  studies,  increased  ANGII  levels  were  associated  with  a 
decrease  in  insulin  sensitivity  in  the  current  study.  The  major  difference  between 
this  study  using  dietary  sodium  restriction  and  studies  involving  acute  infusions  of 
ANGII  was  a  more  sustained  physiological  elevation  of  plasma  ANGH 
concentrations.  Down-regulation  of  vascular  angiotensin  receptors  occurs  at  high 
endogenous  levels  of  ANGII  (Hollenberg  et  al  1974),  and  thus  a  temporal  effect 
may  account  for  the  discrepancy  between  the  effects  of  acute  and  chronic 
elevation  of  ANGII.  Aldosterone  release  in  response  to  ANGII  is  enhanced 
during  hyperinsulinaemia  (Rocchini  et  al  1990)  and  sodium  restriction  (Dawson- 
Hughes  et  al  1981),  but  the  decrease  in  insulin  sensitivity  observed  in  the  present 
study  cannot  readily  be  attributed  to  aldosterone  itself  as  measured  concentrations 
were  comparable  to  those  observed  during  acute  ANGII  infusion,  which  was 
associated  with  an  increase  in  insulin  sensitivity.  Steady-state  serum  insulin  levels 
achieved  during  the  clamp  procedures  were  similar  on  both  dietary  regimes, 
despite  the  theoretical  possibility  of  plasma  volume  contraction  on  the  sodium 
deplete  diet. 
The  effect  of  activation  of  the  RAS  on  insulin  sensitivity  has  previously  been 
examined  in  studies  of  dietary  sodium  depletion  in  healthy  volunteers,  but  results 
182 have  been  conflicting.  For  example,  Sharma  et  al  reported  no  change  in  insulin 
sensitivity,  as  measured  by  the  insulin  suppression  test,  when  subjects  were 
maintained  on  240  mmol/day  vs  20  mmol/day  dietary  sodium  for  7  days  (Sharma 
et  al  1993).  Donovan  et  al  reported  increased  insulin  sensitivity  measured  by  the 
euglycaemic  clamp  technique  when  subjects  were  maintained  on  very  low  (10 
mmol/day)  compared  with  very  high  (200  mmol/day)  sodium  diets  for  5  days 
(Donovan  et  at  1993).  In  contrast,  in  a  further  study  using  the  euglycaemic  clamp, 
insulin  sensitivity  was  higher  after  3  days  on  a  high  sodium  diet  (Fliser  et  al 
1995).  All  three  of  these  studies  were  open  in  design  and  used  either  very  high  or 
very  low  sodium  diets.  These  are  only  easily  administered  in  a  clinical  research 
setting  and  are  not  generally  applicable  to  the  management  of  patients  with 
NIDDM. 
The  effect  of  inhibition  of  the  RAS,  and  hence  withdrawal  of  angiotensin  II,  on 
insulin-mediated  glucose  uptake  has  been  more  widely  investigated  than 
activation  of  the  RAS  in  studies  of  the  metabolic  effects  of  ACE  inhibitors. 
However,  as  already  discussed  (Section  1.1.6),  many  studies  in  the  literature  are 
compromised  by  use  of  indirect  measures  of  insulin  sensitivity,  before-and-after 
design,  and  lack  of  placebo  data  (Donnelly  1992).  In  addition,  in  those  studies  in 
which  an  effect  is  reported,  inhibition  of  kinin  degradation  cannot  be  dissociated 
from  the  withdrawal  of  ANGII  (Dietze  et  al  1996). 
From  the  present  data  it  is  not  possible  to  be  certain  of  the  mechanism  for  the 
consistent  decrease  in  peripheral  insulin  sensitivity  observed  during  sodium 
183 depletion  in  the  subjects  studied.  However,  RAS  activation  with  elevated  plasma 
ANGII  concentrations  is  a  strong  candidate  mechanism;  given  that  plasma 
concentrations  were  elevated  only  moderately,  and  that  blood  pressure  did  not 
change,  a  metabolic  rather  than  haemodynamic  effect  seems  most  likely.  For 
example,  ANGII  has  recognised  effects  on  hepatic  glucose  metabolism  (DeWitt  et 
al  1983,  Kneer  et  al  1983),  consistent  with  the  trend  observed  towards  blunting  of 
insulin-mediated  suppression  of  endogenous  glucose  production.  In  addition, 
there  is  evidence  that  the  hormone  alters  the  intracellular  signalling  pathway 
initiated  by  activation  of  the  insulin  receptor.  ANG  H  activates  protein  kinase  C 
via  receptor-linked  formation  of  diacylglycerol  (Smrcka  et  al  1991),  and  inhibits 
insulin-stimulated  P13-kinase  activity  (Velloso  et  al  1996);  inhibition  of  the 
phosphorylation  cascades  initiated  by  insulin  may  result  in  decreased  translocation 
to  the  plasma  membrane  of  the  facilatative  transporter  protein  GLUT-4.  In  the 
present  study,  plasma  catecholamines  were  not  measured,  but  a  further  possible 
mechanism  for  the  decrease  in  insulin  sensitivity  observed  would  be  RAS- 
mediated  activation  of  the  sympathetic  nervous  system. 
Measurements  of  endogenous  glucose  production  showed  the  expected  inhibitory 
effect  of  hyperinsulinaemia.  In  the  technique  used,  the  aim  of  labelling  both 
constant  and  variable  rate  glucose  infusions  when  measuring  endogenous  glucose 
production  in  clamp  studies  was  to  prevent  a  fall  in  glucose  specific  activity 
during  the  procedure,  and  thereby  to  reduce  the  intercompartmental  fluxes  which 
are  thought  to  be  responsible  for  negative  values  for  hepatic  glucose  production 
(Levy  et  al  1989).  The  technique  is  known  not  to  abolish  the  occurrence  of  such 
184 values  entirely,  even  when  specific  activity  matching  is  achieved  (Hother-Nielsen 
and  Beck-Nielsen  1990,  Hother-Nielsen  et  al  1992).  In  the  present  study,  despite 
a  rise  in  glucose  specific  activity  between  baseline  and  steady-state 
hyperinsulinaemia,  some  of  the  EGP  values  during  hyperinsulinaemia  were 
negative.  However,  reassuringly,  mean  values  were  very  similar  to  those  reported 
by  other  investigators  in  similar  groups  of  patients  (Harper  et  al  1995). 
Regardless  of  the  underlying  mechanism  for  the  deterioration  in  insulin  sensitivity 
associated  with  dietary  sodium  depletion  in  these  patients,  the  result  may  have 
clinical  as  well  as  metabolic  relevance.  Current  dietary  recommendations  for 
diabetes  (in  both  Europe  and  the  US)  are  for  normotensive  patients  to  restrict 
sodium  intake  to  100  mmol/day  (6g),  and  for  patients  with  co-existing 
hypertension  to  restrict  intake  to  50  mmol/day  (3g)  (Nutrition  Study  Group, 
European  Association  for  the  Study  of  Diabetes  1988,  American  Diabetes 
Association  1996).  The  regimen  used  in  this  study,  in  normotensive  patients  with 
NMDM,  allowed  40  mmol/day  (mean  sodium  excretion  67  mmol/day)  and 
resulted  in  impaired  insulin  sensitivity;  moderate  dietary  sodium  restriction  may 
not  therefore  be  optimal  for  metabolic  function  in  these  patients. 
In  conclusion,  dietary  sodium  restriction  decreases  insulin  sensitivity  in  patients 
with  NIDDM,  and  this  may  be  a  result  of  RAS  activation.  These  findings  provide 
further  insights  into  the  effects  of  the  RAS  on  glucose  metabolism  and,  if 
confirmed,  have  implications  for  dietary  sodium  intake  recommendations  for 
these  patients. 
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Insulin  sensitivity  and  endothelial  function:  a  physiological  link  with 
implications  for  pathogenesis  of  cardiovascular  disease 
7.0  Summary 
The  clinical  study  described  in  this  chapter  was  designed  to  examine  in  vivo  in 
man  the  relationship  between  basal  and  stimulated  endothelial  nitric  oxide 
production,  as  assessed  by  forearm  vasoconstrictor  responses  to  intra-arterial 
infusions  of  N(;  -monomethyl  L-arginine  (L-NMMA)  and  acetyl-choline,  and 
insulin-mediated  glucose  uptake  (insulin  sensitivity),  measured  using  the 
euglycaemic  clamp  technique. 
7.1  Introduction 
The  elucidation  of  the  mechanism  of  insulin  resistance  in  common  insulin 
resistant  states  has  been  complicated  by  the  threefold  variation  in  insulin 
sensitivity  observed  within  groups  of  apparently  healthy  non-obese 
individuals  (Section  1.1.2)  (Hollenbeck  et  al  1987).  The  similarities  between  the 
conditions  in  which  endothelial  function  and  insulin  sensitivity  are  impaired,  and 
between  the  interventions  which  are  thought  to  improve  them,  raise  the  hypothesis 
that  they  are  physiologically  linked  (Section  1.7.3). 
Insulin  is  an  arterial  vasodilator  in  skeletal  muscle  vascular  beds,  and  there  is 
evidence  that  insulin-mediated  vasodilatation  is  reduced  in  states  of  insulin 
resistance  (Baron  et  al  1990,1991a,  1993)  (Section  1.7.3).  It  has  recently  been 
186 reported  that  the  vascular  effects  of  insulin  are  dependent  on  endothelial  nitric 
oxide  synthesis/release  (Scherrer  et  al  1994;  Steinberg  et  al  1994),  while 
decreased  basal  endothelial  nitric  oxide  synthesis  has  been  reported  in  essential 
hypertension  (Calver  et  al  1992). 
If  endothelial  function  and  insulin  sensitivity  are  physiologically  linked,  there 
should  be  a  correlation  between  these  two  variables  across  the  range  of  insulin 
sensitivity  found  in  healthy  man.  The  aim  of  this  study  was  to  examine  this 
hypothesis. 
7.2  Methods 
7.2.1  Subjects 
Nineteen  healthy  nonnotensive  male  volunteers  aged  21-35  years  with  normal 
glucose  tolerance  participated  in  this  study.  At  a  screening  visit,  supine 
blood  pressure  was  measured  in  triplicate  (Section  2.3.3).  In  order  to  quantify 
habitual  physical  activity  as  a  potentially-confounding  variable,  all  subjects  were 
asked  to  complete  the  self-reported  section  of  a  previously  described 
questionnaire  assessing  moderate  and  vigorous  physical  activity  level  (Sallis  et 
al  1985).  In  addition,  age,  BMI  (body  mass  index),  MAP  (mean  arterial 
pressure),  plasma  glucose  level,  serum  cholesterol  level,  alcohol  intake,  and 
family  history  of  cardiovascular  disease  were  recorded. 
187 7.2.2  Clinical  procedures 
i)  Hyperinsulinaemic  euglycaemic  clamp.  On  the  first  study  day,  subjects 
underwent  assessment  of  sensitivity  to  insulin-mediated  glucose  uptake  using  a 
three  hour  euglycaemic  clamp  (Section  2.4.1). 
ii)  Forearm  venous  occlusion  plethysmography.  On  two  further  study  days, 
subjects  attended  for  measurement  of  basal  and  stimulated  endothelial  nitric 
oxide  production.  Forearm  blood  flow  (FBF)  was  measured  using  venous 
occlusion  plethysmography.  A  30  minute  stabilisation  period  was  allowed  prior 
to  baseline  measurements,  and  a  30  minute  washout  period  was  intercalated 
between  drug  infusions. 
iii)  Intra-arterial  drug  infusion.  A  27G  unmounted  steel  needle  (Cooper's 
Needleworks,  Birmingham,  U.  K.  )  was  inserted  under  local  anaesthesia  into  the 
brachial  artery  of  the  non-dominant  arm  for  drug  infusion  (Section  2.7). 
Local  incremental  doses  of  drugs  [acetylcholine  20,40,80,160  pmol/min 
(Miochol,  Cibavision,  Southampton,  U.  K.  );  sodium  nitroprusside  3,10,30 
pmol/min  (Roche,  Basel,  Switzerland);  noradrenaline  15,30,150,300  pmolmin 
(Levophed,  Sanofi-Winthrop,  U.  K.  );  N  -monomethyl-L  -arginine  1,2,4 
µmol/min  (L-NMMA;  Clinalfa  AG,  Läufelfingen,  Switzerland)]  were  dissolved 
in  0.9%  saline  and  infused  intra-arterially  at  a  constant  rate  of  lmi/min. 
7.2.3  Experimental  protocol 
i)  Day  1.  Subjects  received  ascending  doses  of  acetylcholine,  an  endothelium- 
dependent  stimulator  of  nitric  oxide  synthase,  and  sodium  nitroprusside, 
an  endothelium-independent  donor  of  nitric  oxide. 
188 ii)  Day  2.  Subjects  received  ascending  doses  of  noradrenaline,  a  "control" 
vasoconstrictor,  and  L-NMMA,  a  substrate  inhibitor  of  nitric  oxide  synthase. 
Blood  flow  was  measured  in  both  forearms  and  each  value  was  the  mean  of 
five  sequential  measurements.  Percentage  change  from  basal  values  in  the 
ratio  of  blood  flow  between  infused  and  non-infused  arms  was  calculated 
with  blood  flow  in  the  non-infused  arm  as  a  concurrent  control  (Benjamin  et 
al  1995). 
7.2.4  statistical  analysis 
Insulin  sensitivity  and  drug  response  data  were  normally  distributed  (Section  2.9). 
Because  serial  measurements  were  made,  and  log  dose-response  plots  were 
linear,  each  subject's  mean  response  to  all  administered  doses  of  each  drug  was 
calculated  as  a  summary  measure  (Matthews  et  al  1990).  Data  were  initially 
examined  using  simple  correlation;  multiple  regression  analysis  was  performed  in 
order  to  examine  potential  confounders. 
7.3  Results 
19  subjects  completed  acetylcholine  and  sodium  nitroprusside  infusions;  15 
completed  noradrenaline  and  L-NMMA  infusions  (arterial  cannulation  could 
not  be  repeated  in  two  subjects,  and  two  withdrew  for  personal  reasons). 
Characteristics  of  the  subjects  are  shown  in  Table  7.1. 
189 7.3.1  Forearm  blood  flow  (FBF)  responses  to  intra-arterial  drug  infusion 
Vasodilator  responses  to  acetylcholine  and  sodium  nitroprusside,  and 
vasoconstrictor  responses  to  noradrenaline  are  shown  in  Figure  7.1. 
7.3.2  Insulin  sensitivity 
Insulin  sensitivity  (M)  ranged  from  6.2  to  11.6  mg/kg/min  (Figure  7.2). 
7.3.3  Insulin  sensitivity  and  FBF  responses  to  intra-arterial  drug  infusion 
In  univariate  analysis,  individual  measurements  of  insulin  sensitivity  (M) 
were  positively  related  to  individual  mean  L-NMMA  responses  (r=0.52, 
p<0.05,95%  CI  0.01,0.81)(Figure  7.2).  However,  no  relationships  were 
observed  between  M-values  and  noradrenaline  responses  (r=0.14,  p=0.62, 
95%  Cl  -0.40,0.61)  acetylcholine  responses  (r=0.15,  p=0.53,95%  CI  -0.33, 
0.56)  or  sodium  nitroprusside  responses  (i=0.31,  p=0.20,95%CI  -0.17, 
0.67)(Figure  7.2).  Similar  results  were  obtained  when  the  area  under  the  curve 
was  used  as  an  alternative  summary  measure  of  drug  response  (Matthews  et  al 
1990). 
7.3.4  Multiple  regression  analysis 
One  subject,  identified  by  the  Minitab  statistical  package  (Section  2.9)  as  an 
"unusual  observation,  "  was  excluded  from  this  analysis.  The  results,  taking  into 
account  age,  BMI  (body  mass  index),  MAP  (mean  arterial  pressure),  plasma 
glucose  level,  serum  cholesterol  level,  alcohol  intake,  family  history  and  physical 
activity  level,  are  shown  in  Table  7.2. 
190 Table  7.1  Haemodynamic  and  metabolic  characteristics  of  the  subjects 
(n=19) 
(mean±SD) 
Age  (years)  27.1±5.3 
Body  mass  index  (kg/m2) 
Fasting  glucose  (mmol/1) 
Fasting  cholesterol  (mmol/1) 
Blood  pressure  (mmHg) 
Smokers 
Family  history  of 
cardiovascular  disease 
or  diabetes 
Median  alcohol 
consumption  (units) 
191 
24.6±3.0 
5.1±0.3 
4.40±0.74 
130±10/69±7 
3/19 
6/19 
16  (interquartile  range  6-20) 
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The  results  of  this  study  demonstrate,  for  the  first  time,  a  positive 
relationship  between  basal  vascular  endothelial  nitric  oxide  production  and 
insulin  sensitivity  in  healthy  young  males.  Under  physiological 
circumstances,  insulin  causes  arterial  vasodilatation  in  skeletal  muscle  vascular 
beds  (Section  1.7.3).  By  increasing  its  own  delivery,  and  that  of  glucose,  to 
insulin-sensitive  tissues  it  may  amplify  its  own  action  in  promoting  glucose 
uptake  into  skeletal  muscle.  If  local  insulin-mediated  vasodilatation  insulin  is 
impaired,  a  reduction  in  insulin  sensitivity  may  occur. 
It  has  previously  been  reported  that  insulin-mediated  vasodilatation  is 
impaired  in  insulin  resistant  states  (Baron  et  al  1990,1991a,  1993).  The 
present  data,  along  with  recent  evidence  that  endothelial  nitric  oxide  may 
mediate  insulin's  vascular  effects  (Scherrer  et  al  1994,  Steinberg  et  al  1994), 
suggest  a  direct  physiological  link  between  vascular  endothelial  function  and 
insulin  sensitivity  i.  e.  individuals  who  are  relatively  insensitive  to 
insulin-mediated  glucose  uptake  appear  also  to  have  a  corresponding 
decrease  in  basal  endothelial  nitric  oxide  production. 
No  relationship  was  observed  between  noradrenaline  responses  and  insulin 
sensitivity:  this  argues  against  a  non-specific  decrease  in  vascular  reactivity  in 
subjects  who  are  less  sensitive  to  insulin-mediated  glucose  uptake. 
Furthermore,  the  absence  of  a  relationship  between  either  acetylcholine  or 
195 sodium  nitroprusside  responses  and  insulin  sensitivity  suggests  that 
decreased  insulin  sensitivity  is  not  associated  with  a  reduced  ability  of 
the  vascular  endothelium  to  synthesise  nitric  oxide  when  stimulated,  or 
with  a  reduction  in  sensitivity  of  vascular  smooth  muscle  to  nitric  oxide 
released  from  the  endothelium. 
Insulin  sensitivity  has  been  shown  to  be  related  to  age,  body  mass  index, 
and  maximal  aerobic  capacity  in  normal  subjects,  but  may  vary  up  to 
threefold  in  subjects  apparently  similar  in  these  respects  (Hollenbeck  et  al 
1987).  The  present  study  group  was  as  homogeneous  as  possible  for  these 
variables,  with  only  a  twofold  variation  in  insulin  sensitivity.  The 
relationship  between  L-NMMA  response  and  insulin  sensitivity  was  stronger 
than  the  relationships  between  all  of  the  other  variables  and  insulin 
sensitivity,  accounting  for  48%  of  the  variance,  and  was  not  explained  by 
a  known  confounding  variable.  Age  was  not  associated  with  insulin  sensitivity, 
perhaps  because  of  the  homogeneity  of  the  group. 
The  relationship  identified  in  this  study  is  compatible  with  three 
hypotheses:  1)  decreased  basal  endothelial  nitric  oxide  production  results 
in  decreased  insulin  sensitivity,  possibly  due  to  reduced  insulin-mediated 
vasodilatation  in  skeletal  muscle;  2)  decreased  insulin  sensitivity  results 
in  decreased  basal  production  of  nitric  oxide  by  the  vascular 
endothelium;  3)  decreased  basal  endothelial  nitric  oxide  production  and 
impaired  insulin  sensitivity  are  manifestations  of  a  common  genetic  or 
environmental  antecedent. 
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endothelial  function,  but  do  not  provide  evidence  of  causality.  However,  there  are 
a  number  of  putative  mechanisms  by  which  endothelial  dysfunction  might  cause 
impairment  of  insulin  action.  Insulin  must  cross  the  endothelial  barrier  in  order  to 
exert  its  metabolic  effects  in  target  tissues;  dysfunction  of  an  active  transport 
mechanism  might  result  in  a  decrease  insulin  sensitivity.  Alternatively,  reduced 
activity  of  an  endothelial  enzyme  such  as  lipoprotein  lipase  could  result  in 
dyslipidaemia  with  secondary  effects,  perhaps  via  oxidation  of  LDL  (DiCorleto 
and  Soyombo  1993),  on  insulin-mediated  glucose  metabolism  (Ahn  et  al  1993). 
It  is  also  possible  to  hypothesise  mechanisms  by  which  insulin  resistance  might 
cause  endothelial  dysfunction.  The  substrate  for  endothelial  nitric  oxide  synthase 
is  the  amino-acid,  L-arginine;  although  availability  of  L-arginine  is  not  thought  to 
be  rate-limiting  for  nitric  oxide  synthesis  under  physiological  conditions,  it  is 
conceivable  that  L-arginine  transport,  which  is  activated  in  human  endothelial 
cells  by  glucose  and  insulin  (Sobrevia  et  al  1996),  might  be  impaired  in  conditions 
of  insulin  resistance. 
Lastly,  both  endothelial  function  and  insulin  resistance  may  arise  as  a  result  of  a 
common  antecedent.  For  example,  high  concentrations  of  free  fatty  acids  in 
insulin  resistant  states  (Section  1.1.3)  are  known  to  compete  with  glucose  for 
peripheral  uptake  (Randle  et  al  1963),  and  in  addition  appear  to  inhibit  endothelial 
nitric  oxide  synthesis  (Davda  et  al  1995).  Other  potential  common  antecedents 
include  low  skeletal  muscle  capillary  density  (Section  1.6.3),  and  oxidative  stress 
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intra-uterine  development  (Barker  et  al  1993a,  1993b). 
Important  candidate  mechanisms  for  physiological  processes  potentially  linking 
insulin-mediated  vasodilatation,  insulin-mediated  glucose  metabolism  and 
endothelial  function  may  be  gleaned  from  investigation  of  the  mechanisms  of 
local  insulin-mediated  vasodilatation  in  skeletal  muscle  vascular  beds.  Clearly, 
further  studies  are  required:  a)  to  determine  whether  a  relationship  between 
endothelial  function  and  insulin  sensitivity  is  observed  in  insulin  resistant 
pathophysiological  states;  b)  to  investigate  the  effects  of  manipulating  endothelial 
function  on  insulin-mediated  glucose  uptake;  and  c)  to  investigate  the  effects  of 
therapeutic  interventions  on  insulin  sensitivity  and  endothelial  function  in  the 
same  subjects. 
198 Chapter  8 
General  discussion 
Variations  in  sensitivity  to  insulin  treatment  in  patients  with  diabetes  were 
observed  by  Himsworth  over  60  years  ago  (Himsworth  1936),  and 
hyperinsulinaemia  was  reported  in  patients  with  essential  hypertension  (Welborn 
et  al  1966)  only  6  years  after  the  introduction  of  early  immunoassays  for  insulin 
(Yalow  and  Berson  1960).  It  is  now  recognised  that  hyperinsulinaemia  in 
essential  hypertension  occurs  as  a  pancreatic  compensatory  response  to  resistance 
to  insulin-mediated  glucose  uptake  in  skeletal  muscle  tissue  (Ferrannini  et  al 
1987,  Natali  et  al  1991).  However,  the  relationship  between  serum  insulin 
concentrations  and  blood  pressure  is  variable  between  studies  (Modan  et  al  1985, 
Asch  et  al  1991),  and  insulin  sensitivity  varies  up  to  threefold  in  apparently 
healthy  individuals  (Hollenbeck  and  Reaven  1987).  The  mechanism  and 
pathophysiological  significance  of  insulin  resistance  in  common  cardiovascular 
disease  states  such  as  non-insulin  dependent  diabetes  mellitus,  essential 
hypertension,  dyslipidaemia,  and  obesity  remain  obscure,  although 
hyperinsulinaemia  appears  to  be  an  independent  risk  factor  for  ischaemic  heart 
disease  (Despres  et  al  1996),  and  may  be  directly  modifiable  by  non- 
pharmacological  and  pharmacological  interventions. 
Investigation  of  the  mechanisms  of  insulin  resistance  has  focused  on  the  insulin 
receptor  and  post-receptor  signalling  mechanisms.  However,  abnormalities 
recognised  to  date  in  these  processes  do  not  account  for  insulin  resistance  in 
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possible  role  for  pre-receptor  haemodynamic  factors  in  the  physiological 
regulation  of  insulin  sensitivity  and  in  the  pathogenesis  of  insulin  resistance  in 
cardiovascular  disease.  Considerable  controversy  surrounds  the  phenomenon  of 
insulin-mediated  vasodilatation  and  whether  attenuation  of  the  physiological 
vasodilator  effect  of  insulin  might  account  directly  for  decreased  tissue  glucose 
uptake  during  hyperinsulinaemia  in  skeletal  muscle  vascular  beds  in  insulin 
resistant  states  (Baron  et  al  1993). 
This  thesis  is  comprised  of  a  series  of  studies  which  have  used  specific  and 
conventional  insulin  immunoassays,  the  hyperinsulinaemic  clamp  technique  and 
forearm  venous  occlusion  plethysmography  with  local  intra-arterial  infusions  to 
address  some  of  these  issues.  The  major  emphases  are  on  the  relationship 
between  serum  insulin  concentrations  and  blood  pressure,  and  the  role  of 
haemodynamic  factors  in  determining  insulin  sensitivity. 
The  following  hypotheses  were  investigated: 
1)  are  variations  in  specificity  for  insulin  (vs.  proinsulin-like  molecules)  among 
conventional  insulin  immunoassays  responsible  for  variations  in  the  reported 
relationships  among  serum  insulin  concentrations,  insulin  sensitivity,  and  blood 
pressure? 
2)  does  sustained  physiological  activation  of  the  renin-angiotensin  system 
induced  by  moderate  dietary  sodium  restriction  affect  insulin  sensitivity  in 
patients  with  non-insulin-dependent  diabetes  mellitus? 
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healthy  subjects? 
(i)  The  reproducibility  of  venous  occlusion  plethysmography 
Venous  occlusion  plethysmography  was  chosen  as  a  method  of  blood  flow 
measurement  for  studies  investigating  putative  haemodynamic  factors  in  the 
physiological  regulation  of  insulin  sensitivity.  It  was  noted  that  studies  using  this 
technique  to  report  changes  in  forearm  blood  flow  (FBF)  during  intra-arterial 
infusions  of  vasoactive  substances  often  quoted  changes  in  flow  ratio  between 
infused  and  control  arms  rather  than  absolute  values  for  flow,  although  unilateral 
measurements  and  forearm  vascular  resistance  data  were  quoted  by  other 
investigators.  The  possibility  was  considered  that  the  method  used  for  expressing 
responses  might  influence  the  conclusions  reached,  or  lead  to  performance  of  a 
relatively  invasive  technique  on  an  unnecessarily  large  number  of  subjects  to 
detect  small  differences  between  groups.  A  reproducibility  study  was  therefore 
performed  which  demonstrated: 
1)  that  the  between-day  infra-subject  variability  of  bilateral  forearm  venous 
occlusion  plethysmography  (FBF  ratios)  was  19%  at  rest; 
2)  FBF  ratios  were  more  reproducible  than  unilateral  FBF  measurements  (CV  31- 
39%)  at  rest  and  during  intra-arterial  infusions; 
3)  expressing  results  as  forearm  vascular  resistance  resulted  in  only  a  small 
improvement  in  reproducibility  over  FBF  at  rest. 
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the  intervention  arm  as  a  ratio  of  responses  in  the  control  arm,  was  more 
reproducible  than  unilateral  plethysmography:  the  bilateral  technique  was 
therefore  used  where  possible  in  further  studies. 
(ii)  The  effect  of  hand-warming  on  insulin  sensitivity  and  forearm  blood  flow 
The  methodology  for  the  reproducible  measurement  of  insulin  sensitivity  using 
the  hyperinsulinaemic  euglycaemic  clamp  technique  had  previously  been 
established  in  the  Clinical  Investigation  and  Research  Unit.  However,  given  that 
investigation  of  haemodynamic  influences  on  insulin-mediated  glucose  uptake 
were  a  major  theme  of  these  studies,  further  validation  studies  were  performed  to 
investigate  whether  vasodilatation  produced  during  arterialisation  of  venous  blood 
by  the  commonly-used  technique  of  hand-warming  had  systemic  haemodynamic 
effects  or  effects  on  the  measurement  of  insulin  sensitivity.  The  results  of  these 
controlled  studies  in  healthy  subjects  showed  that  hand-warming  by  the  heated-air 
hand  box  was  associated  with  a  decrease  in  derived  insulin  sensitivity  when 
clamps  were  performed  according  to  samples  from  a  site  unlikely  to  be  affected  by 
arterialisation  (the  contralateral  antecubital  vein).  However,  no  difference  in 
insulin  sensitivity  associated  with  hand-warming  was  demonstrated  when  the 
infusion  rate  was  adjusted  on  the  basis  of  samples  from  a  site  in  which  arteriali- 
sation  could  be  demonstrated  (the  ipsilateral  dorsal  hand  vein).  In  addition,  hand- 
warming  appeared  to  cause  an  increase  in  heart  rate  during  hyperinsulinaemia  and 
an  increase  in  contralateral  forearm  blood  flow  under  basal  conditions.  It  was 
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have  the  potential  to  confound  the  results  of  studies  using  the  euglycaemic  clamp 
technique,  particularly  those  with  a  case-control  design  and  those  assessing  the 
haemodynamic  effects  of  insulin.  It  was  reassuring  that  hand-warming  had 
negligible  effects  on  derived  insulin  sensitivity  when  clamps  were  performed  in 
the  usual  manner,  but  it  was  decided  that  future  measurements  of  forearm  blood 
flow  would  be  conducted  in  the  absence  of  hand-warming. 
(iii)  The  effect  of  insulin  assay  specificity  on  the  relationships  among  serum 
insulin  concentrations,  insulin  sensitivity,  and  blood  pressure 
Serum  insulin  concentrations  have  been  used  as  markers  of  insulin  resistance  in 
population  studies  examining  the  relationship  between  insulin  resistance  and 
blood  pressure,  but  the  relationship  between  insulin  and  blood  pressure  is  variable 
among  studies  (Modan  et  al  1985,  Asch  et  al  1991).  Insulin  assay  methodology  is 
not  standardised  between  centres  (Robbins  et  al  1996),  and  epidemiological 
studies  have  used  a  variety  of  commercially-available  assay  kits  for  the 
measurement  of  insulin  concentrations.  It  was  hypothesised  that  variability  in  the 
reported  relationship  between  insulin  and  blood  pressure  might  be  accounted  for 
by  variability  in  cross-reactivity  of  antibodies  used  in  insulin  assay  kits  with  intact 
proinsulin  and  its  split  and  des-amino  products.  It  appeared  that  epidemiological 
studies  which  had  used  assay  systems  which  were  relatively  specific  for  insulin 
had  observed  a  weaker  relationship  betwen  hyperinsulinaemia  and  blood  pressure 
than  those  which  had  used  antibodies  with  a  higher  degree  of  specificity 
(Winocour  et  al  1991).  Indeed,  reports  of  a  (statistically  non-significant) 
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rise  to  the  hypothesis  that  circulating  proinsulin-like  molecules  might  be 
associated  with  cardiovascular  disease  (Galloway  et  al  1992). 
The  relationships  were  therefore  examined  among  fasting  and  post-glucose  load 
serum  insulin  concentrations  (determined  by  both  specific  and  conventional 
assays),  insulin  sensitivity  (measured  by  the  euglycaemic  clamp  technique),  and 
blood  pressure,  in  a  group  of  56  patients  with  NIDDM  and  non-diabetic  subjects. 
Insulin  concentrations  as  measured  by  the  two  methods  were  highly  correlated 
(r=0.97,  p<0.0001),  and  the  relationships  among  serum  insulin  concentrations, 
insulin  sensitivity  and  blood  pressure  were  independent  of  assay  method;  for 
example,  in  non-diabetic  subjects  the  univariate  correlation  between  logio  AUC 
insulin  and  insulin  sensitivity  index  was  similar  with  both  methods  [r=-0.81  vs  r-- 
0.82,  p<0.0001  (specific  assay  vs.  conventional  assay)].  It  was  concluded  that 
variations  among  insulin  assay  kits  in  cross-reactivity  for  insulin  vs  proinsulin- 
like  molecules  were  unlikely  to  account  for  discrepancies  in  the  relationship 
between  serum  insulin  concentrations  and  blood  pressure,  and  that  these  were 
therefore  likely  to  be  accounted  for  either  by  other  non-standardised  aspects  of 
insulin  assay  methodology,  or  by  genuine  differences  among  the  populations 
studied. 
Although  proinsulin-like  molecules  were  not  measured  in  this  series  of  studies,  a 
study  published  during  the  period  that  this  work  was  conducted  has  reported 
similar  correlations  between  proinsulin-like  molecules  and  cardiovascular  risk 
factors  as  those  previously  reported  between  insulin  and  the  same  risk  factors 
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report  suggested  that  the  detection  of  correlations  between  circulating 
concentrations  of  proinsulin-like  molecules  and  cardiovascular  risk  factors  is 
evidence  against  a  modulating  role  for  insulin  in  cardiovascular  disease,  as 
proinsulin-like  molecules  are  equally  strongly  related  to  cardiovascular  risk 
factors,  yet  circulate  at  less  that  10%  of  the  concentration  of  insulin. 
(iv)  The  effect  of  dietary  sodium  restriction  on  insulin  sensitivity  in  non- 
insulin-dependent  diabetes  mellitus 
Angiotensin  II  is  a  potent  vasoconstrictor  hormone  with  counter-regulatory 
metabolic  effects.  A  haemodynamic  hypothesis  of  insulin  sensitivity  would 
predict  that  acute  infusion  of  ANGII  would  result  in  an  exacerbation  of  the 
decrease  in  insulin-mediated  glucose  uptake  that  would  be  expected  from  its 
metabolic  effects.  However,  previous  studies  conducted  in  the  CIRU 
demonstrated  an  insulin-sensitising  effect  of  acute  ANG  II  infusion  in  patients 
with  NIDDM  (Morris  et  al  1994c).  Data  from  studies  in  which  acute  infusions  of 
ANGII  were  administered  to  healthy  male  subjects  allowed  this  effect  to  be 
reconciled  with  a  haemodynamic  hypothesis:  acute  systemic  ANGII  infusion  is 
associated  with  a  redistribution  of  blood  flow  away  from  visceral  and  splanchnic 
vascular  beds  towards  insulin-sensitive  skeletal  muscle  beds  (Buchanan  et  al 
1993). 
The  apparent  haemodynamically-mediated  insulin-sensitising  effects  of  acute 
ANGII  infusion  remained  at  odds  with  its  counter-regulatory  metabolic  effects 
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enzyme  (Pollare  et  al  1989a,  Vuorinen-Markkola  and  Yki-Jarvinen  1995).  It  was 
therefore  hypothesised  that  the  effect  of  ANGII  on  insulin  sensitivity  was 
temporal,  with  a  discrepancy  between  acute  and  chronic  responses.  The  effect  on 
insulin  sensitivity  of  more  sustained  physiological  activation  of  the  renin- 
angiotensin  system  was  therefore  examined  in  patients  with  NIDDM  using 
sodium  restriction  (40  mmol/day)  in  a  randomised,  double-blind,  placebo- 
controlled  crossover  protocol.  Investigation  of  the  effect  of  sodium  restriction  on 
insulin  sensitivity  was  of  both  metabolic  importance  and  clinical  relevance  as 
current  dietary  recommendations  suggest  dietary  sodium  restriction  for  both 
hypertensive  and  normotensive  patients  with  diabetes. 
The  results  of  the  study  demonstrated  that  moderate  dietary  sodium  restriction 
was  associated  with  a  12%  reduction  in  insulin  sensitivity  in  patients  with 
NIDDM.  This  decrease  in  insulin  sensitivity,  associated  with  sustained  elevation 
of  plasma  ANGII  levels,  is  more  consistent  with  the  expected  metabolic  and 
haemodynamic  effects  of  ANGII  and  with  the  reported  effect  of  ACE  inhibition 
on  glucose  metabolism  than  the  effect  observed  during  acute  ANGII  infusion. 
Although  there  is  clear  in  vitro  evidence  for  cross-talk  between  the  insulin  and 
angiotensin  post-receptor  signalling  mechanisms  (Velloso  et  al  1996),  a  recently- 
reported  study  has  provided  direct  evidence  for  a  haemodynamic  mechanism: 
sodium  depletion  resulted  in  increased  vascular  reactivity  in  normotensive 
subjects  and  hypertensive  patients  (Feldman  et  al  1996). 
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The  importance  of  the  vascular  endothelium  in  determining  regional  blood  flow 
has  been  increasingly  recognised  over  the  last  fifteen  years  (Furchgott  and 
Zawadzki  1980).  The  balance  of  evidence  is  in  favour  of  a  local  arterial 
vasodilator  action  of  insulin  in  skeletal  muscle  vascular  beds  (Section  1.7.3). 
There  is  both  in  vivo  (Scherrer  et  al  1994;  Steinberg  et  al  1994)  and  in  vitro 
(Chen  and  Messina  1996)  evidence  that  insulin-mediated  vasodilatation  is 
endothelium  dependent,  and  that  it  is  attenuated  in  states  of  insulin  resistance 
(Baron  et  al  1990,  Baron  et  al  1991a,  Baron  et  al  1991b,  Baron  et  al  1993). 
Observation  of  the  co-existence  of  endothelial  dysfunction  and  insulin  resistance 
in  a  number  of  cardiovascular  disease  states  (essential  hypertension,  non-insulin 
dependent  diabetes  mellitus,  obesity,  dyslipidaemia,  and  atherosclerosis) 
generated  the  hypothesis  of  the  existence  of  a  physiological  link  between 
endothelial  nitric  oxide  production  and  insulin-mediated  glucose  uptake.  The 
threefold  variation  in  insulin  sensitivity  reported  within  groups  of  apparently 
healthy  non-obese  individuals  (Hollenbeck  and  Reaven  1987),  afforded  the 
opportuniy  to  examine  forearm  vascular  endothelial  function  in  a  series  of  healthy 
subjects  across  a  range  of  insulin  sensitivity. 
The  results  of  this  study  demonstrated,  for  the  first  time,  a  positive 
relationship  between  basal  endothelial  nitric  oxide  production  and  insulin 
sensitivity  in  healthy  young  males.  These  data  raise  a  further  hypothesis  that 
insulin  sensitivity  may  in  part  be  determined  by  an  endothelium-dependent  effect 
of  insulin  to  promote  glucose  uptake  by  increasing  blood  flow  (and  hence  delivery 
of  insulin  and  its  substrate  glucose)  to  insulin-sensitive  tissues.  It  might  be 
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states  may  at  least  in  part  be  a  result  of  endothelial  dysfunction,  although  there  are 
some  data  to  suggest  that  the  metabolic  effect  of  insulin  to  increase  fractional 
glucose  extraction  is  more  important  in  determining  glucose  uptake  than  its  effect 
on  blood  flow  within  physiological  ranges  of  insulinaemia  (Utriainen  et  al  1995, 
Raitakari  et  al  1996;  Nuutila  et  al  1996). 
An  independent  group  of  investigators  have  recently  attempted  to  replicate  the 
relationship  demonstrated  in  the  present  thesis  between  insulin  sensitivity  and 
endothelial  function.  Interestingly,  their  study  demonstrated  a  positive 
relationship  between  insulin-mediated  vasodilatation  and  endothelial  function  in 
30  healthy  male  subjects,  although  the  data  are  compromised  to  some  extent  by 
measurements  of  blood  flow  conducted  during  hand-warming  (Utriainen  et  al 
1996a).  No  relationship  was  detected  between  insulin  sensitivity  and  forearm 
vasoconstrictor  response  to  L-NMMA  (Utriainen  et  al  1996b).  The  major 
difference  between  the  protocol  used  by  this  group  of  investigators  and  the 
protocol  used  in  the  present  study  is  that  L-NMMA  was  infused  at  the  end  of  a 
long  study  morning,  after  infusions  of  acetylcholine  and  sodium  nitroprusside, 
rather  than  after  a  simple  infusion  of  a  control  vasoconstrictor. 
Although  it  is  attractive  to  hypothesise  mechanisms  by  which  endothelial 
dysfunction  can  result  in  insulin  resistance,  it  is  also  possible  to  suggest 
mechanisms  by  which  insulin  resistance  might  cause  endothelial  dysfunction.  The 
substrate  for  endothelial  nitric  oxide  synthase  is  the  amino-acid,  L-arginine; 
availability  of  L-arginine  is  not  thought  to  be  rate-limiting  for  nitric  oxide 
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transport,  which  is  activated  in  human  endothelial  cells  by  glucose  and  insulin 
(Sobrevia  et  al  1996),  might  be  impaired  in  conditions  of  insulin  resistance. 
Alternatively,  both  endothelial  function  and  insulin  resistance  may  arise  as  a  result 
of  a  common  antecedent.  For  example,  low  skeletal  muscle  capillary  density 
(Section  1.6.3),  abnormal  free  fatty  acid  metabolism  (Section  1.1.3),  or  oxidative 
stress  (Section  1.7.3)  might  be  associated  with  both  phenotypes,  perhaps  as  a 
consequence  of  abnormal  intra-uterine  development  (Barker  et  al  1993a,  1993b). 
Data  from  the  studies  described  in  this  thesis  do  not  allow  a  decision  to  be  made 
amongst  these  possibilities.  Important  candidate  mechanisms  for  the 
physiological  processes  linking  insulin-mediated  vasodilatation,  insulin-mediated 
glucose  uptake  and  endothelial  function  may  be  gleaned  from  investigation  of  the 
mechanisms  of  local  insulin-mediated  vasodilatation  in  skeletal  muscle  vascular 
beds. 
Conclusions 
This  series  of  studies  has  used  specific  and  conventional  immunoassays,  the 
hyperinsulinaemic  clamp  technique,  and  forearm  venous  occlusion 
plethysmography  with  local  intra-arterial  infusions  to  demonstrate  that: 
1)  discrepancies  between  studies  in  the  relationship  between  serum  insulin 
concentrations  and  blood  pressure  in  diabetic  and  non-diabetic  subjects  are  likely 
to  be  due  to  factors  other  than  cross-reactivity  of  conventional  insulin  assays  with 
proinsulin-like  molecules. 
209 2)  moderate  dietary  sodium  restriction  (which  is  associated  with  sustained 
elevation  of  plasma  angiotensin  II)  results  in  a  12%  reduction  in  insulin  sensitivity 
in  patients  with  non-insulin  dependent  diabetes  mellitus 
3)  a  physiological  relationship  may  exist  between  insulin  sensitivity  and  vascular 
endothelial  function. 
210 Publications  containing  work  undertaken  for  this  thesis: 
i)  Reviews 
Petrie  J.  R.,  Donnelly  R.  (1994)  New  pharmacological  approaches  to 
insulin  and  lipid  metabolism.  Drugs,  47,701-710. 
Moms  A.  D.,  Petrie  J.  R.,  Connell  J.  M.  C.  (1994)  Insulin  and  hypertension. 
J  Hypertension,  12,633-642. 
ii)  Papers 
Petrie  J.  R.,  Ueda  S.,  Webb  D.  J.,  Elliott  H.  L.,  Connell  J.  M.  C.  (1996) 
Endothelial  nitric  oxide  production  and  insulin  sensitivity:  a  physiological 
link  with  implications  for  pathogenesis  of  cardiovascular  disease. 
Circulation,  93,1331-1333. 
Petrie  J.  R.,  Ueda  S.,  Morris  A.  D.,  Elliott  H.  L.,  Connell  J.  M.  C.  (1996) 
Potential  confounding  effect  of  hand-warming  in  the  measurement  of 
insulin  sensitivity. 
Clin  Sci,  91,65-71. 
Petrie  J.  R.,  Ueda  S.,  Morris  A.  D.,  Elliott  H.  L.,  Connell  J.  M.  C.  (1997) 
How  reproducible  is  bilateral  forearm  venous  occlusion  plethysmography 
in  man? 
Br  J  Clin  Pharm  (in  press) 
Petrie  JR,  Morris  AD,  Dorrian  CA,  Small  M,  Connell  JMC. 
Insulin  levels,  insulin  sensitivity,  and  blood  pressure:  is  assay  specificity 
important? 
Quarterly  Journal  of  Medicine  (in  press) 
iii)  Abstracts 
Petrie  J.  R.,  Morris  A.  D.,  Minamisawa  K.,  Elliott  H.  L.,  Small  M.,  Connell 
J.  M.  C.  (1996)  Salt  depletion  impairs  insulin  sensitivity  in  NIDDM. 
Diabetes,  45  (Suppl  2),  306A,  A1140. 
(full  paper  submitted  to  Journal  of  Clinical  Endocrinology  and 
Metabolism) 
211 Oral  presentations  to  Learned  Societies  containing  work  undertaken 
for  this  thesis 
Caledonian  Clinical  Pharmacology  Society,  September  1993. 
The  reproducibility  of  forearm  venous  occlusion  plethysmography  in  man. 
British  Hypertension  Society,  Dublin,  September  1994. 
Is  hand-warming  an  unnecessary  and  confounding  factor  in  the 
measurement  of  insulin  sensitivity? 
British  Hypertension  Society,  Glasgow,  September  1995 
Basal  endothelial  nitric  oxide  synthesis  and  endothelial  function  are 
positively  correlated  in  man. 
British  Diabetic  Association,  Harrogate,  October  1995 
Salt  depletion  impairs  insulin  sensitivity  in  NIDDM. 
European  Association  for  the  Study  of  Diabetes  "Hypertension  in 
Diabetes"  Study  Group  Padua,  Italy,  March  1996. 
Endothelial  nitric  oxide  production  and  insulin  sensitivity. 
Caledonian  Society  for  Endocrinology,  Dalmahoy,  May  1996 
Specific  insulin  levels,  insulin  sensitivity,  and  cardiovascular  phenotype: 
is  assay  specificity  important? 
I&  Anniversary  Meeting  Anglo-Danish  Dutch  Diabetes  Group 
Aberfoyle,  May  1996. 
Measurement  of  insulin  sensitivity:  gold  standards  and  good  surrogates. 
Investigator-led  satellite  of  International  Society  of  Hypertension  "Blood 
pressure  and  insulin  resistance:  can  we  reconcile  clinical  and 
epidemiological  evidence?  " 
Naples,  Italy,  June  1996. 
Insulin  sensitivity  and  endothelial  function:  a  physiological  relationship 
with  potential  pathophysiological  significance. 
212 References 
Abramson  D.  I.,  Tuck  S.,  Chu  L.  S.  W.,  Lee  S.  W.,  Gibbons  C.,  Richardson  G. 
(1965)  Indirect  vasodilation  in  thermotherapy.  Arch  Phys  Med  Rehab,  46,412- 
420. 
Accili  D.,  Cama  A.,  Barbetti  F.,  Kadowaki  H.,  Kadowaki  T.,  Taylor  S.  I  (1992) 
Insulin  resistance  due  to  mutations  of  the  insulin  receptor  gene:  an  overview.  J 
Endocr  Invest,  15,857-864. 
Ahn  Y.  I.,  Ferrel  R.  E.,  Hamman  R.  F.,  Kamboh  M.  I.  (1993)  Association  of 
lipoprotein  lipase  gene  variation  with  the  physiological  components  of  the  insulin 
resistance  syndrome.  Diabetes  Care,  16,1502-1505. 
Alpha  B.,  Cox  L.,  Crowther  N.,  Clark  P.  M.  S.,  Hales  C.  N.  (1992)  Sensitive 
amplified  immunoenzymometric  assays  (IEMA)  for  human  insulin  and  intact 
proinsulin.  Eur  J  Clin  Chem  Clin  Biochem,  30,27-32. 
Altenkirch  H-U.,  Koch  G.,  Koralewski  H.  E.  (1990)  Variability  and 
reproducibility  of  arterial  and  venous  circulation  parameters  in  the  forearm  and 
calf  measured  at  one-week  intervals.  Vasa,  19,21-25. 
Altman  D.  G.  (1991)  Practical  statistics  for  medical  research  (1  s`  edition). 
London,  Chapman  and  Hall. 
American  Diabetes  Association.  (1996)  Nutrition  recommendations  and  principles 
for  people  with  diabetes  mellitus.  Diabetes  Care,  19,  S  16-S  19. 
Anderson  E.  A.,  Hoffman  R.  P.,  Babon  T.  W.,  Sinkey  C.  A.,  Mark  A.  L.  (1991) 
Hyperinsulinaemia  produces  both  sympathetic  neural  activation  and  vasodilation 
in  normal  humans.  J  Clin  Invest,  87,2246-2252. 
Anderson  E.  A.,  Mark  A.  L.  (1993)  The  vasodilator  action  of  insulin:  implications 
for  the  insulin  hypothesis  of  hypertension.  Hypertension  21,136-141. 
Anderson  T.  J,  Meredith  LT.,  Yeung  A.  C.,  Frei  B.,  Selwyn  A.  P.,  Ganz  P.  (1995) 
The  effect  of  cholesterol-lowering  and  antioxidant  therapy  on  endothelium- 
dependent  coronary  vasomotion.  N Engl  J  Med,  332,488-493. 
Andres  R.,  Swerdloff  R.,  Pozefsky  T.,  Coleman  D.  (1966)  Manual  feedback 
technique  for  the  control  of  blood  glucose  concentration.  In:  Skeggs  Jr,  LT  (ed). 
Automation  in  Analytical  Chemistry,  Medicaid  Inc,  New  York,  pp  486-497. 
Andrews  J.,  Klimes  I.,  Vasquez  B.,  Nagulesparan  M.,  Reaven  GM.  (1984)  Can 
mixed  venous  blood  be  used  to  measure  insulin  action  during  the 
hyperinsulinaemic  euglycaemic  clamp?  Horm  Metab  Res  (Suppl),  16,164-166. 
Asch  S.,  Wingard  D.  L.,  Barrett-Connor  E.  L.  (1991)  Are  insulin  and  hypertension 
independently  related?  Annals  of  Epidemiology,  1,231-244. 
213 Astrup  A.,  Simonsen  L.,  Bulow  J.,  Christensen  N.  J.  (1988)  Measurement  of 
forearm  oxygen  consumption:  role  of  heating  the  contralateral  hand.  Am  J  Physiol 
1988,255,  E572-E578. 
Attvall  S.,  Fowelin  J.,  Lager  I.,  Von  Schenck  H.,  Smith  U.  (1993)  Smoking 
induces  insulin  resistance  -a  potential  link  with  the  insulin  resistance  syndrome. 
J  Int  Med,  233,327-332. 
Aznar  J.,  Estelles  A.,  Tormo  G.,  Sapena  P.,  Tormo  V.,  Blanch  S.,  Espana  F. 
(1988)  Plasminogen  activator  inhibitor  activity  and  other  fibrinolytic  variables  in 
patients  with  coronary  artery  disease.  Br  Heart  J,  59,535-541. 
Baltzan  M.  A.,  Andres  R.,  Cader  G.,  Zierler  K.  L.  (1962)  Heterogeneity  of  forearm 
metabolism  with  special  reference  to  free  fatty  acids.  J  Clin  Invest,  41,116-125. 
Banskota  N.  K.,  Taub  R.,  Zellner  K.,  King  G.  L.  (1989)  Insulin,  insulin  like  growth 
factor-1  and  PDGF  interact  additively  in  the  induction  of  the  proto-oncogene  c- 
myc  and  cellular  proliferation  in  cultured  bovine  aortic  smooth  muscle  cells.  Mol 
Endocrinol,  3,1183-1190. 
Barcroft  H.,  Bonnar  W.  McK.,  Edholm  O.  G.  (1947)  Reflex  vasodilatation  in 
human  skeletal  muscle  in  response  to  heating  the  body.  J  Physiol,  106,271-278. 
Barcroft  H.,  Gaskell  P.,  Shepherd  J.  T.,  Whelan  R.  F.  (1954)  The  effect  of 
noradrenaline  infusions  on  blood  flow  through  the  human  forearm.  J  Physiol,  123, 
443-450. 
Barker  D.  J.  P.,  Hales  C.  N.,  Fall  C.  H.  D.,  Osmond  C.,  Phipps  K.,  Clark  P.  M.  S. 
(1993a)  Type  2  (non-insulin-dependent)  diabetes  mellitus,  hypertension,  and 
hyperlipidaemia  (syndrome  X):  relation  to  reduced  fetal  growth.  Diabetologia,  36, 
62-67. 
Barker  D.  J.  P.,  Gluckman  P.  D.,  Godfrey  K.  M.,  Harding  J.  E.,  Owens  J.  A., 
Robinson  J.  S.  (1993b)  Foetal  nutrition  and  cardiovascular  disease  in  later  adult 
life.  Lancet,  341,938-941. 
Baron  A.  D.,  Laakso  M.,  Brechtel  G.,  Hoit  B.,  Watt  C.,  Edelman  S.  V.  (1990) 
Reduced  postprandial  skeletal  muscle  blood  flow  contributes  to  glucose 
intolerance  in  human  obesity.  J  Clin  End  Metab,  70,1525-1533. 
Baron  A.  D.,  Laakso  M.,  Brechtel  G.,  Edelman  S.  V.  (1991a)  Reduced  capacity  and 
affinity  of  skeletal  muscle  for  insulin-mediated  glucose  uptake  in  non-insulin 
dependent  diabetic  subjects.  Effects  of  insulin  therapy.  J  Clin  Invest,  87,1186- 
1194. 
Baron  A.  D.,  Laakso  M.,  Brechtel  G.,  Edelman  S.  V.  (1991b).  Mechanism  of 
insulin  resistance  in  insulin-dependent  diabetes  mellitus:  A  major  role  for 
reduced  skeletal  muscle  blood  flow.  J  Clin  End  Metab,  73,637-643. 
214 Baron  A.  D.,  Brechtel-Hook  G.,  Johnston  A.,  Hardin  D.  (1993)  Skeletal  muscle 
blood  flow:  a  possible  link  between  insulin  resistance  and  blood  pressure. 
Hypertension,  21,129-135. 
Baron  A.  D.,  Brechtel  G.,  Johnson  A.,  Fineberg  N.,  Henry  D.  P.,  Steinberg  H.  O. 
(1994a)  Interactions  between  insulin  and  norepinephrine  on  blood  pressure  and 
insulin  sensitivity.  J  Clin  Invest,  93,2453-2462. 
Baron  A.  D.,  Steinberg  H.,  Brechtel  G.,  Johnson  A.  (1994b)  Skeletal  muscle 
blood  flow  independently  modulates  insulin-mediated  glucose  uptake.  Am  J 
Physiol,  266,  E248-E253. 
Bastard  J-P.,  Hainque  B.,  Jadel  C.,  Cohen  S.,  Bruckert  E.,  Grimaldi  A.,  Robert  J- 
J.,  Guerre-Millo  M.  (1995)  Tissue-specific  regulation  of  GLUT4  and  GLUTS 
expression  in  non-insulin-dependent  diabetes  mellitus.  Endocrinol  Metab,  2,259- 
268. 
Baum  M.  (1987)  Insulin  stimulates  volume  absorption  in  the  proximal  convoluted 
tubule.  J  Clin  Invest,  56,335-340. 
Bavenholm  P.,  Proudler  A.,  Tornvall  P.,  Godlsand  L,  Landou  C.,  DeFaire  U., 
Hamsten  A.  (1995)  Insulin,  intact  and  split  proinsulin,  and  coronary  artery 
disease  in  young  men.  Circulation  92,1422-1429 
Bell  P.  M.  (1996)  Clinical  significance  of  insulin  resistance.  Diab  Med,  13,504- 
509. 
Benjamin  N.,  Cockcroft  J.  R.,  Collier  J.  G.,  Dollery  C.  T.,  Ritter  J.  M.,  Webb  D.  J. 
(1989)  Local  inhibition  of  converting  enzyme  and  vascular  responses  to 
angiotensin  and  bradykinin  in  the  human  forearm  J  Physiol,  412,543-555. 
Benjamin  N.,  Calver  A.,  Collier  J.,  Robinson  B.,  Valiance  P.,  Webb  D.  (1995) 
Measuring  forearm  blood-flow  and  interpreting  the  responses  to  drugs  and 
mediators.  Hypertension,  25,918-23. 
Beretta-Piccoli  C.,  Davies  D.  L.,  Boddy  K.,  Brown  J.  J.,  Cumming  A.  M.  M.,  East 
B.  W.,  Fraser  R.,  Lever  A.  F.,  Padfield  P.  L.,  Semple  P.  F.,  Robertson  U.  S., 
Weidmann  P.,  Williams  E.  D.  (1982)  Relation  of  arterial  pressure  with  body 
sodium,  body  potassium  and  plasma  potassium  in  essential  hypertension.  Clin  Sci, 
63,257-270. 
Berglund  G.,  Larsson  B.,  Andersson  0.,  Larsson  0.,  Svarsudd  K.,  Bjorntrop  P., 
Wilhelmsen  L.  (1976)  Body  composition  and  glucose  metabolism  in 
hypertensive  middle-aged  men.  Act  Med  Scand  200,163-169. 
Bland  J.  M.,  Altman  D.  G.  (1996)  Measurement  error.  Br  Med  J,  312,654. 
Bergman  R.  N  (1989)  Toward  physiological  understanding  of  glucose  tolerance: 
minimal  model  approach.  Diabetes,  38,1512-1527. 
215 Bergman  R.  N.,  Prager  R.,  Volund  A.,  Olefsky  J.  M.  (1987)  Equivalence  of  the 
insulin  sensitivity  index  in  man  derived  by  the  minimal  model  method  and  the 
euglycaemic  glucose  clamp.  J  Clin  Invest,  79,790-800. 
Blann  A.  D.,  Daly  R.  J.,  Amiral  J.  (1996)  The  influence  of  age,  gender  and  ABO 
blood  group  on  soluble  endothelial  cell  markers  and  adhesion  molecules.  Br  J 
Haematology,  92,498-500. 
Bogardus  C.,  Lillioja  S.,  Stone  K.,  Mott  D.  (1984)  Correlation  between  muscle 
glycogen  synthase  activity  and  in  vivo  insulin  action  in  man.  J  Clin  Invest,  73, 
1185-1190. 
Bonadonna  R.  C.,  Groop  L.  C.,  Kraemer  N.,  Ferrannini  E.,  Del-Prato  S.,  De  Fronzo 
R.  A.  (1990)  Obesity  and  insulin  resistance  in  humans:  a  dose-response  study. 
Metabolism,  39,452-459. 
Boulanger  C.  M.,  Vanhoutte  P.  M.  The  endothelium:  a  pivotal  role  in  health  and 
cardiovascular  disease.  Cedex:  Servier,  1994. 
Brands  M.  W.,  Mizelle  H.  L.,  Gaillard  D.  A.,  Hildebrandt  D.  A.,  Hall  J.  E.  (1991a) 
The  haemodynamic  response  to  chronic  hyperinsulinaemia  in  conscious  dogs.  Am 
J  Hypertens,  4,164-168. 
Brands  M.  W.,  Hildebrandt  D.  A.,  Mizelle  H.  L.,  Hall  J.  E.  (1991b)  Sustained 
hyperinsulinaemia  increases  arterial  pressure  in  conscious  rats.  Am  J  Physiol,  260, 
R764-768. 
Buchanan  T.  A.,  Thawani  H.,  Kades  W.,  Modrall  J.  G.,  Weaver  F.  A.,  Laurel  C., 
Poppiti  R.,  Xiang  A.,  Hsueh  W.  (1993)  Angiotensin  II  increases  glucose 
utilization  during  acute  hyperinsulinaemia  via  a  hemodynamic  mechanism.  J  Clin 
Invest,  92,720-726. 
Calver  A.,  Collier  J.,  Moncada  S.,  Valiance  P.  (1992)  Effect  of  infra-arterial  NG- 
monomethyl-L-arginine  in  patients  with  essential  hypertension:  the  nitric  oxide 
dilator  system  appears  abnormal.  J  Hypertens,  10,1025-1031. 
Cambien  F.,  Warner  J-M.,  Eachwege  E.,  Jacqueson  A.,  Richard  J.  L.,  Rosselin  G. 
(1987)  Body  mass,  blood  pressure,  glucose  and  lipids:  does  plasma  insulin  explain 
their  relationships?  Arteriosclerosis,  7,197-202. 
Canessa  M.,  Adragna  N.,  Solomon  H.  S.,  Connolly  T.  M.,  Tosteson  D.  C.  (1980) 
Increased  sodium-lithium  countertransport  in  red  cells  of  patients  with  essential 
hypertension.  N  Engl  J  Med,  302,772-776. 
Capaldo  B.,  Santoro  D.,  Riccardi  G.,  Perrotti  N.,  Sacca  L.  (1986)  Direct  evidence 
for  a  stimulatory  effect  of  hyperglycaemia  per  se  on  peripheral  glucose  disposal  in 
type  II  diabetes.  J  Clin  Invest,  77,1285-1290. 
216 Capaldo  B.,  Napoli  R.,  DiBonito  P.,  Albano  G.,  Sacca  L  (1990)  Glucose  and 
gluconeogenic  substrate  exchange  by  the  forearm  skeletal  muscle  in 
hyperglycaemia  and  insulin  treated  type  H  diabetic  patients.  J  Clin  End  Metab,  71, 
1220-1223. 
Capaldo  B.,  Lembo  G.,  Napoli  R.,  Rendina  V.,  Albano  G.,  Sacca  L.,  Trimarco  B. 
(1991)  Skeletal  muscle  metabolism  is  a  primary  site  of  insulin  resistance  in 
essential  hypertension.  Metabolism,  40,1320-1322. 
Caro  J.  F.  (1991)  Insulin  resistance  in  obese  and  non-obese  man.  J  Clin  Endocrin 
Metab,  73,691-695. 
Castillo  C.,  Bogardus  C.,  Bergman  R.,  Thuillez  P,  Lillioja  S.  (1994)  Interstitial 
insulin  concentrations  determine  glucose  uptake  rates  but  not  insulin  resistance  in 
lean  and  obese  men.  J  Clin  Invest,  93,10-16. 
Celermajer  D.  S.,  Sorensen  K.  E.,  Gooch  V.  M.,  Spiegelhalter  D.  J.,  Miller  O.  I., 
Sullivan  I.  D.,  Lloyd  J.  K.,  Deandfield  J.  E.  (1992)  Non-invasive  detection  of 
endothelial  dysfunction  in  children  and  adults  at  risk  of  atherosclerosis.  Lancet, 
340,1111-1115. 
Celermajer  D.  S.,  Sorensen  K.  F.,  Georgakapolous  D.,  Bull  C.,  Thomas  0., 
Robinson  J.,  Deanfield  J.  E.  (1993)  Cigarette  smoking  is  associated  with  dose- 
dependent  and  potentially  reversible  impairment  of  endothelium-dependent 
dilation  in  healthy  young  adults.  Circulation,  88,2149-2155. 
Chan  P.,  Tomlison  B.,  Lee  C.  B.,  Pan  W.  H.,  Lee  Y.  S.  (1996)  Beneficial  effect  of 
pravastatin  on  fasting  hyperinsulinaemia  in  elderly  hypertensive 
hypercholesterolaemic  subjects.  Hypertension,  28,647-651. 
Chan  S.  J.,  Seino  S.,  Gruppuso  P.  A.,  Schwartz  R.,  Steiner  D.  F.  (1987)  A  mutation 
in  the  B  chain  coding  region  is  associated  with  impaired  proinsulin  conversion  in 
a  family  with  hyperproinsulinaemia.  Proc  Nat!  Acad  Sci  USA,  84,2194-2197. 
Chen  Y.  L.,  Messina  E.  J.  (1996)  Dilation  of  isolated  skeletal  muscle  arterioles  by 
insulin  is  endothelium-dependent  and  nitric  oxide  mediated.  Am  J  Physiol,  270, 
H2120-2124. 
Cherrington  A.  D.,  Williams  P.  E.,  and  Harris  M.  S.  (1978)  Relationship  between 
the  plasma  glucose  level  and  glucose  uptake  in  the  conscious  dog.  Metabolism, 
27,787-791. 
Chester  A.  H.,  O'Neil  G.  S.,  Moncada  S.,  Tadjkarimi  S.,  Yacoub  M.  H.  (1990)  Low 
basal  and  stimulated  release  of  nitric  oxide  in  atherosclerotic  epicardial  coronary 
arteries.  Lancet,  336,897-900. 
Chiang  B.  N.,  Perlman  L.  V.,  Epstein  F.  H.  (1969)  Overweight  and  hypertension:  a 
review.  Circulation,  39,403-421. 
217 Chin  J.  H.,  Azhar  S.,  Hoffman  B.  B.  (1992)  Inactivation  of  endothelial  derived 
relaxing  factor  by  oxidised  lipoprotein.  J  Clin  Invest,  89,10-18. 
Chin  J.  P.  F.,  Dart  A.  M.  (1994)  Therapeutic  restoration  of  endothelial  function  in 
hypercholesterolaemic  subjects:  effect  of  fish  oils.  Clin  Exp  Pharmacol  Physiol, 
21,749-755. 
Chowienczyk  P.  J.,  Watts  G.  F.,  Cockcroft  J.  R.,  Ritter  J.  M.  (1992)  Impaired 
endothelium-dependent  vasodilatation  of  forearm  resistance  vessels  in 
hypercholesterolaemia.  Lancet,  340,1430-1432. 
Clarke  R.  S.  J.  and  Hellon  R.  F.  (1957)  Venous  collection  in  forearm  and  hand 
measured  by  the  strain  gauge  and  volume  plethysmograph.  Clin  Sci,  16,103-116. 
Clarke  J.  G.,  Benjamin  N.,  Larkin  S.  W.,  Webb  D.  J.,  Davies  G.  J.,  Maseri  A.  (1989) 
Endothelin  is  a  potent  and  long-lasting  vasoconstrictor  in  man.  Am  J  Physiol, 
257,  H2033-2035. 
Clarkson  P.,  Adams  M.  R.,  Powe  A.  J.,  Donald  A.  E.,  McCredie  R.,  Robinson  J., 
McCarthy  S.  N.,  Keech  S.  N.,  Celermajer  D.  S.,  Deanfield  J.  E.  (1996)  Oral  L- 
arginine  improves  endothelium-dependent  dilation  in  hypercholesterolaemic 
young  adults.  J  Clin  Invest,  97,1989-1994. 
Clausen  J.  O.,  Hansen  T.,  Bjorbaek  C.,  Echwald  S.  M.,  Urhammer  S.  A., 
Rasmussen  S.,  Andersen  C.  B.,  Hansen  L.,  Almind  K.,  Winther  K.,  Haraldsdottir 
J.,  Borch-Johnsen,  Pedersen  O.  (1995)  Insulin  resistance:  interactions  between 
obesity  and  a  common  variant  of  insulin  receptor  substrate-1.  Lancet,  346,397- 
402. 
Cockcroft  J.  R.,  Scibenas  D.  G.,  Goldberg  M.  R.,  Ritter,  J.  M.  (1993)  Comparision 
of  angiotensin-converting  enzyme  inhibition  with  angiotensin  II  antagonism  in  the 
human  forearm.  J  Cardiovasc  Pharm,  22,579-584. 
Cockcroft  J.  R.,  Chowienczyk  P.  J.,  Benjamin  N.,  Ritter  J.  M.  (1994)  Preserved 
endothelium-dependent  vasodilatation  in  patients  with  essential  hypertension.  N 
Engl  J  Med,  330,1036-1040. 
Collier  J.  G.  and  Robinson  B.  F.  (1974)  Comparison  of  effects  of  locally  infused 
angiotensin  I  and  II  on  hand  veins  and  forearm  arteries  in  man:  evidence  for 
converting  enzyme  activity  in  limb  vessels.  Clin  Sci  Mol  Med,  47,189-192. 
Collins  R.,  Peto  R.,  MacMahon  S.,  Hebert  P.,  Fiebach  N.  H.,  Eberlein  K.  H., 
Godwin  I.,  Qizilbach  N.,  Taylor  J.  O.,  Hennekens  C.  H.  (1990)  Blood  pressure, 
stroke  and  coronary  heart  disease.  Part  2.  Short-term  reductions  in  blood  pressure: 
overview  of  randomised  drug  trials  in  their  epidemiological  context.  Lancet,  335, 
827-838. 
Considine  R.  V.,  Caro  J.  F.  (1993)  Protein  kinase  C:  mediator  or  inhibitor  of 
insulin  action?  J  Cell  Biochem,  52,8-13. 
218 Conway  G.  S.,  Clark  P.  M.  S.,  Wong  D.  (1993)  Hyperinsulinaemia  in  the  polycystic 
ovary  syndrome  confirmed  with  a  specific  immunoradiometric  assay  for  insulin. 
Clin  Endocrin,  38,219-222. 
Creager  M.  A.,  Liang  C-S.,  Coffman  J.  D.  (1985)  Beta  adrenergic-mediated 
vasodilator  response  to  insulin  in  the  human  forearm.  J  Pharmacol  Exper  Ther, 
235,709-714. 
Creager  M.  A.,  Cooke  J.  P.,  Mendehlson  M.  D.,  Gallagher  S.  G.,  Coleman  S.  M., 
Loscalzo  J.,  Dzau  V.  J.  (1990)  Impaired  vasodilation  of  forearm  resistance  vessels 
in  hypercholesterolaemic  humans.  J  Clin  Invest,  86,228-234. 
Creager  M.  A.,  Gallagher  S.  G.,  Girerd  X.  J.,  Coleman  S.  M.,  Dzau  V.  J.,  Cooke  J.  P. 
(1992)  L-arginine  improves  endothelium-dependent  vasodilatation  in 
hypercholesterolaemic  humans.  J  Clin  Invest,  90,1248-1253. 
Crowther  N.  J.,  Xiao  B.,  Jorgensen  P.  N.,  Dodson  G.  G.,  Hales  C.  N.  (1994)  Epitope 
analysis  of  human  insulin  and  intact  proinsulin.  Prot  Eng,  7,137-144. 
Dahn  I.  and  Hallbrook  T.  (1970)  Simultaneous  blood  flow  measurements  by 
water  and  strain  gauge  plethysmography.  Scand  J  Clin  Lab  Invest,  25,419-428. 
Davda  R.  K.,  Stepniakowski  K.  T.,  Lu  G.,  Ullian  M.  E.,  Goodfriend  T.  L.,  Egan 
B.  M.  (1995)  Oleic  acid  inhibits  endothelial  nitric  oxide  synthesis  by  a  protein 
kinase  C-independent  mechanism.  Hypertension,  26,764-770. 
Davies  M.  J.,  Rayman  G.,  Gray  I.  P.,  Day  J.  L.,  Hales  C.  N.  (1992)  Insulin 
deficiency  and  increased  plasma  concentration  of  intact  and  32-33  split  proinsulin 
in  subjects  with  impaired  glucose  tolerance.  Diab  Med,  10,313-320. 
Davies  M.  J.,  Metcalfe  J.,  Day  J.  L.,  Grenfell  A.,  Hales  C.  N.,  Gray  I.  P.  (1994) 
Improved  ß-cell  function,  with  reduction  in  secretion  of  intact  and  32/33  split 
proinsulin,  after  dietary  intervention  in  subjects  with  Type  2  diabetes  mellitus. 
Diab  Med,  11,71-78. 
Dawson-Hughes  B.  F.,  Moore  T.  J.,  Dluhy  R.  G.,  Hollenberg  N.  K.,  Williams  G.  H. 
(1981)  Plasma  angiotensin  II  concentration  regulates  vascular  but  not  adrenal 
responsiveness  to  restriction  of  sodium  intake  in  normal  man.  Clin  Sci,  61,527- 
534. 
DeBodo  R.  C.,  Steele  R.,  Altszuler  N.,  Dunn  A.,  Bishop  J.  S.  (1963)  On  the 
hormonal  regulation  of  carbohydrate  metabolism:  studies  with  C14  glucose.  Rec 
Prog  Horm  Res  19,445-488 
DeFronzo  R.  A.,  Cooke  C.  R.,  Andres  R.,  Faloona  G.  R.,  David  P.  J.  (1975)  The 
effect  of  insulin  on  renal  handling  of  sodium,  potassium,  calcium  and  phosphate 
in  man.  J  Clin  Invest,  55,845-855. 
219 DeFronzo  R.  A.,  Soman  V.,  Sherwin  R.  S.,  Hendler  R.,  Felig  P.  (1978)  Insulin 
binding  to  monocytes  and  insulin  action  in  human  obesity,  starvation,  and 
refeeding.  J  Clin  Invest  62,204-213. 
DeFronzo  R.  A.,  Tobin  J.,  Andres  R.  (1979).  Glucose  clamp  technique:  a  method 
for  quantifying  insulin  secretion  and  resistance.  Am  J  Physiol,  237,  E214-E223. 
DeFronzo  R.  A.,  Felig  P.,  Ferrannini  E.,  Wahren  J.  (1980)  Effect  of  graded  doses 
of  insulin  on  splanchnic  and  peripheral  metabolism  in  man.  Am  J  Physiol,  238, 
E421-E427. 
DeFronzo  R.  A.  (1981a)  The  effects  of  insulin  on  renal  sodium  metabolism. 
Diabetologia,  21,165-171. 
DeFronzo  R.  A.,  Jacot  E.,  Jequier  E.  (1981b)  The  effect  of  insulin  on  the  disposal 
of  intravenous  glucose:  results  from  indirect  calorimetry  and  hepatic  and  femoral 
venous  catheterisation.  Diabetes,  30,1000-1007. 
De  Fronzo  R.  A.,  Barzilai  N.,  Simonson  D.  C.  (1991)  Mechanism  of  metformin 
action  in  obese  and  lean  non-insulin-dependent  diabetic  subjects.  J  Clin  End 
Metab,  73,1294-1301. 
DeFronzo  R.  A.,  Bonadonna  R.  C.,  Ferrannini  E.  (1992)  Pathogenesis  of  NIDDM: 
a  balanced  overview.  Diabetes  Care,  15,318-367. 
Dela  F.,  Larsen  J.  J.,  Mikines  K.  J.,  Galbo  H.  (1995)  Normal  effect  of  insulin  to 
stimulate  leg  blood  flow  in  NIDDM.  Diabetes,  44,221-226. 
Del  Prato  S.,  Leonetti  F.,  Simonson  D.  C.,  Sheehan  P.,  Matsuda  M.,  DeFronzo 
R.  A.  (1994)  Effect  of  sustained  physiologic  hyperinsulinaemia  and 
hyperglycaemia  on  insulin  secretion  and  insulin  sensitivity  in  man.  Diabetologia, 
37,1025-1035. 
Despres  J-P.,  Lamarche  B.,  Mauriege  P.,  Cantin  B.,  Dagenais  G.  R.,  Moorjani  S., 
Lupien  P-J.  (1996)  Hyperinsulinaemia  as  an  independent  risk  factor  for  ischaemic 
heart  disease.  N  Eng  J  Med,  334,952-957. 
DeWitt  L.  M.,  Putney  J.  W.  (1983)  Stimulation  of  glycogenolysis  in  hepatocytes 
by  angiotensin  II  may  involve  both  calcium  release  and  calcium  influx.  FEBS 
Lett,  160,259-263. 
DiCorleto  P.  E.,  Soyombo  A.  A.  (1993)  The  role  of  the  endothelium  in 
atherogenesis.  Curr  Op  Lipid,  4,364-372. 
Dietze  G.  J.,  Wicklmayr  M.,  Rett  K.,  Jacob  S.,  Henriksen  E.  J.  (1996)  Potential 
role  of  bradykinin  in  forearm  muscle  metabolism  in  humans.  Diabetes,  45  (Suppl 
1),  S105-S109. 
220 Dohm  G.  L.,  Elton  C.  W.,  Friedman  J.  E.,  Pilch  P.  F.,  Porles  W.  J.,  Atkinson  S.  M., 
Caro  J.  F.  (1991)  Decreased  expression  of  glucose  transporter  in  muscle  from 
insulin  resistant  patients.  Am  J  Physiol,  260,  E459-E463. 
Donovan  D.  S.,  Solomon,  C.  G.,  Seely,  E.  W.,  Williams,  G.  H.,  Simonson,  D.  C. 
(1993)  Effect  of  sodium  intake  on  insulin  sensitivity.  Am  J  Physiol,  264,  E730- 
E734. 
Donnelly  R.  (1992)  Angiotensin-converting  enzyme  inhibitors  and  insulin 
sensitivity:  metabolic  effects  in  hypertension,  diabetes,  and  heart  failure.  J 
Cardiovasc  Pharm,  20  (Suppl  11),  S38-S44. 
Doria A.,  Fioretto  P.,  Avogaro  A.,  Carraro  A.,  Morocutti  A.,  Trevisan  R.,  Frigato 
F.,  Crepaldi  G.,  Viberti  G.,  Nosadini  R.  (1991)  Insulin  resistance  is  associated 
with  high  sodium-lithium  countertransport  in  essential  hypertension.  Am  J 
Physiol,  261,  E684-E691. 
Dowse  G.  K.,  Collins  V.  R.,  Alberti  K.  G.  M.,  Zimmet  P.  Z.,  Tuomilehto  J.,  Chitson 
P.,  Gareeboo  H.  (1993)  Insulin  and  blood  pressure  levels  are  not  independently 
related  in  Mauritians  of  Asian  Indian,  Creole  or  Chinese  origin.  J  Hypertens,  11, 
297-307. 
Ducimetiere  P.,  Eschwege  E.,  Papoz  L.,  Richard  J.  L.,  Claude  J.  R.,  Roselin  G. 
(1980)  Relationship  of  plasma  insulin  levels  to  the  incidence  of  myocardial 
infarction  and  coronary  heart  disease  mortality  in  a  middle-aged  population. 
Diabetologia,  19,205-210. 
Ducsterdieck  G.,  McElwee  G.  (1971)  Estimation  of  angiotensin  H  in  human 
plasma  by  radioimmunoassay.  Some  applications  to  physiological  and  clinical 
states.  Eur  J  Clin  Invest,  2,32-38. 
Duncan  M.  H.,  Singh  B.  M.,  Wise  P.  H.,  Carter  G.,  Allaghband-Zadeh  J.  (1996)  A 
simple  measurement  of  insulin  resistance  (letter).  Lancet  1995,346,120-121. 
Ebina  Y.,  Ellis  L.,  Jarnagin  K.,  Edery  M.,  Graf  L.,  Clauser  E.,  Ou  J-h.,  Masiarz  F., 
Kan  Y.  W.,  Goldfine  I.  D.,  Roth  R.  A.,  Rutter  W.  J.  (1985)  The  human  insulin 
receptor  cDNA:  the  structural  basis  for  hormone-activated  transmembrane 
signalling.  Cell,  40,747-758. 
Edholm  OG,  Fox  RH,  MacPherson  RK  (1956).  The  effect  of  body  heating  on  the 
circulation  in  skin  and  muscle.  J  Physiol,  134,612-619. 
Egan  B.,  Schork  N.,  Panis  R.,  Hinderliter  A.  (1988)  Vascular  structure  enhances 
regional  resistance  responses  in  mild  essential  hypertension.  J  Hypertens,  6,41- 
48. 
Egashira  K.,  Inou  T.,  Hirooka  Y.,  Yamada  A,  Maruoka  Y.,  Kai  H.,  Sugimachi  M, 
Suzuki  S.,  Takeshita  A.  (1993)  Impaired  coronary  blood  flow  response  to 
acetylcholine  in  patients  with  coronary  risk  factors  and  proximal  atherosclerotic 
lesions.  J  Clin  Invest,  91,29-37. 
221 Facchini  F.  S.,  Hollenbeck  C.  B.,  Jeppesen  J.  Chen  Y-D.  I.,  Reaven  G.  M.  (1992) 
Insulin  resistance  and  cigarette  smoking.  Lancet,  339,1128-31. 
Fall  C.  H.  D,  Osmond  C.,  Barker  D.  J.  P.,  Clark  P.  M.  S,  Hales  C.  N.,  Stirling  Y., 
Meade  T.  W.  (1995)  Fetal  and  infant  groth  and  cardiovascular  risk  in  women.  Br 
Med  J,  310,428-432. 
Feldman  R.  D.,  Hramiak  I.  M.,  Finegood  D.  T.,  Behme  M.  T.  (1995)  Parallel 
regulation  of  the  local  vascular  and  systemic  metabolic  effects  of  insulin.  J  Clin 
Endocrin  Metab,  80,1556-1559. 
Feldman  R.  D.,  Logan  A.  G.,  Schmidt  N.  D.  (1996)  Dietary  salt  restriction  increases 
vascular  insulin  resistance.  Clinical  Pharmacology  and  Therapeutics,  60,444- 
451. 
Ferrannini  E.,  Buzzicoli  G.,  Bonadonna  R.,  Giorico  M.  A.,  Oleggini  M.,  Graziadei 
L.,  Pedrinelli  R.,  Brandi  L.,  Bevilqacqua  S.  (1987).  Insulin  resistance  in  essential 
hypertension.  N  Engl  J  Med,  317,350-357. 
Ferrara  A.,  Barrett-Connor  E.  L.,  Edelstein  S.  L.  (1994)  Hyperinsulinaemia  does 
not  increase  the  risk  of  fatal  cardiovascular  disease  in  elderly  men  or  women 
without  diabetes:  The  Rancho  Bernardo  Study  (1984-1991).  Am  J  Epidemiol 
140,857-869. 
Ferrari  P.,  Weidmann  P.,  Shaw  S.,  Giachino  D.,  Riesen  W.,  Allemann  Y.,  Heynan 
G.  (1991)  Altered  insulin  sensitivity,  hyperinsulinaemia  and  dyslipidaemia  in 
individuals  with  a  hypertensive  parent.  Am  J  Med,  91,589-596. 
Feskens  E.  J.  M.,  Tuomilehto  J.,  Stengard  J.  H.,  Pekkanen  J.,  Nissinen  A., 
Kromhout  D.  (1995)  Hypertension  and  overweight  associated  with 
hyperinsulinaemia  and  glucose  tolerance:  a  longitudinal  study  of  the  Finnish  and 
Dutch  cohorts  of  the  Seven  Countries  Study.  Diabetologia  38,839-847 
Finegood  D.  T.,  Bergman  R.  N.,  Vranic  M.  (1987)  Estimation  of  endogenous 
glucose  production  during  hyperinsulinaemic-euglycaemic  clamps.  Comparison 
of  labelled  and  unlabelled  exogenous  glucose  infusates.  Diabetes,  36,914-924. 
Finegood  D.  T.,  Hramiak  I.  M.,  Dupre  J.  (1990)  A  modified  protocol  for 
estimation  of  insulin  sensitivity  with  the  minimal  model  of  glucose  kinetics  in 
patients  with  insulin-dependent  diabetes.  J  Clin  Endocrin  Metab,  70,1538-1549. 
Fliser  D.,  Arnold  U.,  Kohl  B.,  Hartung  R.,  Ritz  E.  (1993)  Angiotensin  II  enhances 
insulin  sensitivity  in  healthy  volunteers  under  euglycaemic  conditions.  J 
Hypertens,  11,983-988. 
Fliser  D,  Fode  P,  Arnold  U,  Nowicki  M,  Kohl  B,  Ritz  E  (1995)  The  effect  of 
dietary  salt  on  insulin  sensitivity.  Eur  J  Clin  Invest,  25,39-43 
222 Floras  J.  S.,  Hara  K.  (1993)  Sympathoneural  and  haemodynamic  characteristics  of 
young  subjects  with  mild  essential  hypertension.  J  Hypertens,  11,647-655. 
Folkow  B.  (1979)  Cardiovascular  structural  adaptation:  its  role  in  the  initiation 
and  maintenance  of  primary  hypertension.  Clin  Sci  Mol  Med,  55,3s-22s. 
Frank  B.  H.,  Veros  A.  J.,  Pekar  A.  H.  (1972)  Physical  studies  on  proinsulin:  a 
comparison  of  the  titration  behaviour  of  the  tyrosine  residues  in  insulin  and 
proinsulin.  Biochemistry,  11,4926-4931. 
Frayn  K.  N.,  Williams  C.  M.,  Amer P.  (1996)  Are  increased  plasma  non-esterified 
fatty  acid  concentrations  a  risk  marker  for  coronary  heart  disease  and  other 
chronic  diseases?  Clin  Science,  90,243-253. 
Freidenberg  G.  R.,  Henry  R.  R.,  Klein  H.  H.,  Reichart  D.  R.,  Olefsky  J.  M.  (1987) 
Decreased  kinase  activity  of  insulin  receptors  from  adipocytes  of  non-insulin- 
dependent  diabetic  (NIDDM)  subjects.  J  Clin  Invest,  79,240-250. 
Froguel  P.  (1996)  Glucokinase  and  MODY:  from  the  gene  to  the  disease. 
Diabetic  Medicine,  13,  S96-S97. 
Froguel  P.  H.,  Vaxillaire  M.,  Sun  F.,  Velho  G.,  Zouali  H.,  Butel  M.  O.,  Lesage  S., 
Vionnet  N.,  Clement  K.,  Fougerousse  F.,  Tanizawa  Y.,  Weissenbach  J., 
Beckmann  J.  S.,  Lathrop  G.  M.,  Passa  P.,  Permutt  M.  A.,  Cohen  D.  (1992)  Close 
linkage  of  the  glucokinase  locus  on  chromosome  7p  to  early-onset  non-insulin- 
dependent  diabetes  mellitus.  Nature,  356,162-164. 
Fujita  N.,  Baba  T.,  Tomiyami  T.,  Kodama  T.,  Kako  N.  (1992)  Hyperinsulinaemia 
and  blood  pressure  in  patients  with  insulinoma.  Br  Med  J,  304,1157. 
Furchgott  R.  F.,  Zawadzki  J.  V.  (1980)  The  obligatory  role  of  endothelial  cells  in 
the  relaxation  of  vascular  smooth  muscle  by  acetylcholine.  Nature,  288,373-376. 
Gallen  I.  W.,  MacDonald  LA.  (1990)  Effect  of  two  methods  of  hand-heating  on 
body  temperature,  forearm  blood  flow,  and  deep  venous  oxygen  saturation.  Am  J 
Physiol,  259,  E639-643. 
Galloway  J.  A.,  Hooper  S.  A.,  Spradlin  C.  T.,  Howey  D.  C.,  Frank  B.  H.,  Bowsher 
R.  R.,  Anderson  J.  H.  (1992)  Biosynthetic  human  proinsulin:  review  of  chemistry, 
in  vitro  an  in  vivo  receptor  binding,  animal  and  human  pharmacology  studies,  and 
clinical  trial  experience.  Diabetes  Care,  15,666-692. 
Gans  R.  O.  B.,  Bilo  H.  J.  G.,  Maarschalkerweerd  W.  W.  A.,  Heine  R.  J.  (1991) 
Exogenous  insulin  augments  in  healthy  volunteers  the  cardiovacular  reactivity  to 
noradrenaline  but  not  to  angiotensin  U.  J  Clin  Invest,  88,512-518. 
Ganten  D.,  Mullins  J.,  Lindpaintner  K.  (1989)  The  tissue  renin-angiotensin 
system:  a  target  for  angiotensin-converting  enzyme  inhibitors.  J  Hum  Hypertens, 
3,63-70. 
223 Garvey  W.  T.,  Hucecksteadt  T.  P.,  Matthaei  S.,  Olefsky  J.  M.  (1988)  Role  of 
glucose  transporters  in  the  cellular  insulin  resistance  of  type  II  non  insulin 
dependent  diabetes  mellitus.  J  Clin  Invest,  81,1528-1536. 
Garvey  W.  T.,  Birnbaum  M.  J.  (1993)  Cellular  insulin  action  and  insulin  resistance. 
Bailliere's  Clinical  Endocrinology  and  Metabolism,  7,785-873. 
Ginsberg  H.  N.  (1991)  Lipoprotein  physiology  in  nondiabetic  and  diabetic  states. 
Relationship  to  atherogenesis.  Diabetes  Care,  14,839-855. 
Giorda  C.,  Appendino  M.,  Mason  M.  G.,  Imperiale  E.,  Pagano  G.  (1995)  a- 
blocker  doxazosin  improves  peripheral  insulin  sensitivity  in  diabetic  hypertensive 
patients.  Metabolism,  44,673-676. 
Giordano  M.,  Matsuda  M.,  Sanders  L.,  Canessa  M.  L.,  DeFronzo  R.  A.  (1995) 
Effects  of  angiotensin-converting  enzyme  inhibitors,  Ca"  channel  antagonists, 
and  alpha-adrenergic  blockers  on  glucose  and  lipid  metabolism  in  NIDDM 
patients  with  hypertension.  Diabetes,  44,665-671. 
Goh  Y.  K.,  Jumpsen  J.  A.,  Ryan  E.  A.,  Claudinin  M.  T.  (1997)  Effect  of  omega3 
fatty  acid  on  plasma  lipids,  cholesterol  and  lipopotein  fatty  acid  content  in 
NIDDM  patients.  Diabetologia,  40,45-52. 
Goldstein  D.  S.  (1983)  Plasma  catecholamines  and  essential  hypertension:  an 
analytical  review.  Hypertension,  5,86-99. 
Gould  G.  W.,  Jess  T.  J.,  Andrews  G.  C.,  Herbst  J.  J.,  Plevin  R.  J.,  Gibbs  E.  M.  (1994) 
Evidence  for  a  role  of  phosphatidylinositol  3-kinase  in  the  regulation  of  glucose 
transport  in  Xenopus  oocytes.  J  Biol  Chem,  260,26622-26625. 
Greenfield  A.  D.  M.  and  Paterson  G.  C.  (1954)  Reactions  of  the  blood  vessels  of 
the  human  forearm  to  increases  in  transmural  pressure.  J  Physiol,  125,508-524. 
Greenfield  A.  D.  M.,  Whitney  R.  J.,  Mowbray  J.  F.  (1963)  Methods  for  the 
investigation  of  peripheral  blood  flow.  Br  Med  Bull,  19,101-109. 
Greenfield  M.  S.,  Doberne  L.,  Kraemer  F.,  Tobey  T.,  Reaven  G.  (1981) 
Assessment  of  insulin  resistance  with  the  insulin  suppression  test  and  the 
euglycaemic  clamp.  Diabetes,  30,387-392. 
Groop  L.  C.,  Saloranta  C.,  Shank  M.,  Bonadonna  R.  C.,  Ferrannini  E.,  DeFronzo 
R.  A.  (1991)  The  role  of  free  fatty  acid  metabolism  in  the  pathogenesis  of  insulin 
resistance  in  obesity  and  non-insulin  dependent  diabetes  mellitus.  J  Clin  End 
Metab,  72,96-107. 
Groop  L.  C.  (1992)  Sulphonylureas  in  NIDDM.  Diabetes  Care,  15,737-754. 
224 Grootenhuis  P.  A.,  Mooy  J.  M.,  Popp-Snijders  C.,  Bouter  L.  M.,  Heine  R.  J.  (1994) 
Total  immunoreactive  insulin,  specific  insulin  and  proinsulin  levels  in  relation  to 
serum  lipid  and  blood  pressure  levels  in  a  non-diabetic  Caucasian  population.  In: 
Grootenhuis  P.  A.  Epidemiological  aspects  of  the  insulin  resistance  syndrome:  the 
Hoorn  Study.  Ph.  D.  Thesis,  submitted  to  Free  University,  Amsterdam,  The 
Netherlands,  1994  (available  by  request  from  the  senior  author). 
Gudbjornsdottir  S.,  Elam  M.,  Sellgren  J.,  Anderson  E.  A.  (1995)  Insulin  increases 
forearm  vascular  resistance  in  obese  insulin-resistant  hypertensives.  J  Hypertens, 
14,91-97. 
Gulli  G.,  Ferrannini  E.,  Stern  M.,  Haffner  S.,  DeFronzo  R.  A.  (1992)  The 
metabolic  profile  is  fully  established  in  the  glucose  tolerant  offspring  of  two 
Mexican  American  non-insulin-dependent  diabetic  parents.  Diabetes,  41,1575- 
1586. 
Gupta  A.  K.,  Clark  R.  V.,  Kirchner  K.  A.  (1992)  Effects  of  insulin  on  renal  sodium 
excretion.  Hypertension,  19  (suppl  1),  I78-I82. 
Haffner  S.  M.,  Stern  M.  P.,  Hazuda  H.  P.,  Mitchell  B.  D.,  Patterson  J.  K.  (1988) 
Increased  insulin  concentrations  in  nondiabetic  offspring  of  diabetic  parents.  N 
Engl  J  Med,  319,337-343. 
Haffner  S.  M.,  Valdez  R.  A.,  Hazuda  H.  P.,  Mitchell  B.  D.,  Morales  P.  A.,  Stern  M.  P. 
(1992)  Prospective  analysis  of  the  insulin  resistance  syndrome.  Diabetes,  41,715- 
722. 
Haffner  S.  M.  (1993)  Insulin  and  blood  pressure:  fact  or  fantasy?  J  Clin  End 
Metab,  76,541-543. 
Haffner  S.  M.,  Mykkanen  L.,  Stern  M.  P.,  Valdez  R.  A.,  Heisserman  J.  A., 
Bowsher  R.  R.  (1993)  Relationship  of  proinsulin  and  insulin  to  cardiovascular 
risk  factors  in  non-diabetic  subjects.  Diabetes  42,1297-1302 
Haffner  S.  M.,  Mykkanen  L.,  Valdez  R.  A.,  Stern  M.  P.  (1994)  Evaluation  of  two 
insulin  assays  in  insulin  resistance  syndrome  (Syndrome  X).  Arterioscler 
Thrombosis,  14,1430-1437. 
Hales  C.  N.,  Barker  D.  J.  P.,  Clark  P.  M.  S.,  Cox  L.  J.,  Fall  C.,  Osmond  C.,  Winter 
P.  D.  (1991)  Fetal  and  infant  growth  and  impaired  glucose  tolerance  at  64  years. 
Br  Med  J,  303,1019-1022. 
Hales  C.  N.  (1994)  The  pathogenesis  of  NIDDM.  Diabetologia,  37(Suppl  2), 
S162-S168. 
Hall  J.  E.,  Coleman  T.  G.,  Mizelle  H.  L.,  Smith  M.  J.  (1990)  Chronic 
hyperinsulinaemia  and  blood  pressure  regulation.  Am  J  Physiol,  258,  F722-F731. 
225 Handberg  A.,  Vaag  A.,  Dambso  P.,  Beck-Nielsen  H.,  Vinten  J.  (1990)  Expression 
of  insulin  regulatable  glucose  transporters  in  skeletal  muscle  from  type  II  (non- 
insulin-dependent)  diabetic  patients.  Diabetologia,  33,625-627. 
Harano  Y.,  Hidaka  H.,  Takatsuki  K.  Ohgaku  S.,  Haneda  M.,  Motoi  S.,  Kawagoe 
K.,  Shigeta  Y.,  Abe  H.  (1978)  Glucose,  insulin  and  somatostatin  infusion  for  the 
determination  of  insulin  sensitivity  in  vivo.  Metabolism,  27,1449-56. 
Haring  H.  U.,  Mehnert  H.  (1993)  Pathogenesis  of  type  2  (non-insulin-dependent 
diabetes  mellitus):  candidates  for  a  signal  transmitter  defect  causing  insulin 
resistance  of  the  skeletal  muscle.  Diabetologia  36,176-182. 
Harper  R.,  Ennis  C.,  Atkinson  A.  B.,  Johnston  G.  D.,  Bell  P.  M.  (1994)  Effect  of 
low  and  conventional  dose  bendrofluazide  on  insulin  action  in  essential 
hypertension.  Br  Med  J,  309,226-230. 
Harper  R.,  Ennis  C.  N.,  Heaney  A.  P.,  Sheridan  B.,  Gormley  M.,  Atkinson  A.  B., 
Johnston,  G.  D.,  Bell,  P.  M.  (1995)  A  comparison  of  the  effect  of  low-  and 
conventional-dose  thiazide  diuretic  on  insulin  action  in  hypertensive  partients 
with  NIDDM.  Diabetologia,  38,853-859. 
Heding  L.  G.  (1977)  Specific  and  direct  radioimmunoassay  for  human  proinsulin 
in  serum.  Diabetologia,  13,467-474. 
Heinemann  L.,  Heise  T.,  Ampudia  J.,  Sawicki  P.,  Sindelka  G.,  Brunner  G.,  Starke 
A.  A.  R.  (1995)  Four  week  administration  of  an  ACE  inhibitor  and  a 
cardioselective  ß-blocker  in  healthy  volunteers:  no  influence  on  insulin 
sensitivity.  Eur  J  Clin  Invest,  25,595-600. 
Henderson  A.  H.  (1996)  Endothelium,  for  example.  J  Roy  Coll  Phys,  30,42-51. 
Hespel  P.,  Vergauwen  L.,  Vandenberghe  K.,  Richter  E.  A.  (1995)  Important  role 
for  insulin  and  flow  in  stimulating  glucose  uptake  in  contracting  skeletal  muscle. 
Diabetes,  44,210-215. 
Himsworth  H.  Diabetes  mellitus:  a  differentiation  into  insulin-sensitive  and 
insulin-insensitive  types.  Lancet  1936,  (i),  127-130. 
Hirshsman  M.  F.,  Goodyear  L.  J.,  Wardzala  L.  J.,  Horton  E.  D.,  Horton  E.  S.  (1990) 
Identification  of  an  intracellular  pool  of  glucose  transporters  from  basal  and 
insulin-stimulated  rat  skeletal  muscle.  J  Biol  Chem,  265,987-991. 
Hokanson  D.  E.,  Sumner  D.  S.,  Strandness  D.  E.  (Jr.  )  (1975)  An  electrically 
calibrated  plethysmograph  for  direct  measurement  of  limb  blood  flow.  IEEE 
Trans  Biomed  Engin,  22,25-29 
Hollenberg  N.  K.,  Chenitz  W.  R.,  Adams  D.  F.,  Williams  G.  H.  (1974)  Reciprocal 
influence  of  salt  intake  on  adrenal  glomerulosa  and  renal  vascular  responses  to 
angiotensin  H  in  normal  man.  J  Clin  Invest,  54,34-42 
226 Hollenbeck  G.,  Reaven  G.  M.  (1987)  Variations  in  insulin-stimulated  glucose 
uptake  in  healthy  individuals  with  normal  glucose  tolerance.  J  Clin  End  Metab, 
64,1169-1173. 
Hornig  B,  Maier  V,  Drexler  H.  (1996)  Physical  training  improves  endothelial 
function  in  patients  with  chronic  heart  failure.  Circulation,  93,210-214. 
Hother-Nielsen  0.,  Beck-Nielsen  H.  (1990)  On  the  determination  of  basal 
glucose  production  rate  in  patients  with  type  2  (non-insulin-dependent)  diabetes 
mellitus  using  primed  continuous  3-3H  glucose  infusion.  Diabetologia  33,603- 
610. 
Hother-Nielsen  0.,  Mengel  A.,  Moller  J.,  Rasmussen  0.,  Schmitz  0.,  Beck- 
Nielsen  H.  (1992)  Assessment  of  glucose  turnover  rates  in  euglycaemic  clamp 
studies  using  primed-constant  3-3H  glucose  infusion  and  labelled  or  unlabelled 
glucose  infusates.  Diab  Med,  9,840-849. 
Howard  G.,  O'Leary  D.  H.,  Zaccaro  D.,  Haffner  S.,  Rewers  M.,  Hamman  R.,  Selby 
J.  V.,  Saad  M.,  Savage  P.,  Bergman  R.  (1996)  Insulin  sensitivity  and 
atherosclerosis.  Circulation,  93,1809-1817. 
Hubbard  S.  R.,  Wei  L.,  Ellis  L.,  Hendrickson  W.  A.  (1994)  Crystal  structure  of  the 
tyrosine  kinase  of  the  human  insulin  receptor.  Nature,  372,746-754. 
Hunter  Si.,  Harper  R.,  Ennis  C.  N.,  Crothers  E.,  Sheridan  B.,  Atkinson  A.  B.,  Bell 
P.  M.  (1994)  Relationship  between  blood  flow  and  insulin  action  in  essential 
hypertension  (abstract).  Diab  Med,  I1(Suppl  2),  S20  (A29). 
Ikeda  T.,  Gomi  T.,  Hirawa  N.,  Sakurai  J.,  Yoshikawa  N.  (1996)  Improvement  of 
insulin  sensitivity  contributes  to  blood  pressure  reduction  after  weight  loss  in 
hypertensive  subjects  with  obesity.  Hypertension,  27,1180. 
Imaizumi  T.,  Hirooka  Y.,  Masaki  H.,  Harada  S.,  Momohara  M.,  Tagawa  T., 
Takeshita  A.  (1992)  Effects  of  L-arginine  on  forearm  vessels  and  responses  to 
acetylcholine.  Hypertension,  20,511-517. 
Iwamoto  Y.,  Kosaka  K.,  Kuzuya  T.,  Akanuma  Y.,  Shigeta  Y.,  Kaneko  T.  (1996) 
Effect  of  combination  therapy  of  troglitazone  and  sulphonylureas  in  patients  with 
type  2  diabetes  who  were  poorly  controlled  by  sulphonylurea  therapy  alone.  Diab 
Med,  13,365-370. 
Jacobs  M-C,  Lenders  J.  W.  M.,  Kapma  J.  A.,  Smits  P.,  'Mien  T.  (1993)  Effect  of 
chronic  smoking  on  endothelium-dependent  vascular  relaxation  in  humans.  Clin 
Sci,  85,51-55. 
Jamerson,  K.  A.,  Julius,  S.,  Gudbrandsson,  T.,  Andersson,  O.,  O'Brant,  D.  (1992) 
Reflex  sympathetic  activation  induces  acute  insulin  resistance  in  the  human 
forearm.  Hypertension,  21,618-623. 
227 Jansson  P-A.  E.,  Fowelin  J.  P.,  Von  Schenk  H.  P.,  Smith  U.  P.,  Lonroth  P.  N.  (1993) 
Measurement  by  microdialysis  of  the  insulin  concentration  in  subcutaneous 
interstitial  fluid:  importance  of  the  endothelial  barrier  for  insulin.  Diabetes,  42, 
1469-1473. 
Jarrett  R.  J.  (1992)  In  defence  of  insulin:  a  critique  of  syndrome  X.  Lancet,  340, 
469-471. 
Jauch  K.  W.,  Hard  W.,  Guenther  B.,  Wicklmays  M.,  Rett  K.,  Dietze  G.  (1987). 
Captopril  enhances  insulin  responsiveness  of  forearm  muscle  tissue  in  non- 
insulin-dependent  diabetes  mellitus.  Eur  J  Clin  Invest,  17,448-454. 
Jensen  T.,  Feldt-Rasmussen  B..  Bjerre-Knudsen  J.,  Deckert  T.  (1989)  Features  of 
endothelial  dysfunction  in  early  diabetic  nephropathy.  Lancet,  i,  461-463. 
Jiang  X.,  Srinivasa  S.  R.,  Bao  W.,  Berenson  G.  S.  (1993a)  Association  of  fasting 
insulin  with  longitudinal  changes  in  blood  pressure  in  children  and  adolescents. 
The  Bogalusa  Heart  Study.  Am  J  Hypertens,  6,564-569. 
Jiang  X.,  Srinivasa  S.  R.,  Bao  W.,  Berenson  G.  S.  (1993b)  Association  of  fasting 
insulin  with  blood  pressure  in  young  individuals.  Arch  Intern  Med,  153,323-328. 
Juhlin-Dannfelt  A.,  Frisk-Holmberg  M.,  Karlsson  J.,  Tesch  P.  (1979)  Central  and 
peripheral  circulation  in  relation  to  muscle  fibre  type  composition  in  normotensive 
and  hypertensive  man.  Clin  Sci,  56,335-340. 
Julius  S.,  Gudbrandsson  T.,  Jamieson  K.,  Shabab  S.  T.,  Andersson  0.  (1991)  The 
haemodynamic  link  between  insulin  resistance  and  hypertension.  J  Hypertens,  9, 
983-986. 
Kadowaki  T.,  Bevies  C.  L.,  Cama  A.,  Ojamaa  K.,  Marcus-Samuels  B.,  Kadowaki 
H.,  Beitz  L.,  McKeon  C.,  Taylor  S.  L  (1988)  Two  mutant  alleles  of  the  insulin 
receptor  gene  in  a  patient  with  extreme  insulin  resistance.  Science,  240,787-790. 
Kahn  A.  M.,  Seidel  C.  L.,  Allen  J.  C.,  O'Neil  R.  G.,  Shelat  H.,  Song  T.  (1993) 
Insulin  reduces  contraction  and  intracellular  calcium  concentration  in  vascular 
smooth  muscle.  Hypertension,  22,735-742. 
Kahn  A.  M.,  Lichtenberg  R.  A.,  Allen  J.  C.,  Seidel  C.  L.,  Song  T.  (1995)  Insulin- 
stimulated  glucose  transport  inhibits  Ca++  influx  and  contraction  in  vascular 
smooth  muscle.  Circulation,  92,1597-1603. 
Kahn  C.  R.  (1995).  Causes  of  insulin  resistance.  Nature,  373,384-385. 
Kahn  S.  E.,  Prigeon  R.  L.,  McCulloch  D.  K.,  Boyko  E.  J.,  Bergman  R.  N.,  Schwartz 
M.  W.,  Neifing  J.  L.,  Ward  K.,  Beard  J.  C.,  Palmer  J.  P.,  Porte  D.  (Jr.  )  (1994)  The 
contribution  of  insulin-dependent  and  insulin-independent  glucose  uptake  to 
intravenous  glucose  tolerance  in  healthy  human  subjects.  Diabetes,  43,587-592. 
228 Kannell  W.  B.,  McGhee  D.  L.  (1979)  Diabetes  and  cardiovascular  risk  factors:  the 
Framingham  Study.  Circulation,  59,8-13. 
Kaplan  N.  M.  (1989)  The  deadly  quartet:  upper-body  obesity,  glucose  intolerance, 
hypertriglyceridemia,  and  hypertension.  Arch  Intern  Med,  149,1514-1520. 
Karhapaa  P.,  Voutilainen  E.,  Kovanen  P.  T.,  Laakso  M.  (1993)  Insulin  resistance 
in  familial  and  nonfamilial  hypercholesterolaemia.  Arterioscler  Thromb,  13,41- 
47 
Karlsson  A.  K.,  Attvall  S.,  Jansson  P-A.,  Sullivan  L.,  Lonroth  P.  (1995)  Influence 
of  the  sympathetic  nervous  system  on  insulin  sensitivity  and  adipose  tissue 
metabolism:  a  study  in  spinal-cord  injured  subjects.  Metabolism,  44,52-58. 
Kasigawi  A.,  Verso  M.  A.,  Andrews  J.,  Vasquez  B.,  Reaven  G.,  Foley  J.  E.  (1983) 
In  vitro  insulin  resistance  of  human  adipocytes  isolated  from  subjects  with  non- 
insulin  dependent  diabetes  mellitus.  J  Clin  Invest,  72,1246-1254. 
Keaney  J.  F.  (Jr),  Gaziano  J.  M.,  Xu  A.,  Frei  B.,  Curran-Celentano  J.,  Shwaery  GT, 
Loscalzo  J.,  Vita  J.  A.  (1993)  Dietary  antioxidants  preserve  endothelium- 
dependent  vessel  relaxation  in  cholesterol-fed  rabbits.  Proc  Nail  Acad  Sci  USA, 
90,11880-11884. 
Kearney  M.  T.,  Cowley  A.  J.,  Stubbs  T.  A.,  MacDonald  I.  A.  (1996)  Effect  of  a 
physiological  infusion  of  insulin  on  the  cardiovascular  responses  to  a  high  fat 
meal:  evidence  supporting  a  role  for  insulin  in  modulating  postprandial 
cardiovascular  homeostasis  in  man.  Clin  Sci,  91,415-423. 
Keegan  A.,  Walbank  H.,  Cotter  M.  A.,  Cameron  N.  E.  (1995)  Chronic  vitamin  E 
treatment  prevents  defective  endothelium-dependent  relaxation  in  diabetic  rat 
aorta.  Diabetologia,  38,1475-1478. 
Keen  H.  (1994)  Insulin  resistance  and  the  prevention  of  diabetes  mellitus.  N Eng 
J  Med,  331,1226-1227. 
Kelm  M.,  Preik  M.,  Hafner  D.,  Strauer  B.  E.  (1996)  Evidence  for  a  multifactorial 
process  in  the  impaired  response  to  nitric  oxide  in  hypertensive  patients  with 
endothelial  dysfunction.  Hypertension,  27,346-353. 
Kendall  M.  J.,  Lewis  H.,  Griffith  M.,  Barnett  A.  H.  (1988)  Drug  treatment  of  the 
hypertensive  diabetic.  Hypertension,  1,249-258. 
Kiowski  W.,  Linder  L.,  Nuesch  R.,  Martina  B.  (1993)  Effects  of  angiotensin 
converting  enzyme  inhibition  on  endothelial  vasodilator  function  in  primary 
human  hypertension.  Eur  Heart  J,  14(Suppl  C),  5-9. 
Kiowski  W.,  Linder  L.,  Stoschitzky  K.,  Pfisterer  M.,  Burckhardt  D.,  Burkart  F., 
Buhler  F.  R.  (1994)  Diminshed  vascular  response  to  inhibition  of  endothelium- 
derived  nitric  oxide  and  enhanced  vasoconstriction  to  exogenously-administered 
endothelin-1  in  clinically  healthy  smokers.  Circulation,  90,27-34. 
229 K.  issebah  A.  H.,  Vydelingum  N.,  Murray  R.,  Evans  D.  J.,  Hartz  A.  J.,  Kalkhoff 
R.  K.,  Adams  P.  W.  (1982)  Relation  of  body  fat  distribution  to  metabolic 
complications  of  obesity.  J  Clin  End  Metab,  54,254-260. 
Klip  A.,  Tsakiridis  T.,  Marette  A.,  Ortiz  P.  A.  (1994)  Regulation  of  glucose 
transporters  by  glucose:  a  review  of  studies  in  vivo  and  in  cell  cultures.  FASEB  J, 
8,43-54. 
Kneer  N.  M.,  Lardy  H.  A.  (1983)  Regulation  of  gluconeogenesis  by 
norepinephrine,  vasopressin  and  angiotensin  II:  a  comparative  study  in  the 
absence  and  presence  of  extracellular  calcium.  Arch  Biochem  Biophys,  225,187- 
195 
Ko  Y.,  Sachinidis  A.,  Wieczorek  A.  J.,  Apenheimer  M.,  Dusing  R.,  Vetter  H. 
(1993)  Insulin  enhances  angiotensin  II  induced  DNA  synthesis  in  vascular  smooth 
muscle  cells.  Clin  Invest,  71,379-382. 
Krentz  AT,  Clark  P.  M.,  Cox  L.,  Nattrass  M.  (1993)  Hyperproinsulinaenia  in 
impaired  glucose  tolerance.  Clin  Sci,  85,97-100. 
Laakso  M.,  Pyorala  K.,  Voutilainen  E.,  Marniemi  J.  (1987)  Plasma  insulin  and 
serum  lipids  and  lipoproteins  in  middle-aged  non-insulin  dependent  diabetic  and 
non-diabetic  subjects.  Am  J  Epidemiol,  125,611-619. 
L,  aakso  M.,  Edelman  S.  V.,  Brechtel  G.,  Baron  A.  D.,  (1990a)  Decreased  effect  of 
insulin  to  stimulate  skeletal  muscle  blood  flow  in  obese  man:  a  novel  mechanism 
for  insulin  resistance.  J  Clin  Invest,  85,1844-1852. 
Laakso  M.,  Sarlund  H.,  Mykkanen  L.  (1990b)  Insulin  resistance  is  associated  with 
lipid  and  lipoprotein  abnormalities  in  subjects  with  varying  degrees  of  glucose 
tolerance.  Arteriosclerosis,  10,223-231. 
Landsberg  L.,  Krieger  D.  R.  (1989)  Obesity,  metabolism,  and  the  sympathetic 
nervous  system.  Am  J  Hypertens,  2,165-171. 
Lembo  G.,  Napoli  R.,  Capaldo  B.,  Rendina  V.,  laccarino  G.,  Volpe  M.,  Trimarco 
B.,  Sacca  L.  (1992)  Abnormal  sympathetic  overactivity  evoked  by  insulin  in  the 
skeletal  muscle  of  patients  with  essential  hypertension.  J  Clin  Invest,  90,24-29. 
Lembo  G.,  Rendina  V.,  laccarino  G.,  Lamenza  F.,  Massimo  V.,  Trimarco  B. 
(1993)  Insulin  reduces  reflex  forearm  sympathetic  vasoconstriction  in  healthy 
humans.  Hypertension,  21,1015-1019. 
Lembo  G.,  laccarino  V.,  Rendina  V..  Massimo  V.,  Trimarco  B.  (1994)  Insulin 
blunts  sympathetic  vasoconstriction  through  the  a2-adrenergic  pathway  in 
humans.  Hypertension  24,429-483. 
230 Leung  W.  H.,  Lau  C.  P.,  Wong  C.  K.  (1993)  Beneficial  effect  of  cholesterol  therapy 
on  coronary  endothelium-dependent  relaxation  in  hypercholesterolaemic  patients. 
Lancet,  341,1496-1500. 
Levy  JC,  Brown  G,  Matthews  DR,  Turner  RC.  (1989)  Hepatic  glucose  output 
measured  with  labelled  glucose  to  reduce  negative  errors.  Am  J  Physiol  257, 
E531-E539. 
Levy  J.,  Gavin  J.  R.  (1994)  Diabetes  mellitus:  a  disease  of  abnormal  calcium 
metabolism?  Am  J  Med,  96,260-273. 
Lewis  T.,  Pickering  G.  (1931)  Vasodilatation  in  the  limbs  in  response  to  warming 
the  body:  with  evidence  for  sympathetic  vasodilator  fibres  in  man.  Heart,  16,33- 
51. 
Lichtenstein  M.  J.,  Yarnell  J.  W.  G.,  Elwood  P.  C.,  Beswick  A.  D.,  Sweetnam  P.  M., 
Marks  V.,  Teale  D.,  Riad-Fahmy  D.  (1987)  Sex  hormones,  insulin,  lipids  and 
prevalent  ischaemic  heart  disease.  Am  J  Epidemiol,  126,647-57. 
Lillioja  S.,  Young  A.  A.,  Culter  C.  L.,  Ivy  J.  L.,  Abbott  W.  G.,  Zawadzki  J.  K.,  Yki- 
Jarvinen  H.,  Christin  L.,  Secomb  T.  W.,  Bogardus  C.  (1987)  Skeletal  muscle 
capillary  density  and  fibre  type  are  possible  determinants  of  in-vivo  insulin 
resistance  in  man.  J  Clin  Invest,  80,415-425. 
Lindqvist  M.,  Kahan  T.,  Melcher  A.,  Hjemdahl  P.  (1993)  Cardiovascular  and 
sympathoadrenal  responses  to  mental  stress  in  primary  hypertension.  Clin  Sci,  85, 
401-409. 
Liu  D.,  Moberg  E.,  Kollind  M.,  Lins  P-E.,  Adamson  U.,  MacDonald  LA.  (1992) 
Arterial,  arterialised  venous,  venous,  and  capillary  blood  glucose  measurements  in 
normal  man  during  hyperinsulinaemic  euglycaemia  and  hypoglycaemia. 
Diabetologia,  35,287-290. 
Livingstone  C.,  Dominiczak  A.  F.,  Campbell  I.  W.,  Gould  G.  W.  (1995)  Insulin 
resistance  and  the  insulin-responsive  glucose  transporter,  GLUT-4.  Clin  Sci,  89, 
109-116. 
Ludvik  B.,  Nolan  J.  J.,  Baloga  J.,  Sacks  D.,  Olefsky  J.  (1995)  Effect  of  obesity  on 
insulin  resistance  in  normal  subjects  and  patients  with  NIDDM.  Diabetes  44, 
1121-1125. 
Lyons  D.,  Webster  J.,  Benjamin  N.  (1994)  The  effect  of  antihypertensive  therapy 
on  responsiveness  to  intra-arterial  NG-monomethyl-L-arginine  in  patients  with 
essential  hypertension.  J  Hypertens,  12,1047-1052. 
McFadyen  R.  J.,  Elliott  H.  L.,  Meredith  P.  A.,  Reid  J.  L.  (1993)  Haemodynamic  and 
hormonal  responses  to  oral  enalapril  in  salt-depleted  normotensive  man.  Br  J  Clin 
Pharm,  35,299-301. 
231 McKay  M.  K.,  Hester  R.  L.  (1996)  Role  of  nitric  oxide  and  ATP-sensitive 
potassium  channels  in  insulin-induced  vasodilatation.  Hypertension,  28,202-208. 
MacKenzie  J.  K.,  Clements  J.  A.  (1974).  Simplified  radioimmunoassay  for  serum 
aldosterone  utilising  increased  antibody  specificity.  J  Clin  End  Metab,  38,622- 
627. 
McVeigh  G.  E.,  Brennan  G.  M.,  Johnston  G.  D.,  McDermott  B.  J.,  McGrath  L.  T., 
Henry  W.  R.,  Andrews  J.  W.,  Hayes  J.  R.  (1992)  Impaired  endothelium-dependent 
vasodilation  in  patients  with  type  2  (non-insulin  dependent)  diabetes  mellitus. 
Diabetologia,  35,771-776. 
Maasen  J.  A.,  Kadowaki  T.  (1996)  Maternally  inherited  diabetes  and  deafness:  a 
new  diabetes  subtype.  Diabetologia  39,375-382. 
Maddux  B.  A.,  Sbraccia  P.,  Kumakura  S.,  Sasson  S.,  Youngren  J.,  Fisher  A., 
Spencer  S.,  Grupe  A.,  Henzel  W.,  Stewart  TA.,  Reaven  G.  M.,  Goldfine  LD. 
(1995)  Membrane  glycoprotein  PC-1  and  insulin  resistance  in  non-insulin 
dependent  diabetes  mellitus.  Nature,  373,448-451. 
Maheux  P.,  Jeppesen  J.,  Sheu  W.  H.  H.,  Hollenbeck  C.  B.,  Clinkingbeard  C., 
Greenfield  M.  S.,  Chen  Y-D.  I.,  Reaven  G.  M..  (1994)  Additive  effects  of  obesity, 
hypertension,  and  type  2  diabetes  on  insulin  resistance.  Hypertension,  24,695- 
698. 
Mahtani  M.  M.,  Widen  E.,  Lehto  M.,  Thomas  J.,  McCarthy  M.,  Brayer  J.,  Bryant 
B.,  Chan  G.,  Daly  M.,  Forsblom  C.,  Kanninen  T.,  Kirby  A.,  Kruglyak  L., 
Munnelly  K.,  Parkkonen  M.,  Reeve-Daly  M.  P.,  Weaver  A.,  Brettin  T.,  Duyk  G., 
Lander  E.  S.,  Groop  L.  C.  (1996)  Mapping  of  a  gene  for  type  2  diabetes  associated 
with  an  insulin  secretion  defect  by  a  genome  scan  in  a  Finnish  population.  Nature 
Genetics,  14,90-94. 
Mako  M.  E.,  Starr  J.  I.,  Rubenstein  A.  H.  (1977)  Circulating  proinsulin  in  patients 
with  maturity  onset  diabetes.  Am  J  Med,  63,865-869. 
Matthews  D.  R.,  Hosker  J.  P.,  Rudenski  J.  S.,  Naylor  B.  A.,  Treacher  B.  F.,  Turner 
R.  C.  (1985)  Homeostasis  model  assessment:  insulin  resistance  and  8-cell  function 
from  fasting  plasma  glucose  and  insulin  concentrations  in  man.  Diabetologia,  28, 
412-419. 
Matthews  J.  N.  S.,  Altman  D.  G.,  Campbell  M.  J.,  Royston  P.  (1990)  Analysis  of 
serial  measures  in  medical  research.  Br  Med  J  1990,300,230-35. 
Mbanya  J.  C.,  Thomas  T.  H.,  Wilkinson  R.,  Alberti  K.  G.  M.  M.,  Taylor  R.  (1988) 
Hypertension  and  hyperinsulinaemia:  a  relation  in  diabetes  but  not  in  essential 
hypertension.  Lancet,  i,  733-744. 
Medical  Research  Council  Working  Party.  (1985)  MRC  trial  of  treatment  of  mild 
hypertension:  principal  results.  Br  Med  J,  291,97-104. 
232 Mijares  A.  H..  Jensen  M.  D.  (1995)  Contribution  of  blood  flow  to  leg  glucose 
uptake  during  a  mixed  meal.  Diabetes.  44,1165-1169. 
Miles  L.  E.  M.,  Hales  C.  N.  (1968)  Labelled  antibodies  and  immunological  assay 
systems.  Nature,  219,186-189. 
Mimura  A.,  Kageyama  S.,  Maruyama  M.,  Ikeda  Y.,  Isogai  Y.  (1994)  Insulin 
sensitivity  test  using  a  somatostatin  analogue,  octreotide  (sandostatin).  Horm  Met 
Res,  26.184-187. 
Moan  A.,  Hoieggen  A.,  Nordby  G.,  Birkeland  K.,  Eide  I.,  Kjeldsen  S.  E.  (1995) 
The  glucose  clamp  procedure  activates  the  sympathetic  nervous  system  even  in 
the  absence  of  hyperinsulinaemia.  J  Clin  Endocrinol  Metab,  80,3151-3154. 
Modan  M.,  Halkin  H.,  Almog  S.,  Lusky  A.,  Eshkol  A.,  Shefi  M.,  Shitrit  A.,  Fuchs 
Z.  (1985)  Hyperinsulinaemia:  a  link  between  hypertension,  obesity  and  glucose 
intolerance.  J  Clin  Invest,  75,809-817. 
Mohamed-Ali  V.,  Gould  M.  M.,  Gillies  S.,  Goubet  S.,  Yudkin  J.  S.,  Haines  A.  P. 
(1995)  The  association  of  proinsulin-like  molecules  with  lipids  and  fibrinogen  in 
non-diabetic  subjects  -  evidence  against  a  modulating  role  for  insulin. 
Diabetologia,  38,1110-1116. 
Moller  D.  E.,  Flier  J.  S.  (1991)  Insulin  resistance  -  mechanisms,  syndromes  and 
implications.  N  Engl  J  Med,  325,938-948. 
Moore  R.  D.  (1983)  Effects  of  insulin  upon  ion  transport.  Biochem  Biophys  Acta, 
737,1-49. 
Mooy  J.  J.,  Grootenhuis  P.  A.,  de  Vries  H.,  Kostense  P.  J.,  Popp-Snijders  C.,  Heine 
R.  J.  (1996)  Intra-individual  variation  of  glucose,  specific  insulin,  and  proinsulin 
concentrations  measured  by  two  oral  glucose  tolerance  tests  in  a  general 
Caucasian  population:  the  Hoorn  Study.  Diabetologia  39,298-305. 
Morales  P.  A.,  Mitchell  B.  D.,  Valdez  R.  A.,  Hazuda  H.  P.,  Stem  M.  P.,  Haffner  S.  M. 
(1993)  Incidence  of  NIDDM  and  impaired  glucose  tolerance  in  hypertensive 
subjects.  Diabetes,  42,154-  161. 
Morris  A.  D.,  Petrie  J.  R.,  Ueda  S.,  Elliott  H.  L.,  Connell  J.  M.  C.  (1993)  The  effects 
of  angiotensin  11  on  insulin  sensitivity:  a  placebo-controlled  study.  Clin  Sci,  85, 
431-436. 
Morris  A.  D.,  Ueda  S.,  Petrie  J.  R.,  Donnelly  R.,  Connell  J.  M.  C.  (1994a)  How 
reproducible  is  the  euglycaemic  hyperinsulinaemic  clamp  (abstract)?  J  Hyperzens, 
12(Suppl  13),  A127. 
Morris  A.  D.,  Donnelly  R.,  Connell  J.  M.  C.,  Reid  J.  L.  (1994b)  Effects  of  the 
calcium  antagonist  lacidipine  on  insulin  sensitivity  in  essential  hypertension:  a 
placebo-controlled  study.  Horm  Met  Res,  26,257-259. 
233 Morris  A.  D.,  Petrie  J.  R.,  Ueda  S.,  Connell  J.  M.  C.,  Elliott  H.  L.,  Small  M., 
Donnelly  R.  (1994c)  Pressor  and  subpressor  doses  of  angiotensin  II  increase 
insulin  sensitivity  in  NIDDM:  dissociation  of  metabolic  and  blood  pressure 
effects.  Diabetes,  43,1445-1449. 
Morton  J.  J.,  Webb  D.  J.  (1985)  Measurement  of  plasma  angiotensin  H.  Clin  Sci, 
68,483-4. 
Muller  D.  C.,  Elahi  D.,  Pratley  R.  E.,  Tobin  J.  D.,  Andres  R.  (1993)  An 
epidemiological  test  of  the  hyperinsulinaemia-hypertension  hypothesis.  J  Clin 
Endocrinol  Metab  76,544-548 
Murphy  M.  B.,  Lewis  P.  J.,  Kohner  E.,  Schumer  B.,  Dollery  C.  T.  (1982)  Glucose 
intolerance  in  hypertensive  patients  treated  with  diuretics;  a  fourteen-year  follow- 
up.  Lancet,  2,1293-1295. 
Mykannen  L.,  Ronnemaa  T.,  Marniemi  J.,  Haffner  S.,  Bergman  R.,  Laakso  M. 
(1994)  Insulin  sensitivity  is  not  an  independent  determinant  of  plasminogen 
activator  inhibitor-1  activity.  Arterioscler  Thromb,  14,1264-1271. 
Nagi  D.  K.,  Hendra  T.  J.,  Ryle  A.  J.,  Cooper  T.  M.,  Temple  R.  C.,  Clarke  P.  M.  S., 
Schneider  A.  G.,  Hales  C.  N.,  Yudkin  J.  S..  (1990)  The  relationships  of  insulin, 
intact  proinsulin,  and  32/33  split  proinsulin  with  cardiovascular  risk  factors  in 
type  II  (non-insulin  dependent)  diabetic  subjects.  Diabetologia,  33,532-537. 
Natali  A.,  Buzzigoli  G,  Taddei  S,  Santoro  D.,  Cerri  M.,  Pedrinelli  R.,  Ferranini  E. 
(1990)  Haemodynamics  and  metabolism  in  human  forearm:  effects  of  insulin. 
Diabetes,  39,490-500. 
Natali  A.,  Santoro  D.,  Palombo  C.,  Cerri  M.,  Ghione  S.,  Ferranini  E.  (1991) 
Impaired  insulin  action  on  skeletal  muscle  metabolism  in  essential  hypertension. 
Hypertension,  17,170-178. 
Natali  A.,  Bonadonna.  R,  Santoro  D.,  Galvan  A.  Q.,  Baldi  S.,  Frascerra  S., 
Palombo  C.,  Ghione  S.,  Ferrannini  E.  (1994)  Insulin  resistance  and  vasodilatation 
in  essential  hypertension:  studies  with  adenosine.  J  Clin  Invest,  94,1570-1576. 
Nauck  M.  A.,  Blietz  R.  W.,  Qualmann  C.,  (1996)  Comparison  of 
hyperinsulinaemic  clamp  experiments  using  venous  or  capillary  euglycaemia. 
Clinical  Physiology,  16,589-602. 
Neahring  J.  M.,  Stepniakowski  A.  S.,  Greene  A.  S.,  Egan  B.  M.  (1993)  Insulin  does 
not  reduce  forearm  a-vasoreactivity  in  obese  hypertensive  or  lean  nomotensive 
men.  Hypertension,  22,584-590. 
Neely  R.  D.  G.,  Rooney  D.  P.,  Bell  P.  M.,  Bell  N.  P.,  Sheridan  B.,  Atkinson  A.  B., 
Trimble  E.  R.  (1992)  Influence  of  growth  hormone  on  glucose-glucose  6- 
phosphate  cycle  and  insulin  action  in  normal  humans.  Am  J  Physiol,  263,  E980- 
E987 
234 Negri  M.,  Sheiban  I.,  Arigliano  P.  L.,  Tonni  S.,  Montresor  G.,  Carlini  S.,  Manzato 
F.  (1993)  Interrelation  between  angiographic  severity  of  coronary  artery  disease 
and  plasma  levels  of  insulin,  C-peptide,  and  plasminogen  activator  inhibitor-1. 
Am  J  Cardiol,  72,397-401. 
Nilsson  P.,  Lind  L.,  Andersson  P.  -E.,  Hanni  A.,  Baron  J.,  Berne  C.,  Lithell  H. 
(1994)  Higher  correlations  found  between  insulin  sensitivity  and  24-hour  ABPM 
than  between  fasting  insulin  and  office  blood  pressure.  Diabetologia,  37  (Suppl  1), 
A22. 
Nolan  J.  J.,  Ludvik  B.,  Beerdsen  P.,  Joyce  M., Olefsky  J.  (1994)  Improvement  in 
glucose  tolerance  and  insulin  resistance  in  obese  subjects  treated  with 
troglitazone.  N  Engl  J  Med,  331,1188-1193. 
Nordt  T.  K.,  Schneider  D.  J.,  Sobel  B.  E.  (1994)  Augmentation  of  the  synthesis  of 
plasminogen  activator  inhibitor  type-1  by  precursors  of  insulin:  a  potential  risk 
factor  for  vascular  disease.  Circulation,  89,321-330. 
Nutrition  Study  Group,  European  Association  for  the  Study  of  Diabetes.  (1988). 
Nutritional  recommendations  for  individuals  with  diabetes  mellitus.  Diabetes 
Nutr  Metab,  1,145-149. 
Nuutila  P.,  Raitakari  M.,  LLaine  H.,  Kirvela  0.,  Takala  T.,  Utrianen  T., 
Makimattila  S.,  Pitkanen  O-P.,  Ruotsalainen  U.,  Iida  H.,  Knuuti  J,  Yki-Jarvinen 
H.  (1996)  Role  of  blood  flow  in  regulating  insulin-stimulated  glucose  uptake  in 
humans:  studies  using  bradykinin,  [150]water,  and  [18F]fluoro-deoxy-glucose  and 
positron  emission  tomography.  J  Clin  Invest,  97,1741-1747. 
Ogihara  T.,  Rakugi  H.,  Mikaini  H.,  Masuo  K.  (1995)  Enhancement  of  insulin 
sensitivity  by  troglitazone  lowers  blood  pressure  in  diabetic  hypertensives.  Am  J 
Hypertens  8,316-320. 
O'Hare  J.  A.,  Ferriss  B.,  Brady  D.,  Twomey  B.,  O'Sullivan  D.  J.  Exchangeable 
sodium  and  renin  in  hypertensive  diabetic  patients  with  and  without  nephropathy. 
Hypertension  7(Suppl  II):  43-48,1985. 
Olefsky  J.,  Reaven  G.  M.,  Farquhar  J.  W.  (1974)  Effects  of  weight  reduction  on 
obesity:  studies  of  lipid  and  carbohydrate  metabolism  in  normal  and 
hyperlipoproteinaemic  subjects.  J  Clin  Invest,  53,64-76. 
Olefsky  J.  (1981)  Insulin  resistance  and  insulin  action.  Diabetes,  30,148-162. 
Olefsky  J.  M.,  Kolterman  O.  G.  (1981)  Mechanisms  of  insulin  resistance  in  obesity 
and  non-insulin-dependent  (type  2)  diabetes  mellitus.  Am  J  Med,  70,151-168. 
Orchard  T.  J.,  Becker  D.  J.,  Bates  M.,  Kuller  L.  H.,  Drash  A.  L.  (1983)  Plasma 
insulin  and  lipoprotein  concentrations:  an  atherogenic  association?  Am  J 
Epidemiol,  118,326-327. 
235 Orchard  T.  J.,  Eichner  J.,  Kuller  L.  H.,  Becker  D.  J.,  McCallum  L.  M.,  Grandits  G.  A. 
(1994)  Insulin  as  a  predictor  of  coronary  heart  disease:  interaction  with  ApoE 
phenotype  -a  report  from  MRFIT.  Ann  Epidemiol4,40-45 
Ostrega  D.,  Polonsky  K.,  Nagi  D.,  Yudkin  J.,  Cox  U.,  Clark  P.  M.  S.,  Hales  C.  N. 
(1995)  Measurement  of  proinsulin  and  intermediates:  validation  of  immunoassay 
methods  by  high  performance  liquid  chromatography.  Diabetes,  44,437-440. 
Pacini  G.,  Bergman  R.  N.  (1986)  MINMOD:  a  computer  program  to  calculate 
insulin  sensitivity  and  pancreatic  responsivity  from  the  frequently  sampled 
intravenous  glucose  tolerance  test.  Comp  Meth  Prog  Biomed,  23,113-122. 
Palmer  R.  M.  J.,  Ferrige  A.  G.,  Moncada  S.  (1987)  Nitric  oxide  release  accounts  for 
the  biological  activity  of  endothelium-derived  relaxing  factor.  Nature,  327,524- 
526. 
Panahloo  A.,  Mohamed-Ali  V.,  Lane  A.,  Green  F.,  Humphries  S.  E.,  Yudkin  J.  S. 
(1995)  Determinants  of  plasminogen  activator  inhibitor-1  activity  in  treated 
NIDDM  and  its  relation  to  a  polymorphism  in  the  plasminogen  activator  inhibitor- 
1  gene.  Diabetes,  44,37-42. 
Panza  J.  A.,  Quyyumi  A.  A.,  Brush  J.  E.,  Epstein  S.  E.  (1990)  Abnormal 
endothelium-dependent  vascular  relaxation  in  patients  with  essential  hypertension. 
N Engl  J  Med,  323,22-27. 
Paolisso  G.,  DiMaro  G.,  Galzerano  D.,  Cacciapuoti  F.,  Varrichio  G.,  Varrichio 
M.,  Donofrio  F.  (1994)  Pharmacological  doses  of  vitamin  E  and  insulin  action  in 
elderly  subjects.  Am  J  Clin  Nut,  59,1291-1296. 
Paolisso  G.,  Gambardella  A.,  Tagliamonte  M.  R.,  Saccomanno  F.,  Salvatore  T., 
Gualdiero  P.,  D'Onofrio  M.  V.  F.,  Howard  B.  (1996)  Does  free  fatty  acid  infusion 
impair  insulin  action  also  through  an  increase  in  oxidative  stress?  J  Clin  End 
Metab,  81,4244-4248. 
Peavy  D.  E.,  Brunner  M.  R.,  Duckworth  W.  C.,  Hooker  C.  S.,  Frank  B.  H.  (1985) 
Receptor  binding  and  biological  potency  of  several  split  forms  (conversion 
intermediates)  of  human  proinsulin.  J  Biol  Chem,  260,13989-13994. 
Pedersen  0.,  Bak  J.  F.,  Andersen  P.  H.,  Lund  S.,  Moller  D.  E.,  Flier  J.  S.,  Kahn  B.  B. 
(1990)  Evidence  against  altered  expression  of  GLUT-1  and  GLUT-4  in  skeletal 
muscle  of  patients  with  obesity  or  NIDDM.  Diabetes  39,865-870. 
Peiris,  AN,  Struve,  M.  F.,  Mueller,  R.  A.,  Lee,  M.  B.,  Kissebah,  A.  H.  (1988) 
Glucose  metabolism  in  obesity:  influence  of  body  fat  distribution.  J  Clin  End 
Metab,  67,760-767. 
Petrie  J.  C.,  O'Brien  E.  T.,  Littler  W.  A.,  de  Swiet  M.  (1986)  Recommendations  on 
blood  pressure  measurement.  Br  Med  J,  293,611-615. 
236 Petrie  J.  R.,  Donnelly  R.  (1994)  New  pharmacological  approaches  to  insulin  and 
lipid  metabolism.  Drugs,  47,701-710. 
Pinkney  J.  H.,  Mohamed-Ali  V.,  Denver  E.,  Foster  C.,  Sampson  M.  J.,  Yudkin  J.  S. 
(1994).  Insulin  resistance,  insulin,  proinsulin,  and  ambulatory  blood  pressure  in 
type  II  diabetes.  Hypertension,  24,362-367. 
Pollare  T.  G.,  Lithell  H.,  Berne  C.  (1989a).  A  comparison  of  the  effects  of 
hydrochlorothiazide  and  captopril  on  glucose  and  lipid  metabolism  in  patients 
with  hypertension.  N  Engl  J  Med,  321,686-673. 
Pollare  TO.,  Lithell  H.,  Selinus  I.,  Berne  C.  (1989b).  Sensitivity  to  insulin 
treatment  with  atenolol  and  metoprolol:  a  randomised,  double-blind  study  of 
effects  on  carbohydrate  and  lipoprotein  metabolism  in  hypertensive  patients.  Br 
Med  J,  297,1147-1152. 
Ponchner  M.,  Heine  R.  J.,  Pernet  A.,  Hanning  L,  Francis  A.  J.,  Cook  D.,  Orskov  H., 
Alberti  K.  G.  (1984)  A  comparison  of  the  artificial  pancreas  (glucose  controlled 
insulin  infusion  system)  and  a  manual  technique  for  assessing  insulin  sensitivity 
during  euglycaemic  clamping.  Diabetologia,  26,420-425. 
Pyorala  K.  (1979)  Relationships  of  glucose  intolerance  and  plasma  insulin  to  the 
incidence  of  coronary  artery  disease:  results  from  two  population  studies  in 
Finland.  Diabetes  Care,  2,131-141. 
Raitakari  M.,  Nuutila  P.,  Ruotsalainen  U.,  Laine  H.,  Teras  M.,  lida  H., 
Makimattila  S.,  Utriainen  T.,  Oikonen  V.,  Sipila  H.,  Haaparanta  M.,  Solin  0., 
Wegelius  U.,  Knuuti  J.,  Yki-Jarvinen  H.  (1996)  Evidence  for  a  dissociation  of 
insulin  stimulation  of  blood  flow  and  glucose  uptake  in  human  skeletal  muscle: 
studies  using  ['50]H20,  ['8F]fluoro-2-deoxy-D-glucose,  and  positron  emission 
tomography.  Diabetes,  45,1471-1477. 
Randle  P.  J.,  Garland  P.  B.,  Hales  C.  N.,  Newsholme  E.  A.  (1963)  The  glucose-fatty 
acid  cycle:  its  role  in  insulin  sensitivity  and  the  metabolic  disturbances  of  diabetes 
mellitus.  Lancet,  i,  785. 
Reaven  G.  M.  (1988)  Role  of  insulin  resistance  in  human  disease.  Diabetes,  37, 
1495-1507. 
Reaven  G.  M.,  Chen  Y-D.  L  (1988)  Role  of  insulin  in  the  regulation  of  lipoprotein 
metabolism  in  diabetes.  Diabetes  Metab  Rev,  7,639-652. 
Reaven  G.  M.,  Chang  H.,  Hoffman  B.  B.,  Azhar  S.  (1989)  Resistance  to  insulin- 
stimulated  glucose  uptake  in  adipocytes  isolated  from  spontaneously  hypertensive 
rats.  Diabetes,  38,1155-1160. 
Reaven  G.  M.,  Chen  Y-D.  I.,  Hollenbeck  C.  B.,  Sheu  W.  H.  H.,  Ostrega  D.,  Polonsky 
K.  S.  (1993)  Plasma  insulin,  C-peptide  and  proinsulin  concentrations  in  obese  and 
non-obese  individuals  with  varying  degrees  of  glucose  tolerance.  J  Clin  End 
Metab,  76,44-48. 
237 Rett  K.,  Jauch  K.  W.,  Wicklmayr  M.,  Dietze  G.,  Fink  E.,  Mehnert  H.  (1986) 
Angiotensin  converting  enzyme  inhibitors  in  diabetes:  experimental  and  human 
experience.  Postgrad  Med  J  62(Suppl  1),  59-64 
Rivellese  A.  A.,  Maffettone  A.,  Iovine  C.,  DiMarino  L.,  Annuzzi  G.,  Maincini  M., 
Riccardi  G.  (1996)  Long-term  effects  of  fish  oil  on  insulin  resistance  and  plasma 
lipoproteins  in  NIDDM  patients  with  hypertriglyceridaemia.  Diabetes  Care,  19, 
1207-1213. 
Rizza  R.,  Haymond  M.,  Cryer  P.,  Gerich  J.  (1979)  Differential  effects  of 
epinephrine  on  glucose  production  and  disposal  in  man.  Am  J  Physiol,  237, 
E356-362. 
Rizza  R.,  Mandarino  L.,  Gerich  J.  (1981)  Mechanism  and  significance  of  insulin 
resistance  in  non-insulin  dependent  diabetes  mellitus.  Diabetes,  37,990-995. 
Robbins  D.  C.,  Andersen  L.,  Bowsher  R.,  Chance  R.,  Dinesen  B.,  Frank  B., 
Gingerich  R.,  Goldstein  D.,  Widemeyer  H.  M.,  Haffner  S.,  Hales  N.,  Jarett  L., 
Polonsky  K.,  Porte  D.,  Skyler  J.,  Webb  G.,  Gallagher  K.  (1996)  Report  of  the 
American  Diabetes  Association's  Task  Force  on  Standardisation  of  the  Insulin 
assay.  Diabetes,  45,242-256. 
Roberts  D.  H.,  Tsao  Y.,  Breckenridge  A.  M.  (1986)  The  reproducibility  of  limb 
blood  flow  measurements  in  huma  volunteers  at  rest  and  after  exercise  by  using 
mercury-in-Silastic  strain  gauge  plethysmography  under  standardized  conditions. 
Clin  Sci,  70,635-638. 
Rocchini  A.  P.,  Moorehead  C.,  DeRemer  S.,  Goodfriend  T.  L.,  Ball  D.  L.  (1990) 
Hyperinsulinaemia  and  the  aldosterone  and  pressor  responses  to  angiotensin  II 
Hypertension,  15,861-866. 
Roddie  LC.,  Shepherd  J.  T.,  Whelan  R.  F.  (1956)  Evidence  from  venous  oxygen 
saturation  measurements  that  the  increase  in  forearm  blood  flow  during  body 
heating  is  confined  to  the  skin.  J  Physiol,  134,444-450. 
Rodnick  K.  J.,  Haskell  W.  L.,  Swislocki  A.  L.  M.,  Foley  J.  E.,  Reaven  G.  M.  (1987) 
Improved  insulin  action  in  muscle,  liver  and  adipose  tissue  in  physically  trained 
human  subjects.  Am  J  Physiol  253,  E489-E495. 
Rogers  M.  A.,  Yamamoto  C.,  King  D.  S.,  Hagberg  J.  M.,  Ehsani  A.  A.,  Holloszy 
J.  O.  (1988)  Improvement  in  glucose  tolerance  after  one  week  of  exercise  in 
patients  with  mild  NIDDM.  Diabetes  Care,  11,613-618. 
Ross  R.  (1993)  The  pathogenesis  of  atherosclerosis:  a  perspective  for  the  1990s. 
Nature,  362,801-809. 
Rowe  J.  W.,  Young  J.  B.,  Mimaker  K.  L.,  Stevens  A.  L.,  Pallotta  J.,  Landsberg  L. 
(1981)  Effect  of  insulin  and  glucose  infusions  on  sympathetic  nervous  system 
activity  in  normal  man.  Diabetes,  30,219-225. 
238 Saad  M.  F.,  Lillioja  S.,  Nyomba  B.  L.,  Castillo  C.,  Ferraro  R.,  De  Gregorio  M., 
Ravussin  M.,  Knowler  W.  C.,  Bennett  P.  H.,  Howard  B.  V.  (1991)  Racial 
differences  in  the  relation  between  blood  pressure  and  insulin  resistance.  N  Eng  J 
Med,  324,733-739. 
Saad  M.  F.,  Anderson  R.  L.,  Laws  A.,  Watanabe  R.  M.,  Kades  W.  W.,  Chen  Y-D.  I., 
Sands  R.  E.,  Pei  D.,  Savage  P.  J.,  Bergman  R.  N.  (1994)  A  comparison  between  the 
minimal  model  and  the  euglycaemic  clamp  in  the  assessment  of  insulin  sensitivity 
across  the  spectrum  of  glucose  tolerance.  Diabetes,  43,1114-1121. 
Sacca  L.,  Morrone  G.,  Cicala  M.,  Corso  G.,  Ungaro  B.  (1980)  Influence  of 
epinephrine,  norepinephrine  and  isoproterenol  on  glucose  homeostasis  in  normal 
man.  J  Clin  Endocrin  Metab,  50,680-684. 
Sakai  K.,  Imaizumi  T.,  Masaki  H.,  Takeshita  A.  (1993)  Intra-arterial  infusion  of 
insulin  attenuates  vasoreactivity  in  the  human  forearm.  Hypertension,  22,67-73. 
Sallis  J.  F.,  Haskell  W.  L.,  Wood  P.  D.,  Fortmann  S.  P.,  Rogers  T.,  Blair  S., 
Paffenbarger  R.  S.  (1985)  Physical  activity  assessment  methodology  in  the  five- 
city  project.  Am  J  Epidemiol  1985,121,91-106. 
Salomaa  V.  V.,  Strandberg  T.  E.,  Vanhanen  H.,  Naukkarinen  V.,  Sarna  S., 
Miettinen  T.  A.  (1991)  Glucose  tolerance  and  blood  pressure:  long  term  follow  up 
in  middle  aged  men.  Br  Med  J,  302,493-496. 
Scheen  A.  J.,  Lethiexhe  M.  R.,  Lefebvre  P.  J.  (1995)  Short  administration  of 
metformin  improves  insulin  sensitivity  in  android  obese  subjects  with  impaired 
glucose  tolerance.  Diab  Med,  12,985-989. 
Schmidli  R.  S.,  Hagan  C.,  Scott  R.  S.,  Livesey  J.,  Forbes  L.  V.  (1993)  Plasma 
proinsulin  in  recently-diagnosed  type  2  diabetes  mellitus.  Diab  Res  Clin  Pract,  20, 
133-138. 
Scherrer  U.,  Vollenweider  P.,  Randin  D.,  Jequier  E.,  Nicod  P.,  Tappy  L.  (1993) 
Suppression  of  insulin  induced  sympathetic  nervous  system  activation  and 
vasodilation  in  skeletal  muscle  in  humans.  Circulation,  88,388-384. 
Scherrer  U.,  Randin  D.,  Vollenweider  P.,  Vollenweider  L.,  Nicod  P.  (1994)  Nitric 
oxide  accounts  for  insulin's  vascular  effects  in  humans.  J  Clin  Invest,  94,2511- 
2515. 
Schoonjans  K.,  Staels  B.,  Auwerx  J.  (1996)  The  peroxisome  proliferator  activated 
receptors  (PPARS)  and  their  effects  on  lipid  metabolism  and  adipocyte 
differentiation.  Biochim  Biophys  Acta,  1302,93-109. 
Service  F.  J.,  Nelson  R.  L.,  Rubenstein  A.  H.,  Go  V.  W.  (1978)  Direct  effect  of 
insulin  on  secretion  of  insulin,  glucagon,  gastric  inhibitory  polypeptide,  and 
gastrin  during  maintenance  of  normoglycaemia.  J  Clin  Endocrinol  Metab,  47, 
488-493. 
239 Sever  P.,  Beevers  G.,  Bulpitt  C.,  Lever  A.,  Ramsay  L.,  Reid  J.,  Swales  J.  (1993) 
Management  guidelines  in  essential  hypertension:  Report  of  the  Second  Working 
Party  of  the  British  Hypertension  Society.  Br  Med  J,  306,983-7. 
Shamiss  A.,  Carroll  J.,  Rosenthal  T.  (1992)  Insulin  resistance  in  secondary 
hypertension.  Am  J  Hypertens,  5,26-28. 
Sharma  A.  M.,  Schorr  U.,  Distler  A.  (1993)  Insulin  resistance  in  young  salt- 
sensitive  subjects.  Hypertension,  21,273-279. 
Shen  S.  W.,  Reaven  G.  M.,  Farquhar  J.  W.  (1970)  Comparison  of  impedance  to 
insulin-mediated  glucose  uptake  in  normal  subjects  and  in  subjects  with  latent 
diabetes.  J  Clin  Invest,  49,2151-2560. 
Shen  D.  C.,  Shieh  S.  M.,  Fuh  M.  T.,  Wu  D-A.,  Chen  Y-D.  I.,  Reaven  G.  M.  (1988) 
Resistance  to  insulin  stimulated  glucose  uptake  in  patients  with  hypertension.  J 
Clin  End  Metab,  66,580-583. 
Shepherd  J.,  Cobbe  S.  M.  Ford  I.,  Isles  C.  G.,  Lorimer  A.  R.,  MacFarlane  P.  W., 
McKillop  J.  H.,  Packard  C.  J.  (1995)  Prevention  of  coronary  artery  disease  with 
pravastatin  in  men  with  hypercholesterolaemia.  N  Engl  J  Med,  333,1301-1307. 
Sheu  WH-H.,  Shieh  S-M.,  Fuh  M.  M-T.,  Shen  D.  D.  C.,  Jeng  C.  Y.,  Chen  Y-D.  I, 
Reaven  G.  M.  (1993)  Insulin  resistance,  glucose  intolerance,  and 
hyperinsulinaemia.  Hypertriglyceridaemia  versus  hypercholesterolaemia. 
Arterioscler  Thromb,  13,367-370. 
Shiraishi  I.,  Iwamoto  Y.,  Kuzuya  T.,  Matsuda  A.,  Kimakura  S.  (1991) 
Hyperinsulinaemia  in  obesity  is  not  accompanied  by  an  increase  in  serum 
insulin/proinsulin  ratio  in  groups  of  human  subjects  with  and  without  glucose 
intolerance.  Diabetologia  34,737-741. 
Skarfors  E.  T.,  Lithell  H.  O.,  Selinus  I.,  Aberg  H.  (1989)  Do  antihypertensive  drugs 
precipitate  diabetes  in  predisposed  men?  Br  Med  J,  298,1147-1152. 
Smrcka  AN.,  Helper  J.  R.,  Brown  K.  O.,  Stemweis  P.  (1991)  Regulation  of 
polyphoinositide  specific  phospholipase  C  activity  by  purified  Gq.  Science,  251, 
804-807. 
Sobel  B.  E.  (1996)  Potentiation  of  vasculopathy  by  insulin:  implications  from  an 
NHBLI  clinical  alert.  Circulation,  93,1613-1615. 
Sobey  W.  J.,  Beer  S.  F.,  Carrington  C.  A.,  Clark  P.  M.  S.,  Frank  B.  H.,  Gray  P.,  Luzio 
S.  D.,  Owens  D.  R.,  Schneider  A.  E.,  Siddle  K.,  Temple  R.,  Hales  CN.  (1989) 
Sensitive  and  specific  two-site  immunoradiometric  assay  for  human  insulin, 
proinsulin,  65-66  split  and  32-33  split  proinsulins.  Biochem  J,  260,535-541. 
240 Sobrevia  L.,  Nadal  A.,  Yudilevich  D.  L.,  Mann  G.  E.  (1996)  Activation  of  L- 
arginine  transport  (system  y+)  and  nitric  oxide  synthase  by  elevated  glucose  and 
insulin  in  human  endothelial  cells.  J  Physiol,  490,775-781. 
Somogyi  M  (1945).  Determination  of  blood  sugar.  J  Biol  Chem  160,69-73. 
Sowers  J.  R.  (1990)  Insulin  resistance  and  hypertension.  Mol  Cell  Endocrinol,  74, 
C87-C89. 
Stalder  M.,  Pometta  B.,  Suenram  A.  (1981)  Relationship  between  plasma  insulin 
levels  and  high  density  lipoprotein  cholesterol  levels  in  healthy  men. 
Diabetologia,  21,544-548. 
Steil  G.  M.,  Murray  J.,  Bergman  R.  N.,  Buchanan  T.  A.  (1994)  Repeatability  of 
insulin  sensitivity  and  glucose  effectiveness  from  the  minimal  model:  implications 
for  study  design.  Diabetes  43,1365  -  1371. 
Steiner  D.  F.,  Oyer  P.  E.  (1967).  The  biosynthesis  of  insulin  and  a  probable 
precursor  of  insulin  by  a  human  islet  cell  adenoma.  Proc  Natl  Acad  Sci  USA,  57, 
473-480. 
Steele  R.,  Wall  J.  S.,  DeBodo  R.  C.,  Altszuler  N.  (1956)  Measurement  of  size  and 
turnover  rate  of  body  glucose  pool  by  the  isotope  dilution  method.  Am  J  Physiol, 
187,15-25 
Stehouwer  C.  D.  A.,  Stroes  E.  S.  G.,  Hackeng  W.  H.  L.,  Mulder  P.  G.  H.,  Den 
Ottolander  G.  J.  H.  (1991)  Von  Willebrand  factor  and  development  of  diabetic 
nephropathy.  Diabetes,  40,971-976. 
Steinberg  H.  O.,  Brechtel  G.,  Johnson  A.,  Fineberg  N.,  Baron  A.  D.  (1994)  Insulin- 
mediated  skeletal  muscle  vasodilatation  is  nitric  oxide  dependent.  J  Clin  Invest, 
94,1172-1174. 
Steinberg  H.  O.,  Chaker  H.,  Learning  R.,  Johnson  A.,  Brechtel  G.,  Baron  A.  D. 
(1996)  Obesity/insulin  resistance  is  associated  with  endothelial  dysfunction.  J  Clin 
Invest,  97,2601-2610. 
Steiner  D.  F.,  Tager  H.  S.,  Chan  S.  J.,  Nanjo  K.,  Sanke  T.,  Rubenstein  A.  H.  (1990) 
Lessons  learned  from  the  molecular  biology  of  insulin-gene  mutations.  Diabetes 
Care,  13,600-609. 
Stephens  N.  G.,  Parsons  A.,  Schofield  P.  M.,  Kelly  F.,  Cheeseman  K.,  Mitchinson 
M.  J.,  Brown  M.  J.  (1996).  Randomised  controlled  trial  of  vitamin  E  in  patients 
with  coronary  disease:  Cambridge  Heart  Antioxidant  Study.  Lancet,  347,781- 
786. 
Stout  R.  W.,  Bierman  E.  L.,  Ross  R.  (1980)  The  effect  of  insulin  on  the 
proliferation  of  cultured  primate  arterial  smooth  muscle  cells.  Circ  Res,  36,319- 
327. 
241 Stout  R.  W.  (1989).  Insulin  and  atheroma.  Diabetes  Care,  13,631-654. 
Tack  C.  J.  J.,  Smits  P.,  Willemsen  J.  J.,  Lenders  J.  W.  M.,  Thien  T.,  Lutterman  J.  A. 
(1996a)  Effects  of  insulin  on  vacular  tone  and  sympathetic  nervous  system  in 
MDDM.  Diabetes,  45,15-22. 
Tack  C.  J.  J.,  Lutterman  J.  A.,  Vervoort  G.,  Thien  T.,  Smits  P.  (1996b)  Activation 
of  the  sodium-potassium  pump  contributes  to  insulin-induced  vasodilatation  in 
humans.  Hypertension  28,426-432. 
Taddei  S.,  Virdis  A.,  Mattei  P.,  Arzilli  F.,  Salvetti  A.  (1992)  Endothelium- 
dependent  forearm  vasodilatation  is  reduced  in  normotensive  subjects  with 
familial  history  of  hypertension.  J  Cardiovasc  Pharm,  20(Suppl  12),  S  193-S  195. 
Taddei  S.,  Virdis  A.,  Mattei  P.,  Favilla  S.,  Salvetti  A.  (1995)  Angiotensin  II  and 
sympathetic  nervous  system  activity  in  sodium-restricted  essential  hypertension. 
Hypertension  25,595-601. 
Takeshita  A.,  Mark  A.  L.  (1980)  Decreased  vasodilator  capacity  of  forearm 
resistance  vessels  in  borderline  hypertension.  Hypertension,  2,610-616. 
Taskinen  M.  R.,  Nikkila  E.  A.,  Kuusi  T.,  Harno  K.  (1982)  Lipoprotein  lipase 
activity  and  serum  lipoproteins  in  untreated  type  2  (insulin-independent)  diabetes 
associated  with  obesity.  Diabetologia,  22,46-50. 
Taylor  R.  (1996)  Insulin  resistance:  circumventing  nature's  blocks.  Lancet,  348, 
1045-1046. 
Temple  R.  C.,  Carrington  C.  A.,  Luzio  S.  D.,  Owens  D.  R.,  Schneider  A.  E.,  Sobey 
W.  J.,  Hales  C.  N.  (1989)  Insulin  deficiency  in  non-insulin  dependent  diabetes. 
Lancet,  i,  293-295. 
Ting  H.  H.,  Timimi  F.  K.,  Boles  K.  S.,  Creager  S.  J.,  Ganz  P.,  Creager  M.  A.  (1996) 
Vitamin  C  improves  endothelium-dependent  vasodilation  in  patients  with  non- 
insulin-dependent  diabetes  mellitus.  J  Clin  Invest,  97,22-28. 
Tonino  R.  P.  (1989)  Effect  of  physical  training  on  the  insulin  resistance  of  ageing. 
Am  J  Physiol,  256,  E352-E356. 
Tong  P.,  Thomas  T.,  Berrish  T.,  Humphriss  D.,  Barriocanal  L.,  Stewart  M., 
Walker  M.,  Wilkinson  R.,  Alberti  K.  G.  M.  M.  (1995)  Cell  membrane  dynamics 
and  insulin  resistance  in  non-insulin-dependent  diabetes  mellitus.  Lancet,  345, 
357-358. 
Treasure  C.  B.,  Klein  L.,  Weintraub  W.  S.,  Talley  D.,  Stillabower  M.  E.,  Kosinski 
A.  S.,  Zhang  J.,  Boccuzzi  S.  J.,  Cedarholm  J.  C.,  Alexander  R.  W.  (1995)  Beneficial 
effects  of  cholesterol-lowering  therapy  on  the  coronary  endothelium  in  patients 
with  coronary  artery  disease.  N  Engl  J  Med,  332,481-487. 
242 Ueda  S.,  Petrie  J.  R.,  Connell  J.  M.  C.,  Elliott  H.  L.  (1995)  Insulin-mediated 
vasodilatation  in  the  human  forearm  is  dependent  on  local  glucose  concentrations 
(abstract)  Hypertension  1995,25,  P58 
University  Group  Diabetes  Program.  (1970)  A  study  of  the  effects  of 
hypoglycaemic  agents  on  vascular  complications  in  patients  with  adult-onset 
diabetes.  II.  Mortality  results.  Diabetes,  19,789-830. 
Utriainen  T.  R.,  Malurstrom  S.,  Makimattila  S.,  Yki-Jarvinen  H.  (1995) 
Methodological  aspects  and  dose-response  characteristics  and  causes  of  inter- 
individual  variation  in  insulin  stimulation  of  limb  blood  flow  in  normal  subjects. 
Diabetologia,  38,555-564. 
Utriainen  T.,  Makimattila  S.,  Virkamaki  A.,  Lindholm  H.,  Sovijarvi  A.,  Yki- 
Jarvinen  H.  (1996a)  Physical  fitness  and  endothelial  function  (nitric  oxide 
synthesis)  are  independent  determinants  of  insulin-stimulated  blood  flow  in 
normal  subjects.  J  Clin  End  Metab,  81,4258-4263. 
Utriainen  T.,  Makimattila  S.,  Virkamaki  A.,  Bergholm  R.,  Yki-Jarvinen  H. 
(1996b)  Dissociation  between  insulin  sensitivity  of  glucose  uptake  and  endothelial 
function  in  normal  subjects.  Diabetologia,  39,1477-1482. 
Vaag  A.,  Henriksen  J.  E.,  Beck-Nielsen  H.  (1992)  Decreased  insulin  activation  of 
glycogen  synthase  in  skeletal  muscles  in  young  non-obese  Caucasian  first  degree 
relatives  of  patients  with  non-insulin-dependent  diabetes  mellitus.  J  Clin  Invest, 
89,782-788. 
Vaag  A.,  Henriksen  J.  E.,  Madsbad  S.,  Holm  N.,  Beck-Nielsen  H  (1995)  Insulin 
secretion,  insulin  action,  and  hepatic  glucose  production  in  identical  twins 
disconcordant  for  non-insulin-dependent  diabetes  mellitus.  J  Clin  Invest,  95,690- 
698. 
Vaccaro  0.,  Imperatore  G.,  lovine  C.,  Rivellese  A.  A.,  Riccardi  G.  (1996)  Does 
impaired  glucose  tolerance  predict  hypertension?  A  prospective  analysis. 
Diabetologia  39,70-76. 
van  den  Berg  M.,  Boers  G.  H.  J.,  Franken  D.  G.,  Blom  H.  J.,  Van  Kamp  G.  J.,  Jakobs 
C.,  Rauwerda  J.  A.,  Kluft  C.,  Stehouwer  C.  D.  A.  (1995)  Hyperhomocystinuria  and 
endothelial  dysfunction  in  young  patients  with  arterial  occlusive  disease.  Eur  J 
Clin  Invest  25,176-181. 
Valiance  P.,  Collier  J.,  Moncada  S.  (1989)  Effects  of  endothelium-derived  nitric 
oxide  on  peripheral  arteriolar  tone  in  man.  Lancet,  ii,  997-1000. 
Velloso  L.  A.,  Folli  F.,  Sun  X.  J.,  White  M.  F.,  Saad  M.  J.  A.,  Kahn  C.  R.  (1996) 
Cross-talk  between  the  insulin  and  angiotensin  signalling  systems.  Proc  Natl  Acad 
Sci  USA,  93,12490-12495. 
243 Vionnet  N.,  Stoffel  M.,  Takeda  J.,  Yasuda  K.,  Bell  G.  I.,  Zouali  H.,  Lesage  S., 
Velho  G.,  Iris  F.,  Passa  P.,  Froguel  P.,  Cohen  D.  O.  (1992)  Nonsense  mutation  in 
the  glucokinase  gene  causes  early-onset  non-insulin-dependent-diabetes  mellitus. 
Nature,  356,721-722. 
Vollenweider  P.,  Tappy  L.,  Randin  D.,  Schneiter  P.,  Jequier  E.,  Nicod  P.,  Scherrer 
U.  (1993)  Differential  effects  of  hyperinsulinaemia  and  carbohydrate  metabolism 
on  sympathetic  nervous  system  activity  in  humans.  J  Clin  Invest,  92,147-154. 
Vollenweider  P.,  Randin  D.,  Tappy  L.,  Jequier  E.,  Nicod  P.,  Scherrer  U.  (1994) 
Impaired  insulin-induced  sympathetic  neural  activation  and  vasodilation  in 
skeletal  muscle  of  obese  humans.  J  Clin  Invest,  93,2365-2371. 
Vuorinen-Markkola  H.,  Yki-Jarvinen  H.  (1995)  Antihypertensive  therapy  with 
enalapril  improves  glucose  storage  and  insulin  sensitivity  in  hypertensive  patients 
with  non-insulin-dependent  diabetes  mellitus.  Metabolism,  44,85-89. 
Wahab  P.  J.,  Rijnsburger  A.  W.  E.,  Oolbekkink  M.,  Heine  R.  J.  (1992)  Venous 
versus  arterialised  venous  blood  for  assessment  of  blood  glucose  levels  during 
glucose  clamping:  comparison  in  healthy  men.  Horm  Metab  Res,  24,576-579. 
Walker  B.  R.,  Connacher  A.  A.,  Lindsay  R.  M., Webb  D.  J.,  Edwards  C.  R.  W.  (1995) 
Carbenoxolone  increases  hepatic  insulin  sensitivity  in  man:  a  novel  role  in 
enhancing  glucocorticoid  receptor  activation.  J  Clin  Endocrinol  Metab,  80,3155- 
3159. 
Weidmann  P.,  Ferrari  P.,  Shaw  S.  Renin  in  Diabetes  Mellitus.  In:  Robertson  J.  LS, 
Nicholls  G.  M.,  eds.  The  Renin  Angiotensin  System.  London,  Gower,  1993,75.1- 
75.26. 
Weinsier  R.  L.,  Norris  D.  J.,  Birch  R.,  Bernstein  R.  S.,  Wang  J.,  Yang  M-U., 
Pierson  R.  N.  (Jr.  ),  Van  Itallie  T.  B.  (1985)  The  relative  contribution  of  body  fat  and 
fat  pattern  to  blood  pressure  level.  Hypertension,  7,578-585. 
Welborn  T.  A.,  Breckenridge  A.,  Dollery  C.  T.,  Rubinstein  A.  H.,  Russell  Fraser  T. 
(1966)  Serum  insulin  in  essential  hypertension  and  in  peripheral  vascular  disease. 
Lancet,  1,1336-1337. 
Welborn  T.  A.,  Wearne  K.  (1979).  Coronary  heart  disease  and  cardiovascular 
mortality  in  Busselton  with  reference  to  glucose  and  insulin  concentrations. 
Diabetes  Care,  2,154-160. 
Welin,  L.  Eriksson  H.,  Larsson  B.,  Ohlson  L.  O.,  Svardsudd  K.,  Tibblin  G.,  (1992) 
Hyperinsulinaemia  is  not  a  major  coronary  risk  factor  in  elderly  men:  the  study  of 
men  born  in  1913.  Diabetologia,  35,766-770. 
White  M.  F.,  Kahn  C.  R.  (1994)  The  insulin  signalling  system.  J  Biol  Chem,  269, 
1-4. 
244 Whitney  R.  J.  (1953)  The  measurement  of  volume  changes  in  human  limbs.  J 
Physiol,  121,1-27. 
Widgren  B.  R.,  Urbanavicius  V.,  Wikstrand  J.,  Attval  S.,  Persson  B.  (1993)  Low 
dose  angiotensin  II  increases  glucose  disposal  rate  during  euglycaemic 
hyperinsulinaemia.  Am  J  Hypertens,  6,892-895. 
Wiggam  M.  I.,  Hunter  S.  J.,  Ennis  C.,  Henry  B.,  Sheridan  B.,  Atkinson  A.  B.,  Bell 
P.  M.  (1996)  Effect  of  captopril  on  glucose  metabolism  and  skeletal  muscle  blood 
flow  in  essential  hypertension:  a  placebo-controlled  study  (abstract).  J  Hypertens, 
14,  S142  (9C.  4). 
Winocour  P.  H.,  Kaluvya  S.,  Brown  L.,  Farrer  M.,  Millar  J.  P.,  Neil  H.,  Alberti 
K.  G.  M.  M.  (1991)  The  association  of  different  measures  of  insulinaemia  with 
vascular  risk  factors  in  healthy  normoglycaemic  normotensive  non-obese  men  and 
women.  QJ  Med,  79,539-560. 
Witzum  J.  L.  (1993)  Susceptibility  of  low-density  lipoprotein  to  oxidative 
modification.  Am  J  Med,  94,348-349. 
World  Health  Organisation  (1980)  WHO  Expert  Committee  on  Diabetes  Mellitus. 
(Technical  Report  Series,  no.  646).  Geneva,  WHO. 
Yalow  R.  S.  and  Berson  S.  A.  (1960)  Immunoassay  of  endogenous  plasma  insulin 
in  man.  J  Clin  Invest,  39,1157. 
Yarnell  J.  W.  G.,  Sweemam  P.  M.,  Marks  V.,  Teale  J.  D.,  Bolron  C.  H..  (1994). 
Insulin  in  ischaemic  heart  disease:  are  associations  explained  by  triglyceride 
concentrations?  The  Caerphilly  prospective  study.  Brit  Heart  J,  71,293-296. 
Yang  Y.  J.,  John  J.  H.,  Bergman  R.  N.  (1987)  Modified  protocols  improve  insulin 
sensitivity  estimation  using  the  minimal  model.  Am  J  Physiol,  16,  E595-E602. 
Yang  Y.  J.,  Hope  I.  D.,  Ader  M.,  Bergman  R.  N.  (1989)  Insulin  transport  across 
capillaries  is  rate-limiting  for  insulin  action  in  dogs.  J  Clin  Invest,  84,1620- 
1628. 
Yki-Jarvinen  H.,  Koivisto  V.  A.  (1983)  Effect  of  body  composition  on  insulin 
sensitivity.  Diabetes,  32,965-969. 
Yki-Jarvinen  H.,  Young  A.  A.,  Lamkin  C.,  Foley  J.  E.  (1987)  Kinetics  of  glucose 
disposal  in  whole  body  and  across  the  forearm  in  man.  J  Clin  Invest,  79,1713- 
1719. 
Yki-Jarvinen  H.  (1995)  Role  of  insulin  resistance  in  the  pathogenesis  of  NIDDM. 
Diabetologia,  38,1378-1388. 
Yokota  C.,  Ikebuchi  M.,  Suzuki  M.,  Norioka  M.,  Ikeda  K.,  Shinozaki  K.,  Harano 
Y.  (1995)  Insulin  resistance  rather  than  hyperinsulinaemia  more  closely 
associated  with  essential  hypertension.  Clin  Exp  Hypertens,  17,523-526. 
245 Zavaroni  I.,  Bonora  E.,  Pagliara  M.,  Dall'Aglio  E,  Luchetti  L.,  Buonanno  G., 
Bonati  PA.,  Bergonzani  M.,  Gnudi  L.,  Passeri,  M.,  Reaven,  G.  M.  (1989)  Risk 
factors  for  coronary  artery  disease  in  healthy  persons  with  hyperinsulinaemia  and 
normal  glucose  tolerance.  N  Engl  J  Med,  320,702-706. 
Zemel  M.  B.,  Sowers  J.  R.,  Shehin  S.,  Walsh  M.  F.,  Levy  J.  (1990)  Impaired 
calcium  metabolism  associated  with  hypertension  in  Zucker  obese  rats. 
Metabolism,  39,704-708. 
Zimmermann  S.,  Phillips  R.  A.,  Dunaif  A.,  Finegood  D.  T.,  Wilkenfeld  C., 
Ardeijan  M.,  Gorlin  R.,  Krakoff  L.  R.  (1992)  Polycystic  ovary  syndrome:  lack  of 
hypertension  despite  profound  insulin  resistance.  J  Clin  End  Metab,  75,508-513. 
246 Abbreviations: 
ACE  angiotensin-converting  enzyme 
ANGU  angiotensin  H 
ANOVA  analysis  of  variance 
AUC  area-under-the-curve 
BMI  body  mass  index 
BP  blood  pressure 
CIRU  Clinical  Investigation  and  Research  Unit 
CI  confidence  interval 
CV  coefficient  of  variation 
EGP  endogenous  glucose  production 
eNOS  endothelial  nitric  oxide  synthase 
EDRF  endothelium-derived  relaxing  factor 
FBF  forearm  blood  flow 
FFA  free  fatty  acid 
FVR  forearm  vascular  resistance 
FIRI  fasting  insulin  resistance  index 
GLUT  glucose  transporter 
HDL  high-density  lipoprotein 
HOMA  homeostasis  model  assessment 
HPLC  high  performance  liquid  chromatography 
IGT  impaired  glucose  tolerance 
IST  insulin  suppression  test 
IVGTT  intravenous  glucose  tolerance  test 
247 L-NMMA  NG-monomethyl-L-arginine 
LDL  Low-density  lipoprotein 
LPL  Lipoprotein  lipase 
M  insulin  sensitivity  (glucose  metabolised) 
MAP  mean  arterial  pressure 
NIDDM  non-insulin-dependent  diabetes  mellitus 
NO  nitric  oxide 
OGTT  oral  glucose  tolerance  test 
PAI-1  Plasminogen  Activator  Type-1  (PAI-1) 
PRA  plasma  renin  activity 
R.  rate  of  appearance 
Rd  rate  of  disappearance 
RAS  renin-angiotensin  system 
RIA  radioimmunoassay 
SSPG  steady  state  plasma  glucose  concentration 
SC  space  correction 
UC  urinary  correction  for  glucose  loss 
VLDL  very-low-density  lipoprotein 
WHR  waist-to-hip  ratio 
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